

# Standards for Oncology Registry Entry

## **ST**andards for **O**ncology **R**egistry **E**ntry **STORE 2022**

---

Effective for Cases Diagnosed  
January 1, 2022

**Cancer**  
PROGRAMS

QUALITY PROGRAMS  
of the AMERICAN COLLEGE  
OF SURGEONS



AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:  
Highest Standards, Better Outcomes*

100+years

# ***STORE***

## **S**Tandards for **O**ncology **R**egistry **E**ntry Released 2022

(Incorporates all updates to Commission on Cancer, National Cancer Database  
Data standards since FORDS was revised in 2016, STORE 2018, STORE 2021)

Effective for cases diagnosed January 1, 2022



© 2021 AMERICAN

COLLEGE OF SURGEONS

All Rights Reserved

## Table of Contents

### Table of Contents

<b>Table of Contents</b> .....	<b>2</b>
<b>Foreword</b> .....	<b>28</b>
FROM “FORDS” TO “STORE” .....	28
<b>STORE 2022 Summary of Changes</b> .....	<b>29</b>
<b>2022 Source References</b> .....	<b>35</b>
<b>Section One: Case Eligibility and Overview of Coding Principles</b> .....	<b>37</b>
<b>Case Eligibility</b> .....	<b>38</b>
Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Database (NCDB).....	38
Reportable-by-Agreement Cases .....	38
Ambiguous Terms at Diagnosis .....	39
Ambiguous Terminology Lists: References of Last Resort .....	40
Class of Case.....	41
Analytic Cases .....	41
Nonanalytic Cases .....	41
Modifications to Class of Case in 2010 .....	41
Date of First Contact .....	41
<b>Overview of Coding Principles</b> .....	<b>43</b>
Unique Patient Identifier Codes.....	43
National Provider Identifier .....	43
Coding Dates .....	44
Cancer Identification.....	44
Primary Site.....	44
Occult Cervical Lymph Node .....	44
Cutaneous Carcinoma of the Head and Neck .....	45
Hematopoietic and Lymphoid Cancers .....	45
Kaposi Sarcoma .....	45
Melanoma .....	45
Specific Tissues with Ill-Defined Sites .....	45
Laterality .....	46
Revising the Original Diagnosis .....	47
Patient Address and Residency Rules .....	48

Rules for Persons with Ambiguous Residences .....	48
Coding Country and State .....	49
In Utero Diagnosis and Treatment.....	50
Comorbidities and Complications/Secondary Diagnoses .....	50
Stage of Disease at Initial Diagnosis.....	51
AJCC Prognostic Staging .....	51
First Course of Treatment.....	52
Treatment Plan .....	53
Time Periods for First Course of Treatment .....	53
All Malignancies except Leukemias .....	53
Leukemias .....	53
Surgery .....	54
Relationships among Surgical Items .....	54
Radiation Therapy .....	57
Radiation Data Items Update.....	58
Radiation Treatment Phase-specific Data Items.....	58
Relationships among Radiation Items .....	59
Systemic Therapy .....	60
Relationships Among Systemic Therapy Items .....	61
Other Treatment .....	62
Palliative Care.....	62
Treatment, Palliative, and Prophylactic Care.....	63
Embolization .....	63
Outcomes.....	64
Follow-up items that are required to be in the facility's database.....	64
Recurrence Definition .....	65
Case Administration.....	65
Administrative Tracking .....	65
EDITS Overrides.....	66
Code Versions Used .....	66
Data Submission Type.....	66
<b>Section Two: Instructions for Coding .....</b>	<b>67</b>
<b>Patient Identification .....</b>	<b>68</b>
<b>Accession Number .....</b>	<b>69</b>

Description .....	69
Rationale .....	69
Coding Instructions .....	69
Examples .....	69
<b>Sequence Number .....</b>	<b>71</b>
Description .....	71
Rationale .....	71
Coding Instructions .....	71
Malignant or In Situ Primaries .....	71
Non-Malignant Primaries .....	72
Examples .....	72
<b>City/Town at Diagnosis (City or Town) .....</b>	<b>73</b>
Description .....	73
Rationale .....	73
Coding Instructions .....	73
Examples .....	73
<b>State at Diagnosis (State) .....</b>	<b>74</b>
Description .....	74
Rationale .....	74
Coding Instructions .....	74
<b>Postal Code at Diagnosis (Zip Code) .....</b>	<b>76</b>
Description .....	76
Rationale .....	76
Coding Instructions .....	76
<b>Address at Dx--Country .....</b>	<b>77</b>
Description .....	77
Rationale .....	77
Coding Instructions .....	77
Examples .....	77
<b>County at Diagnosis .....</b>	<b>78</b>
Description .....	78
Rationale .....	78
Coding Instructions .....	78
<b>Birthplace—State.....</b>	<b>79</b>

Description .....	79
Rationale .....	79
Coding Instructions .....	79
Examples .....	79
<b>Birthplace—Country .....</b>	<b>80</b>
Description .....	80
Rationale .....	80
Coding Instructions .....	80
Examples .....	80
<b>Date of Birth .....</b>	<b>81</b>
Description .....	81
Rationale .....	81
Coding Instructions .....	81
<b>Date of Birth Flag .....</b>	<b>82</b>
Description .....	82
Rationale .....	82
Coding Instructions .....	82
<b>Age at Diagnosis .....</b>	<b>83</b>
Description .....	83
Rationale .....	83
Coding Instructions .....	83
<b>Race 1 .....</b>	<b>84</b>
Description .....	84
Rationale .....	84
Coding Instructions .....	84
Examples .....	85
<b>Spanish Origin—All Sources (Spanish/Hispanic Origin) .....</b>	<b>86</b>
Description .....	86
Rationale .....	86
Coding Instructions .....	86
<b>Sex.....</b>	<b>87</b>
Description .....	87
Rationale .....	87
Coding Instructions .....	87

<b>Primary Payer at Diagnosis .....</b>	<b>88</b>
Description .....	88
Rationale .....	88
Coding Instructions .....	88
Examples .....	89
<b>Comorbidities and Complications #1 (Secondary Diagnoses) .....</b>	<b>91</b>
Description .....	91
Rationale .....	91
Coding Instructions .....	91
Examples .....	92
<b>Comorbidities and Complications #2 (Secondary Diagnoses) .....</b>	<b>93</b>
Description .....	93
Rationale .....	93
Coding Instructions .....	93
<b>Comorbidities and Complications #3 (Secondary Diagnoses) .....</b>	<b>94</b>
Description .....	94
Rationale .....	94
Coding Instructions .....	94
<b>Comorbidities and Complications #4 (Secondary Diagnoses) .....</b>	<b>95</b>
Description .....	95
Rationale .....	95
Coding Instructions .....	95
<b>Comorbidities and Complications #5 (Secondary Diagnoses) .....</b>	<b>96</b>
Description .....	96
Rationale .....	96
Coding Instructions .....	96
<b>Comorbidities and Complications #6 (Secondary Diagnoses) .....</b>	<b>97</b>
Description .....	97
Rationale .....	97
Coding Instructions .....	97
<b>Comorbidities and Complications #7 (Secondary Diagnoses) .....</b>	<b>98</b>
Description .....	98
Rationale .....	98
Coding Instructions .....	98

<b>Comorbidities and Complications #8 (Secondary Diagnoses)</b> .....	<b>99</b>
Description .....	99
Rationale .....	99
Coding Instructions .....	99
<b>Comorbidities and Complications #9 (Secondary Diagnoses)</b> .....	<b>100</b>
Description .....	100
Rationale .....	100
Coding Instructions .....	100
<b>Comorbidities and Complications #10 (Secondary Diagnoses)</b> .....	<b>101</b>
Description .....	101
Rationale .....	101
Coding Instructions .....	101
<b>Secondary Diagnosis #1 (Secondary Diagnoses)</b> .....	<b>102</b>
Description .....	102
Rationale .....	102
Coding Instructions .....	102
Examples .....	103
<b>Secondary Diagnosis #2 (Secondary Diagnoses)</b> .....	<b>104</b>
Description .....	104
Rationale .....	104
Coding Instructions .....	104
Examples .....	104
<b>Secondary Diagnosis #3 (Secondary Diagnoses)</b> .....	<b>105</b>
Description .....	105
Rationale .....	105
Coding Instructions .....	105
Examples .....	105
<b>Secondary Diagnosis #4 (Secondary Diagnoses)</b> .....	<b>106</b>
Description .....	106
Rationale .....	106
Coding Instructions .....	106
Examples .....	106
<b>Secondary Diagnosis #5 (Secondary Diagnoses)</b> .....	<b>107</b>
Description .....	107



Rationale .....	107
Coding Instructions .....	107
Examples .....	107
<b>Secondary Diagnosis #6 (Secondary Diagnoses).....</b>	<b>108</b>
Description .....	108
Rationale .....	108
Coding Instructions .....	108
Examples .....	108
<b>Secondary Diagnosis #7 (Secondary Diagnoses).....</b>	<b>109</b>
Description .....	109
Rationale .....	109
Coding Instructions .....	109
Examples .....	109
<b>Secondary Diagnosis #8 (Secondary Diagnoses).....</b>	<b>110</b>
Description .....	110
Rationale .....	110
Coding Instructions .....	110
Examples .....	110
<b>Secondary Diagnosis #9 (Secondary Diagnoses).....</b>	<b>111</b>
Description .....	111
Rationale .....	111
Coding Instructions .....	111
Examples .....	111
<b>Secondary Diagnosis #10 (Secondary Diagnoses).....</b>	<b>112</b>
Description .....	112
Rationale .....	112
Coding Instructions .....	112
Examples .....	112
<b>NPI–Primary Surgeon .....</b>	<b>113</b>
Description .....	113
Rationale .....	113
Coding Instructions .....	113
<b>NPI–Physician #3 (Radiation Oncologist–CoC Preferred).....</b>	<b>114</b>
Description .....	114

Rationale .....	114
Coding Instructions .....	114
<b>NPI–Physician #4 (Medical Oncologist–CoC Preferred) .....</b>	<b>115</b>
Description .....	115
Rationale .....	115
Coding Instructions .....	115
<b>Cancer Identification .....</b>	<b>116</b>
<b>Class of Case .....</b>	<b>117</b>
Description .....	117
Rationale .....	117
Coding Instructions .....	117
Examples .....	120
<b>NPI–Institution Referred From .....</b>	<b>121</b>
Description .....	121
Rationale .....	121
Coding Instructions .....	121
<b>NPI–Institution Referred To .....</b>	<b>122</b>
Description .....	122
Rationale .....	122
Coding Instructions .....	122
<b>Date of First Contact .....</b>	<b>123</b>
Description .....	123
Rationale .....	123
Coding Instructions .....	123
Examples .....	124
<b>Date of First Contact Flag .....</b>	<b>125</b>
Description .....	125
Rationale .....	125
Coding Instructions .....	125
<b>Date of Initial Diagnosis .....</b>	<b>126</b>
Description .....	126
Rationale .....	126
Coding Instructions .....	126
Examples .....	126

<b>Primary Site .....</b>	<b>128</b>
Description .....	128
Rationale .....	128
Coding Instructions .....	128
Examples .....	128
<b>Laterality .....</b>	<b>130</b>
Description .....	130
Rationale .....	130
Coding Instructions .....	130
<b>Histology .....</b>	<b>131</b>
Description .....	131
Rationale .....	131
Coding Instructions .....	131
Examples .....	131
<b>Behavior Code .....</b>	<b>132</b>
Description .....	132
Rationale .....	132
Coding Instructions .....	132
Examples .....	133
<b>Grade Clinical.....</b>	<b>134</b>
Description .....	134
Rationale .....	134
Coding Instructions .....	134
<b>Grade Pathological.....</b>	<b>135</b>
Description .....	135
Rationale .....	135
Coding Instructions .....	135
<b>Diagnostic Confirmation .....</b>	<b>136</b>
Description .....	136
Rationale .....	136
Coding Instructions – Solid Tumors (all tumors <i>except</i> M9590-9993).....	136
Coding Instructions – Hematopoietic or Lymphoid Tumors (M9590-9993).....	137
<b>Stage of Disease at Diagnosis .....</b>	<b>139</b>
<b>Date of Surgical Diagnostic and Staging Procedure.....</b>	<b>140</b>

Description .....	140
Rationale .....	140
Coding Instructions .....	140
<b>Rx Date–Dx/Stg Proc Flag .....</b>	<b>141</b>
Description .....	141
Rationale .....	141
Coding Instructions .....	141
<b>Surgical Diagnostic and Staging Procedure .....</b>	<b>142</b>
Description .....	142
Rationale .....	142
Coding Instructions .....	142
Examples .....	143
<b>Surgical Diagnostic and Staging Procedure at This Facility .....</b>	<b>144</b>
Description .....	144
Rationale .....	144
Coding Instructions .....	144
<b>Lymphovascular Invasion .....</b>	<b>146</b>
Description .....	146
Rationale .....	146
Coding Instructions .....	146
<b>Macroscopic Evaluation of the Mesorectum .....</b>	<b>151</b>
<b>Sentinel and Regional Lymph Nodes .....</b>	<b>152</b>
<b>Date of Sentinel Lymph Node Biopsy .....</b>	<b>153</b>
Rationale .....	153
Coding Instructions .....	153
<b>Sentinel Lymph Nodes Examined .....</b>	<b>154</b>
Description .....	154
Rationale .....	154
Coding Instructions .....	154
<b>Sentinel Lymph Nodes Positive .....</b>	<b>156</b>
Description .....	156
Rationale .....	156
Coding Instructions .....	156
<b>Date Regional Lymph Node Dissection .....</b>	<b>158</b>

Description .....	158
Rationale .....	158
Coding Instructions .....	158
<b>Regional Lymph Nodes Examined .....</b>	<b>159</b>
Description .....	159
Rationale .....	159
Coding Instructions .....	159
<b>Regional Lymph Nodes Positive .....</b>	<b>162</b>
Description .....	162
Rationale .....	162
Coding Instructions .....	162
<b>Tumor Size and Mets .....</b>	<b>165</b>
<b>Tumor Size Summary .....</b>	<b>166</b>
Description .....	166
Rationale .....	166
Coding Instructions .....	166
Coding Rules.....	167
<b>Mets at Diagnosis – Bone .....</b>	<b>171</b>
Description .....	171
Rationale .....	171
Coding Instructions .....	171
<b>Mets at Diagnosis – Brain.....</b>	<b>173</b>
Description .....	173
Rationale .....	173
Coding Instructions .....	173
<b>Mets at Diagnosis – Distant Lymph Nodes.....</b>	<b>175</b>
Rationale .....	175
Coding Instructions .....	175
<b>Mets at Diagnosis – Liver .....</b>	<b>177</b>
Description .....	177
Rationale .....	177
Coding Instructions .....	177
<b>Mets at Diagnosis – Lung .....</b>	<b>179</b>
Description .....	179

Rationale .....	179
Coding Instructions .....	179
<b>Mets at Diagnosis – Other .....</b>	<b>181</b>
Description .....	181
Rationale .....	181
Coding Instructions .....	181
<b>AJCC TNM Stage, Current Edition .....</b>	<b>183</b>
<b>AJCC TNM Clin T .....</b>	<b>184</b>
Description .....	184
Rationale .....	184
Coding Instructions .....	184
<b>AJCC TNM Clin T Suffix .....</b>	<b>185</b>
Description .....	185
Rationale .....	185
Coding Instructions .....	185
<b>AJCC TNM Clin N .....</b>	<b>186</b>
Description .....	186
Rationale .....	186
Coding Instructions .....	186
<b>AJCC TNM Clin N Suffix.....</b>	<b>187</b>
Description .....	187
Rationale .....	187
Coding Instructions .....	187
<b>AJCC TNM Clin M .....</b>	<b>188</b>
Description .....	188
Rationale .....	188
Coding Instructions .....	188
<b>AJCC TNM Clin Stage Group .....</b>	<b>189</b>
Description .....	189
Rationale .....	189
<b>AJCC TNM Post Therapy Clin (yc) T .....</b>	<b>190</b>
Description .....	190
Rationale .....	190
Coding Instructions .....	190

<b>AJCC TNM Post Therapy Clin (yc) T Suffix .....</b>	<b>191</b>
Description .....	191
Rationale .....	191
Coding Instructions .....	191
<b>AJCC TNM Post Therapy Clin (yc) N .....</b>	<b>192</b>
Description .....	192
Rationale .....	192
Coding Instructions .....	192
<b>AJCC TNM Post Therapy Clin (yc) N Suffix.....</b>	<b>193</b>
Description .....	193
Rationale .....	193
Coding Instructions .....	193
<b>AJCC TNM Post Therapy Clin (yc) M.....</b>	<b>194</b>
Description .....	194
Rationale .....	194
Coding Instructions .....	194
<b>Grade Post Therapy Clin (yc) .....</b>	<b>195</b>
Description .....	195
Rationale .....	195
Coding Instructions .....	195
<b>AJCC TNM Path T .....</b>	<b>196</b>
Description .....	196
Rationale .....	196
Coding Instructions .....	196
<b>AJCC TNM Path T Suffix.....</b>	<b>197</b>
Description .....	197
Rationale .....	197
Coding Instructions .....	197
<b>AJCC TNM Path N.....</b>	<b>198</b>
Description .....	198
Rationale .....	198
Coding Instructions .....	198
<b>AJCC TNM Path N Suffix .....</b>	<b>199</b>
Rationale .....	199

Coding Instructions .....	199
<b>AJCC TNM Path M .....</b>	<b>200</b>
Description .....	200
Rationale .....	200
Coding Instructions .....	200
<b>AJCC TNM Path Stage Group .....</b>	<b>201</b>
Description .....	201
Rationale .....	201
Coding Instructions .....	201
<b>AJCC TNM Post Therapy Path (yp) T .....</b>	<b>202</b>
Description .....	202
Rationale .....	202
Coding Instructions .....	202
<b>AJCC TNM Post Therapy Path (yp) T Suffix.....</b>	<b>203</b>
Description .....	203
Rationale .....	203
Coding Instructions .....	203
<b>AJCC TNM Post Therapy Path (yp) N.....</b>	<b>204</b>
Description .....	204
Rationale .....	204
Coding Instructions .....	204
<b>AJCC TNM Post Therapy Path (yp) N Suffix .....</b>	<b>205</b>
Description .....	205
Rationale .....	205
Coding Instructions .....	205
<b>AJCC TNM Post Therapy Path (yp) M.....</b>	<b>206</b>
Description .....	206
Rationale .....	206
Coding Instructions .....	206
<b>AJCC TNM Post Therapy Path (yp) Stage Group .....</b>	<b>207</b>
Description .....	207
Rationale .....	207
Coding Instructions .....	207
<b>Grade Post Therapy Path (yp) .....</b>	<b>208</b>



Description .....	208
Rationale .....	208
Coding Instructions .....	208
<b>Site-Specific Data Items .....</b>	<b>209</b>
<b>First Course of Treatment .....</b>	<b>211</b>
<b>Date of First Course of Treatment .....</b>	<b>212</b>
Description .....	212
Rationale .....	212
Coding Instructions .....	212
Examples .....	212
<b>Rx Summ – Treatment Status .....</b>	<b>213</b>
Description .....	213
Rationale .....	213
Coding Instructions .....	213
Examples .....	213
<b>Surgery Data Items .....</b>	<b>215</b>
<b>Date of First Surgical Procedure .....</b>	<b>216</b>
Description .....	216
Rationale .....	216
Coding Instructions .....	216
Examples .....	216
<b>Rx Date–Surgery Flag .....</b>	<b>217</b>
Description .....	217
Rationale .....	217
Coding Instructions .....	217
<b>Date of Most Definitive Surgical Resection of the Primary Site .....</b>	<b>218</b>
Description .....	218
Rationale .....	218
Coding Instructions .....	218
<b>Surgical Procedure of Primary Site .....</b>	<b>219</b>
Description .....	219
Rationale .....	219
Coding Instructions .....	219
<b>Surgical Procedure of Primary Site at this Facility .....</b>	<b>221</b>

Description .....	221
Rationale .....	221
Coding Instructions .....	221
<b>Rx Hosp—Surg Breast .....</b>	<b>223</b>
<b>Description .....</b>	<b>223</b>
Records the surgical procedure performed of the primary site <b>at this facility</b> . This data item is required for date of diagnosis 2022 breast cases only. ....	223
<b>Rationale .....</b>	<b>223</b>
Field study for updating the surgery codes in Appendix A, to support the Synoptic Operative Reporting and to allow for more descriptive surgery codes. This data item can be used to compare the efficacy of treatment options. ....	223
<b>Coding Instructions .....</b>	<b>223</b>
<b>Rx Summ-- Surg Breast.....</b>	<b>226</b>
<b>Description .....</b>	<b>226</b>
<b>Rationale.....</b>	<b>226</b>
<b>Coding Instructions.....</b>	<b>226</b>
<b>Rx Hosp-- Recon Breast .....</b>	<b>229</b>
<b>Description .....</b>	<b>229</b>
<b>Rationale.....</b>	<b>229</b>
<b>Coding Instructions.....</b>	<b>229</b>
<b>Rx Summ-- Recon Breast .....</b>	<b>231</b>
<b>Description .....</b>	<b>231</b>
<b>Rationale.....</b>	<b>231</b>
<b>Coding Instructions.....</b>	<b>231</b>
Codes and Code Definitions .....	232
<b>Approach - Surgery of the Primary Site at this Facility (RxHospSurgApp 2010).....</b>	<b>233</b>
Description .....	233
Rationale .....	233
Coding Instructions .....	233
Examples .....	234
<b>Surgical Margins of the Primary Site.....</b>	<b>235</b>
Description .....	235
Rationale .....	235
Coding Instructions .....	235
Example.....	236
<b>Scope of Regional Lymph Node Surgery .....</b>	<b>237</b>

Description .....	237
Rationale .....	237
Coding Instructions .....	237
Codes and Labels.....	238
Examples .....	243
<b>Scope of Regional Lymph Node Surgery at this Facility .....</b>	<b>244</b>
Description .....	244
Rationale .....	244
Coding Instructions .....	244
Codes and Labels.....	245
<b>Surgical Procedure/Other Site.....</b>	<b>250</b>
Description .....	250
Rationale .....	250
Coding Instructions .....	250
Examples .....	251
<b>Surgical Procedure/Other Site at this Facility .....</b>	<b>252</b>
Description .....	252
Rationale .....	252
Coding Instructions .....	252
<b>Date of Surgical Discharge.....</b>	<b>254</b>
Description .....	254
Rationale .....	254
Coding Instructions .....	254
<b>Readmission to the Same Hospital within 30 Days of Surgical Discharge .....</b>	<b>255</b>
Description .....	255
Rationale .....	255
Coding Instructions .....	255
Examples .....	256
<b>Reason for No Surgery of Primary Site .....</b>	<b>257</b>
Description .....	257
Rationale .....	257
Coding Instructions .....	257
Examples .....	258
<b>Radiation Data Items .....</b>	<b>259</b>

<b>Date Radiation Started.....</b>	<b>260</b>
Description .....	260
Rationale .....	260
Coding Instructions .....	260
Examples .....	260
<b>Location of Radiation Treatment.....</b>	<b>261</b>
Description .....	261
Rationale .....	261
Coding Instructions .....	261
Examples .....	262
<b>Phase I-II-III Radiation Primary Treatment Volume.....</b>	<b>263</b>
Description .....	263
Rationale .....	263
Coding Instructions .....	263
Examples .....	268
<b>Phase I-II-III Radiation to Draining Lymph Nodes.....</b>	<b>269</b>
Description .....	269
Rationale .....	269
Coding Instructions .....	269
Examples .....	270
<b>Phase I-II-III Radiation Treatment Modality.....</b>	<b>271</b>
Description .....	271
Rationale .....	271
Coding Instructions .....	271
Examples .....	272
<b>Phase I-II-III External Beam Radiation Planning Technique .....</b>	<b>273</b>
Description .....	273
Rationale .....	273
Coding Instructions .....	273
Examples .....	275
<b>Phase I-II-III Dose per Fraction .....</b>	<b>277</b>
Description .....	277
Rationale .....	277
Coding Instructions .....	277

Examples .....	278
<b>Phase I-II-III Number of Fractions .....</b>	<b>279</b>
Description .....	279
Rationale .....	279
Coding instructions .....	279
Examples .....	280
<b>Phase I-II-III Total Dose .....</b>	<b>281</b>
Description .....	281
Rationale .....	281
Coding instructions .....	281
Examples .....	282
<b>Number of Phases of Radiation Treatment.....</b>	<b>283</b>
Description .....	283
Rationale .....	283
Coding Instructions .....	283
Examples .....	283
<b>Radiation Treatment Discontinued Early.....</b>	<b>284</b>
Description .....	284
Rationale .....	284
Coding Instructions .....	284
Examples .....	285
<b>Radiation Course Total Dose .....</b>	<b>286</b>
Description .....	286
Rationale .....	286
Coding Instructions .....	286
Examples .....	287
<b>Radiation/Surgery Sequence.....</b>	<b>288</b>
Description .....	288
Rationale .....	288
Coding Instructions .....	288
Examples .....	289
<b>Date Radiation Ended .....</b>	<b>290</b>
Description .....	290
Rationale .....	290

Coding Instructions .....	290
Examples .....	290
<b>Reason for No Radiation .....</b>	<b>291</b>
Description .....	291
Rationale .....	291
Coding Instructions .....	291
Examples .....	292
<b>Systemic Therapy Data Items .....</b>	<b>293</b>
<b>Date Systemic Therapy Started .....</b>	<b>294</b>
Description .....	294
Rationale .....	294
Coding Instructions .....	294
Examples .....	294
<b>Chemotherapy .....</b>	<b>295</b>
<b>Date Chemotherapy Started .....</b>	<b>296</b>
Description .....	296
Rationale .....	296
Coding Instructions .....	296
<b>Rx Date–Chemo Flag .....</b>	<b>297</b>
Description .....	297
Rationale .....	297
Coding Instructions .....	297
<b>Chemotherapy .....</b>	<b>298</b>
Description .....	298
Rationale .....	298
Coding Instructions .....	298
Examples .....	300
<b>Chemotherapy at this Facility.....</b>	<b>301</b>
Description .....	301
Rationale .....	301
Coding Instructions .....	301
<b>Hormone Therapy.....</b>	<b>304</b>
<b>Date Hormone Therapy Started .....</b>	<b>305</b>
Description .....	305

Rationale .....	305
Coding Instructions .....	305
<b>Rx Date–Hormone Flag .....</b>	<b>306</b>
Description .....	306
Rationale .....	306
Coding Instructions .....	306
<b>Hormone Therapy (Hormone/Steroid Therapy).....</b>	<b>307</b>
Description .....	307
Rationale .....	307
Coding Instructions .....	307
Examples .....	308
<b>Hormone Therapy at this Facility (Hormone/Steroid Therapy) .....</b>	<b>309</b>
Description .....	309
Rationale .....	309
Coding Instructions .....	309
<b>Immunotherapy.....</b>	<b>311</b>
<b>Date Immunotherapy Started .....</b>	<b>312</b>
Description .....	312
Rationale .....	312
Coding Instructions .....	312
<b>Rx Date–BRM Flag.....</b>	<b>313</b>
Description .....	313
Rationale .....	313
Coding Instructions .....	313
<b>Immunotherapy.....</b>	<b>314</b>
Description .....	314
Rationale .....	314
Coding Instructions .....	314
Examples .....	315
<b>Immunotherapy at this Facility .....</b>	<b>316</b>
Description .....	316
Rationale .....	316
Coding Instructions .....	316
<b>Hematologic Transplant and Endocrine Procedures .....</b>	<b>318</b>

Description .....	318
Rationale .....	318
Coding Instructions .....	318
<b>Systemic/Surgery Sequence .....</b>	<b>320</b>
Description .....	320
Rationale .....	320
Coding Instructions .....	320
Examples .....	321
<b>Other Treatment.....</b>	<b>322</b>
<b>Date Other Treatment Started .....</b>	<b>323</b>
Description .....	323
Rationale .....	323
Coding Instructions .....	323
Examples .....	323
<b>Other Treatment.....</b>	<b>324</b>
Description .....	324
Rationale .....	324
Coding Instructions .....	324
<b>Other Treatment at this Facility .....</b>	<b>326</b>
Description .....	326
Rationale .....	326
Coding Instructions .....	326
<b>Palliative Care (Palliative Procedure) .....</b>	<b>328</b>
Description .....	328
Rationale .....	328
Coding Instructions .....	328
Examples .....	329
<b>Palliative Care at this Facility (Palliative Procedure at this Facility).....</b>	<b>330</b>
Description .....	330
Rationale .....	330
Coding Instructions .....	330
<b>Outcomes .....</b>	<b>331</b>
<b>Date of First Recurrence.....</b>	<b>332</b>
Description .....	332



Rationale .....	332
Coding Instructions .....	332
<b>Type of First Recurrence .....</b>	<b>333</b>
Description .....	333
Rationale .....	333
Coding Instructions .....	333
Examples .....	335
<b>Date of Last Cancer (tumor) Status.....</b>	<b>336</b>
Description .....	336
Rationale .....	336
Coding Instructions .....	336
<b>Cancer Status .....</b>	<b>337</b>
Description .....	337
Rationale .....	337
Coding Instructions .....	337
Examples .....	337
<b>Date of Last Contact or Death .....</b>	<b>338</b>
Description .....	338
Rationale .....	338
Coding Instructions .....	338
<b>Vital Status .....</b>	<b>339</b>
Description .....	339
Rationale .....	339
Coding Instructions .....	339
Examples .....	339
<b>Follow-Up Source.....</b>	<b>340</b>
Description .....	340
Rationale .....	340
Coding Instructions .....	340
<b>Next Follow-Up Source (Next Follow-Up Method).....</b>	<b>341</b>
Description .....	341
Rationale .....	341
Coding Instructions .....	341
<b>Case Administration.....</b>	<b>342</b>

<b>Abstracted By .....</b>	<b>343</b>
Description .....	343
Rationale .....	343
Coding Instructions .....	343
<b>Facility Identification Number (FIN) .....</b>	<b>344</b>
Description .....	344
Rationale .....	344
Coding Instructions .....	344
Examples .....	344
<b>NPI–Reporting Facility.....</b>	<b>345</b>
Description .....	345
Rationale .....	345
Coding Instructions .....	345
Examples .....	345
<b>Archive FIN .....</b>	<b>346</b>
Description .....	346
Rationale .....	346
Coding Instructions .....	346
Examples .....	347
<b>NPI–Archive FIN .....</b>	<b>348</b>
Description .....	348
Rationale .....	348
Coding Instructions .....	348
Examples .....	348
<b>Date Case Completed – CoC .....</b>	<b>349</b>
Description .....	349
Rationale .....	349
Coding Instructions .....	349
.....	<b>351</b>
<b>Override Site/TNM-Stage Group .....</b>	<b>351</b>
Description .....	351
Rationale .....	351
EDITS Use .....	351
Coding Instructions .....	351

.....	352
<b>Override Site/Type.....</b>	<b>352</b>
Description .....	352
Rationale .....	352
EDITS Use .....	352
Coding Instructions .....	352
<b>TNM Edition Number .....</b>	<b>353</b>
Description .....	353
Rationale .....	353
Coding Instructions .....	353
<b>APPENDIX A: Site-Specific Surgery Codes .....</b>	<b>354</b>
ORAL CAVITY .....	355
PAROTID AND OTHER UNSPECIFIED GLANDS .....	357
PHARYNX.....	359
ESOPHAGUS .....	361
STOMACH.....	362
COLON .....	364
RECTOSIGMOID.....	366
RECTUM .....	368
ANUS .....	370
LIVER AND INTRAHEPATIC BILE DUCTS .....	371
PANCREAS .....	373
LARYNX.....	374
LUNG .....	376
HEMATOPOIETIC/RETICULOENDOTHELIAL/ .....	378
IMMUNOPROLIFERATIVE/MYELOPROLIFERATIVE DISEASE.....	378
BONES, JOINTS, AND ARTICULAR CARTILAGE .....	379
PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM .....	379
CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES .....	379
SPLEEN .....	380
SKIN .....	381
BREAST .....	383
CERVIX UTERI .....	386
CORPUS UTERI.....	388

---

OVARY .....	390
PROSTATE.....	392
TESTIS .....	394
KIDNEY, RENAL PELVIS, AND URETER .....	395
BLADDER .....	397
BRAIN .....	399
THYROID GLAND .....	400
LYMPH NODES.....	401
ALL OTHER SITES .....	402
UNKNOWN AND ILL-DEFINED PRIMARY SITES.....	403
<b>APPENDIX B: ICD-O-3 Eligibility Reporting Table.....</b>	<b>404</b>
<b>APPENDIX C: Country and State Codes .....</b>	<b>406</b>
General.....	417
Obsolete.....	418

## Table of Contents

(For NHSCR-required data items NOT included in *STORE 2022*)

<b>Foreword from NHSCR</b> .....	28a
<b>NHSCR Preface 2022</b> .....	28b
Introduction.....	28b
NHSCR Data Collection Manual and STORE.....	28b
Reportable Cases.....	28c
Casefinding.....	28c
Data Collection.....	28c
Data Transmissions.....	28d
2022 Changes.....	28d

### SECTION ONE: Case Eligibility and Overview of Coding Principles

#### Case Eligibility

Determining Multiple Primaries.....	42a
-------------------------------------	-----

### SECTION TWO: Coding Instructions

#### Patient Identification

Medical Record Number.....	72a
Social Security Number.....	72b
Last Name.....	72c
First Name.....	72d
Middle Name (Middle Initial).....	72e
Name--Birth Surname.....	72f
Name--Alias.....	72g
Name--Prefix.....	72g
Name--Suffix.....	72g
Patient Address (Number and Street) at Diagnosis.....	72h
Patient Address at Diagnosis—Supplemental.....	72i
Race 2, 3, 4, 5.....	85a
Marital Status at DX.....	87a
Height at DX.....	90a
Weight at DX.....	90b
Tobacco Use Smoking Status.....	90c

**Patient Identification, cont.**

Text--Usual Occupation.....	90d
Text--Usual Industry.....	90e
NPI--Managing Physician.....	112a
NPI--Following Physician.....	112b

**Cancer Identification**

Type of Reporting Source.....	116a
Casefinding Source.....	116b
Text--Place of Diagnosis .....	125a
Text--Primary Site Title.....	130a
Text--Histology Title.....	135a
Text--DX Proc--PE.....	138a
Text--DX Proc--Lab Tests.....	138c
Text--DX Proc--Path.....	138e
Text--Remarks.....	138g

**Stage of Disease at Diagnosis**

Date of Sentinel Lymph Node Biopsy Flag.....	153a
Date Regional Lymph Node Dissection Flag.....	158a
Tumor Size Clinical.....	165a
Tumor Size Pathologic.....	165b
Summary Stage 2018.....	182a
Text--Staging.....	208a
Text--DX Proc--X-ray/Scan.....	210a
Text--DX Proc--Op.....	210c
Text--DX Proc--Scopes.....	210e

**First Course of Treatment**

Date 1 <sup>st</sup> Crs Rx CoC Flag.....	212a
Rx Date Mst Defn Srg Flag.....	218a
RX Text--Surgery.....	258a
Rx Date Radiation Flag.....	260a
RX Text Radiation (Beam).....	292a
RX Text Radiation Other.....	292c

**First Course of Treatment, cont.**

Rx Date Systemic Flag.....	294a
RX Text--Chemo.....	303a
RX Text--Hormone.....	310a
RX Text--BRM.....	317a
Rx Date Other Flag.....	323a
RX Text--Other.....	327a
Neoadjuvant Therapy.....	327c
Neoadjuvant Therapy--Clinical Response.....	327d
Neoadjuvant Therapy--Treatment Effect.....	327e

**Outcomes**

Recurrence Date--1 <sup>st</sup> Flag.....	332a
Date of Last Cancer (Tumor) Status Flag.....	336a
Date of Last Contact Flag.....	338a
Cause of Death.....	339a
Place of Death--State.....	339b
Place of Death--Country.....	339c

**Case Administration**

Override Age/Site/Morph.....	351a
Override Surg/DXConf.....	351b
Override Histology.....	352a
Override Leuk, Lymphoma.....	352d
Override Site/Behavior.....	352e
Override Site/Lat/Morph.....	352g

**APPENDIX D:** New Hampshire Town/County & Zip Codes**APPENDIX E:** NHSCR Supplement to STORE**APPENDIX F:** New Hampshire Rules & Regulations**APPENDIX G:** NHSCR Non-Analytic Tracking Form**APPENDIX H:** Casefinding List**APPENDIX I:** Table of Required Data Items

## Foreword

### FROM “FORDS” TO “STORE”

The Facility Oncology Registry Data Standards, better known as FORDS, was developed in 2003 by the Commission on Cancer (CoC) of the American College of Surgeons (ACS) for its CoC accredited programs. Although updated periodically to ensure that appropriate codes were being assigned by registrars in reporting required tumors, there had not been any major overhaul of the manual since its inception. Prior updates of FORDS, while benefiting from the expertise of cancer registrars and others involved in the cancer surveillance community, had never included the recommendations of cancer clinicians working in the major oncologic specialties.

In 2014, Dr. David P. Winchester, Director of Cancer Programs at the ACS, asked me to lead a concerted effort to update and ensure that FORDS would have greater relevance to current oncologic practice and data collection. A multidisciplinary approach was begun to include leading registrars representing CoC hospitals, state registries and the SEER program of the National Cancer Institute. This effort was coordinated by the outstanding professional staff at the National Cancer Database (NCDB) of the CoC. In addition, many clinicians representing surgical oncology, medical oncology and radiation oncology were invited to join in this effort to assure that diagnostic and treatment codes were updated and reflected current practice. This coding structure is vital to hospital registry data that ultimately are entered into the NCDB and also determines the CoC quality measures which are currently being used in the Rapid Quality Reporting System (RQRS), Cancer Quality Improvement Program (CQIP) and the CP<sup>3</sup>R Program which tracks quality within all of the CoC-accredited institutions.

The culmination of these efforts over the last four years has resulted in an entirely new and updated coding compendium: STORE--Standards for Oncology Registry Entry. This new name was selected to reflect our entirely new approach to this revision that includes both registry and surveillance leaders and clinicians who care for the cancer patient.

To all these dedicated individuals and our dedicated NCDB staff – especially Kathleen Thoburn whose hard work and commitment has brought the STORE manual to fruition – I offer my sincere gratitude for a job well done.

Frederick L. Greene, MD FACS

August 2018



## Foreword

### NHSCR Data Collection Manual

In an ongoing effort to facilitate the data collection of cancer cases by reporting facilities, the New Hampshire State Cancer Registry (NHSCR) has developed the *NHSCR Data Collection Manual*. With permission from the American College of Surgeons and the Commission on Cancer, the NHSCR used the *Standards for Oncology Registry Entry (STORE 2022)*<sup>1</sup> manual as the basis for the *NHSCR Data Collection Manual*. Per copyright law, the context of the *STORE 2022* information itself is not altered in any way. Instead, sections of *STORE 2022* are highlighted and notations added that reference NHSCR-specific requirements. NHSCR has also been granted permission by SEER to reference sections from the *SEER Program Coding and Staging Manual 2022*<sup>2</sup>. Definitions for required data items that are not included in *STORE 2022* were taken from the *NAACCR Data Standards and Data Dictionary*<sup>3</sup>.

**NHSCR thanks the CoC, SEER, and NAACCR for allowing the use of the STORE<sup>1</sup>, SEER<sup>2</sup>, and NAACCR<sup>3</sup> coding manuals as a basis for the NHSCR Data Collection Manual.**

NHSCR provides additional definitions and coding instructions for data items not included in *STORE 2022*. These are listed in the [NHSCR Table of Contents](#). NHSCR differences with items in *STORE 2022* are noted with NH and hyperlinked throughout *STORE 2022* for easy reference to the corresponding notations located in [Appendix E: NHSCR Supplement to STORE 2022](#).

This data collection manual is formatted for electronic use; it is not intended for printing in paper form. NHSCR is using the most current version of *STORE 2022* available online and will update it as changes to *STORE 2022* are made available.

### References

1. *Standards for Oncology Registry Entry (STORE 2022)*. Chicago: American College of Surgeons Commission on Cancer; 2021. Available at <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-call-for-data/cocmanuals/>. (Accessed June 1, 2022.)
2. Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). SEER Program Coding and Staging Manual 2022. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Available at: <https://seer.cancer.gov/tools/codingmanuals/index.html> (Accessed June 1, 2022.)
3. Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23<sup>rd</sup> ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022. Available at: <https://www.naacr.org/data-standards-data-dictionary/>. (Accessed June 1, 2022.)

### Acknowledgement

The NHSCR is supported by the Centers for Disease Control (CDC) and Prevention's National Program of Cancer Registries (NPCR) through cooperative agreement NU58DP006298 awarded to the New Hampshire Department of Health and Human Services, Division of Public Health Services, Bureau of Disease Control and Health Statistics, Health Statistics and Data Management Section. The contents of this manual are solely the responsibility of the NHSCR and do not necessarily represent the official views of the Centers for Disease Control and Prevention. Strict policies and procedures have been developed to maintain confidentiality in disclosure of data.

## Preface 2022

### NHSCR Data Collection Manual

#### Introduction

Cancer became a reportable disease in New Hampshire in 1985, and since 1986, the New Hampshire State Cancer Registry (NHSCR) has been charged to collect incidence data on all cancer cases seen and/or treated in New Hampshire. As required by NH Administrative Rules ([Appendix F](#)), the NHSCR currently collects reports from hospital registrars operating in all the large hospitals in NH. Hospitals with relatively smaller caseloads of cancer (fewer than 105 cases per year) generally do not have their own cancer registry and NHSCR staff helps these hospitals with their abstracting duties. NHSCR also receives reports of cases from physician practices, free standing radiation oncology centers, pathology laboratories, and other sources. In addition, the NHSCR receives reports for cases diagnosed and treated in other states who are NH residents at diagnosis, based on agreements of information exchange with other states.

The NHSCR has an innovative, two-phase reporting system. An initial *rapid* report that provides the most elemental aspects of case identification is reported within 45 days of diagnosis. A *definitive* case report is reported 180 days from the date of diagnosis and includes more specific information, such as treatment and staging information. The timeliness of the receipt of information is essential to the ability of the NHSCR to provide meaningful data.

#### NHSCR Data Collection Manual and STORE 2022

Continued efforts by standard-setting organizations, facility-based registries and population-based central registries now follow nearly identical standards for determining reportable tumors that are to be included in the registry; however, some differences in reportability remain.<sup>1</sup> The Commission on Cancer (CoC) stipulates the tumors that must be included in accredited facility registries to meet their standards.<sup>2,3</sup> Most population-based registries, such as the NHSCR, follow the standards set by NPCR<sup>4</sup> and enforce these standards on the facilities that report data to them under state cancer reporting laws ([Appendix F](#)).

To ensure the integrity of cancer data that are collected and submitted by reporting facilities, the NHSCR has developed the *NHSCR Data Collection Manual*. This manual is a combination of the *STandards for Oncology Registry Entry (STORE 2022)* with additional material pertaining to NHSCR-specific requirements and clarifications. NHSCR has been granted permission by the American College of Surgeons and the CoC to use the *STORE 2022* manual as the basis for the *NHSCR Data Collection Manual*. Per copyright law, the context of *STORE 2022* information itself is not altered in any way. Instead, sections of *STORE 2022* are highlighted and hyperlinked notations are added that further define NHSCR-specific requirements. This manual is effective for cases diagnosed **January 1, 2022 and forward**.

NHSCR specific notations can be found in [Appendix E: NHSCR Supplement to STORE 2022](#). The main differences between NHSCR requirements and *STORE 2022* are as follows:

- All cases seen with evidence of cancer or for cancer-directed treatment since the NHSCR reference date of June 1986 are reportable to the NHSCR.
- Non-analytic cases ARE reportable IF the case has not been reported by the diagnosing or treating facility (see [Appendix G: NHSCR Non-Analytic Tracking Form](#)). For example, patients receiving transient care, with active cancer admitted for medical conditions other than cancer, and with a history of cancer that are now undergoing cancer-directed treatment **ARE** reportable. NHSCR does not require the reporting of historical cases when they do not have active disease. Place of diagnosis, residence, and class of case are **NOT** determining factors for reportability.

- Intraepithelial neoplasia, grade III, are reportable, EXCEPT carcinoma in situ of cervix (CIS, CIN III) and of the prostate (PIN III).
- Reportable-by-agreement cases that fall outside the NHSCR's reportable list should not be transmitted to the NHSCR. Only count NHSCR reportable cancers when assigning sequence numbers.
- Effective with cases diagnosed January 1, 2010, the recording of Comorbidities and Complications or Secondary Diagnosis is required by NHSCR.
- NHSCR requires directly coded AJCC and SEER Summary Stage on all cases diagnosed prior to 2004 and 2015 forward, regardless of Class of Case. Collaborative Stage is to be used for cases diagnosed 2004-2015.
- The NHSCR is a population-based incidence registry only. NHSCR does not conduct annual follow-up on cases once initial diagnosis and complete first-course treatment has been reported. If a completed definitive case is revised as a result of additional information becoming available, submit a revised abstract to the NHSCR with a notation indicating the revision. ([See note NH-25 in Appendix E](#))
- Descriptions and coding instructions of additional data items that are not included in *STORE 2022*, but required by NHSCR, are provided throughout [Section Two](#) (e.g., marital status, text fields). These pages are marked and noted to be NH-specific.

## Reportable Cases

[Section One: Case Eligibility](#) and [Appendix F: NH Rules and Regulations](#) of this manual provide detailed criteria of cancers that are reportable by the NHSCR.

## Casefinding

To successfully identify reportable cancers, reporting facilities should have casefinding procedures in place to confirm whether a case is required. While there are many sources for the identification of cancer cases, the principle sources are **pathology reports** (histology, cytology, bone marrow, and autopsy) and **medical disease indices**. [Appendix H: Casefinding Lists](#) provides a list of ICD-10-CM codes used to identify reportable cancers. Note that this casefinding list is **not** the same as a reportable list. Some codes contain conditions that are not reportable; however, these diagnoses may indicate a reportable condition. Casefinding should include both primary and up to four (4) secondary diagnoses. The patient medical record will need to be reviewed to verify whether or not the case is reportable. Facilities are encouraged to keep record of casefinding efforts, especially of non-reportable cases, in case the NHSCR requests these as part of a casefinding audit.

## Data Collection

[Appendix I: NHSCR Table of Required Data Items](#) lists the data items required to be collected; [Section Two](#) provides coding definitions of individual data items. In the case where NHSCR and CoC requirements differ, NHSCR requirements take precedence over the CoC.

NHSCR participated in CDC's Enhancing Cancer Registries for Comparative Effectiveness Research (CER) project. This project aimed to collect more detailed cancer registry data beyond SEER, CoC and NAACCR standards. As part of this project, facilities were required to collect additional variables for cases diagnosed in year 2011. These data items are defined in *Comparative Effectiveness Research Data Dictionary* and *Patient-Centered Outcomes Data Dictionary* available at <https://geiselmed.dartmouth.edu/nhscr/reporting/registrars/>.

## Data Transmissions

Reporting facilities should have an agreement with the NHSCR for the submission of both rapid and definitive cancer reports. [Appendix F: NHSCR Rules and Regulations](#) of this manual specifies the methods of cancer case reporting. Cases must be retransmitted to the NHSCR if a change is made *after* the completed cases have already been transmitted. ([See note NH-25 in Appendix E](#))

Records sent from reporting facilities to central cancer registries must use the NAACCR XML Data Exchange Standard starting in 2021. Central cancer registries are already required to submit their NAACCR Call for Data cases using the XML standard.<sup>5</sup> The [XML website](#) provides links to resources as well as CDC and SEER XML software products. The XML NAACCR ID for each data item can be found in the [NAACCR Data Standards and Data Dictionary Version 2022](#).

## 2022 Changes

Effective with 2022, there are a number of changes to national data standards that affect multiple aspects of cancer reporting. Changes related to cancer coding and staging include updates to the following:

- [SEER Hematopoietic Manual and Database](#)
- [Solid Tumor Rules \(STR\)](#)
- [Grade Manual](#)
- [Site-Specific Data Items \(SSDI\) Manual](#)
- [ICD-O-3.2 Histology Code and Behavior Update \(published for 2022\)](#)
- [NAACCR Version 22](#)

[Appendix E: NHSCR Supplement to STORE 2022](#) includes additional major NHSCR-specific changes that are not included in *STORE 2022* [Summary of Changes](#).

## References

1. Thornton ML, (ed). Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022. Available at: <https://www.naaccr.org/data-standards-data-dictionary/>. (Accessed June 1, 2022.)
2. Optimal Resources for Cancer Care (2020 Standards). Effective January 2020; updated April 2022. American College of Surgeons Commission on Cancer. Available at: <https://www.facs.org/quality-programs/cancer-programs/commission-on-cancer/standards-and-resources/2020/>. (Accessed June 1, 2022.)
3. *Standards for Oncology Registry Entry (STORE 2022)*. Chicago: American College of Surgeons Commission on Cancer; 2021. Available at <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-call-for-data/cocmanuals/>. (Accessed June 1, 2022.)
4. Centers for Disease Control and Prevention. Program Announcement CDC-RFA-DP22-2202. Program 3: National Program of Cancer Registries. 2022–2027 NPCR Program Standards. Available at: <https://www.cdc.gov/cancer/dcpc/about/foa-dp22-2202/npcr/>. (Accessed June 1, 2022.)
5. *2022 Implementation Guidelines and Recommendations*. (For NAACCR Data Standards and Data Dictionary, Version 22, effective with cases diagnosed on or after January 1, 2022). Available at: <https://www.naaccr.org/implementation-guidelines/>. (Accessed June 1, 2022.)

## STORE 2022 Summary of Changes

### New Data Items **NH-1, NH-2**

#### Macroscopic Evaluation of the Mesorectum [3950]

Macroscopic Eval of Mesorectum instructions will include coding data items from the Total Mesorectal Excision procedure's pathology report.

Specimen will be evaluated for completeness of the Total Mesorectal Excision (TME) or completeness of the Mesorectal Envelope.

Four new custom data items will be collected for diagnosis year 2022 only.

#### Rx Hosp—Surg Breast [10104]

#### Rx Summ—Surg Breast [10105]

These two data items record the breast surgical procedure performed at this facility [10104] and at any facility [10105]. The collection of data will be used for updating the surgery codes to support the Synoptic Operative Reporting and to allow for more descriptive Appendix A surgery codes in 2023.

#### Rx Hosp—Recon Breast [10106]

#### Rx Summ—Recon Breast [10107]

Records the immediate reconstruction procedure performed the same day as the surgical procedure at the reporting facility [10106] and at any facility [10107]. Breast reconstruction was previously collected within the breast surgery codes. CoC will collect these data items to support the Synoptic Operative Reports and allow for more descriptive reconstruction codes. This is being collected in anticipation for a 2023 Site Specific Disease Item.

### Deleted Data items

#### NCDB—SARSCoV2—Test [3943]

#### NCDB--SARSCoV2—Pos [3944]

#### NCDB--SARSCoV2--Pos Date [3945]

#### NCDB--COVID19--Tx Impact [3946]

SARSCoV2 data items are not required to be collected on cases with a reportable malignancy with a diagnosis date during calendar year 2022 and beyond. However, SARSCoV2 data items should continue to be collected on all cases with a reportable malignancy with a diagnosis date during the calendar years of 2020 and/or 2021 following STORE v2021 rules and instructions.

### Data Items with Changes **NH-3**

#### Lymphovascular Invasion [1182]

##### Word Changes

AJCC was contacted by CAP requesting a change to the LVI data item. CAP pathologists noted they were getting questions from registrars when coding LVI for thyroid and adrenal cancer. The wording on the CAP protocol is slightly different, and we added the terminology to the coding table. Lymphatic invasion for L instead of lymphatic and small vessel invasion, and angioinvasion for V instead of venous large vessel invasion.

#### Allowable values and format:

Code	Label
0	Lymphovascular Invasion stated as Not Present
1	Lymphovascular Invasion Present/Identified (NOT used for thyroid and adrenal)
2	Lymphatic and small vessel invasion only (L) OR Lymphatic invasion only (thyroid and adrenal only)
3	Venous (large vessel) invasion only (V) OR Angioinvasion (thyroid and adrenal only)
4	BOTH lymphatic and small vessel AND venous (large vessel) invasion OR BOTH lymphatic AND angioinvasion (thyroid and adrenal only)
8	Not Applicable
9	Unknown/Indeterminate/not mentioned in path report

### Code Changes

#### Lymphovascular Invasion [1182]

Instructions were modified to code lymph vascular invasion to codes 0, 2, 3, 4, or 9 for the Schema IDs in the following list:  
 thyroid (schema ID 00730)  
 thyroid medullary (schema ID 00740)  
 adrenal gland (schema ID 00760)

### Word Changes

The following items have been updated in STORE with a word change from patient record to medical record:

Tumor Size Summary [756]  
 Regional Lymph Nodes Positive [820]  
 Regional Lymph Nodes Examined [830]  
 Sentinel Lymph Nodes Examined [834]  
 Sentinel Lymph Nodes Positive [835]

### Code Changes

#### Mets at Diagnosis – Bone [1112], Mets at Diagnosis – Brain [1113], Mets at Diagnosis – Liver [1115], Mets at Diagnosis – Lung [1116] and Mets at Diagnosis – Other [1117]

In STORE 2021 (pages 178, 180, 184, 186 and 188), the coding instructions have been updated, to align with SEER.

- The “C770-C779” codes for any histology in the last row, under coding instruction table have been removed.
- For ICD-O-3 sites C000-C809
  - The following histologies were removed: 9740-9809, 9840-9992
  - The following histologies were added: 9671
- For ICD-O-3 sites C000-C440, C442- C689, C691-C694, C698-C809
  - The following histologies were removed: 9820, 9826, 9831- 9834
 For ICD-O-3 sites C000-C440, C442- C689, C691-C694, C698-C809 was changed to C000-C809 for histologies:

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

### Reportability Change NH-4

The Eligibility section in STORE has been updated to include the new ICD-O codes for new terminology, behavior changes, reportability changes, and specific histology for specific primary.

The table below represents the ICD-O-3 terms that CoC is required to collect (Appendix B).

ICD-O Code	Term	Required and collected by CoC	Remarks
8033/3	Carcinoma with sarcomatoid component	Y	New related term
8085/3	Squamous cell carcinoma, HPV-associated	Y	New term for uterine cervix
8086/3	Squamous cell carcinoma, HPV-independent	Y	New term for uterine cervix
8144/2	Intestinal-type adenoma, high grade (C16.0 – C16.9, C17.0 -C17.9)	Y Reportable for Stomach and Small Intestine only	Term is reportable for stomach and small intestines ONLY beginning 1/1/2022
8213/2	Serrated dysplasia, high grade (C16.0 – C16.9, C17.0 -C17.9)	Y for Stomach and Small Intestine	Term is reportable for stomach and small intestines ONLY beginning 1/1/2022
8243/3	Goblet cell adenocarcinoma	Y	New preferred term
8262/3	Adenoma-like adenocarcinoma	Y	New term
8310/3	Adenocarcinoma, HPV-independent, clear cell type	Y	New term for uterine cervix
8455/2	Intraductal oncocytic papillary neoplasm, NOS	Y	New ICD-O code/term

8455/3	Intraductal oncocytic papillary neoplasm with associated invasive carcinoma	Y	New ICD-O code/term
8480/2	Low-grade appendiceal mucinous neoplasm (LAMN)	Y	New behavior/term
8480/3	Low-grade appendiceal mucinous neoplasm (LAMN)	Y	New behavior/term
8480/2	High grade appendiceal mucinous neoplasm (HAMN)	Y	New behavior/term
8480/3	Appendiceal mucinous neoplasm with extra-appendiceal spread	Y	New behavior/term
8482/3	Adenocarcinoma, HPV-independent, gastric type	Y	New term
8483/3	Adenocarcinoma, HPV-associated	Y	New ICD-O code/term
8484/3	Adenocarcinoma, HPV-independent, NOS	Y	New ICD-O code/term
8503/2	Ductal carcinoma in situ, papillary	Y	New preferred term
8509/3	Tall cell carcinoma with reversed polarity	Y	New preferred term
8859/3	Myxoid pleomorphic liposarcoma	Y	New ICD-O code/term
8912/3	Congenital spindle cell rhabdomyosarcoma with VGLL2/NCOA2/CITED2 rearrangements	Y	New term
8912/3	MYOD1-mutant spindle cell/sclerosing rhabdomyosarcoma	Y	New term
8912/3	Intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements	Y	New term
8976/3	Gastroblastoma (C16.0 – C16.9)	Y	New ICD-O code/term
9110/3	Adenocarcinoma, HPV-independent, mesonephric type	Y	New preferred term
9111/3	Mesonephric-like adenocarcinoma	Y	New ICD-O code/term for ovary and corpus uterus
9120/3	Post radiation angiosarcoma of the breast	Y	New term
9133/3	Epithelioid hemangioendothelioma	Y	New term



	with WWTR1-CAMTA1 fusion		
9133/3	Epithelioid hemangioendothelioma with YAP1-TFE3 fusion	Y	New term
9222/3	Chondrosarcoma, grade 1	Y	Behavior change. Reportable 1/1/2022 forward
9366/3	Round cell sarcoma with EWSR1-non-ETS fusions	Y	New ICD-O code/term
9367/3	CIC-rearranged sarcoma	Y	New ICD-O code/term
9368/3	Sarcoma with BCOR genetic alterations	Y	New ICD-O code/term

Histologies and sites CoC Accredited programs will NOT be required to collect are:

- 8210/2 Adenomatous polyp, high grade dysplasia (**C160 – C166, C168-C169, C170-C173, C178-C179**) **NH-5**
- 8211/2 Tubular adenoma, high grade
- 8261/2 Villous adenoma, high grade
- 8263/2 Tubulovillous adenoma, high grade
- 8483/2 Adenocarcinoma in situ, HPV-associated (**C530-C531, C538-C539**)
- 8484/2 Adenocarcinoma in situ, HPV-independent, NOS (**C530-C531, C538-C539**)
- 8509/1 Uterine tumor resembling ovarian sex cord tumor
- 9200/1 Osteblastoma
- 9261/1 Osteofibrous dysplasia-like adamantinoma.

Ambiguous terms

Words in parenthesis are optional.

#### Updates in STORE APPENDIX A-Site Specific Surgery Codes:

List of excluded histologies in COC lists in site-specific surgery code tables have been removed in STORE v2022.

The following surgery codes from Site-Specific Surgery Codes for Colon (C18.0–C18.9), Rectosigmoid (C19.9), Rectum (C20.9) and Anus (C21.0-C21.8) have been removed as these are obsolete treatments for these primary sites.

11 and 21 Photodynamic therapy (PDT)  
 13 and 23 Cryosurgery  
 14 and 24 Laser Ablation  
 25 Laser Excision

- The word Wedge was removed from Rectum (C20.9) surgical code 30.
- The word Wedge was removed from Rectosigmoid (C19.9) surgical code 30.
- The word Miles Procedure was removed from Rectum (C20.9) surgical code 50.
- The word Miles Procedure was removed from Anus (C21.0-C21.8) surgical code 60.
- The word Total Mesorectal Excision (TME) was removed from Rectum (C20.9) surgical code 30.

#### Code Clarification

#### Scope of Regional Lymph Node Surgery [1292] and Scope of Regional Lymph Node Surgery at this Facility [672]

Coding instructions clarified to code 9 for:

- Lymphoma (excluding CLL/SLL) (schema ID 00790)
- Lymphoma (CLL/SLL) (schema ID 00795)

Phase I-II-III Radiation Primary Treatment Volume [1504, 1514, 1524]

Code 64 Prostate-whole description changed to Prostate with /without seminal vesicles

## 2022 Source References

**2022 SEER Program Manual:** <https://seer.cancer.gov/tools/codingmanuals/>

Questions regarding the SEER Program Coding and Staging Manual 2022 should be directed to Ask a SEER Registrar at: <https://seer.cancer.gov/registrars/contact.html>

**AJCC 8<sup>th</sup> Edition Chapter Updates and Histologies:** <https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx>

Questions regarding AJCC Cancer Staging should be directed to the CAnswer Forum at: <http://cancerbulletin.facs.org/forums/>

**AJCC API:** <https://cancerstaging.org/Pages/Vendors.aspx>

**AJCC Cancer Staging Form Supplement:** <https://cancerstaging.org/references-tools/deskreferences/Pages/Cancer-Staging-Forms.aspx>

**Cancer Surveillance DLL:** AJCC licensees can request the licensed version of the library from Martin Madera, [mmadera@facs.org](mailto:mmadera@facs.org). The version for unlicensed users will be available from the AJCC website, please contact Martin Madera ([mmadera@facs.org](mailto:mmadera@facs.org)) for access.

**CAnswer Forum:** <http://cancerbulletin.facs.org/forums/help>

**Commission on Cancer STORE Manual:** <https://www.facs.org/quality-programs/cancer/ncdb/call-for-data/cocmanuals>

**Data Exchange Standard, XML Specifications for Cancer Registry Records, Version 1.4:** <https://www.naaccr.org/xml-data-exchange-standard/>

**Data Standards and Data Dictionary (Volume II):** <https://www.naaccr.org/data-standards-data-dictionary/>

**EDITS:** <https://www.naaccr.org/standard-data-edits/>

Questions regarding the NAACCR edits metafile should be directed to Jim Hofferkamp at [jhofferkamp@naaccr.org](mailto:jhofferkamp@naaccr.org).

**EOD 2018:** <https://seer.cancer.gov/tools/staging/rsa.html>

Questions regarding EOD 2018 should be directed to Ask a SEER Registrar at: <https://seer.cancer.gov/registrars/contact.html>

**Grade Manual:** <https://www.naaccr.org/SSDI/Grade-Manual.pdf>

Questions regarding the Grade Manual should be directed to the CAnswer Forum at: <http://cancerbulletin.facs.org/forums/>

**Hematopoietic and Lymphoid Neoplasm Database:** <https://seer.cancer.gov/tools/heme/>

Questions regarding the SEER Hematopoietic and Lymphoid Neoplasm Database should be directed to Ask a SEER Registrar at: <https://seer.cancer.gov/registrars/contact.html>

**ICD-O-3.2:** [http://www.iacr.com.fr/index.php?option=com\\_content&view=article&id=149:icd-o-3-2&catid=80:newsflashes&Itemid=545](http://www.iacr.com.fr/index.php?option=com_content&view=article&id=149:icd-o-3-2&catid=80:newsflashes&Itemid=545)

Questions regarding ICD-O-3 Histology changes should be directed to Ask a SEER Registrar at: <https://seer.cancer.gov/registrars/contact.html>

**ICD-O-3 SEER Site/Histology Validation List:** <https://seer.cancer.gov/icd-o-3/>

Questions regarding the SEER Site/Histology Validation List should be directed to Ask a SEER Registrar at:  
<https://seer.cancer.gov/registrars/contact.html>

**NPCR Northcon 210 Registry Plus Utility Program:**

[https://www.cdc.gov/cancer/npcr/tools/registryplus/up\\_download.htm](https://www.cdc.gov/cancer/npcr/tools/registryplus/up_download.htm)

**NPCR Registry Plus Software:** <https://www.cdc.gov/cancer/npcr/tools/registryplus/index.htm>

**Radiation Conversion Specifications:** <https://www.naaccr.org/data-standards-data-dictionary/>

**SEER API:** <https://api.seer.cancer.gov/>

**SEER Registrar Staging Assistant (SEER\*RSA):** <https://seer.cancer.gov/tools/staging/rsa.html>

Questions regarding SEER\*RSA should be directed to Ask a SEER Registrar at:  
<https://seer.cancer.gov/registrars/contact.html>

**SEER\*Rx:** <https://seer.cancer.gov/tools/seerrx/>

Questions regarding SEER\*Rx should be directed to Ask a SEER Registrar at:  
<https://seer.cancer.gov/registrars/contact.html>

**Site-Specific Data Items Manual:** <https://www.naaccr.org/SSDI/SSDI-Manual.pdf>

Questions regarding SSDIs should be directed to the CAnswer Forum at: <http://cancerbulletin.facs.org/forums/>

**Solid Tumor Rules:** <https://seer.cancer.gov/tools/solidtumor/>

Questions regarding the Solid Tumor Rules should be directed to Ask a SEER Registrar at:  
<https://seer.cancer.gov/registrars/contact.html>

**Summary Stage 2018:** <https://seer.cancer.gov/tools/ssm/>

Questions regarding Summary Stage 2018 should be directed to Ask a SEER Registrar at:  
<https://seer.cancer.gov/registrars/contact.html>

## Section One: Case Eligibility and Overview of Coding Principles

## Case Eligibility

NH-6

The American College of Surgeons Commission on Cancer (CoC) requires registries in accredited programs to accession, abstract, and conduct follow-up activities for required tumors diagnosed and/or initially treated at the abstracting facility. The tumors must meet the criteria for analytic cases (*Class of Case 00-22*), and pathologically and clinically diagnosed inpatients and outpatients must be included.

## Tumors Required by the CoC to be Accessioned, Abstracted, Followed and Submitted to the National Cancer Database (NCDB)

NH-7

Malignancies with an ICD-O-3 behavior code of 2 or 3 are required for all sites. NH-8

EXCEPTION 1: Juvenile astrocytoma, listed as 9421/1 in ICD-O-3, *is required* and should be recorded as 9421/3 in the registry.

EXCEPTION 2: Effective in 2015, code 8240/1 for Carcinoid tumor, NOS, of appendix (C18.1) becomes obsolete. Carcinoid tumors of the appendix (C18.1) must be coded to 8240/3, effective with 2015. This is *required* and must be coded with a behavior 3. Prior appendix primaries coded 8240/1 are converted to 8240/3 by the implementation conversions for 2015.

EXCEPTION 3: Malignant primary skin cancers (C44. \_) with histology codes 8000–8110 *are not required* by the CoC. Skin primaries with those histologies diagnosed prior to January 1, 2003, were required to be accessioned and followed if the AJCC stage group at diagnosis was II, III, or IV. Those cases should remain in the registry data and continue to be followed.

EXCEPTION 4: Carcinoma in situ of the cervix (CIS), intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), anus (AIN III), larynx (LIN III), and squamous intraepithelial neoplasia excluding cervix (SIN III) *are not required* by CoC. SIN III is a specific instance of intraepithelial neoplasia, grade III which is listed in ICD-O-3 as /2. NH-9

EXCEPTION 5: Effective diagnosis January 1, 2022 these codes and histologies *are not required* by the CoC: 8210/2 Adenomatous polyp, high grade dysplasia (C160 – C166, C168-C169, C170-C173, C178-C179); 8211/2 Tubular adenoma, high grade; 8261/2 Villous adenoma, high grade; 8263/2 Tubulovillous adenoma, high grade; 8483/2 Adenocarcinoma in situ, HPV-associated (C530-C531, C538-C539); 8484/2 Adenocarcinoma in situ, HPV-independent, NOS C530-C531, C538-C539); 8509/1 Uterine tumor resembling ovarian sex cord tumor; 8976/1, Osteoblastoma; 9261/1 Osteofibrous dysplasia-like adamantinoma ([See Appendix B](#)). NH-5

Nonmalignant primary intracranial and central nervous system tumors diagnosed on or after January 1, 2004, with an ICD-O-3\* behavior code of 0 or 1 are required for the following sites: meninges (C70. \_), brain (C71. \_), spinal cord, cranial nerves, and other parts of central nervous system (C72. \_), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3). NH-10

All gastro-intestinal stromal tumors (GIST) and thymomas with a Behavior Code of 3 are reportable effective January 1, 2021, Gastro-intestinal stromal tumors (GIST) and thymomas that are non-malignant must be abstracted and assigned a Behavior Code of 3 if they are noted to have multiple foci, metastasis or positive lymph nodes.

## Reportable-by-Agreement Cases

Registries may be requested to collect information about tumors that are not required to be abstracted by the CoC for accredited programs. Ordinarily, such requests will come from the facility's cancer committee or the central registry. The CoC does not require that reportable-by-agreement cases be accessioned, abstracted, followed, or submitted, but the requestor may identify the extent of information needed. NH-11

**Examples of Reportable-by-Agreement Cases:**

- The cancer committee requests abstracting and follow-up of Class of Case 30 cases. **NH-12**
- The state central registry requests abstracting and reporting of pathology-only cases.

**Ambiguous Terms at Diagnosis** **NH-13**

As part of the registry casefinding activities, all diagnostic reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included. Words or phrases that appear to be synonyms of these terms do not constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis. Words in parenthesis are optional.

<b>Ambiguous Terms that Constitute a Diagnosis</b> <b>NH-13</b>	
Apparent(ly)	Presumed
Appears	Probable
Comparable with	Suspect(ed)
Compatible with	Suspicious (for)
Consistent with	Tumor* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3) <b>NH-10</b>
Favors	Typical of
Malignant appearing	
Most likely	
Neoplasm* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)	

\*additional terms for nonmalignant primary intracranial and central nervous system tumors only

EXCEPTION: If cytology is identified only with an ambiguous term, do not interpret it as a diagnosis of cancer. **NH-14**

- Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.

**Examples of Diagnostic Terms:**

- The inpatient discharge summary documents a chest x-ray *consistent with carcinoma* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with carcinoma* is indicative of cancer.
- The pathology report states *suspicious for malignancy*. *Suspicious for malignancy* is indicative of cancer.

<b>Ambiguous Terms That Do Not Constitute a Diagnosis without additional information</b> <b>NH-15</b>	
Cannot be ruled out	Questionable
Equivocal	Rule out
Possible	Suggests
Potentially malignant	Worrisome

**Examples of Nondiagnostic Terms:**

- The inpatient discharge summary documents a chest x-ray *consistent with neoplasm* of the right upper lobe. The patient refused further work-up or treatment. *Consistent with neoplasm* is not indicative of cancer. While “consistent with” can indicate involvement, “neoplasm” without specification of malignancy is not diagnostic except for non-malignant primary intracranial and central nervous system tumors.
- Final diagnosis is reported as *possible carcinoma* of the breast. *Possible* is not a diagnostic term for cancer.

Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

**Ambiguous Terminology Lists: References of Last Resort**

This section clarifies the use of Ambiguous Terminology as listed in STORE 2018 for case reportability in Commission on Cancer (CoC)-accredited programs. When abstracting, registrars are to use the [“Ambiguous Terms at Diagnosis”](#) list with respect to case reportability, however, the list needs to be used correctly.

The first and foremost resource for the registrar for questionable cases is the physician who diagnosed and/or staged the tumor. The ideal way to approach abstracting situations when the medical record is not clear is to follow up with the physician. If the physician is not available, the medical record, and any other pertinent reports (e.g., pathology, etc.) should be read closely for the required information. The purpose of the Ambiguous Terminology list is so that in the case where wording in the patient record is ambiguous with respect to reportability or tumor spread and no further information is available from any resource, registrars will make consistent decisions. When there is a clear statement of malignancy or tumor spread (i.e., the registrar can determine malignancy or tumor spread from the resources available), they should not refer to the Ambiguous Terminology lists. Registrars should only rely on these lists when the situation is not clear and the case cannot be discussed with the appropriate physician/pathologist.

The CoC recognizes that not every registrar has access to the physician who diagnosed and/or staged the tumor, as a result, the Ambiguous Terminology list delineated above must be used in CoC-accredited programs as “references of last resort.”



## Class of Case

All accessioned cases are assigned a *Class of Case* [610] based on the nature of involvement of the facility in the care of the patient.

### Analytic Cases

Cases diagnosed and/or administered any of the first course of treatment at the accessioning facility are analytic (*Class of Case* 00-22). A network clinic or outpatient center belonging to the facility is part of the facility. The CoC is aligned with the Joint Commission accreditation status for your hospital/facility. Any services or facility covered under your Joint Commission accreditation would then be covered under your CoC accreditation and you would be responsible for reporting the associated data that is reportable as defined in the STORE.

Analytic cases *Class of Case* 10-22 are included in treatment and survival analysis.

Analytic cases *Class of Case* 00 are not required to be staged or followed, regardless of the year of diagnosis. *Class of Case* 00 is reserved for patients who are originally diagnosed by the reporting facility and receive all of their treatment elsewhere or a decision not to treat is made elsewhere. If the patient receives no treatment, either because the patient refuses recommended treatment or a decision is made not to treat, the *Class of Case* is 14. If there is no information about whether or where the patient was treated, the *Class of Case* is 10. **NH-16**

### Nonanalytic Cases

Nonanalytic cases (*Class of Case* 30-99) are not usually included in routine treatment or survival statistics. The CoC does not require registries in accredited programs to accession, abstract, or follow these cases, but the program or central registry may require them. **NH-17**

### Modifications to Class of Case in 2010

*Class of Case* was redefined for use beginning in 2010. The codes in this manual allow differentiation between analytic and nonanalytic cases and make additional distinctions. For analytic cases, the codes distinguish cases diagnosed in a staff physician's office from those diagnosed initially by the facility and patients fully treated at the facility from those partially treated by the reporting facility. Nonanalytic cases are distinguished by whether the patient received care at the facility or did not personally appear there. Patients who received care from the facility are distinguished by the reasons a case may not be analytic: type of cancer that is not required by CoC to be abstracted, consultation, in-transit care, and care for recurrent or persistent disease. Patients who did not receive care from the reporting facility are distinguished by care given in one or more staff physician offices, care given through an agency whose cancer cases are abstracted by the reporting facility but are not part of it, pathology only cases, and death certificate only cases. Treatment in staff physician offices is now coded "treated elsewhere" because the hospital has no more responsibility over this treatment than it would if the patient were treated in another hospital.

## Date of First Contact

### [Coding instructions for Date of First Contact](#)

The *Date of First Contact* [580] is the date of the facility's first inpatient or outpatient contact with the patient for diagnosis or treatment of the cancer. For analytic cases, the *Date of First Contact* is the date the patient qualifies as an analytic case *Class of Case* 00-22. Usually, the *Date of First Contact* is the date of admission for diagnosis or for treatment. If the patient was admitted for noncancer-related reasons, the *Date of First Contact* is the date the cancer was first suspected during the hospitalization. If the patient's diagnosis or treatment is as an outpatient of the facility, the *Date of First Contact* is the date the patient first appeared at the facility for that purpose.

If the patient was initially diagnosed at the facility and went elsewhere for treatment (*Class of Case* 00), but then returned for treatment that was initially expected to occur elsewhere, the *Class of Case* is updated to 13 or 14 but the *Date of First Contact* is not changed because it still represents the date the patient became analytic. If the *Class of Case* changes from nonanalytic (for example, consult only, *Class of Case* 30) to analytic (for example, part of first course treatment administered at the facility, *Class of Case* 21), the *Date of First Contact* is updated to the date the case became analytic (the date the patient was admitted for treatment).

When a pathology specimen is collected off site and submitted to the facility to be read (and the specimen is positive for cancer), the case is not required by the Commission on Cancer to be abstracted unless the patient receives first course treatment from the facility. **NH-18**

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment; and the *Class of Case* [610] is 11 or 12 if the diagnosing physician is a staff physician at the reporting facility or 20 or 21 for any other physician. A staff physician is one who is employed by the facility, is under contract with it, or has routine admitting privileges there.

When a staff physician performs a biopsy off site, and the specimen is not submitted to the facility to be read, the case is not required to be abstracted unless the patient receives some first course care at the facility. **NH-19**

- If the patient subsequently receives first course treatment at the facility, the case is analytic and must be abstracted and followed. The *Date of First Contact* is the date the patient reported to the facility for the treatment and the *Class of Case* is 11 or 12.

For nonanalytic cases, the *Date of First Contact* is the date the patient's nonanalytic status begins with respect to the cancer. For example, for a patient diagnosed and treated entirely in a staff physician's office (*Class of Case* 40), the date the physician initially diagnosed the cancer is the *Date of First Contact*. For autopsy only cases, the *Date of First Contact* is the date of death.

If the state or regional registry requires pathology-only cases to be abstracted and reported, the *Date of First Contact* is the date the specimen was collected, and the *Class of Case* is 43. If a patient whose tumor was originally abstracted as a *Class of Case* 43 receives first course treatment subsequently as an inpatient or outpatient at the facility, update both *Class of Case* and *Date of First Contact* to reflect the patient's first in-person contact with the facility. **NH-20, NH-21**

## Determining Multiple Primaries<sup>1</sup>

### Solid Tumors

Apply the general instructions and site-specific instructions for determining multiple primaries in the current [Solid Tumor Rules](#).

Apply the site-specific multiple primary rules in the current [Solid Tumor Rules](#).

Site-specific multiple primary rules cover the following

Primary Site	Topography Code
Head & Neck	C000-C148, C300-C329, C410, C411, C442
Colon	C180-C189, C199, C209
Lung	C340-C349
Cutaneous Melanoma	C440-C449 with Histology 8720 – 8780
Breast	C500-C506, C508-C509
Kidney	C649
Urinary Sites	C659, C669, C670-C679, C680-C681, C688-C689
Malignant CNS and Peripheral Nerves	C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
Other Sites	Excludes Head and Neck, Colon, Rectosigmoid, Rectum, Lung, Cutaneous Melanoma, Breast, Kidney, Urinary Sites, Peripheral Nerves, CNS

The General rules do not apply to hematopoietic primaries (lymphoma and leukemia) of any site. The head and neck, colon, rectosigmoid and rectum, breast, kidney, urinary sites, and malignant CNS and peripheral nerves rules exclude lymphoma and leukemia (M9590-M9993) and Kaposi sarcoma (M9140). All other sites rules exclude lymphoma and leukemia (M9590-M9993).

### Hematopoietic and Lymphoid Neoplasms

Updates to the *Hematopoietic and Lymphoid Neoplasm Coding Manual and Database* have been made for 2022 cases. Apply the Multiple Primary Rules in the [Hematopoietic and Lymphoid Neoplasm Coding Manual and Database](#).

### Transplants

Transplanted organs or tissue may originate from

- a. Organs or tissue from the patient's own body (called autograft) or
- b. Another human donor (homograft or allograft)

Accession a new primary in the transplanted organ as you would any new primary, applying the current Solid Tumor Rules. Code the primary site to the location of the transplanted organ, i.e., code the malignancy where it resides/lies.

*Example:* Diagnosis of malignancy in transplanted section of colon serving as esophagus. Code the primary site as esophagus. Document the situation in a text field.

<sup>1</sup>Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

<sup>2</sup>Dickie L., Johnson, CH., Adams, S., Negoita, S. (December 2020). [Solid Tumor Rules](#). National Cancer Institute, Rockville, MD 20850.

## Overview of Coding Principles

### Unique Patient Identifier Codes

[Coding instructions for Accession Number](#)

*Accession Number* [550] and *Sequence Number* [560] uniquely identify the patient and the tumor. Each cancer patient in a registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The accession number *never* changes.

- Accession numbers are never reassigned, even if a patient is removed from the registry.
- Once cases are submitted to RCRS or the NCDB, accession numbers are not to be changed for any reason. Even if there is a clerical error, or if cases are found in an out-of-order fashion when casefinding (i.e., find an old case after abstraction of a newer one), the accession number serves as a permanent identifier for a patient at your facility. NCDB does not accommodate any requests for accession number changes for cases already submitted.
- The sequence number is the sequence of all tumors over the lifetime of a patient and is counted throughout the patient's lifetime. [Coding instructions for Sequence Number](#)
- Only tumors that would have been reportable at the time of diagnosis for CoC or by agreement with a central registry or the program's cancer committee are required to be counted when assigning sequence numbers. A registry may contain a single abstract for a patient with a sequence number of 02, because the first tumor was not cared for by the program or was not otherwise required to be accessioned. Because of differences in requirements, it is possible for two registries with dissimilar eligibility requirements (for example, a facility registry and a state central registry) to assign different sequence numbers to the same tumor, even though the sequence number codes and instructions applied are the same. **NH-22**

### National Provider Identifier

[See also Determining Multiple Primaries](#)

The National Provider Identifier (NPI) is a unique identification number for health care providers that was implemented in 2007 and 2008 by the Centers for Medicare and Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008. Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions.

The NPI data items are:

**NH-23**

*NPI–Archive FIN* [3105]

*NPI–Institution Referred From* [2415]

*NPI–Institution Referred To* [2425]

*NPI–Physician #3* [2495]

*NPI–Physician #4* [2505]

*NPI–Primary Surgeon* [2485]

*NPI–Reporting Facility* [545]

## Coding Dates

Beginning in 2010, the way dates are transmitted between facility registries and central registries or the National Cancer Database (NCDB) was changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format. Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In the traditional form, some dates also permit 88888888 or 00000000 for special meaning. Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date. The following table illustrates the relationship among these items for *Date of Most Definitive Surgical Resection of the Primary Site*, where each lower case 'b' represents a blank space. Flags are not used for software-generated dates.

Description	<b><i>Traditional Date of Most Definitive Surgical Resection of the Primary Site</i></b>	<b><i>Interoperable Date of Most Definitive Surgical Resection of the Primary Site</i></b>	Rx Date Mst Defn Srg Flag
	Date entered in MMDDCCYY sequence; unknown portions represented by 99 or 9999	Date entered in CCYYMMDD sequence, leaving unknown portions blank (spaces) indicated as 'b'; omit the date if the date is completely unknown or not applicable.	
Full date known	MMDDCCYY (example: 02182007)	CCYYMMDD (example: 20070218)	bb
Month and year known	MM99CCYY (example: 02992007)	CCYYMMbb (example: 200702bb)	bb
Year only known	9999CCYY (example: 99992007)	CCYYbbbb (example: 2007bbbb)	bb
Unknown if any surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	10
No surgery performed	00000000 (example: 00000000)	bbbbbbbb (example: bbbbbbbb)	11
Date is unknown, surgery performed	99999999 (example: 99999999)	bbbbbbbb (example: bbbbbbbb)	12

## Cancer Identification

The following instructions apply to *Primary Site* [400], *Laterality* [410], *Histology* [522], *Behavior Code* [523] and *Grade Clinical* [3843], *Grade Pathological* [3844], *Grade Post Therapy (yc)* [1068] and *Grade Post Therapy Path (yp)* [3845].

### Primary Site NH-24 [Coding instructions for Primary Site](#)

The instructions for coding primary site are found in the "Topography" section of the ICD-O-3 "Coding Guidelines for Topography and Morphology" (ICD-O-3 pp. 23–26). The following guidelines should be followed for consistent analysis of primary sites for particular histologies.

### Occult Cervical Lymph Node

Beginning with cases diagnosed 1/1/2018 and later, for a head and neck primary lymph node involvement with no head and neck tumor found or specified by a physician (i.e., Occult Head and Neck Lymph Node), the primary site will be coded:

- C76.0 if the neck node has not been tested or is negative for both HPV and EBV. The AJCC Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck will be used.
- C10.9 if the neck node is p16 positive indicating human papillomavirus (HPV). The AJCC HPV-Mediated (p16+) Oropharyngeal Cancer will be used.
- C11.9 if the neck node is EBER positive, or both EBER and p16 positive, indicating Epstein Barr Virus (EBV). The AJCC Nasopharynx will be used.

Please refer to the SSDI Manual schema discriminators for further information and follow the instructions provided within the SSDI Schema Discriminator to assign the final primary site.

### Cutaneous Carcinoma of the Head and Neck

Beginning with cases diagnosed 1/1/2018 and later, for skin cancers overlapping sites in the head and neck ONLY, assign the primary site code for the site where the bulk of the tumor is or where the epicenter is. These cases will be staged with AJCC Cutaneous Carcinoma of the Head and Neck. Do not use code C44.8 Overlapping lesion of skin. Cases coded to C44.8 will represent skin lesions overlapping between head and neck sites AND/OR skin in other parts of the body. These cases will not be staged with AJCC 8<sup>th</sup> Edition.

### Hematopoietic and Lymphoid Cancers

Beginning with cases diagnosed in 2010, the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual is to be used for coding primary site and histology of hematopoietic and lymphoid tumors (M-9590-9993) and to determine whether multiple conditions represent one or more tumors to be abstracted. *Appendix A* in FORDS 2016 has the former table for use for tumors diagnosed prior to January 1, 2010, for determining unique or same hematopoietic tumors.

### Kaposi Sarcoma

- Code Kaposi sarcoma to the site in which it arises.
- Code to Skin, NOS (C44.9) if Kaposi sarcoma arises simultaneously in the skin and another site or the primary site is not identified.

### Melanoma

- Code to Skin, NOS (C44.9) if a patient is diagnosed with metastatic melanoma and the primary site is not identified.

### Specific Tissues with Ill-Defined Sites

- If any of the following histologies appears only with an ill-defined site description (e.g., “abdominal” or “arm”), code it to the tissue in which such tumors arise rather than the ill-defined region (C76.\_) of the body, which contains multiple tissues. Use the alphabetic index in **ICD-O-3** to assign the most specific site if only a general location is specified in the record.

Histology	Description	Code to This Site
8720–8790	Melanoma	C44._, Skin
8800–8811, 8813–8830, 8840–8921, 9040–9044	Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
8990–8991	Mesenchymoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9120–9170	Blood vessel tumors, lymphatic vessel tumors	C49._, Connective, Subcutaneous and Other Soft Tissues

9580–9582	Granular cell tumor and alveolar soft part sarcoma	C49._, Connective, Subcutaneous and Other Soft Tissues
9240–9252	Mesenchymal chondrosarcoma and giant cell tumors	C40._, C41._ for Bone and Cartilage C49._, Connective, Subcutaneous and Other Soft Tissues
8940–8941	Mixed tumor, salivary gland type	C07._ for Parotid Gland C08._ for Other and Unspecified Major Salivary Glands

**Laterality****[Coding instructions for Laterality](#)**

*Laterality* [410] must be recorded for the following paired organs as 1-5 or 9. Organs that are not paired, unless they are recorded “right” or “left” laterality, are coded 0. When the primary site is unknown (C80.9), code 0. Midline origins are coded 5. “Midline” in this context refers to the point where the “right” and “left” sides of paired organs come into direct contact and a tumor forms at that point. Most paired sites cannot develop midline tumors. For example, skin of the trunk can have a midline tumor, but the breasts cannot.

Paired Organ Sites	
ICD-O-3	Site
C07.9	Parotid gland
C08.0	Submandibular gland
C08.1	Sublingual gland
C09.0	Tonsillar fossa
C09.1	Tonsillar pillar
C09.8	Overlapping lesion of tonsil
C09.9	Tonsil, NOS
C30.0	Nasal cavity (excluding nasal cartilage and nasal septum)
C30.1	Middle ear
C31.0	Maxillary sinus
C31.2	Frontal sinus
C34.0	Main bronchus (excluding carina)
C34.1–C34.9	Lung
C38.4	Pleura
C40.0	Long bones of upper limb and scapula
C40.1	Short bones of upper limb
C40.2	Long bones of lower limb
C40.3	Short bones of lower limb
C41.3	Rib and clavicle (excluding sternum)
C41.4	Pelvic bones (excluding sacrum, coccyx, and symphysis pubis)
C44.1	Skin of eyelid
C44.2	Skin of external ear



Paired Organ Sites	
ICD-O-3	Site
C44.3	Skin of other and unspecified parts of face
C44.4	Skin of Scalp and Neck
C44.5	Skin of trunk
C44.6	Skin of upper limb and shoulder
C44.7	Skin of lower limb and hip
C47.1	Peripheral nerves and autonomic nervous system of upper limb and shoulder
C47.2	Peripheral nerves and autonomic nervous system of lower limb and hip
C49.1	Connective, subcutaneous, and other soft tissues of upper limb and shoulder
C49.2	Connective, subcutaneous, and other soft tissues of lower limb and hip
C50.0–C50.9	Breast
C56.9	Ovary
C57.0	Fallopian tube
C62.0–C62.9	Testis
C63.0	Epididymis
C63.1	Spermatic cord
C64.9	Kidney, NOS
C65.9	Renal pelvis
C66.9	Ureter
C69.0–C69.9	Eye and lacrimal gland
C70.0	Cerebral meninges, NOS (excluding diagnoses prior to 2004)
C71.0	Cerebrum (excluding diagnoses prior to 2004)
C71.1	Frontal lobe (excluding diagnoses prior to 2004)
C71.2	Temporal lobe (excluding diagnoses prior to 2004)
C71.3	Parietal lobe (excluding diagnoses prior to 2004)
C71.4	Occipital lobe (excluding diagnoses prior to 2004)
C72.2	Olfactory nerve (excluding diagnoses prior to 2004)
C72.3	Optic nerve (excluding diagnoses prior to 2004)
C72.4	Acoustic nerve (excluding diagnoses prior to 2004)
C72.5	Cranial nerve, NOS (excluding diagnoses prior to 2004)
C74.0–C74.9	Adrenal gland
C75.4	Carotid body

### Revising the Original Diagnosis **NH-25**

Data are gathered from multiple sources using the most recent and complete information available. Over time, the patient's records may contain new information such as tests, scans, and consults. Change the primary site, laterality, histology, grade and stage as the information becomes more complete. If the primary site or histology is changed, it may also be necessary to revise site-specific staging and



treatment codes. There is no time limit for making revisions that give better information about the original diagnosis or stage. However, if staging information is updated, it is important to adhere to the staging timeframe and criteria for the respective staging system applicable at the time of the original diagnosis. Most cases that require revision are unknown primaries.

### Example 1

The institution clinically diagnoses a patient with carcinomatosis. The registry enters the case as an unknown primary (C80.9), carcinoma, NOS (8010/3), stage of disease unknown. Nine months later, a paracentesis shows serous cystadenocarcinoma. The physician says that the patient has an ovarian primary. Change the primary site to ovary (C56.9), histology to serous cystadenocarcinoma (8441/3), and diagnostic confirmation to positive cytologic study, no positive histology (code 2). If enough information is available that meets the AJCC time frame requirements for staging, change the stage from not applicable (88) to the appropriate staging classification, TNM categories, and stage group, or to unknown. If first course surgery was performed, the surgery codes should be reviewed. For cases diagnosed 2004-2015, update the Collaborative Stage input items and rerun the derivation program.

### Example 2

A physician decides that a previously clinically diagnosed malignancy is a benign lesion. The patient is referred from a nursing home to the facility. The chest x-ray shows a cavitory lesion in the right lung. The family requests that the patient undergo no additional workup or treatment. Discharge diagnosis is “probable carcinoma of right lung.” The registry abstracts a lung primary (C34.9). Two years later a chest x-ray shows an unchanged lesion. The physician documents “lung cancer ruled out.” Delete the case from the database. Adjust the sequence number(s) of any other primaries the patient may have. If the deleted case is the patient’s only primary, do not reuse the accession number.

## Patient Address and Residency Rules

The patient’s address at diagnosis is the patient’s place of residence at the time of original diagnosis. It does not change if the patient moves. If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

The current address initially is the patient’s residence at the time the patient was first seen at the accessioning facility for this primary. The current address is updated if the patient moves. If the patient has more than one primary tumor, the current address should be the same for each primary. **NH-26**

Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau whenever possible. The registry can resolve residency questions by using the Census Bureau’s definition, “the place where he or she lives and sleeps most of the time or the place the person considers to be his or her usual home.” State Vital Statistics rules may differ from Census rules. Do not record residence from the death certificate. Review each case carefully. **NH-27**

### Rules for Persons with Ambiguous Residences **NH-28**

*Persons with More than One Residence* (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.

*Persons with No Usual Residence* (transients, homeless): Use the address of the place the patient was staying when the cancer was diagnosed. This location may be a shelter or the diagnosing facility.

*Persons Away at School*: College students are residents of the school area. Boarding school students below the college level are residents of their parents' homes.

*Persons in Institutions*: The Census Bureau states, "Persons under formally authorized, supervised care or custody" are residents of the institution. This classification includes the following:

- Incarcerated persons
- Persons in nursing, convalescent, and rest homes
- Persons in homes, schools, hospitals, or wards for the physically disabled, mentally retarded, or mentally ill.
- Long-term residents of other hospitals, such as Veterans Affairs (VA) hospitals.

*Persons in the Armed Forces and on Maritime Ships*: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community's address. The Census Bureau has detailed residency rules for Navy personnel, Coast Guard, and maritime ships. Refer to Census Bureau publications for the detailed rules.

#### [Coding instructions for State at Diagnosis](#)

#### **Coding Country and State**

Beginning in 2013, "country" fields accompany "state" fields in addresses. The following state and country address data items are found in FORDS/STORE:

*State at Diagnosis (not changed)*

*Addr at Diagnosis--Country (associated with State at Diagnosis)*

*State—Current (not changed)*

*Address Current – Country (associated with State—Current)*

*Place of Birth (discontinued, replaced by Birthplace—State and Birthplace—Country)*

*Birthplace—State (coded similarly to the other two "state" fields) Birthplace—*

*Country (associated with Birthplace—State)*

[Appendix C](#) has a list of all country codes and corresponding state codes. State codes for all U.S. states and possessions and all Canadian provinces are included in [Appendix C](#). State codes for the United States and its possessions are those used by the United States Postal Service. Canadian province or territory codes are from Canada Post sources. Country codes are based on the International Standards Organization (ISO) 3166-1 Country Three Character Codes. State and country codes also include some custom codes, which are included in [Appendix C](#).

The list in [Appendix C](#) is divided into three parts.

- The first part is the preferred codes to use when sufficient detail is known to identify the U.S. state, Canadian province, or other country to assign precise codes.
- The second part consists of codes for more general regions for use when a precise code cannot be assigned (for example, "Near East"). If there is no indication at all of location in the patient record, the country is coded ZZU and the state will be ZZ.

- The third section is a list of obsolete codes that may have been assigned when the registry data were upgraded from former codes. This information is provided to assist registries in interpreting their historic data, but the obsolete codes must not be assigned for current abstracting.

## In Utero Diagnosis and Treatment **NH-29**

Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born. The exact date may be used for cases diagnosed prior to 2009.

## Comorbidities and Complications/Secondary Diagnoses

The CoC requires that the registry record include up to 10 comorbid conditions, factors influencing the health status of the patient, and treatment complications, to be copied from the patient record. All are secondary diagnoses. Prior to 2018, the information was recorded in the International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9-CM or ICD-10-CM) code form, typically on the patient's discharge abstract or face sheet of the medical/billing record. Most hospitals in the United States were expected to implement use of ICD-10-CM in 2015. Separate data item series were used to record the two series. ICD-10-CM codes can have up to 7 characters, whereas ICD-9-CM codes only have 5 characters or fewer. Both the specific codes and the rules for recording them differ. The underlying meanings of the codes are similar. That is, the concepts originally described as "comorbidities and complications" are also known as "secondary diagnoses"; in this instance, the separate names are given to distinguish the separate registry data items. **NH-30**

### **Beginning with cases diagnosed in 2018, the following data items are no longer required:**

*The items describing patient comorbid conditions and complications ICD-9-CM codes are:*

*Comorbidities and Complications #1 [3110]*

*Comorbidities and Complications #2 [3120]*

*Comorbidities and Complications #3 [3130]*

*Comorbidities and Complications #4 [3140]*

*Comorbidities and Complications #5 [3150]*

*Comorbidities and Complications #6 [3160]*

*Comorbidities and Complications #7 [3161]*

*Comorbidities and Complications #8 [3162]*

*Comorbidities and Complications #9 [3163]*

*Comorbidities and Complications #10 [3164]*

[Coding instructions for Comorbidities and Complications](#)

### **Beginning with cases diagnosed in 2018, only the following data items are required:**

*The items describing patient comorbid secondary diagnoses ICD-10-CM codes are:*

*Secondary Diagnosis #1 [3780]*

*Secondary Diagnosis #2 [3782]*

*Secondary Diagnosis #3 [3784]*

*Secondary Diagnosis #4 [3786]*

*Secondary Diagnosis #5 [3788]*

*Secondary Diagnosis #6 [3790]*

*Secondary Diagnosis #7 [3792]*

*Secondary Diagnosis #8 [3794]*

[Coding instructions for Secondary Diagnosis](#)

*Secondary Diagnosis #9 [3796]*

*Secondary Diagnosis #10 [3798]*

Three general categories of information are collected: comorbidities, complications, and factors influencing the health status of patients.

Comorbidities are preexisting medical conditions or conditions that were present at the time the patient was diagnosed with this cancer (for example, chronic conditions such as COPD, diabetes, and hypertension).

Complications are conditions that occur during the hospital stay, while the patient is being treated for the cancer (for example, postoperative urinary tract infection or pneumonia). Complications may also occur following the completion of therapy and be a cause for readmission to the hospital. Complications are identified by codes which classify environmental events, circumstances, and conditions as the cause of injury, poisoning, and other adverse effects. Only complication codes that describe adverse effects occurring during medical care are collected in this data item. They include misadventures to patients during surgical and medical care, and drugs and medicinal and biologic substances causing adverse effects in therapeutic use.

Factors influencing the health status of patients are circumstances or problems that are not themselves a current illness or injury (for example, women receiving postmenopausal hormone replacement therapy, or a history of malignant neoplasm). Only specific codes which describe health characteristics are collected in this data item. They include prophylactic measures, personal health history, pregnancy, contraception, artificial opening and other postsurgical states, and prophylactic organ removal.

## Stage of Disease at Initial Diagnosis **NH-31**

### AJCC Prognostic Staging

AJCC Prognostic Stage is determined at key time points in a patient's care based on criteria including the clinical examination, imaging, operative procedures, and pathologic assessment of the anatomic extent of disease – plus additional prognostic factors as required – and is used to make appropriate treatment decisions, determine prognosis, and measure end results. Use the rules in the current *AJCC Cancer Staging Manual* to assign AJCC T, N, M, required prognostic factor(s), and Stage Group values. The following general rules apply to AJCC staging of all sites.

- Clinical staging includes any information obtained about the extent of cancer before initiation of definitive treatment (surgery, systemic or radiation therapy, active surveillance, or palliative care) or within four months after the date of diagnosis, whichever is shorter, as long as the cancer has not clearly progressed during that time frame. This stage classification is designated as cTNM.
- Pathological staging includes any information obtained about the extent of cancer through completion of definitive surgery as part of first course treatment or identified within 4 months after the date of diagnosis, whichever is longer, as long as there is no systemic or radiation therapy initiated or the cancer has not clearly progressed during that time frame. This stage classification is designated as pTNM.
- Post therapy clinical staging (post-neoadjuvant therapy staging) includes any information obtained about the extent of cancer after completion of neoadjuvant therapy and before the planned surgery, and the time frame should be such that the post neoadjuvant therapy staging occurs within a time frame that accommodates disease specific circumstances. This stage classification is designated as ycTNM. Registrars are only required to complete yc staging when the planned surgery following neoadjuvant therapy has been cancelled.
- Post therapy pathological staging (post-neoadjuvant therapy staging) includes any information obtained about the extent of cancer after completion of neoadjuvant therapy followed by surgery,

and the time frame should be such that the post neoadjuvant surgery and staging occur within a time frame that accommodates disease specific circumstances. This stage classification is designated as ypTNM.

- If a patient has multiple primaries, stage each primary independently.
- If the stage group cannot be determined from the recorded categories, then record it as unknown.
- When a patient with multiple primaries develops metastases, a biopsy may distinguish the source of distant disease. Stage both primaries as having metastatic disease if the physician is unable to conclude which primary has metastasized. If, at a later time, the physician identifies which primary has metastasized, update the stage(s) as appropriate.
- If pediatric staging is used and AJCC staging is not applied, code 88 for clinical and pathological T, N, and M as well as stage group. If either clinical, pathological or post therapy staging was applied for a pediatric tumor, enter the appropriate codes and do not code 88.
- If a site/histology combination is not defined in the AJCC Manual code 88 for clinical, pathological and post therapy T, N, and M as well as stage group.
- For in situ tumors that are considered as “impossible diagnoses” in the AJCC manual code 88 for clinical and pathological T, N, and M as well as stage group.
- For additional information on AJCC’s general staging rules, download [Chapter 1: Principles of Cancer Staging](#) from [www.cancerstaging.org](http://www.cancerstaging.org).

### First Course of Treatment

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. “Active surveillance” is a form of planned treatment for some patients; its use is coded in the *RX Summ–Treatment Status* [1285]. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, the physician recommends no treatment be given or the physician recommends palliative care for pain management only. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities. Maintenance treatment given as part of the first course of planned care (for example, for leukemia) is first course treatment, and cases receiving that treatment are analytic.

### Treatment Plan

A treatment plan describes the type(s) of therapies intended to modify, control, remove, or destroy proliferating cancer cells. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records.

- All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient and before disease progression.
- A discharge plan must be a part of the patient's record in The Joint Commission-accredited hospital's EHR and may contain part or all of the treatment plan.
- An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle: "initial treatment must begin within four months of the date of initial diagnosis."

[Coding instructions for \*Date of First Course of Treatment\*](#)

### Time Periods for First Course of Treatment

If first course treatment was provided, the *Date of First Course of Treatment* [1270] is the earliest of *Date of First Surgical Procedure* [1200], *Date Radiation Started* [1210], *Date Systemic Therapy Started* [3230], or *Date Other Treatment Started* [1250].

- If no treatment is given, record the date of the decision not to treat, the date of patient refusal, or the date the patient expired if the patient died before treatment could be given.
- If active surveillance ("watchful waiting") was selected, record the date of that decision.
- Additional data items further define the parameters for specific treatments and treatment modalities, as described in the following sections.

Data item, *RX Summ—Treatment Status* [1285], implemented in 2010, summarizes whether the patient received any first course treatment, no treatment, or is being managed by active surveillance.

### All Malignancies except Leukemias

The first course of treatment includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Any therapy administered after the discontinuation of first course treatment is subsequent treatment.

### Leukemias **NH-32**

The first course of treatment includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

## Surgery

First course surgery items describe the most definitive type of surgical treatment the patient received from any facility, when it was performed, and its efficacy. When no surgical treatment is given, the reason is recorded. Major aspects of surgical care provided by the individual facility are also recorded so that hospital cancer programs can evaluate local patient care.

Individual item descriptions in [Section Two: Instructions for Coding](#) of this manual should be consulted for specific coding instructions. The paragraphs below describe how the surgery items fit together.

*The following summary items apply to all surgical procedures performed at this facility and at other facilities:*

*Surgical Procedure of Primary Site* [1290] **NH-33** [Coding instructions fro Surgery data items](#)  
*Radiation/Surgery Sequence* [1380]  
*Scope of Regional Lymph Node Surgery* [1292]  
*Date of Regional Lymph Node Dissection* [682]  
*Date of Sentinel Lymph Node Biopsy (for breast and melanoma only)* [832]  
*Sentinel Lymph Nodes Examined (for breast and melanoma only)* [834]  
*Sentinel Lymph Nodes Positive (for breast and melanoma only)* [835]  
*Surgical Procedure/Other Site* [1294]  
*Surgical Margins of the Primary Site* [1320]  
*Reason for No Surgery of Primary Site* [1340]  
*Date of First Surgical Procedure* [1200]  
*RX Date–Surgery Flag* [1201]  
*Date of Most Definitive Surgical Resection of the Primary Site* [3170]  
*Date of Surgical Discharge* [3180]  
*Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190]

*The following items apply to surgical procedures performed at this facility:*

*Surgical Procedure of Primary Site at This Facility* [670]  
*RX Hosp–Surg App 2010* [668]  
*Scope of Regional Lymph Node Surgery at This Facility* [672]  
*Surgical Procedure/Other Site at This Facility* [674]

## Relationships among Surgical Items

*Date of First Surgical Procedure* [1200] is the date that the first *Surgical Procedure of Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292], or *Surgical Procedure/Other Site* [1294] is performed as part of first course treatment.

- If surgery was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date of First Surgical Procedure* [1200] is the same as *Date of First Course of Treatment* [1270]. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.



*Surgical Procedure of Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292], and *Surgical Procedure/Other Site* [1294] record three distinct aspects of first course therapeutic surgical procedures that may be performed during one or multiple surgical events. If multiple primaries are treated by a single surgical event, code the appropriate surgical items separately for each primary.

When multiple first course procedures coded under the same item are performed for a primary, the most extensive or definitive is the last performed, and the code represents the cumulative effect of the separate procedures. Do not rely on your registry software to accumulate separate surgeries into the correct code.

- *Surgical Procedure of Primary Site* [1290] is a site-specific item that describes the most invasive extent of local tumor destruction or surgical resection of the primary site and of surrounding tissues or organs that are removed in continuity with the primary site.
- *Scope of Regional Lymph Node Surgery* [1292] describes the removal, biopsy, or aspiration of sentinel nodes and other regional lymph nodes that drain the primary site and may include surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease as well as removal of nodes for treatment of the disease.
- *Surgical Procedure/Other Site* [1294] describes first course resection of distant lymph node(s) and/or regional or distant tissue or organs beyond the *Surgical Procedure of the Primary Site* range.

If surgery of the respective type was performed, the code that best describes the surgical procedure is recorded whether or not any cancer was found in the resected portion. Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.

The code ranges and corresponding descriptions for site-specific *Surgical Procedure of Primary Site* code are grouped according to the general nature of the procedure:

- Codes 10 through 19 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.
- Codes 20 through 80 are site-specific descriptions of resection procedures.
- The special code 98 applies to specific tumors that cannot be clearly defined in terms of primary/nonprimary site. *Surgical Procedure of Primary Site* should be coded 98 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for *Unknown and Ill-Defined Primary Sites* and *Hematopoietic/Reticuloendothelial/Immunoproliferating/Myeloproliferative Disease*. The item *Surgical Procedure/Other Site* is used to indicate whether surgery was performed for these tumors.

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more extensive forms of resection.

For codes 00 through 79, the descriptions of the surgical procedures are hierarchical. Last-listed responses take precedence over earlier-listed responses (regardless of the code or numeric value).

To the extent possible, codes and their definitions are the same as those previously assigned in *ROADS/FORDS* to accommodate analysis in registries that maintain unconverted data. As a result of



added and modified codes, however, the numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

Example: A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed *after* polypectomy alone, is coded 22.

20	Local tumor excision, NOS
26	Polypectomy
27	Excisional biopsy
Combination of 20 or 26–27 WITH	
21	Photodynamic therapy (PDT)
22	Electrocautery
23	Cryosurgery
24	Laser ablation
25	Laser excision

*Scope of Regional Lymph Node Surgery* [1292] distinguishes between sentinel lymph node biopsy and removal of other regional lymph nodes and distinguishes removal of regional lymph nodes during the same surgical procedure as a sentinel node biopsy from subsequent removal.

- One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment to previously published treatment based on the former codes, or to data still unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. The compromise incorporated in the *Scope of Regional Lymph Node Surgery* [1292] codes separates removal of one to three nodes (code 4) from removal of four or more nodes in the response categories (code 5). It is **very important** to note that this distinction is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than four nodes was not reflected in surgery codes. The distinction between fewer than four nodes and four or more nodes removed is not intended to reflect clinical significance when applied to a particular surgical procedure.

*Surgical Procedure/Other Site* [1294] describes surgery performed on tissue or organs other than the primary site or regional lymph nodes. It is also used to describe whether surgery was performed for tumors having unknown or ill-defined primary sites or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease morphologies. If any surgical treatment was performed on these cancers, *Surgical Procedure/Other Site* is coded 1.

*Surgical Procedure of Primary Site at This Facility* [670], *Scope of Regional Lymph Node Surgery at This Facility* [672], and *Surgical Procedure/Other Site at This Facility* [674] are identical to *Surgical Procedure of Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292], and *Surgical Procedure/Other Site* [1294], respectively, except they each refer solely to surgery provided by the respective facility.

Six surgery items augment the information recorded in *Surgical Procedure of Primary Site* [1290]. The items *Date of Most Definitive Surgical Resection of the Primary Site* [3170], *Surgical Margins of the Primary Site* [1320], *Date of Surgical Discharge* [3180], and *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] apply to the most definitive (most invasive) first course primary site surgery performed, that is, to the event recorded under *Surgical Procedure of Primary Site* [1290]. When no surgical procedure of the primary site is performed, the reason is recorded in the item *Reason for No Surgery of Primary Site* [1340].

- *Date of Most Definitive Surgical Resection* [3170] is the date on which the specific procedure recorded in *Surgical Procedure of Primary Site* [1290] was performed. If only one first course surgical procedure was performed, then the date will be the same as that for *Date of First Surgical Procedure* [1200].
- *Surgical Margins of the Primary Site* [1320] records the pathologist's determination of the presence of microscopic or macroscopic involvement of cancer at the margins of resection following the surgical resection described by *Surgical Procedure of Primary Site* [1290].
- RX Hosp–Surg App 2010 [668] distinguishes among open surgery, laparoscopic surgery, and robotic assisted surgery when it is performed by the reporting facility. If more than one surgical procedure is performed by the facility, this item refers to the most definitive (most invasive) first course primary site surgery performed.
- *Date of Surgical Discharge* [3180] is the date the patient was discharged following the procedure recorded in *Surgical Procedure of Primary Site* [1290]. It is on or after the *Date of Most Definitive Surgical Resection* [3170].
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] distinguishes a planned from an unplanned hospital admission and is used as a quality of care indicator.
- *Reason for No Surgery of Primary Site* [1340] identifies why surgical therapy was not provided to the patient and distinguishes a physician's not recommending surgical therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan.

## Radiation Therapy

The radiation items in *STORE* are clinically relevant and reflect contemporary practice. These items record new "phase" terminology, replacing the traditional terms of "regional" and "boost." The first phase (Phase I) of a radiation treatment may be commonly referred to as an initial plan and a subsequent phase (Phase II) may be referred to as a boost or cone down. A new phase begins when there is a change in the target volume of a body site, treatment fraction size, modality or treatment technique. Up to three phases of radiation treatment can now be documented.

*The following summary items apply to all radiation therapy administered at this facility and at other facilities:*

*Date Radiation Started* [1210]

[Coding instructions for Radiation Data Items](#)

*Location of Radiation Treatment* [1550]

*Radiation/Surgery Sequence* [1380]

*Date Radiation Ended* [3220]

*Reason for No Radiation* [1430]

The following are the new phase-specific data items (Phase I [1501-1507], Phase II [1511-1517], Phase III [1521-1527]):

*Radiation Primary Treatment Volume*

*Radiation to Draining Lymph Nodes*

*Radiation Treatment Modality*

*Radiation External Beam Planning Technique*

*Dose per Fraction*

*Number of Fractions*

*Total Dose*

### Radiation Data Items Update

When the data item Phase I Radiation Treatment Modality [1506] was implemented in v18 a code indicating *radiation was given but type of radiation unknown* was not included. Currently patients that receive radiation but the modality is not known are assigned a code 99. Code 99 is also used when it is unknown if radiation is given. This makes it difficult to distinguish patients that did receive radiation from those where it is unknown if radiation was given.

Code 98 is added to the data item Phase I Radiation Treatment Modality for cases where it is known radiation was given, but modality is unknown. Code 99 is only used when it is unknown if radiation was given. The new code and changed code may be used for all cases abstracted after the v21 implementation regardless of diagnosis year.

Please see a Commission on Cancer training document “CTR Guide to Coding Radiation Therapy Treatment in the STORE” for a wide variety of example cases and detailed discussion on how they should be coded.

The details of the radiation course can typically be found in the radiation oncologist’s radiation treatment summary.

### Radiation Treatment Phase-specific Data Items

To promote consistency across the clinical and registry community, new “phase” terminology has been adopted, replacing the traditional terms of “regional” and “boost.” A course of radiation is made up of one or more phases and each phase includes a target volume and a delivered prescription. At the start of the radiation planning process, physicians write radiation prescriptions to treatment volumes and specify the dose per fraction (session), the number of fractions, the modality, and the planning technique. A phase represents the radiation prescription that has actually been delivered as sometimes the intended prescription differs from the delivered prescription. The first phase (Phase I) of a radiation treatment may be referred to as an initial plan and a subsequent phase (Phase II) may be referred to as a boost or cone down. A. Up to three phases of radiation treatment can now be documented.

Note that phases can be delivered sequentially or simultaneously. In sequential phases, a new phase begins when there is a change in the anatomic target volume of a body site, treatment fraction size, modality or technique.

When phases are delivered simultaneously, this is sometimes referred to as “dose painting” or “simultaneous integrated boost (SIB)”. If multiple phases start on the same date, then summarize in order from highest ‘Total Phase Dose’ to lowest ‘Total Phase Dose’. If multiple phases start on the same date and have the same Total Phase Dose, then any order is acceptable.

Typically, in each phase, the primary tumor or tumor bed is treated. However, radiation treatment also commonly includes draining lymph node regions that are associated with the primary tumor or tumor bed. Because of this, the historical *Radiation Treatment Volume* [1540] has been divided into the phase-specific data items of *Radiation Primary Treatment Volume* and *Radiation to Draining Lymph Nodes*.

Historically, the previously named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. The implementation of separate phase-specific data items for the recording of radiation modality (Radiation Treatment Modality) and radiation treatment planning techniques (Radiation External Beam Planning Technique) will clarify this information using mutually exclusive categories.

### Relationships among Radiation Items

*Date Radiation Started* [1210] is the date that the first radiation therapy was delivered to the patient as part of all of the first course of therapy. This item in combination with *Date Radiation Ended* [3220] allows the duration of treatment to be calculated.

- If radiation was the only type of first course treatment performed or was the first of multiple treatment modalities, *Date Radiation Started* [1210] is the same as *Date of First Course of Treatment* [1270]. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

*Location of Radiation Treatment* [1550] can be used to assess where therapy was provided. This item allows for the distinction between summary treatment and treatment given at the accessioning facility. Codes are provided that allow the description of where regional and boost dose therapy were provided, whether all the therapy was provided at the accessioning facility or if all or some of the radiation therapy was referred out to another treatment location.

The targeted anatomic region is described by *Phase I, II and III Radiation Primary Treatment Volume* [1504, 1514 and 1524, respectively]. The treatment volume may be the same as the primary site of disease; however, the available code values provide descriptions of anatomic regions that may extend beyond the primary site of disease and may be used to describe the treatment of metastatic disease. If two distinct volumes are radiated, and one of those includes the primary site, record the radiation involving the primary site in all radiation fields.

In addition to knowing the duration of treatment and the modalities and doses involved, it is critical to know the number of treatments to be able to gauge the intensity of the dose delivered to the patient. The data item *Number of Phases of Radiation Treatment to This Volume* [1532] describes the total number of therapeutic treatments (phases) delivered to the anatomic volume coded in *Phase I, II and III Radiation Primary Treatment Volume* [1504, 1514, and 1524, respectively].

Two items augment the information recorded in the radiation modality, dose, volume, and number of treatment items.

- *Radiation/Surgery Sequence* [1380] identifies those instances where radiation therapy and the surgical management of the patient are not discrete and overlap with respect to time. Radiation therapy can precede the surgical resection of a tumor and then be continued after the patient's surgery, or radiation can be administered intraoperatively.
- *Reason for No Radiation* [1430] identifies why radiation therapy was not provided to the patient and distinguishes a physician's not recommending this therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan.

## Systemic Therapy

Systemic therapy encompasses the treatment modalities captured by the items chemotherapy, hormone therapy, and immunotherapy. The systemic therapy items in *FORDS/STORE* separate the administration of systemic agents or drugs from medical procedures which affect the hormonal or immunologic balance of the patient.

*The following summary items apply to all systemic therapy administered at this facility and at other facilities:*

*Date Systemic Therapy Started [3230]*

*Date Chemotherapy Started [1220]*

*RX Date–Chemo Flag [1221]*

*Date Hormone Therapy Started [1230]*

*RX Date–Hormone Flag [1231]*

*Date Immunotherapy Started [1240]*

*RX Date BRM Flag [1241]*

*Systemic/Surgery Sequence [1639]*

*Chemotherapy [1390]*

*Hormone Therapy [1400]*

*Immunotherapy [1410]*

*Hematologic Transplant and Endocrine Procedures [3250]*

[Coding instructions for Systemic Therapy Data Items](#)

*The following items describe systemic therapy performed at this facility:*

*Chemotherapy at This Facility [700]*

*Hormone Therapy at This Facility [710]*

*Immunotherapy at This Facility [720]*

Clarification of Systemic Therapy Terms	
Term	Definition
Chemotherapy	Cancer therapy that achieves its antitumor effect through the use of antineoplastic drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.
Hormone therapy	Cancer therapy that achieves its antitumor effect through changes in hormonal balance. This type of therapy includes the administration of hormones, agents acting via hormonal mechanisms, antihormones, and steroids.
Immunotherapy	Cancer therapy that achieves its antitumor effect by altering the immune system or changing the host's response to the tumor cells.
Endocrine therapy	Cancer therapy that achieves its antitumor effect through the use of radiation or surgical procedures that suppress the naturally occurring hormonal activity of the patient (when the cancer occurs at another site) and, therefore, alter or affect the long-term control of the cancer's growth.
Hematologic transplants	Bone marrow or stem cell transplants performed to protect patients from myelosuppression or bone marrow ablation associated with the administration of high-dose chemotherapy or radiation therapy.

Important information affecting classification of some systemic therapies. The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. This change is effective for cases diagnosed January 1, 2013, and forward.

For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER\*Rx Interactive Drug Database*.

Drug Name(s)	Category Prior to 2013	Category 2013 +
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuxumab/Erbix	Chemotherapy	BRM/Immunotherapy

Chemotherapy and hormone therapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more drugs. If a patient has an adverse reaction, the managing physician may change one of the agents in a combination regimen. If the replacement agent belongs to the same group as the original agent, there is no change in the regimen. However, if the replacement agent is of a different group than the original agent, the new regimen represents the start of subsequent therapy, *only the original agent or regimen is recorded as first course therapy*. Refer to the *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) for a list of systemic therapy agents.

This rule does not apply for hormone therapy. If a change is made from Tamoxifen to Arimidex this is still all first course of treatment.

Systemic agents may be administered by intravenous infusion or given orally. Other methods of administration include the following:

Method	Administration
Intrathecal	Administered directly into the cerebrospinal fluid through a lumbar puncture needle into an implanted access device (for example, Ommaya reservoir).
Pleural/pericardial	Injected directly into pleural or pericardial space to control malignant effusions.
Intraperitoneal	Injected into the peritoneal cavity.
Hepatic artery	Injected into a catheter inserted into the artery that supplies blood to the liver.

### Relationships Among Systemic Therapy Items

The data item *Date Systemic Therapy Started* describes the first date on which any first course systemic treatment was administered to the patient. Nine out of 10 patients treated with systemic therapy receive only a single class of drugs (chemotherapy, hormone therapy, or immunotherapy). Of the remaining patients who receive a combined regimen of systemic therapies, two-thirds begin these combined regimens simultaneously. For the purposes of clinical surveillance, the collection of multiple dates to describe the sequence of systemic therapy administration is not necessary.

The data items *Chemotherapy*, *Hormone Therapy*, and *Immunotherapy* describe whether or not each respective class of agent(s) or drug(s) were administered to the patient as part of first course therapy, based on *SEER\*Rx*. In the case of chemotherapy, additional distinction is allowed for instances where single or multiagent regimens were administered. Each of these three items includes code values that

describe the reason a particular class of drugs is not administered to the patient and distinguishes a physician's not recommending systemic therapy due to contraindicating conditions from a patient's refusal of a recommended treatment plan. The associated date items were previously defined by CoC, though discontinued in **FORDS** from 2003 through 2009 and the same fields may be used in STORE to collect them now, if allowed by the registry software.

*Hematologic Transplant and Endocrine Procedures* captures those infrequent instances in which a medical, surgical, or radiation procedure is performed on a patient that has an effect on the hormonal or immunologic balance of the patient. Hematologic procedures, such as bone marrow transplants or stem cell harvests, are typically employed in conjunction with administration of systemic agent(s), usually chemotherapy.

- Endocrine procedures, either radiologic or surgical, may be administered in combination with systemic agent(s), typically hormonal therapeutic agents.
- As first course therapy, hematologic procedures will rarely be administered in conjunction with endocrine radiation or surgery. The use of code 40 in response to this data item should be reviewed and confirmed with the managing physician(s).

### Other Treatment

Other Treatment encompasses first course treatment that cannot be described as surgery, radiation, or systemic therapy according to the defined data items found in this manual.

This item is also used for supportive care treatment for reportable hematopoietic diseases that do not meet the usual definition in which treatment "modifies, controls, removes, or destroys proliferating cancer tissue." Treatments such as phlebotomy, transfusions, and aspirin are recorded in *Other Treatment* data item for certain hematopoietic diseases, and should be coded 1. Consult the most recent version of the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual for instructions for coding care of specific hematopoietic neoplasms in this item.

*The following items apply to all Other Treatment provided at this facility and at other facilities:*

*Date Other Treatment Started* [1250]

[Coding instructions for Other Treatment Data Items](#)

*Other Treatment* [1420]

*Other Treatment at This Facility* [730]

### Palliative Care

Palliative care is provided to prolong the patient's life by controlling symptoms, to alleviate persistent pain, or to make the patient comfortable. Palliative care provided to relieve symptoms may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy. Palliative care is not used to diagnose or stage the primary tumor.

*The following items apply to all palliative care provided at this facility and at other facilities:*

*Palliative Care* [3270]

[Coding instructions for Palliative Care Data Items](#)

*Palliative Care at This Facility* [3280]

Any surgical procedure, radiation therapy, and/or systemic therapy that is provided to modify, control, remove, or destroy primary or metastatic cancer tissue, is coded in the respective first course of treatment fields and also identified in the *Palliative Care* items. Refer to the preceding discussion of the surgery, radiation and systemic therapy data items for specific coding guidelines. Because these treatments are less aggressive when given for palliation than for treatment, the treatment plan or treatment notes will indicate when they are performed for palliative purposes.



- Record as palliative care any of the treatment recorded in the first course therapy items that was provided to prolong the patient's life by managing the patient's symptoms, alleviating pain, or making the patient more comfortable.
- Palliative care can involve pain management that may not include surgery, radiation or systemic treatment.
- It is possible for a patient to receive one or a combination of treatment modalities in conjunction with palliative care intended to reduce the burden of pain. For example, a patient with metastatic prostate cancer may receive an orchiectomy and systemic hormone therapy in combination with palliative radiation for bone metastasis.

### Treatment, Palliative, and Prophylactic Care

Any first course radiation or systemic treatment that acts to kill cancer cells is to be reported as treatment. For example, when total body irradiation (TBI) is given to prepare the patient for a bone marrow transplant (BMT), the TBI acts in two ways. First, it suppresses the immune system to reduce the body's ability to reject the BMT. Second, it contributes to the patient's treatment by destroying cancer cells in the bone marrow, though its use alone would generally not be sufficient to produce a cure. Both the TBI and the BMT should be coded as treatment. The situation is analogous to the use of breast-conserving surgery and adjuvant radiation when the surgery or radiation alone may not be sufficient to produce a cure, though together they are more effective.

When first course surgery, systemic treatment, or radiation is undertaken to reduce the patient's symptoms, that treatment should be coded as palliative care. An example is radiation to bone metastases for prostate cancer to reduce bone pain, which is palliative when there is no expectation that the radiation will effectively reduce the cancer burden. Palliative care involving surgery, systemic treatment, or radiation is also coded as treatment. This treatment qualifies the patient as analytic if it is given as part of planned first course treatment.

The term "prophylactic" is used in medical practice in a variety of ways. An action taken to prevent cancer from developing (such as a double mastectomy for a healthy woman who has several relatives diagnosed with breast cancer when they were young) is not reportable; there is no cancer to report. Actions taken as part of planned first course treatment to prevent spread or recurrence of the cancer are sometimes characterized as "prophylactic" (for example, performing an oophorectomy or providing Tamoxifen to a breast cancer mastectomy patient). These treatments are to be coded as treatment.

### Embolization

The term *embolization* refers to the intentional blocking of an artery or vein. The mechanism and the reason for embolization determine how and whether it is to be recorded.

**Chemoembolization** is a procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This procedure permits a higher concentration of drug to be in contact with the tumor for a longer period of time. Code chemoembolization as *Chemotherapy* when the embolizing agent(s) is a chemotherapeutic drug(s) or when the term *chemoembolization* is used with no reference to the agent. Use *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) to determine whether the drugs used are classified as chemotherapeutic agents. Also code as *Chemotherapy* when the patient has primary or metastatic cancer in the liver and the only information about embolization is a statement that the patient had chemoembolization, tumor embolization or embolization of the tumor in the liver. However, if alcohol is specified as the embolizing agent, even in the liver, code the treatment as *Other Therapy*.



**Radioembolization** is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Code *Radiation Modality* as brachytherapy when tumor embolization is performed using a radioactive agent or radioactive seeds.

Embolization is coded as *Other Therapy* (code 1) if the embolizing agent is alcohol, or if the embolized site is other than the liver and the only information in the record is that the patient was given “embolization” with no reference to the agent.

**Do not code** presurgical embolization of hypervascular tumors with particles, coils or alcohol. These presurgical embolizations are typically performed to make the resection of the primary tumor easier. Examples where presurgical embolization is used include meningiomas, hemangioblastomas, paragangliomas, and renal cell metastases in the brain.

### Outcomes **NH-34**

The outcomes data items describe the known clinical and vital status of the patient. Follow-up information is obtained at least annually for all living *Class of Case* 10-22 patients included in a cancer registry’s database. Recorded follow-up data should reflect the most recent information available to the registry that originates from reported patient hospitalizations, known patient readmissions, contact with the patient’s physician, and/or direct contact with the patient.

Individual item descriptions in Section Two of this manual should be consulted for specific coding instructions. The paragraphs below describe the range of follow-up information that should be obtained.

#### Follow-up items that are required to be in the facility’s database

There may be times when first course treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the necessary treatment information is collected. This includes:

- Complete first course of treatment information when *Surgical Procedure of Primary Site* [1290] is delayed six months or more following the *Date of First Contact* [580].
- *Readmission to the Same Hospital Within 30 Days of Surgical Discharge* [3190] following the most definitive surgery.
- Radiation, chemotherapy, hormone therapy, immunotherapy, hematologic transplant and endocrine procedures, or other treatment that had been indicated as being planned as part of first course of treatment, but not been started or completed as of the most recent follow-up date. Use “reason for no” treatment codes of 88 or 8 as ticklers to identify incomplete treatment information.
- When all planned first course treatment has been recorded, first course treatment items no longer need to be followed.
- The CoC does not require Class 00 cases to be followed.
- Follow-up for disease recurrence should be conducted until (a) evidence of disease recurrence is reported, or (b) the patient dies. If the *Type of First Recurrence* [1880] is coded 70 (never cancer free), when the patient was last seen, but treatment was still underway, then check at follow-up to see whether the patient subsequently became cancer-free. Occasionally, if first course treatment ends due to disease progression, it may be the second course or subsequent treatment that results in a cancer-free status. If the *Type of First Recurrence* is coded 00

(became cancer-free and has had no recurrence), then continue to follow for recurrence and record the type and date when it occurs.

In order to facilitate research on cancer recurrence, two new follow-up data items have been added for 2018 that allow for the recording of the last date on which the patient's cancer status has been updated.

Unlike the *Date of Last Contact or Death* [1750], which is a patient-specific data item, these new data items are tumor-specific to better document tumor recurrence/no evidence of disease (NED).

- Date of Last Cancer (Tumor) Status [1772]
- Cancer Status [1770]

### Recurrence Definition

Local recurrence: recurs in initial primary organ

Trocar recurrence: organ removed, recurs in scar tissue from removal

Regional recurrence: recurs in adjacent organ or lymph nodes draining the organ

Distant recurrence: recurs in a location beyond regional

Once the first recurrence has been recorded, do not update recurrence items further.

While the patient is alive, be sure that contact information is kept current. Contact information includes:

*Date of Last Contact or Death* [1750]

*Follow-Up Source*, [1790]

*Next Follow-Up Source* [1800]

Follow-up for *Vital Status* [1760] and *Cancer Status* [1770] should be conducted annually for all analytic cases in the cancer program's registry. *Class of Case* 00 patients that are not followed will have the most recent information as of the *Date of Last Contact or Death* [1750].

Once the patient's death has been recorded and all care given prior to death is recorded, no further follow-up is performed.

### Case Administration

Correct and timely management of case records in a registry data set are necessary to describe the nature of the data in the cancer record and to facilitate meaningful analysis of data, and it is necessary to understand each item's respective purpose to ensure their accuracy and how to use them in facility analysis.

### Administrative Tracking

The following administrative tracking items are required to be in the facility's database:

*Abstracted By* [570] **NH-35**

*Facility Identification Number (FIN)* [540]

*NPI-Reporting Facility* [545]

*Archive FIN* [3100]

*NPI-Archive FIN* [3105]

*Abstracted By* [570], *Facility Identification Number (FIN)* [540], and *NPI-Reporting Facility* [545] identify the individual and facility responsible for compiling the record. *Archive FIN* and *NPI-Archive FIN* store the identification numbers assigned to the original abstracting facility and are used to convey the original identity assigned to a facility that has since merged with another. In a registry with more than one

abstractor or serving more than one facility, it will ordinarily be necessary to enter these three numbers only when they change. All of these items should be autocoded by the registry software.

*Note:* NPI numbers are available through the facility's billing or accounting department or at <https://nppes.cms.hhs.gov/NPPES/Welcome.do>.

### EDITS Overrides **NH-36**

Some of the CoC edits identify rare, but possible, code combinations. For these edits, an override flag can be set if, upon review, the unusual combination is verified as being correct. Once set, the error message will not be repeated on subsequent EDITS passes.

- When no error message is generated by an edit that uses an override item, no action by the registrar is needed.
- If an error message is generated, the problem can often be resolved by checking the accuracy of the entry for each item that contributes to the edit and correcting any problems identified. If correction of data entry errors resolves the problem, do not make an override entry. If the codes reflect the information in the patient record, check for physician notes indicating the unusual combination of circumstances (for example, a colon adenocarcinoma in a child) has been confirmed.
- Enter the override code according to the instructions for the data item. If no comment regarding the unusual circumstances can be found in the record, it may be necessary to check with the managing physician or pathologist to determine whether it is appropriate to override the edit.

The following override items are required to be in the facility's database:

*Override Site/Type* [2030]

*Override Site/TNM-StgGrp* [1989]

[Coding instructions for Overrides](#)

### Code Versions Used

Fifteen items describe the version of codes applied to record information in the registry record. Because registries cover many years of cases, registry data will be recorded according to many different coding systems. These items are necessary for the analysis of registry data and for further conversions, so it is important that they be maintained accurately.

*The following code version items are required to be in the facility's database:*

*TNM Edition Number* [1060]

*CS Version Input Original* [2935; for cases diagnosed 2004-2017]

*CS Version Input Current* [2937; for cases diagnosed 2004-2017]

*CS Version Derived* [2936; for cases diagnosed 2004 through 2015]

All of these items are capable of being autocoded.

For newly abstracted cases, code version information will be applied both as the current and original code versions. When registry data are converted to an updated version for a coding system, the code for the current version should be updated automatically by the conversion.

It is not possible to convert from one version of AJCC TNM to another. The registrar should ascertain that the correct version number is recorded for autocoding.

### Data Submission Type

The NCDB is moving to submission of data via a single data portal rather than the current separate data portals for RCRS and NCDB.

## Section Two: Instructions for Coding

NH-37

## Patient Identification

## Accession Number

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
550	9	745-753	See Coding Instructions	All Years	01/04, 01/10

### Description

Provides a unique identifier for the patient consisting of the year in which the patient was first seen at the reporting facility and the consecutive order in which the patient was abstracted.

### Rationale

This data item protects the identity of the patient and allows cases to be identified on a local, state and national level.

[See Accession Number rules in Section One for further instructions.](#)

### Coding Instructions

- When a patient is deleted from the database, **do not** reuse the accession number for another patient.
- The first four numbers specify the year and the last five numbers are the numeric order in which the patient was entered into the registry database.
- Numeric gaps are allowed in accession numbers.
- A patient's accession number is never reassigned.

Code	Definition
(fill spaces)	Nine-digit number used to identify the year in which the patient was first seen at the reporting facility for the diagnosis and/or treatment of cancer.

### Examples

Code	Reason
200300033	Patient enters the hospital in 2003, and is diagnosed with breast cancer. The patient is the thirty-third patient accessioned in 2003.
200300033	A patient with the accession number 200300033 for a breast primary returns to the hospital with a subsequent colon primary in 2004. The accession number will remain the same. <i>Sequence Number</i> [560] will distinguish this primary.
200300010	Patient diagnosed in November 2002 at another facility enters the reporting facility in January 2003, and is the tenth case accessioned in 2003.
200300012	Patient diagnosed in staff physician office in December 2002 enters the reporting facility in January 2003, and is the twelfth case accessioned in 2003.

Code	Reason
200300001	First patient diagnosed and/or treated and entered into the registry database for 2003.
200300999	Nine hundred ninety-ninth patient diagnosed and/or treated and entered into the registry database for 2003.
200401504	One thousand five hundred fourth patient diagnosed and/or treated and entered into the registry database for 2004.

## Sequence Number

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
560	2	754-755	00-88, 99	All Years	06/05, 04/07, 01/10, 01/13

### Description

Indicates the sequence of malignant and nonmalignant neoplasms over the lifetime of the patient.

### Rationale

[See Sequence Number in Section One for further instructions.](#)

This data item is used to distinguish among cases having the same accession numbers, to select patients with only one malignant primary tumor for certain follow-up studies, and to analyze factors involved in the development of multiple tumors.

### Coding Instructions

[See also Determining Multiple Primaries.](#)

- Codes 00–59 and 99 indicate neoplasms of malignant (in situ or invasive) behavior (Behavior equals 2 or 3). Codes 60–88 indicate neoplasms of non-malignant behavior (Behavior equals 0 or 1).
- Code 00 only if the patient has a single malignant primary. If the patient develops a subsequent invasive or in situ primary tumor, change the code for the first tumor from 00 to 01, and number subsequent tumors sequentially.
- Code 60 only if the patient has a single non-malignant primary. If the patient develops a subsequent non-malignant primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent non-malignant primaries sequentially.
- If two or more invasive or in situ neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, do not reassign sequence numbers if one of those tumors becomes non-reportable later.
- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence.

### Malignant or In Situ Primaries

Code	Definition
00	One malignant or <i>in situ</i> primary only in the patient's lifetime
01	First of two or more independent malignant or <i>in situ</i> primaries
02	Second of two or more independent or <i>in situ</i> primaries
...	(Actual sequence of this malignant or <i>in situ</i> primary)
59	Fifty-ninth of 59 or more independent malignant or <i>in situ</i> primaries



Code	Definition
99	Unknown number of malignant or <i>in situ</i> primaries

### Non-Malignant Primaries

Code	Definition
60	One nonmalignant primary only in the patient's lifetime
61	First of two or more independent nonmalignant primaries
62	Second of two or more independent nonmalignant primaries
...	(Actual sequence of this nonmalignant primary)
87	Twenty-seventh of 27 or more independent nonmalignant primaries
88	Unspecified number of independent nonmalignant primaries

### Examples

Code	Reason
00	Patient with no previous history of cancer diagnosed with <i>in situ</i> breast carcinoma on June 13, 2003.
01	The sequence number is changed when the patient with an <i>in situ</i> breast carcinoma diagnosed June 13, 2003, is diagnosed with a subsequent melanoma on August 30, 2003.
02	Sequence number assigned to the melanoma diagnosed on August 30, 2003, following a breast cancer <i>in situ</i> diagnosis on June 13, 2003
04	A nursing home patient is admitted to the hospital for first course surgery for a colon adenocarcinoma. The patient has a prior history of three malignant cancers of the type the registry is required to accession, though the patient was not seen for these cancers at the hospital. No sequence numbers 01, 02 or 03 are accessioned for this patient.
60	The sequence number assigned to a benign brain tumor diagnosed on November 1, 2005, following a breast carcinoma diagnosed on June 13, 2003, and a melanoma on August 30, 2003.
63	Myeloproliferative disease (9975/1) is diagnosed by the facility in 2003 and accessioned as Sequence 60. A benign brain tumor was diagnosed and treated elsewhere in 2002; the patient comes to the facility with a second independent benign brain tumor in 2004. Unaccessioned earlier brain tumor is counted as Sequence 61, myeloproliferative disease is resequenced to 62, and second benign brain tumor is Sequence 63.

## Medical Record Number

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2300	15	medicalRecordNumber	Alphanumeric	All Years	2011, 2021

### Description

Records medical record number used by the facility to identify the patient.

### Rationale

This number identifies the patient in a facility. It can be used by a central registry to point back to the patient record, and it helps identify multiple reports on the same patient.

### Coding Instructions

1. Record the medical record number.

### Codes (in addition to the medical record number)

Code	Label
UNK	Medical record number unknown
RT	Radiation therapy department patient without HIM number
SU	1-day surgery clinic patient without HIM number

*Note:* Other standard abbreviations may be used to indicate departments within the facility for patients without HIM numbers assigned.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Social Security Number

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2320	9	socialSecurityNumber	001010001-899999999, 999999999. Invalid values in this range exist.	All Years	2021

### Description

Records patient's social security number. The number is entered without dashes and without any letter suffix. This is not always identical to the Medicare claim number.

### Rational

This data item can be used to identify patients with similar names.

Social Security Number is collected by NHSCR for identification and matching purposes. It is important to record the correct SSN for each patient so that cases reported by multiple sources are correctly merged and consolidated.

### Code Instructions

1. Code the patient's Social Security number.
2. A patient's Medicare claim number may not always be identical to the person's Social Security number.
3. Code Social Security numbers that end with "B" or "D" as 999999999. The patient receives benefits under the spouse's number and this is the spouse's Social Security number.
4. See <https://www.ssa.gov/> for more information.

### Codes (in addition to social security number)

Code	Definition
(fill spaces)	Record the patient's Social Security number without dashes
999999999	Patient does not have a Social Security number; SSN is not available; unknown.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Name--Last

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2230	40	nameLast	Spaces, hyphens and apostrophes are allowed. Do not use other punctuation.	All Years	2004, 2010, 2021

### Description

Identifies the last name of the patient.

### Rationale

This data item is used by hospitals as a patient identifier.

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and maiden names.

### Coding Instructions

1. Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
2. Do not leave blank; code as UNKNOWN if the patient's last name is unknown.
3. This field may be updated if the last name changes.

### Examples

Code	Reason
McDonald	Recorded with space as Mc Donald
O'Hara	Recorded with apostrophe as O'Hara
Smith-Jones	Janet Smith marries Fred Jones and changes her last name to Smith-Jones
UNKNOWN	Patient's last name is not known, use UNKNOWN

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Name--First

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2240	40	nameFirst	Spaces, hyphens and apostrophes are allowed. Do not use other punctuation.	All Years	2010, 2011, 2021

### Description

Identifies the first name of the patient.

### Rationale

This data item is used by hospitals to differentiate between patients with the same last names.

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and maiden names.

### Coding Instructions

1. Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
2. This field may be updated if the name changes.

### Examples

Code	Reason
Michael	Patient's name is Michael David Hogan
(leave blank)	If patient's first name is not known, do not fill in the space.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Name--Middle (Middle Initial)

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2250	40	nameMiddle	Spaces, hyphens and apostrophes are allowed. Do not use other punctuation.	All Years	2010, 2011, 2021

### Description

Identifies the middle name or middle initial of the patient.

### Rationale

This data item helps distinguish between patients with identical first and last names.

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and birth surname/maiden names.

### Coding Instructions

1. Truncate name if more than 40 letters long. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
2. This field may be updated if the name changes.

### Examples

Code	Reason
David	Patient's name is Michael David Hogan
D	Patient's name is Michael D. Hogan
(leave blank)	If patient's middle name is not known or there is none, do not fill in the space.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Name--Birth Surname

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2232	40	nameBirthSurname	Embedded spaces, hyphens, apostrophes. No other special characters are allowed.	All Years	New for 2021

### Description

Last name (surname) of patient at birth, regardless of gender or marital status. Other alternate names should be recorded in the data item, *Name--Alias* [2280].

### Rationale

This can be used to link reports on a person whose surname might be different on different documents. It is also useful when using a Spanish surname algorithm to categorize ethnicity.

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and birth surname/maiden names.

### Code Instructions

The field should be left blank if the birth surname is not known or not applicable. Since a value in this field may be used by linkage software or other computer algorithms, only legitimate surnames are allowable, and any variation of “unknown” or “not applicable” is not allowable.

1. Truncate name if more than 40 letters long.
2. Blanks spaces, hyphens, and apostrophes are allowed. Do not use other punctuation.
3. Record when known regardless of value in the *Sex* data item.
4. Leave blank if the birth surname is not known or not applicable.

### Examples

Code	Reason
Mc Donald	Patient's surname is Mc Donald; recorded with space
O'Hara	Patient's surname is O'Hara; recorded with apostrophe
(leave blank)	If patient's surname is not known, do not fill in the space

*Note:* This data item was introduced to be a gender-neutral birth-surname data item, analogous to *Name--Maiden* [2390]. It is to have been populated in the 2021 conversion by values in [2390]. The original (*Name--Maiden*) data item had been supported by CoC until January 1, 2003.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

## Name--Alias

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2280	40	nameAlias	Blanks, spaces, hyphens, apostrophes are allowed; do not use other punctuation.	All Years	2021

### Description

Records an alternate name or “AKA” (also known as) used by the patient, if known. Note that the birth surname (AKA maiden name) is entered in *Name--Birth Surname* [2232].

### Rationale

The update is needed to reflect that *Maiden Name* [2390] is no longer used as of 2021.

*Note:* This data item is no longer supported by CoC (as of January 1, 2003) but is maintained by NAACCR.

## Name--Prefix

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2260	3	namePrefix		All Years	

### Description

Abbreviated title that precedes name in a letter (e.g., "Rev," "Ms").

*Note:* This data item is no longer supported by CoC (as of January 1, 2003).

## Name--Suffix

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2270	3	nameSuffix		All Years	

### Description

Title that follows a patient's last name, such as a generation order or credential status (e.g., "MD," "Jr.").

*Note:* This data item is no longer supported by CoC (as of January 1, 2003).

The full Patient Name is collected by NHSCR for identification and matching purposes. It is important to record the most complete name available – last, first, middle, prefix, suffix, alias, and birth surname/maiden names.

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Patient Address (Number and Street) at Diagnosis

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2330	60	addrAtDxNoStreet	Valid address or UNKNOWN	All Years	2010, 2012,2021

### Description

Identifies the patient's address (number and street) at the time of diagnosis. Residential street address should not include PO Boxes.

### Rationale

The address is part of the patient's demographic data and has multiple uses. It can be used to evaluate referral patterns, allows for the analysis of cancer cluster concerns, and supports epidemiological studies that use area-based social measures.

### Coding Instructions

- Record the number and street address or the rural mailing address of the patient's usual residence when the cancer was diagnosed.
- Record UNKNOWN when a PO Box or other non-physical, residential mailing address is the only address available, or when no other address information is available in the medical record and no other information sources are available. Record the PO Box or other non-physical, residential mailing address in *Addr At Dx—Supplement I* [2335].
- Additional address information such as facility, nursing home, name of apartment complex, or a PO Box used for mailing purposes, should be entered in *Addr At Dx—Supplement I* [2335].
- If the patient has multiple tumors, address at diagnosis may be different for each tumor.
- Do not update this item if the patient's residential address changes.
- U.S. addresses should conform to the U.S. Postal Service (USPS) Postal Addressing Standards. These standards are referenced in USPS Publication 28, Postal Addressing Standards. The current USPS Pub. 28 may be found and downloaded here: <http://pe.usps.gov/cpim/ftp/pubs/Pub28/pub28.pdf>.
- The address should be fully spelled out with standardized use of abbreviations and punctuation per USPS postal addressing standards (USPS Pub. 28, available at link above). Mixed case allowed.
- Punctuation marks should be avoided, except when punctuation is necessary to convey the meaning. Punctuation normally is limited to periods when the period carries meaning (e.g., 39.2 RD), slashes for fractional addresses (e.g., 101 1/2 Main St), and hyphens when the hyphen carries meaning (e.g., 289-01 Montgomery Ave). Use of the pound sign (#) to designate address units should be avoided whenever possible. The preferred notation is as follows: 102 Main St Apt 101. If a pound sign is used, there must be a space between the pound sign and the secondary number (e.g., 425 Flower Blvd # 72).
- Abbreviations should be limited to those recognized by USPS standard abbreviations. They include, but are not limited to the list below: A complete list of recognized street abbreviations is provided in Appendix C of USPS Pub 28.

APT	apartment	N	north
BLDG	building	NE	northeast
FL	floor	NW	northwest
STE	suite	S	south
UNIT	unit	SE	southeast
RM	room	SW	southwest
DEPT	department	E	east
		W	west

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Patient Address at Diagnosis--Supplemental

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2335	60	addrAtDxSupplementI	Valid address or UNKNOWN	All Years	2006, 2010, 2012, 2021

### Description

Provides the ability to store additional address information such as the name of a place or facility (for example a nursing home, apartment complex, jail or PO Box residential or other mailing address) at the time of diagnosis.

### Rationale

Sometimes the registry receives the name of a facility instead of a proper street address containing the street number, name, direction, and other elements necessary to locate an address on a street file for the purpose of geocoding. By having a second street address field to hold address information, the registry can look up and store the street address and not lose the facility name due to a shortage of space.

The presence of a second street address field to hold additional address information also aids in follow-up. For instance, *Addr At DX--No & Street* [2330] should contain a street address only. However, it is important to retain any known PO Box information when linking for cohort studies or patient contact studies. Retaining facility name can also help correct errors in *Addr At DX--No & Street* [2330] or assist with geocoding or consolidation. Additionally, researchers can use this field to verify if geographic areas of high risk are driven by location of facilities, such as jails, nursing homes, or homeless shelters.

### Coding Instructions

1. Record the place or facility (for example, a nursing home or name of an apartment complex) of the patient's usual residence when the tumor was diagnosed. Do not use this item for information stored in other address items such as *Addr At DX--NO & Street* [2330].
2. Record a full residential PO Box here (including city & zip code) or other non-physical, residential mailing address here.
3. Record HOMELESS here when the street address used is a shelter or diagnosing facility for persons with no usual residence.
4. Leave blank if this address space is not needed.
5. If the patient has multiple tumors, the address may be different for subsequent primaries.
6. Do not use this data item to record the number and street address of the patient.
7. Do not update this data item if the patient's address changes. Only update based on improved information on the residential address at time of diagnosis.
8. See Residency Rules in Section One for further instructions.



Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## City/Town at Diagnosis (City or Town)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
70	50	74-123	See Coding Instructions	1996+	01/10

### Description

Identifies the name of the city or town in which the patient resides at the time the tumor is diagnosed and treated.

### Rationale

The city or town is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

### Coding Instructions

[Refer to Appendix D: NH Town/Country & Zip Codes.](#)

- If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.
- If the patient has multiple malignancies, the city or town may be different for subsequent primaries.
- Do not update this data item if the patient's city or town of residence changes.
- See [Residency Rules](#) in Section One for further instructions.

### Examples

Code	Reason
CITY NAME	Do not use punctuation, special characters, or numbers. The use of capital letters is preferred by the USPS; it also guarantees consistent results in queries and reporting. Abbreviate where necessary.
UNKNOWN	If the patient's city or town is unknown.

## State at Diagnosis (State)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
80	2	124-125	See Coding Instructions	1996+	09/06, 01/10, 01/11, 01/12

### Description

Identifies the patient's state of residence at the time of diagnosis.

### Rationale

The state of residence is part of the patient's demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer clusters or environmental studies.

### Coding Instructions

[See Address and Residency Rules in Section One for further instructions.](#)

[Refer to Appendix D: NH Town/Country & Zip Codes.](#)

- Use U.S. Postal Service abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the tumor is diagnosed and treated.
- If the patient has multiple tumors, the state of residence may be different for subsequent primaries.
- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.
- Do not update this data item if the patient's state of residence changes.

Code	Label	Code	Label	Code	Label
AL	Alabama	MB	Manitoba	PW	Palau
AK	Alaska	MH	Marshall Islands	PA	Pennsylvania
AB	Alberta	MD	Maryland	PE	Prince Edward Island
AS	American Samoa	MA	Massachusetts	PR	Puerto Rico
AA	APO/FPO Armed Services America	MI	Michigan	QC	Quebec
AE	APO/FPO Armed Services Europe	FM	Micronesia	ZZ	Residence unknown.
AP	APO/FPO Armed Services Pacific	MN	Minnesota	XX	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is known.

Code	Label	Code	Label	Code	Label
AZ	Arizona	MS	Mississippi	YY	Resident of a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>unknown</i> .
AR	Arkansas	MO	Missouri	CD	Resident of Canada and the province is <i>unknown</i> .
BC	British Columbia	MT	Montana	US	Resident of the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i>
CA	California	NE	Nebraska	RI	Rhode Island
CD	Canada, province unknown	NV	Nevada	SK	Saskatchewan
CO	Colorado	NB	New Brunswick	SC	South Carolina
CT	Connecticut	NH	New Hampshire	SD	South Dakota
DE	Delaware	NJ	New Jersey	US	United States, state unknown
DC	District of Columbia	NM	New Mexico	TN	Tennessee
FL	Florida	NY	New York	TX	Texas
GA	Georgia	NL	Newfoundland and Labrador	UT	Utah
GU	Guam	NC	North Carolina	VT	Vermont
HI	Hawaii	ND	North Dakota	VI	Virgin Islands
ID	Idaho	NT	Northwest Territories	VA	Virginia
IL	Illinois	NS	Nova Scotia	WA	Washington
IN	Indiana	NU	Nunavut	WV	West Virginia
IA	Iowa	OH	Ohio	WI	Wisconsin
KS	Kansas	OK	Oklahoma	WY	Wyoming
KY	Kentucky	ON	Ontario	YT	Yukon
LA	Louisiana	OR	Oregon		
ME	Maine	UM	Outlying Islands		

## Postal Code at Diagnosis (Zip Code)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
100	9	126-134	See Coding Instructions	All Years	01/04

### Description

Identifies the postal code of the patient's address at diagnosis.

### Rationale

The postal code is part of the patient's demographic data and has multiple uses. It will provide a referral pattern report and allow analysis of cancer clusters or environmental studies.

### Coding Instructions

[Refer to Appendix D: NH Town/Country & Zip Codes.](#)

- For U.S. residents, record the patient's nine-digit extended postal code at the time of diagnosis and treatment.
- For Canadian residents, record the six-character postal code.
- When available, record the postal code for other countries.
- If the patient has multiple malignancies, the postal code may be different for subsequent primaries.
- Do not update this data item if the patient's postal code changes.
- See [Residency Rules](#) in Section One for further instructions.

Code	Definition
(fill spaces)	The patient's nine-digit U.S. extended postal code. Do not record hyphens.
60611_ _ _ _	When the nine-digit extended U.S. ZIP Code is not available, record the five-digit postal code, left justified, followed by four blanks.
M6G2S8_ _ _	The patient's six-character Canadian postal code left justified, followed by three blanks.
88888_ _ _ _ or 888888888	Permanent address in a country other than Canada, United States, or U.S. possessions and postal code is unknown.
99999_ _ _ _ or 999999999	Permanent address in Canada, United States, or U.S. possession and postal code is unknown.

## Address at Dx--Country

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
102	3	464-466	See Coding Instructions	1996+	Added 01/13

### Description

Identifies the country of the patient's residence at the time of diagnosis. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

### Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

### Coding Instructions

- This item corresponds to the other Addr at DX items (state, postal code).
- Do not change if the patient moves to another country. Patients with more than one tumor may have different countries at diagnosis, however.
- See [Appendix C](#) for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

### Examples

Code	Label
USA	United States
CAN	Canada

## County at Diagnosis

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
90	3	135-137	001-997, 998, 999	1996+	09/06, 01/10, 01/15

### Description

Identifies the county of the patient's residence at the time the reportable tumor is diagnosed.

### Rationale

This data item may be used for epidemiological purposes. For example, to measure the cancer incidence in a particular geographic area.

[Refer to Appendix D: NH Town/Country & Zip Codes.](#)

### Coding Instructions

- For U.S. residents, use codes issued by the Federal Information Processing Standards (FIPS) publication Counties and Equivalent Entities of the United States, Its Possessions, and Associated areas. This publication is available in a reference library or can be accessed on the Internet through the U.S. EPA's Envirofacts Data Warehouse and Applications Web site at <https://www.epa.gov/>.
- If the patient has multiple tumors, the county codes may be different for each tumor.
- If the patient is a non-U.S. resident, use code 999.
- Do not update this data item if the patient's county of residence changes.

Code	Label	Definition
001-997	County at diagnosis	Valid FIPS code.
998	Outside state/county code unknown	Known town, city, state, or country of residence, but county code not known and a resident outside of the state of the reporting institution (must meet all criteria).
999	County unknown	The county of the patient is unknown, or the patient is not a United States resident. County is not documented in the patient's medical record.



## Birthplace—State

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
252	2	470-471	See Coding Instructions	2013+	01/13

### Description

Records the patient's state of birth.

### Rationale

This data item is used to evaluate medical care delivery to special populations and to identify populations at special risk for certain cancers.

### Coding Instructions

- Use the most specific code.
- This item corresponds to [Birthplace—Country](#).
- See [Appendix C](#) for a list of state codes and their respective country codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software from the former Place of Birth.

### Examples

Code	Reason
IL	If the state in which the patient was born is Illinois, then use the USPS code for the state of Illinois.
XX	Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is known</i> (code the country in <i>Birthplace-Country</i> ).
YY	Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country <i>is unknown</i> .
US	Born in the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i> .
CD	Born in Canada and the province is <i>unknown</i> .
ZZ	Place of birth is unknown, not mentioned in patient record.

## Birthplace—Country

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
254	3	472-474	See Coding Instructions	2013+	01/13

### Description

Identifies the country where the patient was born. The codes are based on International Organization for Standardization (ISO) 3166-1 alpha-3 country codes, with some custom codes.

### Rationale

The country code is part of the patient's demographic data and has multiple uses. It may be useful for understanding risk factors, assessment of patient prognosis, and chances for survival.

### Coding Instructions

- This item corresponds to [Birthplace—State](#).
- See [Appendix C](#) for a list of country codes and their respective state codes.
- This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software.

### Examples

Code	Reason
USA	United States
CAN	Canada
ZZU	Place of birth is unknown, not mentioned in patient record.

## Date of Birth

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
240	8	226-233	CCYYMMDD	All Years	01/10

### Description

Identifies the date of birth of the patient.

### Rationale

This data item is useful for patient identification. It is also useful when analyzing tumors according to age cohort.

### Coding Instructions

- Record the patient's date of birth as indicated in the patient record. For single-digit day or month, record with a lead 0 (for example, September is 09). Use the full four-digit year for year.
- For in utero diagnosis and treatment, record the actual date of birth. It will follow one or both dates for those events.
- If only the patient age is available, calculate the year of birth from age and the year of diagnosis and leave day and month of birth unknown (for example, a 60 year old patient diagnosed in 2010 is calculated to have been born in 1950).
- If month is unknown, the day is coded unknown. If the year cannot be determined, the day and month are both coded unknown.
- If the date of birth cannot be determined at all, record the reason in Date of Birth Flag [241]
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about date entry in their own systems. The traditional format for Date of Birth is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Birth transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The Date of Birth Flag [241] is used to explain why Date of Birth is not a known date. See [Date of Birth Flag](#) for an illustration of the relationships among these items.

## Date of Birth Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
241	2	234-235	12, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, Date of Birth [240].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if [Date of Birth](#) [240] has a full or partial date recorded.
- Code 12 if the Date of Birth cannot be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Label
12	A proper value is applicable but not known (for example, birth date is unknown)
(Blank)	A valid date value is provided in item <i>Date of Birth</i> [240]

## Age at Diagnosis

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
230	3	223-225	000–120, 999	All Years	09/08

### Description

Records the age of the patient at his or her last birthday before diagnosis.

### Rationale

This data item is useful for patient identification. It may also be useful when analyzing tumors according to specific patient age.

### Coding Instructions

**NH-38**

- If the patient has multiple primaries, then the age at diagnosis may be different for subsequent primaries.

Code	Label
000	Less than one year old; diagnosed <i>in utero</i>
001	One year old but less than two years old
002	Two years old
...	Actual age in years
120	One hundred twenty years old
999	Unknown age

## Race 1

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
160	2	207-208	01–08, 10–17, 20–22, 25–28, 30–32, 96–99	All Years	01/04, 09/08, 01/10, 01/12

### Description

Identifies the primary race of the person.

### Rationale

Racial origin captures information used in research and cancer control activities comparing stage at diagnosis and/or treatment by race. The full coding system should be used to allow for an accurate national comparison.

### Coding Instructions

- Race 1 is the field used to compare with race data on cases diagnosed prior to January 1, 2000.
- “Race” is analyzed with Spanish/Hispanic Origin [190]. Both items must be recorded. All tumors for the same patient should have the same race code.
- If the person is multiracial and one of the races is white, code the other race(s) first with white in the next race field.
- If the person is multiracial and one of the races is Hawaiian, code Hawaiian as Race 1, followed by the other race(s).
- A known race code (other than blank or 99) must not occur more than once.
- Codes 08–13 became effective with diagnoses on or after January 1, 1988.
- Code 14 became effective with diagnoses on or after January 1, 1994.
- In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
- Codes 20–97 became effective with diagnoses on or after January 1, 1991. SEER participants in San Francisco, San Jose–Monterey, and Los Angeles are permitted to use codes 14 and 20–97 for cases diagnosed after January 1, 1987.

Code	Label	Code	Label
01	White	17	Pakistani
02	Black	20	Micronesian, NOS
03	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)	21	Chamorro/Chamoru
04	Chinese	22	Guamanian, NOS
05	Japanese	25	Polynesian, NOS
06	Filipino	26	Tahitian
07	Hawaiian	27	Samoan

Code	Label	Code	Label
08	Korean	28	Tongan
10	Vietnamese	30	Melanesian, NOS
11	Laotian	31	Fiji Islander
12	Hmong	32	New Guinean
13	Kampuchean (Cambodian)	96	Other Asian, including Asian, NOS and Oriental, NOS
14	Thai	97	Pacific Islander, NOS
15	Asian Indian or Pakistani, NOS (formerly code 09)	98	Other
16	Asian Indian	99	Unknown

### Examples

Code	Reason
01	A patient was born in Mexico of Mexican parentage. Code also <i>Spanish/Hispanic Origin</i> [190].
02	A black female patient.
05	A patient has a Japanese father and a Caucasian mother.

## Race 2, 3, 4, 5

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
161	2	race2	01-08, 10-17, 20-22, 25-28, 30-32, 88, 96-99, blank	2000+	2004, 2008, 2010, 2012, 2021
162		race3			
163		race4			
164		race5			

### Description

Identifies the patient's race. Race and ethnicity are defined by specific physical, hereditary and cultural traditions or origins, not necessarily by birthplace, place of residence, or citizenship. 'Origin' is defined by the U.S. Census Bureau as the heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person's parents or ancestors before their arrival in the United States.

### Rationale

Because race has a significant association with cancer rates and outcomes, a comparison between areas with different racial distributions may require an analysis of race to interpret the findings. The race codes listed correspond closely to race categories used by the U.S. Census Bureau to allow calculation of race-specific incidence rates. The full coding system should be used to allow accurate national comparison and collaboration, even if the state population does not include many of the race categories.

### Coding Instructions

The five race data items (Race 1 – Race 5) make it possible to code multiple races for one person, consistent with the 2000 Census. All resources in the facility, including the medical record, face sheet, physician and nursing notes, photographs, and any other sources, must be used to determine race. If a facility does not print race in the medical record but does maintain it in electronic form, the electronic data must also be reviewed.

1. "Race" is analyzed with [Spanish/Hispanic Origin](#) [190]. Both items must be recorded. All tumors for the same patient should have the same race code.
2. If [Race 1](#) [160] is coded 99, then Race 2-5 must be coded 99.
3. If [Race 2](#) [161] is coded 88 or 99, then Race 3-5 must be coded with the same value.
4. Codes 08–13 became effective with diagnoses on or after January 1, 1988.
5. Code 14 became effective with diagnoses on or after January 1, 1994.
6. In 2010, code 09 was converted to the new code 15, and codes 16 and 17 were added.
7. Codes 20–97 became effective with diagnoses on or after January 1, 1991.
8. See the instructions for [Race 1](#) [160] for coding sequences for entering multiple races.

### Codes and Definitions

See the instructions for [Race 1](#) [160] for codes and code definitions.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry](#) (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

Source 3: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.



## Spanish Origin–All Sources (Spanish/Hispanic Origin)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
190	1	219-219	0–7, 9	All Years	09/04

### Description

Identifies persons of Spanish or Hispanic origin.

### Rationale

This code is used by hospital and central registries to identify whether or not the person should be classified as “Hispanic” for purposes of calculating cancer rates. Hispanic populations have different patterns of occurrence of cancer from other populations that may be included in the 01 (White category) of *Race 1*.

### Coding Instructions

- Persons of Spanish or Hispanic origin may be of any race, but these categories are generally not used for Native Americans, Filipinos, or others who may have Spanish names.
- Code 0 (Non-Spanish; non-Hispanic) for Portuguese and Brazilian persons.
- If the patient has multiple tumors, all records should have the same code.

Code	Label
0	Non-Spanish; non-Hispanic
1	Mexican (includes Chicano)
2	Puerto Rican
3	Cuban
4	South or Central America (except Brazil)
5	Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic)
6	Spanish, NOS; Hispanic, NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1–5)
7	Spanish surname only (The only evidence of the person’s Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic)
8	Dominican Republic (for use with patients who were diagnosed with cancer on January 1, 2005, or later)
9	Unknown whether Spanish or not; not stated in patient record

## Sex

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
220	1	222-222	1–6, 9	All Years	01/15, 01/16

## Description

Identifies the sex of the patient.

## Rationale

This data item is used to compare cancer rates and outcomes by site. The same sex code should appear in each medical record for a patient with multiple tumors.

## Coding Instructions

**NH-39**

- Record the patient’s sex as indicated in the medical record.
- Natality for transsexuals was added for use in 2015, but may be applied for earlier diagnoses.
- The definition of code 3 was updated to “Other (intersex, disorders of sexual development/DSD)” in 2016.

Code	Label
1	Male
2	Female
3	Other (intersex, disorders of sexual development/DSD)
4	Transsexual, NOS
5	Transsexual, natal male
6	Transsexual, natal female
9	Not stated in patient record

## Marital Status at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
150	1	maritalStatusAtDx	1-6, 9	All Years	

### Description

Code for the patient's marital status at the time of diagnosis for the reportable tumor. If the patient has multiple tumors, marital status may be different for each tumor.

### Rationale

Incidence and survival with certain cancers vary by marital status. The item also helps in patient identification.

### Coding Instructions

1. Assign code 2 [Married (including common law)] when the patient declares him/herself as married. Marriage is self-reported.
2. Assign code 6 when the patient is not married and is in a domestic partner relationship other than common law marriage.
3. Assign code 9 for death certificate only (DCO) cases when marital status at the time of diagnosis is unknown.

### Codes

Code	Label
1	Single (never married)
2	Married (including common law*)
3	Separated
4	Divorced
5	Widowed
6	Unmarried or Domestic Partner (same sex or opposite sex, registered or unregistered, other than common law marriage) (effective for cases diagnosed 01/01/2011 and forward)
9	Unknown

\**Definition Common Law Marriage:* A couple living together for a period of time and declaring themselves as married to friends, family, and the community, having never gone through a formal ceremony or obtained a marriage license.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

## Primary Payer at Diagnosis

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
630	2	792-793	01, 02, 10, 20, 21, 31, 35, 60–68, 99	All Years	06/05, 01/10

### Description

Identifies the patient's primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

### Rationale

This item is used in financial analysis and as an indicator for quality and outcome analyses. Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires the patient admission page to document the type of insurance or payment structure that will cover the patient while being cared for at the hospital.

### Coding Instructions **NH-40**

- If the patient is diagnosed at the reporting facility, record the payer at the time of diagnosis.
- If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known record the payer when the patient is initially admitted for treatment.
- Record the type of insurance reported on the patient's admission page.
- Codes 21 and 65–68 are to be used for patients diagnosed on or after January 1, 2006.
- If more than one payer or insurance carrier is listed on the patient's admission page record the first.
- If the patient's payer or insurance carrier changes, do not change the initially recorded code.

Code	Label	Definition
01	Not insured	Patient has no insurance and is declared a charity write-off.
02	Not insured, self-pay	Patient has no insurance and is declared responsible for charges.
10	Insurance, NOS	Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68.
20	Private insurance: Managed Care, HMO, or PPO	An organized system of prepaid care for a group of enrollees usually within a defined geographic area. Generally formed as one of four types: a group model, an independent physician association (IPA), a network, or a staff model. "Gate-keeper model" is another term for describing this type of insurance.
21	Private insurance: Fee-for-Service	An insurance plan that does not have a negotiated fee structure with the participating hospital. Type of insurance plan not coded as 20.
31	Medicaid	State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs.  Medicaid other than described in code 35.

Code	Label	Definition
35	Medicaid administered through a Managed Care plan	Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
60	Medicare without supplement, Medicare, NOS	Federal government funded insurance for persons who are 65 years of age or older, or are chronically disabled (Social Security insurance eligible). Not described in codes 61, 62, or 63.
61	Medicare with supplement, NOS	Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare.
62	Medicare administered through a Managed Care plan	Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
63	Medicare with private supplement	Patient has Medicare and private insurance to pay costs not covered by Medicare.
64	Medicare with Medicaid eligibility	Federal government Medicare insurance with State Medicaid administered supplement.
65	TRICARE	Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military dependents, retirees, and their dependents.  Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).
66	Military	Military personnel or their dependents who are treated at a military facility.
67	Veterans Affairs	Veterans who are treated in Veterans Affairs facilities.
68	Indian/Public Health Service	Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service.  Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service.
99	Insurance status unknown	It is unknown from the patient's medical record whether or not the patient is insured.

## Examples

Code	Reason
01	An indigent patient is admitted with no insurance coverage.

Code	Reason
20	A patient is admitted for treatment and the patient admission page states the primary insurance carrier is an HMO.
62	A 65-year-old male patient is admitted for treatment and the patient admission page states the patient is covered by Medicare with additional insurance coverage from a PPO.

## Height at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
9960	2		00-99	2011+	

### Description

Height of patient at the time of diagnosis for the reportable tumor. Different tumors for the same patient may have different values. It should be collected from source records once for each cancer. Height should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient's hospital medical record or physician office record. The height entered should be that listed at or around the time of diagnosis. If no height was listed on the date of diagnosis, please use the height recorded on the date closest to the date of diagnosis and before treatment was started.

### Coding Instructions

- Entered as 2-digit numbers and measured in inches (note that 1 foot=12 inches).
- All inches values should be rounded to the nearest whole number; values with decimal place x .5 and greater should be rounded up (e.g., 62.5 inches would be 63 inches).
- When coding cases that include chemotherapy or other drugs, please exhaust all potential sources for height before using code "99" ("unknown").
- For all sites/histologies, "blanks" are not permitted and code "99" should be used to reflect unknown height. The CDC will use the volume of cases coded to "99" to help determine the availability of information related to height in the medical record.

### Codes

Code	Label
01-97	Enter height in 2-digit numbers measured in inches
98	98 inches or greater
99	Unknown height

## Weight at DX

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
9961	3		000-999	2011+	

### Description

Weight of patient at the time of diagnosis for the reportable tumor. Different tumors for the same patient may have different values. It should be collected from source records once for each cancer. Weight should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient's hospital medical record or physician office record. The weight entered should be that listed on the date of diagnosis. If no weight was listed on the date of diagnosis, please use the weight recorded on the date closest to the date of diagnosis and before treatment was started.

### Coding Instructions

- Entered as 3-digit numbers and measured in pounds (note that 1 kg = 2.2 pounds).
- All pound values should be rounded to the nearest whole number; values with decimal place x.5 and greater should be rounded up (e.g., 155.5 pounds would be 156 pounds).
- Patients with a weight of less than 100 pounds should be recorded with a leading 0.
- When coding cases that include chemotherapy or other drugs, please exhaust all potential sources for weight before using code "999" ("unknown").
- For all sites/histologies, "blanks" are not permitted and code "999" should be used to reflect unknown weight. The CDC will use the volume of cases coded to "999" to help determine the availability of information related to weight in the medical record. (added July 2011)

### Codes

Code	Label
001-998	Enter weight in 3-digit numbers measured in pounds
999	Unknown weight



## Tobacco Use Smoking Status

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
344	1	tobaccoUseSmokingStatus	0-3, 9	2022	

### Description

Record the patient's past or current use of tobacco (cigarette, cigar and/or pipe). Tobaccos smoking history can be obtained from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or Nursing Assessment section, or other available source from the patient's hospital medical record or physician office record.

### Rationale

Cigarette smoking is the leading preventable cause of death in the US and a major risk factor for cancer. Reducing tobacco use is a focus of CDC's National Center for Chronic Disease Prevention and Health Promotion. Reliable registry-based tobacco use data will help public health planners and clinicians target populations of cancer survivors for tobacco cessation. In addition, individual states have reported smoking data on patients are a useful covariate risk factor for cancer cluster investigations. Some state central cancer registries collect tobacco use data, but these variables are not standardized among registries. In addition to describing tobacco use patterns and trends in patients diagnosed with cancer, the collection of cigarette smoking history can enable researchers to better understand the association of cigarette smoking to cancer outcomes. Cigarette use data at diagnosis may help health professionals better understand how tobacco use impacts cancer prognosis, including how smoking is related to effectiveness of treatment and survival. In addition, this information is important to target and assess tobacco control efforts to cancer survivors and their families.

### Coding Instructions

1. Record the past or current use of tobacco
  - a. Tobacco use includes cigarette, cigar, and/or pipe
2. Do not record the patient's past or current use of e-cigarette vaping devices
3. Assign code 2 when the medical record indicates patient has smoked tobacco in the past but does not smoke now
  - a. If there is evidence in the medical record that the patient quit recently (within 30 days prior to diagnosis), assign code 1, current smoker. The 30 days prior information, if available, is intended to differentiate patients who may have quit recently due to symptoms that lead to a cancer diagnosis.
4. Assign code 9 when the medical record only indicates "No"

### Codes

Code	Label
0	Never used
1	Current some day smoker
2	Former smoker
3	Smoker, current status unknown
9	Unknown if ever smoked

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). *SEER Program Coding and Staging Manual 2022*. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.

## Text--Usual Occupation

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
310	100	textUsualOccupation	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for information about the patient's usual occupation, also known as usual type of job or work.

### Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies occupational groups in which cancer screening or prevention activities may be beneficial.

The data item "usual occupation" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.<sup>25</sup> See related materials in reference list, Chapter VII.

### Abstracting Instructions

Record the patient's usual occupation (i.e., the kind of work performed during most of the patient's working life before diagnosis of this tumor). Do not record "retired." If usual occupation is not available or is unknown, record the patient's current or most recent occupation, or any available occupation.

If later documentation in the patient's record provides an occupation that is more likely to be the usual occupation than what was originally recorded, facility registrars are encouraged to update the abstract with the new information. However, it is not the responsibility of the facility registrars to update abstracts with occupation information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

If the patient was a homemaker and also worked outside the home during most of his/her adult life, record the usual occupation outside the home; if the patient was a homemaker and did not work outside the home for most of his/her adult life, record "homemaker." If the patient was not a student or homemaker and had never worked, record "never worked" as the usual occupation.

If no information is available, record "unknown."

This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Usual Industry

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
320	100	textUsualIndustry	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for information about the patient's usual industry, also known as usual kind of business/industry.

### Rationale

Used to identify new work-related health hazards; serves as an additional measure of socioeconomic status; identifies industrial groups or worksite-related groups in which cancer screening or prevention activities may be beneficial.

The data item "usual industry" is defined identically as on death certificates and conforms to the 1989 revision of the U.S. Standard Certificate of Death.<sup>25</sup> See related materials in reference list, Chapter VII.

### Abstracting Instructions

Record the primary type of activity carried on by the business/industry at the location where the patient was employed for the most number of years before diagnosis of this tumor. Be sure to distinguish among "manufacturing," "wholesale," "retail," and "service" components of an industry that performs more than one of these components.

If the primary activity carried on at the location where the patient worked is unknown, it may be sufficient for facility registrars to record the name of the company (with city or town) in which the patient performed his/her usual industry. In these situations, if resources permit, a central or regional registry may be able to use the employer name and city/town to determine the type of activity conducted at that location.

As noted in the *Text--Usual Occupation* [310] section, in those situations where the usual occupation is not available or is unknown, the patient's current or most recent occupation is recorded, if available. The information for industry should be based upon the information in occupation. Therefore, if current or most recent occupation rather than usual occupation was recorded, record the patient's current or most recent business/industry.

If later documentation in the patient's record provides an industry that is more likely to be the usual industry than what was originally recorded, facility registrars are encouraged to update the abstract with the new information. However, it is not the responsibility of the facility registrars to update abstracts with industry information provided on death certificates. Comparison with death certificate information should be the function of a central or regional registry.

There should be an entry for *Text--Usual Industry* if any occupation is recorded. If no information is available regarding the industry in which the reported occupation was carried out, record "unknown." If the patient was not a student or homemaker and had never worked, record "never worked" as the usual industry. This data item usually is collected only for patients who are age 14 years or older at the time of diagnosis.

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Comorbidities and Complications #1 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3110	5	1527-1531	00000, 00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

[See Comorbidities and Complications in Section One for general overview.](#)

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes only for patients diagnosed before 2018. Use Secondary Diagnosis #1 [3780] to record ICD-10-CM codes for patients diagnosed in 2018 and later. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
  - Surgically treated patients:
    - following the most definitive surgery of the primary site
    - following other non-primary site surgeries
  - Non-surgically treated patients:
    - following the first treatment encounter/episode
  - In cases of non-treatment:
    - following the last diagnostic/evaluative encounter
- If the data item Readmission to the Same Hospital within 30 Days of Surgical Discharge [3190] is coded 1, 2, or 3, report Comorbidities and Complications ICD-9-CM codes appearing on the "readmission" discharge abstract.
- If no ICD-9-CM secondary diagnoses were documented, then code 00000 in this data item, and leave the remaining Comorbidities and Complications data items blank.
- If fewer than 10 ICD-9-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Comorbidities and Complications data items blank.

Code	Label
00000	No comorbid conditions or complications documented.
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

### Examples

Code	Reason
49600	COPD (ICD-9-CM code 496)
25001	Type 1 diabetes mellitus (ICD-9-CM code 250.01)
E8732	The patient was inadvertently exposed to an overdose of external beam radiation (ICD-9-CM code E873.2)
E9300	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-9-CM code E930.0)
V1030	The patient has a personal history of breast cancer (ICD-9-CM code V10.3)

## Comorbidities and Complications #2 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3120	5	1532-1536	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #2 [3782] to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only one comorbid condition or complication is listed, then leave this data item blank.
- If only two comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #3 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3130	5	1537-1541	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #3 [3784] to record ICD-10-CM codes. During adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only two comorbid conditions or complications are listed, then leave this data item blank.
- If only three comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #4 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3140	5	1542-1546	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #4 [3786] to record ICD-10-CM codes. During adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only three comorbid conditions or complications are listed, then leave this data item blank.
- If only four comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.



## Comorbidities and Complications #5 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3150	5	1547-1551	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #5 [3788] to record ICD-10-CM codes. During adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only four comorbid conditions or complications are listed, then leave this data item blank.
- If only five comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #6 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3160	5	1552-1556	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2002-2017	06/05, 01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #6 [3790] to record ICD-10-CM codes. During adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- If only five comorbid conditions or complications are listed, then leave this data item blank.
- If only six comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #7 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3161	5	1557-1561	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2006-2017	01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #7 [3792] to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Comorbidities and Complications #7 is to be used for patients diagnosed on or after January 1, 2006.
- If only six comorbid conditions or complications are listed, then leave this data item blank.
- If only seven comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #8 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3162	5	1562-1566	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2006-2017	01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #8 [3794] to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Comorbidities and Complications #8 is to be used for patients diagnosed on or after January 1, 2006.
- If only seven comorbid conditions or complications are listed, then leave this data item blank.
- If only eight comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #9 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3163	5	1567-1571	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2006-2017	01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #9 [3796] to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Comorbidities and Complications #9 is to be used for patients diagnosed on or after January 1, 2006.
- If only eight comorbid conditions or complications are listed, then leave this data item blank.
- If only nine comorbid conditions or complications are listed, then code the diagnoses listed and leave the remaining Comorbidities and Complications items blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Comorbidities and Complications #10 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3164	5	1572-1576	00100–13980, 24000–99990, E8700–E8799, E9300–E9499, V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049, Blank	2006-2017	01/11, 01/12, 01/13, 01/15, 01/18

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-9-CM codes. Use Secondary Diagnosis #10 [3796] to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Comorbidities and Complications #10 is to be used for patients diagnosed on or after January 1, 2006.
- If only nine comorbid conditions or complications are listed, then leave this data item blank.
- For further Instructions for Coding, see [Comorbidities and Complications #1](#) [3110].

Code	Label
00100–13980, 24000–99990	Comorbid conditions: Omit the decimal point between the third and fourth characters.
E8700–E8799, E9300–E9499	Complications: Omit the decimal point between the fourth and fifth characters.
V0720–V0739, V1000–V1590, V2220–V2310, V2540, V4400–V4589, V5041–V5049	Factors affecting health status: Omit the decimal point between the fourth and fifth characters.

## Secondary Diagnosis #1 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3780	7	1577-1583	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

[See Secondary Diagnosis rules in Section One for general overview.](#)

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #1 [3110] to record ICD-9-CM codes only for patients diagnosed before 2018. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available.
- Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.
- Report the secondary diagnoses for this cancer using the following priority rules:
  - Surgically treated patients:
    - following the most definitive surgery of the primary site
    - following other non-primary site surgeries
  - Non-surgically treated patients:
    - following the first treatment encounter/episode
  - In cases of non-treatment:
    - following the last diagnostic/evaluative encounter
- If the data item Readmission to the Same Hospital within 30 Days of Surgical Discharge [3190] is coded 1, 2, or 3, report Secondary Diagnosis ICD-10-CM codes appearing on the "readmission" discharge abstract.

- If no ICD-10-CM secondary diagnoses were documented, then code 0000000 in this data item, and leave the remaining Secondary Diagnosis data items blank.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)
0000000	No applicable ICD-10-CM codes are recorded in this patient's record



## Secondary Diagnosis #2 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3782	7	1584-1590	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #2 [3120] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #3 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3784	7	1591-1597	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #3 [3130] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #4 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3786	7	1598-1604	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #4 [3140] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #5 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3788	7	1605-1611	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #5 [3150] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #6 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3790	7	1612-1618	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #6 [3160] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #7 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3792	7	1619-1625	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #7 [3161] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #8 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3794	7	1626-1632	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #8 [3162] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## Secondary Diagnosis #9 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3796	7	1633-1639	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ, Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #9 [3163] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)



## Secondary Diagnosis #10 (Secondary Diagnoses)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3798	7	1640-1646	0000000; all values beginning with A-B, E, G-P, R-S; and the following ranges: T36-T50996ZZ, U070-U071, Y62- Y849ZZZ, Z1401-Z229ZZZ, Z681- Z6854ZZ, Z751-Z753, Z80-Z809ZZZ, Z8500-Z9989ZZ Blank	2015+	01/15, 02/21, 01/22

### Description

Records the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM values.

### Rationale

Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

### Coding Instructions

- Use this item to record ICD-10-CM codes. Use Comorbidities and Complications #10 [3164] to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
- Note that, while the ICD-9-CM Comorbidities and Complications codes were to be followed by zeroes if they did not fill the field, only the actual ICD-10-CM code is to be entered for Secondary Diagnosis fields, leaving blanks beyond those characters.
- Omit the decimal points when coding.
- If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining Secondary Diagnosis data items blank.

### Examples

Code	Reason
J449	Chronic obstructive pulmonary disease, unspecified (ICD-10-CM code J44.9)
E119	Type 2 diabetes mellitus without complications (ICD-10-CM code E11.9)
Y632	The patient was inadvertently exposed to an overdose of radiation during a medical procedure (ICD-10-CM code E873.2)
T360X5	During hospitalization the patient has an adverse reaction to Ampicillin, a semisynthetic form of penicillin (ICD-10-CM code T36.0X5)
Z853	The patient has a personal history of breast cancer (ICD-10-CM code Z85.3)

## NPI--Physician--Managing

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2465	10	npiPhysicianManaging	10-digit NPI code (9-digit NPI integer plus 1 check digit), blank	2007+	2007, 2008, 2021

### Description

Identifies the physician who is responsible for the overall management of the patient during diagnosis and/or treatment of this cancer.

NPI, a unique identification number for US health care providers, was scheduled for 2007-2008 implementation by the Centers for Medicare & Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008.

### Rationale

Used to monitor patient care. The managing physician is responsible for the patient's work-up, plans the treatment, and directs the delivery of patient care in accordance with CoC Standards. In most cases, the managing physician is responsible for AJCC staging.

### Coding Instructions

- Record the 10-digit NPI for the physician responsible for managing the patient's care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a managing physician for the patient, this item should not be changed even if a different managing physician is assigned.

Code	Label
(fill spaces)	10-digit NPI number for the managing physician.
(leave blank)	NPI for the managing physician is unknown or not available.

*Note:* This item is not supported by CoC as of January 1, 2021.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## NPI--Physician--Follow-Up

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2465	10	npiPhysicianFollowUp	10-digit NPI code (9-digit NPI integer plus 1 check digit), blank	2007+	2007, 2008, 2011, 2021

### Description

Records the NPI (National Provider Identifier) code for the physician currently responsible for the patient's medical care.

NPI, a unique identification number for US health care providers, was scheduled for 2007-2008 implementation by the Centers for Medicare & Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For billing purposes, large practices and large group providers were required to use NPI codes by May 2007; small health plans were required to use NPI codes by May 2008.

### Rationale

Used to monitor post-treatment patient care. The following physician is the first contact for obtaining information on a patient's status and subsequent treatment. This information may be used for outcomes studies.

### Coding Instructions

- Record the 10-digit NPI for the physician currently responsible for the patient's medical care.
- Check with the billing or health information departments to determine the physician's NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Change this data item when patient follow-up becomes the responsibility of another physician.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the following physician.
(leave blank)	NPI for the following physician is unknown or not available.

*Note:* This item is not supported by CoC as of January 1, 2021.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## NPI–Primary Surgeon

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2485	10	5051-5060	10 digits, Blank	2008+	04/07, 09/08, 01/11

### Description

Identifies the physician who performed the most definitive surgical procedure.

### Rationale

Administrative, physician, and service referral reports are based on this item.

### Coding Instructions

- Record the 10-digit NPI for the physician who performed the most definitive surgical procedure.
- Check with the billing or health information departments to determine the physician’s NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Do not update this item. Once the registry has designated a primary surgeon for the patient, the information should not be changed or updated even if the patient receives care from another surgeon.

Code	Label
(fill spaces)	10-digit NPI number for the primary surgeon.
(leave blank)	The patient did not have surgery. NPI for the primary surgeon is unknown or not available. The physician who performed the surgical procedure was not a surgeon (for example, general practitioner).

## NPI–Physician #3 (Radiation Oncologist–CoC Preferred)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2495	10	5069-5078	10 digits, Blank	2008+	4/07, 9/08, 1/10, 1/11

### Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this item identify the physician who performed the most definitive radiation therapy.

### Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

### Coding Instructions

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician’s NPI or search at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- Do not update this item. If the registry has designated a primary radiation oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another radiation oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the primary radiation oncologist.
(leave blank)	NPI for the primary radiation oncologist is unknown or not available.

## NPI–Physician #4 (Medical Oncologist–CoC Preferred)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2505	10	5087-5096	10 digits, Blank	2008+	4/07, 9/08, 1/10, 1/11, 1/12

### Description

Records the NPI for a physician involved in the care of the patient. The Commission on Cancer recommends that this data item identify the physician who gives the most definitive systemic therapy.

### Rationale

Administrative, physician, and service referral reports are based on this data item. It also can be used for follow-up purposes.

### Coding Instructions

- Record the 10-digit NPI for the physician.
- Check with the billing or health information departments to determine the physician’s NPI or search [at https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do](https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do).
- Do not update this item. If the registry has designated a primary medical oncologist for the patient, the information in this data item should not be changed or updated even if the patient receives care from another medical oncologist.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.

Code	Label
(fill spaces)	10-digit NPI number for the primary medical oncologist.
(leave blank)	NPI for the primary medical oncologist is unknown or not available.

## Cancer Identification

## Type of Reporting Source

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
500	1	typeOfReportingSource	1-8	All Years	

### Description

This variable codes the source documents used to abstract the majority of information on the tumor being reported. This may not be the source of original case finding (for example, if a case is identified through a pathology laboratory report review and all source documents used to abstract the case are from the physician's office, code this item 4).

### Rationale

The code in this field can be used to explain why information may be incomplete on a tumor. For example, death certificate only cases have unknown values for many data items, so one may want to exclude them from some analyses. The field also is used to monitor the success of non-hospital case reporting and follow-back mechanisms. All population-based registries should have some death certificate-only cases where no hospital admission was involved, but too high a percentage can imply both shortcomings in case-finding and that follow-back to uncover missed hospital reports was not complete.

### Coding Instructions

Code in the following priority order: 1, 2, 8, 4, 3, 5, 6, 7. This is a change to reflect the addition of codes 2 and 8 and to prioritize laboratory reports over nursing home reports. The source facilities included in the previous code 1 (hospital inpatient and outpatient) are split between codes 1, 2, and 8.

This data item is intended to indicate the completeness of information available to the abstractor. Reports from health plans (e.g., Kaiser, Veterans Administration, military facilities) in which all diagnostic and treatment information is maintained centrally and is available to the abstractor are expected to be at least as complete as reports for hospital inpatients, which is why these sources are grouped with inpatients and given the code with the highest priority.

Sources coded with '2' usually have complete information on the cancer diagnosis, staging, and treatment.

Sources coded with '8' would include, but would not be limited to, outpatient surgery and nuclear medicine services. A physician's office that calls itself a surgery center should be coded as a physician's office. Surgery centers are equipped and staffed to perform surgical procedures under general anesthesia. If a physician's office calls itself a surgery center, but cannot perform surgical procedures under general anesthesia, code as a physician office.

### Codes

Code	Label
1	Hospital inpatient; Managed health plans with comprehensive, unified medical records
2	Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent)
3	Laboratory only (hospital-affiliated or independent)
4	Physician's office/private medical practitioner (LMD)
5	Nursing/convalescent home/hospice
6	Autopsy only
7	Death certificate only
8	Other hospital outpatient units/surgery centers

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Casefinding Source

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
501	2	casefindingSource	10, 20-30, 40, 50, 60, 70, 75, 80, 85, 90, 95, 99	2006+	

### Description

This variable codes the earliest source of identifying information. For cases identified by a source other than reporting facilities (such as through death clearance or as a result of an audit), this variable codes the type of source through which the tumor was first identified. This data item cannot be used by itself as a data quality indicator. The timing of the casefinding processes (e.g., death linkage) varies from registry to registry, and the coded value of this variable is a function of that timing.

### Rationale

This data item will help reporting facilities as well as regional and central registries in prioritizing their casefinding activities. It will identify reportable tumors that were first found through death clearance or sources other than traditional reporting facilities. It provides more detail than "*Type of Reporting Source*."

### Coding Instructions

This variable is intended to code the source that first identified the tumor. Determine where the case was first identified and enter the appropriate code. At the regional or central level, if a hospital and a non-hospital source identified the case independently of each other, enter the code for the non-hospital source (i.e., codes 30-95 have priority over codes 10-29). If the case was first identified at a reporting facility (codes 10-29), code the earliest source (based on patient or specimen contact at the facility) of identifying information.

If a death certificate, independent pathology laboratory report, consultation-only report from a hospital, or other report was used to identify a case that was then abstracted from a different source, enter the code for the source that first identified the case, not the source from which it was subsequently abstracted. If a regional or central registry identifies a case and asks a reporting facility to abstract it, enter the code that corresponds to the initial source, not the code that corresponds to the eventual reporting facility.

### Codes

Code	Label
10	Reporting Hospital, NOS
20	Pathology Department Review (surgical pathology reports, autopsies, or cytology reports)
21	Daily Discharge Review (daily screening of charts of discharged patients in the medical records department)
22	Disease Index Review (review of disease index in the medical records department)
23	Radiation Therapy Department/Center
24	Laboratory Reports (other than pathology reports, code 20)
25	Outpatient Chemotherapy

Source: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Casefinding Source, cont.

### Codes, cont.

Code	Label
26	Diagnostic Imaging/Radiology (other than radiation therapy, codes 23; includes nuclear medicine)
27	Tumor Board
28	Hospital Rehabilitation Service or Clinic
29	Other Hospital Source (including clinic, NOS or outpatient department, NOS)
30	Physician-Initiated Case
40	Consultation-only or Pathology-only Report (not abstracted by reporting hospital)
50	Independent (non-hospital) Pathology-Laboratory Report
60	Nursing Home-Initiated Case
70	Coroner's Office Records Review
75	Managed Care Organization (MCO) or Insurance Records
80	Death Certificate (case identified through death clearance)
85	Out-of-State Case Sharing
90	Other Non-Reporting Hospital Source
95	Quality Control Review (case initially identified through quality control activities such as casefinding audit of a regional or central registry)
99	Unknown

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Class of Case

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
610	2	790-791	00, 10-14, 20-22, 30-38, 40-43, 49, 99	All Years	09/08, 01/10, 05/10, 01/11, 01/12, 01/14, 01/15

### Description

*Class of Case* divides cases into two groups. Analytic cases (codes 00–22) are those that are required by CoC to be abstracted because of the program’s primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and first course of treatment. Nonanalytic cases (codes 30–49 and 99) may be abstracted by the facility to meet central registry requirements or in response to a request by the facility’s cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted. **NH-41**

### Rationale

*Class of Case* reflects the facility’s role in managing the cancer and whether the cancer is required to be reported by CoC.

### Coding Instructions

- Code the Class of Case that most precisely describes the patient’s relationship to the facility.
- Code 00 applies only when it is known the patient went elsewhere for treatment. If it is not known that the patient actually went somewhere else, code Class of Case 10.
- It is possible that information for coding Class of Case will change during the patient’s first course of care. If that occurs, change the code accordingly.
- Document NPI–Institution Referred To [2425] or the applicable physician NPI (NAACCR #s 2585, 2495, 2505) for patients coded 00 to establish that the patient went elsewhere for treatment
- Code 34 or 36 if the diagnosis benign or borderline (Behavior 0 or 1) for any site is diagnosed before 2004 or for any site other than meninges (C70.\_), brain (C71.\_), spinal cord, cranial nerves, and other parts of central nervous system (C72.\_), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3) that was diagnosed in 2004 or later.
- Code 34 or 36 for carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2 or 8148/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III). **NH-42**
- Physicians who are not employed by the hospital but are under contract with it or have routine admitting privileges there are described in codes 10-12 and 41 as physicians with admitting privileges. Treatment provided in the office of a physician with admitting privileges is provided “elsewhere”. That is because care given in the physician’s office is not within the hospital’s realm of responsibility.
- If the hospital purchases a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital’s) or

not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physicians involved have routine admitting privileges or not, as with any other physician.

- “In-transit” care is care given to a patient who is temporarily away from the patient’s usual practitioner for continuity of care. If these cases are abstracted, they are Class of Case 31. Monitoring of oral medication started elsewhere is coded Class of Case 31. If a patient begins first course radiation or chemotherapy infusion elsewhere and continues at the reporting facility, and the care is not in-transit, then the case is analytic (Class of Case 21).
- First course maintenance treatment provided at the reporting facility prior to disease progression or recurrence is reportable IF the maintenance treatment is part of first course treatment plan and is provided by reported facility with documentation of prescription/administration. For example, if a patient is diagnosed and treated at another facility per the treatment plan was started on hormone therapy at the other facility then presents to your facility for continuation of hormone therapy the continuation of hormone therapy by your facility must be documented in medical record to assign class of case 21 (part of first course treatment elsewhere, part of first course of treatment at the reporting facility). This applies even if there is no longer active disease.

Code	Label
Analytic Classes of Case (Required by CoC to be abstracted by accredited programs)	
<i>Initial diagnosis at reporting facility or in a staff physician's office</i>	
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
10	Initial diagnosis at the reporting facility or in an office of a physician with admitting privileges AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Initial diagnosis in an office of a physician with admitting privileges AND part of first course treatment was done at the reporting facility
12	Initial diagnosis in an office of a physician with admitting privileges AND all first course treatment or a decision not to treat was done at the reporting facility
13	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
<i>Initial diagnosis elsewhere</i>	
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
21	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.
22	Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility
Classes of Case not required by CoC to be abstracted (May be required by Cancer Committee, state or regional registry, or other entity) <b>NH-43</b>	
<i>Patient appears in person at reporting facility</i>	
30	Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)
31	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care; or hospital provided care that facilitated treatment elsewhere (for example, stent placement)
32	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease)
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active)
34	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility
35	Case diagnosed before the program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility

Code	Label
36	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
37	Case diagnosed before the program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death
<i>Patient does not appear in person at reporting facility</i>	
40	Diagnosis AND all first course treatment given at the same staff physician's office
41	Diagnosis and all first course treatment given in two or more different offices of physicians with admitting privileges
42	Nonstaff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)
43	Pathology or other lab specimens only
49	Death certificate only <b>NH-44</b>
99	Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases).

## Examples

Code	Reason
00	Leukemia was diagnosed at the facility, and all care was given in an office of a physician with practice privileges. The treatment may be abstracted if the cancer committee desires, but the case is <i>Class of Case 00</i> .
13	Breast cancer was diagnosed at the reporting hospital and surgery performed there. Radiation was given at the hospital across the street with which the reporting hospital has an agreement.
10	Reporting hospital found cancer in a biopsy, but was unable to discover whether the homeless patient actually received any treatment elsewhere.
32	After treatment failure, the patient was admitted to the facility for supportive care.
11	Patient was diagnosed by a physician with practice privileges, received neoadjuvant radiation at another facility, then underwent surgical resection at the reporting facility.
42	Patients from an unaffiliated, free-standing clinic across the street that hospital voluntarily abstracts with its cases because many physicians work both at the clinic and the hospital.
31	Patient received chemotherapy while attending daughter's wedding in the reporting hospital's city, then returned to the originating hospital for subsequent treatments.

## NPI—Institution Referred From

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2415	10	4925-4934	10 digits, Blank	2008+	04/07, 09/08, 01/11

### Description

Identifies the facility that referred the patient to the reporting facility.

### Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

### Coding Instructions

- Record the 10-digit NPI for the referring facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI, or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

Code	Label
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the referring facility is unknown or not available.
(leave blank)	If the patient was not referred to the reporting facility from another facility.

## NPI–Institution Referred To

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2425	10	4945-4954	10 digits, Blank	2008+	04/07, 09/08, 01/11

### Description

Identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

### Rationale

Each facility's NPI is unique. This number is used to document and monitor referral patterns.

### Coding Instructions

- Record the 10-digit NPI for the facility to which the patient was referred.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2006.
- Check with the registry, billing, or health information departments of the facility to determine its NPI or search on <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.

Code	Label
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility referred to is unknown or not available.
(leave blank)	If the patient was not referred to another facility.



## Date of First Contact

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
580	8	759-766	CCYYMMDD	All Years	09/06, 01/04, 01/10, 01/11

### Description

Date of first contact with the reporting facility for diagnosis and/or treatment of this cancer.

### Rationale

This data item can be used to measure the time between first contact and the date that the case was abstracted. It can also be used to measure the length of time between the first contact and treatment for quality of care reports.

[See Date of First Contact in Section One for further instructions.](#)

### Coding Instructions

- Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or first course treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, x-ray, or laboratory test, or the date a pathology specimen was collected at the hospital.
- For analytic cases (Class of Case 00-22), the Date of First Contact is the date the patient became analytic. For non-analytic cases, it is the date the patient first qualified for the Class of Case that causes the case to be abstracted.
- If this is an autopsy-only or death certificate-only case, then use the date of death.
- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of First Contact is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of First Contact transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date. The Date of First Contact Flag [581] is used to explain why Date of First Contact is not a known date. See Date of First Contact Flag for an illustration of the relationships among these items.

## Examples

Code	Label	Definition
20090914	September 14, 2009	Patient undergoes a biopsy in a staff physician's office on September 8, 2009. The pathology specimen was sent to the reporting facility and was read as malignant melanoma. The patient enters that same reporting facility on September 14, 2009 for wide re-excision.
20101207	December 7, 2010	Patient has an MRI of the brain on December 7, 2010, for symptoms including severe headache and disorientation. The MRI findings are suspicious for astrocytoma. Surgery on December 19 removes all gross tumor.
20110499	April 2011	Information is limited to the description "Spring," 2011.
20110799	July 2011	Information is limited to the description "The middle of the year," 2011.
20111099	October 2011	Information is limited to the description "Fall," 2011.
CCYY1299 or CCYY0199	December or January	If information is limited to the description "Winter," try to determine if this means the beginning or the end of the year.

## Date of First Contact Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
581	2	767-768	12, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Contact* [580].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate nondate information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if Date of First Contact [580] has a full or partial date recorded.
- Code 12 if the Date of First Contact cannot be determined at all.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

Code	Label
12	A proper value is applicable but not known (that is, the date of first contact is unknown)
(blank)	A valid date value is provided in item <i>Date of First Contact</i> [580]

## Text--Place of Diagnosis

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2690	60	textPlaceOfDiagnosis	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of the facility, physician office, city, state, or county where the diagnosis was made.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

### Instructions

- Prioritize entered information in the order of the fields listed below.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- The complete name of the hospital or the physician office where diagnosis occurred. The initials of a hospital are not adequate.
- For out-of-state residents and facilities, include the city and the state where the medical facility is located.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

**Item Numbers:** 2410, 2420, 500, 540, 610, 670, 740

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Date of Initial Diagnosis

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
390	8	544-551	CCYYMMDD	All Years	09/04, 09/08, 1/10, 01/11

### Description

Records the date of initial diagnosis by a physician for the tumor being reported.

### Rationale

The timing for staging and treatment of cancer begins with the date of initial diagnosis for cancer.

### Coding Instructions

- Use the first date of diagnosis whether clinically or histologically established.
- If the physician states that in retrospect the patient had cancer at an earlier date, use the earlier date as the date of diagnosis.
- Refer to the list of [Ambiguous Terms](#) in Section One for language that represents a diagnosis of cancer.
- Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a diagnosis is documented.
- The date of death is the date of diagnosis for a Class of Case [610] 38 (diagnosed at autopsy) or 49 (death certificate only).
- Use the actual date of diagnosis for an in utero diagnosis, for cases diagnosed on January 1, 2009, or later. **NH-29**
- If the year of diagnosis cannot be identified, it must be approximated. In that instance, the month and day are unknown.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Initial Diagnosis MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Initial Diagnosis transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date.

### Examples

Code	Label	Definition
20100612	June 12, 2010	Cytology "suspicious" for cancer June 12, 2010; pathology positive July 2, 2010. Do not consider cytology with ambiguous terms to be diagnostic, however positive pathology supports the cytology diagnosis.

Code	Label	Definition
20100517	May 17, 2010	Pathology "suspicious" for cancer May 17, 2010; confirmed positive May 22, 2010
20100499	April 2010	Physician's referral notes dated July 5, 2010, indicate the patient was diagnosed with cancer spring of 2010. Use April for "spring", July for "summer" or "mid-year", October for "fall" or "autumn". In winter, attempt to determine whether the diagnosis was "late in the year" (use December with the applicable year) or "early in year" (use January with the respective year).

## Primary Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
400	4	554-557	C+3 digits	All Years	01/04, 09/08, 01/10

### Description

Identifies the primary site.

### Rationale

Primary site is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

[See Primary Site in Section One for further instructions.](#)

### Coding Instructions

- Record the ICD-O-3 topography code for the site of origin.
- Consult the physician advisor to identify the primary site or the most definitive site code if the medical record does not contain that information.
- Topography codes are indicated by a “C” preceding the three-digit code number. Do not record the decimal point.
- Follow the Instructions for Coding in ICD-O-3, pages 20–40 and in the current SEER Multiple Primary and Histology Coding Rules to assign site for solid tumors. **NH-24**
- Refer to the instructions for [Occult Cervical Lymph Node](#) and [Cutaneous Carcinoma of the Head and Neck](#) found in the Overview of Coding Principles section.
- Follow the instructions in Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB) for assigning site for lymphomas, leukemia and other hematopoietic neoplasms.
- Use subcategory 8 for single tumors that overlap the boundaries of two or more sub-sites and the point of origin is not known.
- Use subcategory 9 for multiple tumors that originate in different subsites of one organ.

### Examples

Code	Reason
C108	Overlapping lesion of oropharynx. Code overlapping lesion when a large tumor involves both the lateral wall of the oropharynx (C10.2) and the posterior wall of the oropharynx (C10.3) and the point of origin is not stated.
C678	Overlapping lesion of bladder. Code overlapping lesion of the bladder when a single lesion involves the dome (C67.1) and the lateral wall (C67.2) and the point of origin is not stated.
C189	Colon, NOS. Familial polyposis with carcinoma and carcinoma in situ throughout the transverse (C18.4) and descending colon (C18.6) would be one primary and coded to colon, NOS (C18.9). For a full explanation see the <i>SEER 2007 Multiple Primary and Histology Coding Rules</i> .

Code	Reason
C16-	Stomach (sub-site as identified). An extranodal lymphoma of the stomach is coded to C16.- (sub-site as identified).



## Laterality

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
410	1	558-558	0-5, 9	All Years	01/10, 05/10, 01/13

### Description

Identifies the side of a paired organ or the side of the body on which the reportable tumor originated. This applies to the primary site only.

### Rationale

Laterality supplements staging and extent of disease information and defines the number of primaries involved.

[See Laterality rules in Section One for further instructions.](#)

### Coding Instructions

- Code laterality for all paired sites. (See Section One for additional information.)
- Do not code metastatic sites as bilateral involvement.
- If both lungs have nodules or tumors and the lung of origin is not known, assign code 4.
- Where the right and left sides of paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Note that “midline of the right breast” is coded 1, right; midline in this usage indicates the primary site is C50.8 (overlapping sites).
- Non-paired sites may be coded right or left, if appropriate. Otherwise, code non-paired sites 0.

Code	Label
0	Organ is not a paired site.
1	Origin of primary is right.
2	Origin of primary is left.
3	Only one side involved, right or left origin not specified.
4	Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors
5	Paired site: midline tumor
9	Paired site, but no information concerning laterality

## Text--Primary Site Title

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2580	100	textPrimarySiteTitle	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding the primary site and laterality of the tumor being reported.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- State the specific location of the primary site, including subsite.
- Include available information on tumor laterality.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Primary site	400
Laterality	410

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Histology

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
522	4	564-567	Four digits	2001+	09/06, 01/10, 03/10

### Description

Identifies the microscopic anatomy of cells.

### Rationale

Histology is a basis for staging and the determination of treatment options. It also affects the prognosis and course of the disease.

### Coding Instructions

- ICD-O-3 identifies the morphology codes with an “M” preceding the code number. Do not record the “M.”
- Record histology using the ICD-O-3, current edition (<https://seer.cancer.gov/icd-o-3/>) codes in the Numeric Lists/Morphology section (ICD-O-3, pp. 69–104) and in the Alphabetic Index (ICD-O-3, pp. 105– 218).
- Follow the coding rules outlined on pages 20 through 40 of ICD-O-3, current edition.
- Use the current Solid Tumor Rules (<https://seer.cancer.gov/tools/solidtumor/>) when coding the histology for all reportable solid tumors. These rules are effective for cases diagnosed January 1, 2007, or later. Do not use these rules to abstract cases diagnosed prior to January 1, 2007.
- Review all pathology reports.
- Code the final pathologic diagnosis for solid tumors.
- For lymphomas, leukemias and other hematopoietic tumors, follow the instructions in Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database (Hematopoietic DB)
- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are **not** interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).

### Examples

Code	Label	Definition
8140	Adenocarcinoma	Final pathologic diagnosis is carcinoma, NOS (8010) of the prostate. Microscopic diagnosis specifies adenocarcinoma (8140) of the prostate.
9680	Diffuse large B-cell lymphoma	Diffuse large B-cell lymphoma, per the WHO Classification of Hematopoietic and Lymphoid Neoplasms.

## Behavior Code

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
523	1	568-568	0–3	>2001	04/04, 01/10, 01/12, 01/13, 01/15

### Description

Records the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code.

### Rationale

The behavior code is used by pathologists to describe whether tissue samples are benign (0), borderline (1), in situ (2), or invasive (3).

### Coding Instructions

- Code 3 if any malignant invasion is present, no matter how limited.
- Code 3 if any malignant metastasis to nodes or tissue beyond the primary is present.
- If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior.

**Note:** The ICD-O-3 behavior code for juvenile astrocytoma (9421/1) is coded as 3 by agreement of North American registry standard-setters. Refer to “Case Eligibility” in Section One for information.

Code	Label	Definition
0	Benign	Benign
1	Borderline	Uncertain whether benign or malignant
		Borderline malignancy
		Low malignant potential
		Uncertain malignant potential
2	In situ and synonymous with in situ	Adenocarcinoma in an adenomatous polyp with no invasion of stalk
		Bowen disease (not reportable for C44._)
		Clark level 1 for melanoma (limited to epithelium)
		Comedocarcinoma, noninfiltrating (C50.–)
		Confined to epithelium
		Hutchinson melanotic freckle, NOS (C44.–)
		Intracystic, noninfiltrating.(carcinoma)

Code	Label	Definition
		Intraductal.(carcinoma)
		Intraepidermal, NOS (carcinoma)
		Intraepithelial, NOS (carcinoma)
		Involvement up to, but not including the basement membrane
		Lentigo maligna (C44.–)
		Lobular neoplasia (C50.–)
		Lobular, noninfiltrating (C50.–) (carcinoma)
		Noninfiltrating (carcinoma)
		Noninvasive (carcinoma only)
		No stromal invasion or involvement
		Papillary, noninfiltrating or intraductal (carcinoma)
		Precancerous melanosis (C44.–)
		Queyrat erythroplasia (C60.–)
3	Invasive	Invasive or microinvasive.

### Examples

Code	Reason
3	Intraductal carcinoma (8500/2) with focal areas of invasion
1	Atypical meningioma (9539/1) invading bone of skull (the meninges, which line the skull, are capable of invading into the bone without being malignant; do not code as malignant unless it is specifically mentioned)
3	Malignant GIST

## Grade Clinical

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3843	1	1286-1286	1-5, 8, 9, A, B, C, D, E, L, H, M, S	2018+	01/18

### Description

This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant).

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Pathological* [3844] and *Grade Post-Therapy* [3845], replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

### Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. **For some sites, grade is required to assign the clinical stage group.**

For those cases that are eligible for AJCC staging, the recommended grading system is specified in the AJCC 8<sup>th</sup> Edition Chapter. The AJCC 8<sup>th</sup> Edition Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

### Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

## Grade Pathological

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3844	1	1287-1287	1-5, 8, 9, A, B, C, D, E, L, H, M, S	2018+	01/18

### Description

This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual. This may include the grade from the clinical workup. Since all clinical information is used in pathological staging. Record the highest grade documented from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection. NH-45

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Clinical* [3843] and *Grade Post Therapy Path (yp)* [3845], replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

### Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the pathological stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC 8<sup>th</sup> Edition Chapter. The AJCC 8<sup>th</sup> Edition Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

### Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

## Text--Histology Title

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2590	100	textHistologyTitle	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding the histologic type, behavior, and grade (differentiation) of the tumor being reported.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Information on histologic type and behavior
- Information on differentiation from scoring systems such as Gleason's Score, Bloom-Richardson Grade, etc.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Histology (92-00) ICD-O-2	420
Behavior (92-00) ICD-O-2	430
Histologic Type ICD-O-3	522
Behavior Code ICD-O-3	523
Grade Clinical	3843
Grade Pathological	3844
Grade Post Therapy	3845

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Diagnostic Confirmation

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
490	1	576-576	1, 2, 4-9	All Years	01/04, 01/10, 01/11, 01/12, 01/13

### Description

Records the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history. The rules for coding differ between solid tumors and hematopoietic and lymphoid neoplasms.

### Rationale

This item is an indicator of the precision of diagnosis. The percentage of solid tumors that are clinically diagnosed only is an indication of whether casefinding includes sources beyond pathology reports. Complete casefinding must include both clinically and pathologically confirmed cases.

### Coding Instructions – Solid Tumors (all tumors except M9590-9993)

- These instructions apply to “Codes for Solid Tumors” below. See the section following this one for “Coding Hematopoietic or Lymphoid Tumors (9590-9992)”.
- The codes are in **priority order**; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This data item must be changed to the lower (higher priority) code if a more definitive method confirms the diagnosis at any time during the course of the disease.
- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy or D&C or from aspiration of biopsy of bone marrow specimens.
- Assign code 2 when the microscopic diagnosis is based on cytologic examination of cells such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.
- Code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer.
- Code 6 when the diagnosis is based only on the surgeon's operative report from a surgical exploration or endoscopy or from gross autopsy findings in the absence of tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

### Coding Instructions – Hematopoietic or Lymphoid Tumors (M9590-9993)

- These instructions apply to “Codes for Hematopoietic and Lymphoid Neoplasms” below. See the preceding section for instructions “Coding Solid Tumors”.
- There is no priority hierarchy for coding Diagnostic Confirmation for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the Hematopoietic Database (DB) for information on the definitive diagnostic confirmation for specific types of tumors.
- Code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, or autopsy or bone marrow specimens from aspiration or biopsy.
- For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC) or peripheral blood smear. Do not use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow, or blood.
- Use code 2 when the microscopic diagnosis is based on cytologic examination of cells (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.
- Assign code 3 when there is a histology positive for cancer AND positive immunophenotyping and/or positive genetic testing results. Do not use code 3 for neoplasms diagnosed prior to January 1, 2010.
- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.
- Assign code 6 when the diagnosis is based only on the surgeon’s report from a surgical exploration or endoscopy or from gross autopsy findings without tissue or cytological findings.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in preceding codes. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient’s clinical presentation.

Code	Label	Definition
1	Positive histology	Histologic confirmation (tissue microscopically examined).
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined).
3	Positive histology PLUS <ul style="list-style-type: none"> <li>• Positive immunophenotyping AND/OR</li> <li>• Positive genetic studies</li> </ul>	Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for acute myeloid leukemia. (9861/3) Genetic testing shows AML with inv(16)(p13.1q22) (9871/3). (Used only for hematopoietic and lymphoid neoplasms M-9590/3-9993/3)
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology.

Code	Label	Definition
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory tests/marker studies which are clinically diagnostic for cancer.
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from an imaging technique report only.
8	Clinical diagnosis only, other than 5, 6 or 7	The malignancy was reported by the physician in the medical record.
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed (usually nonanalytic).

## Text--DX Proc--PE

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2520	1000	textDxProcPe	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation from the history and physical examination about the history of the current tumor and the clinical description of the tumor.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values.

Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date of physical exam
- Age, sex, race/ethnicity
- History that relates to cancer diagnosis
- Primary site
- Histology (if diagnosis prior to this admission)
- Tumor location
- Tumor size
- Palpable lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Impression (when stated and pertains to cancer diagnosis)
- Treatment plan

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--PE, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
Primary Site	400
Laterality	410
Histologic Type ICD-O-3	522
Grade	440
Collaborative Stage variables	2800-2930
Diagnostic confirmation	490
RX Hosp--Surg Prim Site	670
RX Hosp--Scope Reg LN Sur	672
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Prim Site	1290
RX Summ--Scope Reg LN Sur	1292
RX Summ--Surg Oth Reg/Dis	1294
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Date Surgery	1200
Reason for No Surgery	1340
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Lab Tests

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2550	1000	textDxProcLabTests	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information from laboratory examinations other than cytology or histopathology.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Type of lab test/tissue specimen(s)
- Record both positive and negative findings. Record positive test results first.
- Information can include tumor markers, serum and urine electrophoresis, special studies, etc.
- Date(s) of lab test(s)
- Tumor markers included, but are not limited to:
  - Breast Cancer – Estrogen Receptor Assay (ERA), Progesterone Receptor Assay (PRA), Her2/neu
  - Prostate Cancer – Prostatic Specific Antigen (PSA)
  - Testicular Cancer – Human Chorionic Gonadotropin (hCG), Alpha Fetoprotein (AFP), Lactate Dehydrogenase (LDH)

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Lab Tests, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Primary Site	400
Grade	440
Diagnostic Confirmation	490
Collaborative Stage variables	2800-2930
Date of Diagnosis	390
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Path

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2570	1000	textDxProcPath	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information from cytology and histopathology reports.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date(s) of procedure(s)
- Anatomic source of specimen
- Type of tissue specimen(s)
- Tumor type and grade (include all modifying adjectives, i.e., predominantly, with features of, with foci of, elements of, etc.)
- Gross tumor size
- Extent of tumor spread
- Involvement of resection margins
- Number of lymph nodes involved and examined
- Record both positive and negative findings. Record positive test results first.
- Note if pathology report is a slide review or a second opinion from an outside source, i.e., AFIP, Mayo, etc.
- Record any additional comments from the pathologist, including differential diagnoses considered and any ruled out or favored

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Text--DX Proc--Path, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
Primary Site	400
Laterality	410
Histologic Type ICD-O-3	522
Grade	440
Collaborative Stage variables	2800-2930
Diagnostic confirmation	490
RX Hosp--Surg Prim Site	670
RX Hosp--Scope Reg LN Sur	672
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Prim Site	1290
RX Summ--Scope Reg LN Sur	1292
RX Summ--Surg Oth Reg/Dis	1294
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Date Surgery	1200
Reason for No Surgery	1340
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Remarks

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2680	1000	textRemarks	Neither carriage return nor line feed characters allowed	All Years	2021

### Description

Text area for information that is given only in coded form elsewhere or for which the abstract provides no other place. Overflow data can also be placed here. Problematic coding issues can also be discussed in this section.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

### Instructions

- NAACCR-approved abbreviations should be utilized ([see Appendix G](#)).
- Do not repeat information from other text fields.
- Additional comments from other text fields can be continued in the Remarks field. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Smoking history
- Family and personal history of cancer
- Comorbidities
- Information on sequence numbers if a person was diagnosed with another primary out-of-state or before the registry's reference date
- Place of birth
- Justification of over-ride flags
- Information clarifying anything unusual such as reason for reporting a case seemingly not reportable for that facility or reason for coding numerous fields as "unknown."

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Stage of Disease at Diagnosis

NH-46

## Date of Surgical Diagnostic and Staging Procedure

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1280	8	2214-2221	CCYYMMDD	All Years	01/10, 01/11

### Description

Records the date on which the surgical diagnostic and/or staging procedure was performed.

### Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

### Coding Instructions

- Record the date on which the surgical diagnostic and/or staging procedure described in Surgical Diagnostic and Staging Procedure [1350] was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this modification does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Surgical Diagnostic and Staging Procedure is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Surgical Diagnostic and Staging Procedure transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The RX Date-DX/Stg Proc Flag [1281] is used to explain why Date of Surgical Diagnostic and Staging Procedure is not a known date. See RX Date-DX/Stg Proc Flag for an illustration of the relationships among these items.

## Rx Date–Dx/Stg Proc Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1281	2	2222-2223	10–12, Blank	2010+	01/12

### Description

This flag explains why there is no appropriate value in the corresponding date data item, *Date of Surgical Diagnostic and Staging Procedure* [1280].

### Rationale

As part of an initiative to standardize date data items, date flag data items were introduced to accommodate non-date information that had previously been transmitted in date data items.

### Coding Instructions

- Leave this item blank if Date of Surgical Diagnostic and Staging Procedure [1280] has a full or partial date recorded.
- Code 10 if it is unknown whether a surgical diagnostic or staging procedure was performed.
- Code 11 if no surgical diagnostic or staging procedure was performed.
- Code 12 if the Date of Surgical Diagnostic and Staging Procedure cannot be determined, but a surgical diagnostic or staging procedure was performed for the patient.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any diagnostic or staging procedure performed).
11	No proper value is applicable in this context (for example, no diagnostic or staging procedure performed; autopsy only case).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, diagnostic or staging procedure performed but date is unknown).
(blank)	A valid date value is provided in item <i>Date of Surgical Diagnostic and Staging Procedure</i> (NAACCR Item #1280). Case was diagnosed prior to January 1, 2007.

## Surgical Diagnostic and Staging Procedure

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1350	2	2235-2236	00–07, 09	All Years	09/06, 09/08, 01/12, 01/15

### Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

### Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

### Coding Instructions

- Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item Surgical Procedure of Primary Site [1290] to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this data item. Use the data item Scope of Regional Lymph Node Surgery [1292] to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item Date of Surgical Diagnostic and Staging Procedure [1280]. See instructions for Scope of Regional Lymph Node Surgery [1292].
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item Diagnostic Confirmation [490]. These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item Surgical Procedure of Primary Site [1290] to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the Surgical Diagnostic and Staging Procedure [1350] data item and the excisional biopsy or more extensive surgery in the Surgical Procedure of the Primary Site data item [1290].
- Do not code palliative surgical procedures in this data item. Use the data item Palliative Procedure [3270] to code these procedures.

Code	Label
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

### Examples

Code	Reason
00	A lung cancer primary was diagnosed by CT scan. The patient expired. No surgical diagnostic or staging surgical procedure was performed.
00	A sputum sample is examined cytologically to confirm a diagnosis of suspected lung cancer. The procedure is not surgical.
01	A needle biopsy of a liver metastasis in a patient with suspected widespread colon cancer was done. Gross residual tumor is left at the biopsy site.
03	During abdominal exploratory surgery, a gastric lesion and suspicious retroperitoneal lymph nodes were observed. No biopsy or treatment was done.
04	An abdominal exploration of a patient revealed pancreatic carcinoma with extension into surrounding organs and arteries. No attempt to treat. A bypass was performed to alleviate symptoms.
05	An exploratory procedure was performed for primary colon carcinoma with biopsy of suspicious liver lesions.
06	Esophagogastrostomy was performed for infiltrating gastric tumor following a biopsy of the primary site.
07	Stage III lung carcinoma was diagnosed and staged prior to admission.
09	A patient expires in the emergency room with recently diagnosed metastatic melanoma. It is unknown whether a diagnostic or staging procedure was done.

## Surgical Diagnostic and Staging Procedure at This Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
740	2	809-810	00–07, 09	All Years	01/04, 09/08, 01/12

### Description

Identifies the positive surgical procedure(s) performed to diagnose and/or stage disease.

### Rationale

This data item is used to track the use of surgical procedure resources that are not considered treatment.

### Coding Instructions

- Record the type of procedure performed as part of the initial diagnosis and workup at this facility.
- Only record positive procedures. For benign and borderline reportable tumors, report the biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).
- If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item Surgical Procedure of Primary Site at This Facility [670] to code these procedures.
- Do not code surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease in this data item. Use the data item Scope of Regional Lymph Node Surgery at This Facility [672] to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item Date of Surgical Diagnostic and Staging Procedure [1280]. See instructions for Scope of Regional Lymph Node Surgery at This Facility [672].
- Code brushings, washings, cell aspiration, and hematologic findings (peripheral blood smears) as positive cytologic diagnostic confirmation in the data item Diagnostic Confirmation [490]. These are not considered surgical procedures and should not be coded in this item.
- Do not code excisional biopsies with clear or microscopic margins in this data item. Use the data item Surgical Procedure of Primary Site at This Facility [670] to code these procedures.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the Surgical Diagnostic and Staging Procedure at this Facility [740] data item and the excisional biopsy or more extensive surgery in the Surgical Procedure of the Primary Site at this Facility data item [670].
- Do not code palliative surgical procedures in this data item. Use the data item Palliative Procedure at This Facility [3280] to code these procedures.



<b>Code</b>	<b>Label</b>
00	No surgical diagnostic or staging procedure was performed.
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site. No exploratory procedure was done.
02	A biopsy (incisional, needle, or aspiration) was done to the primary site; or biopsy or removal of a lymph node to diagnose or stage lymphoma.
03	A surgical exploration only. The patient was not biopsied or treated.
04	A surgical procedure with a bypass was performed, but no biopsy was done.
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done.
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done.
07	A procedure was done, but the type of procedure is unknown.
09	No information of whether a diagnostic or staging procedure was performed.

## Lymphovascular Invasion

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1182	1	1297-1297	0-4, 8-9	2010+	01/11, 01/18, 01/22

### Description

Indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

### Rationale

Lymphovascular invasion is an indicator of prognosis.

### Coding Instructions

- This coding convention has been developed and implemented for use in the AJCC Cancer Staging Manual, Seventh Edition, and updated with new codes in the AJCC 8<sup>th</sup> Edition staging manual for appropriate disease sites. Additional clarifications implemented for thyroid and adrenal per suggestions from CAP.
  - Revised CAP Protocols and 8<sup>th</sup> Edition chapters will indicate which chapters will use the new codes (2, 3, and 4) and which will only use the existing codes (0, 1, 8, 9), as there are some disease sites where distinguishing between L and V is not medically appropriate.
  - Code 8, Not Applicable for benign/borderline brain and CNS tumors and Gastrointestinal Stromal Tumors (GIST).
  - For cases diagnosed January 1, 2018 and later, new codes indicating lymphatic, small vessel, and/or large vessel invasion were added.
1. **Code from pathology report(s).** Code the absence or presence of lymphovascular invasion as described in the medical record.
    - a. The primary sources of information about lymphovascular invasion are the pathology check lists (synoptic reports) developed by the College of American Pathologists. If the case does not have a checklist or synoptic report, code from the pathology report or a physician's statement, in that order.
    - b. Do not code perineural invasion in this field.
    - c. Information to code this field can be taken from any specimen from the primary tumor (biopsy or resection.)
    - d. If lymphovascular invasion is identified in any specimen, it should be coded as present/identified.
    - e. For cases with benign or borderline behavior, code the lymphovascular invasion documented (negative or positive) and, if not documented, code unknown.
    - f. For cases treated with neoadjuvant therapy, refer to table below in order to code this field. However, if documentation in the medical record indicates information that conflicts with this table, code lymphovascular invasion with the documentation in the medical record.
      - i. If LVI was present prior to neoadjuvant therapy (codes 1-4) but LVI was not present after neoadjuvant therapy (codes 0 or 9), code the LVI to present (codes 1-4).

- ii. If the LVI was not present prior to neoadjuvant therapy (codes 0 or 9), but LVI was present after neoadjuvant therapy (codes 1-4), code LVI to present (codes 1-4).

<b>LVI on pathology report PRIOR to neoadjuvant therapy</b>	<b>LVI on pathology report AFTER neoadjuvant therapy</b>	<b>Code LVI to:</b>
0 - Not present/Not identified	0 - Not present/Not identified	<i>0 - Not present/Not identified</i>
0 - Not present/Not identified	1 - Present/Identified	<i>1 - Present/Identified</i>
0 - Not present/Not identified	9 - Unknown/Indeterminate	<i>9 - Unknown/Indeterminate</i>
1 - Present/Identified	0 - Not present/Not identified	<i>1 - Present/Identified</i>
1 - Present/Identified	1 - Present/Identified	<i>1 - Present/Identified</i>
1 - Present/Identified	9 - Unknown/Indeterminate	<i>1 - Present/Identified</i>
9 - Unknown/Indeterminate	0 - Not present/Not identified	<i>9 - Unknown/Indeterminate</i>
9 - Unknown/Indeterminate	1 - Present/Identified	<i>1 - Present/Identified</i>
9 - Unknown/Indeterminate	9 - Unknown/Indeterminate	<i>9 - Unknown/Indeterminate</i>

2. Use of codes.

- a. Use code 0 when the pathology report indicates that there is no lymphovascular invasion. This includes cases of purely in situ carcinoma, which biologically have no access to lymphatic or vascular channels below the basement membrane.
- b. Use code 1 when the pathology report or a physician's statement indicates that lymphovascular invasion (or one of its synonyms) is present in the specimen.
- c. Lymphovascular invasion must be coded 0, 1, 2, 3, 4, or 9 for the Schema IDs in the following list:

00071	Lip
00072	Tongue Anterior
00073	Gum
00074	Floor of Mouth
00075	Palate Hard
00076	Buccal Mucosa
00077	Mouth Other
00080	Major Salivary Glands
00100	Oropharynx (p16+)
00111	Oropharynx (p16-)
00112	Hypopharynx
00121	Maxillary Sinus
00122	Nasal Cavity and Ethmoid Sinus
00130	Larynx Other
00131	Larynx Supraglottic
00132	Larynx Glottic
00133	Larynx Subglottic
00161	Esophagus (incl GE Junction) Squamous
00169	Esophagus (incl GE Junction) (excl Squamous)
00170	Stomach
00180	Small Intestine
00190	Appendix
00200	Colon and Rectum
00230	Bile Ducts Intrahepatic

00250	Bile Ducts Perihilar
00260	Bile Ducts Distal
00270	Ampulla Vater
00280	Pancreas
00290	NET Stomach
00301	NET Duodenum
00302	NET Ampulla of Vater
00320	NET Appendix
00330	NET Colon and Rectum
00340	NET Pancreas
00350	Thymus
00360	Lung
00460	Merkel Cell Skin
00470	Melanoma Skin
00500	Vulva
00510	Vagina
00520	Cervix
00530	Corpus Carcinoma
00541	Corpus Sarcoma
00542	Corpus Adenosarcoma
00560	Placenta
00570	Penis
00590	Testis
00620	Bladder

d. Lymphovascular invasion must be coded 0, 2, 3, 4, or 9 for the Schema IDs in the following list:

00730	thyroid
00740	thyroid medullary
00760	adrenal gland

e. Lymphovascular invasion may be coded any code (0, 1, 2, 3, 4, 8, or 9) for the remaining Schema IDs (shown in the following list):

00060	Cervical Lymph Nodes, Occult Head and Neck
00090	Nasopharynx
00118	Pharynx Other
00119	Middle Ear
00128	Sinus Other
00140	Melanoma Head and Neck
00150	Cutaneous Carcinoma Head and Neck
00210	Anus
00220	Liver
00241	Gallbladder
00242	Cystic Duct
00278	Biliary Other
00288	Digestive Other
00310	Net Jejunum and Ileum
00358	Trachea
00370	Pleural Mesothelioma
00378	Respiratory Other
00381	Bone Appendicular Skeleton
00382	Bone Spine
00383	Bone Pelvis
00400	Soft Tissue Head and Neck
00410	Soft Tissue Trunk and Extremities

00421	Soft Tissue Abdomen and Thorax
00422	Heart, Mediastinum, and Pleura
00430	GIST (2018-2020)
00440	Retroperitoneum
00450	Soft Tissue Other
00458	Kaposi Sarcoma
00478	Skin Other
00480	Breast (Invasive)
00551	Ovary
00552	Primary Peritoneal Carcinoma
00553	Fallopian Tube
00558	Adnexa Uterine Other
00559	Genital Female Other
00580	Prostate
00598	Genital Male Other
00600	Kidney Parenchyma
00610	Kidney Renal Pelvis
00631	Urethra
00633	Urethra-Prostatic
00638	Urinary Other
00640	Skin Eyelid
00650	Conjunctiva
00660	Melanoma Conjunctiva
00671	Melanoma Iris
00672	Melanoma Choroid and Ciliary Body
00680	Retinoblastoma
00690	Lacrimal Gland
00698	Lacrimal Sac
00700	Orbital Sarcoma
00718	Eye Other
00721	Brain
00722	CNS Other
00723	Intracranial Gland
00750	Parathyroid
00770	NET Adrenal Gland
00778	Endocrine Other
99999	Ill-Defined Other

f. Lymphovascular invasion must be coded 8 (not applicable) for all other Schema IDs:

00430	GIST (2021+)
00710	Lymphoma Ocular Adnexa
00790	Lymphoma
00795	Lymphoma (CLL/SLL)
00811	Mycosis Fungoides
00812	Primary Cutaneous Lymphoma non MF
00821	Plasma Cell Myeloma
00822	Plasma Cell Disorder
830	HemeRetic

g. Use code 9 when:

- i. there is no microscopic examination of a primary tissue specimen
- ii. the primary site specimen is cytology only or a fine needle aspiration
- iii. the biopsy is only a very small tissue sample
- iv. it is not possible to determine whether lymphovascular invasion is present

- v. the pathologist indicates the specimen is insufficient to determine lymphovascular invasion
- vi. lymphovascular invasion is not mentioned in the pathology report
- vii. primary site is unknown

h. Clarification between codes 8 and 9:

- Code 8 should only be used in the following situations: 1. Standard-setter does not require this item and you are not collecting it. 2. Those schemas noted above described in code 8 for which LVI is always not applicable.
- For those cases where there is no information/documentation from the pathology report or other sources, use code 9.

Code	Label
0	Lymphovascular Invasion stated as Not Present
1	Lymphovascular Invasion Present/Identified (NOT used for thyroid and adrenal)
2	Lymphatic and small vessel invasion only (L) OR Lymphatic invasion only (thyroid and adrenal only)
3	Venous (large vessel) invasion only (V) OR Angioinvasion (thyroid and adrenal only)
4	BOTH lymphatic and small vessel AND venous (large vessel) invasion OR BOTH lymphatic AND angioinvasion (thyroid and adrenal only)
8	Not Applicable
9	Unknown/Indeterminate/not mentioned in path report

## Macroscopic Evaluation of the Mesorectum

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3950	2		Alphanumeric, Blank	2022+	01/22

### Description

This data item records whether a Total Mesorectal Excision (TME) was performed and the macroscopic evaluation of the completeness of the excision. Collect on all cases after implementation date regardless of date of diagnosis.

### Rationale

Numerous studies have demonstrated that total mesorectal excision (TME) improves local recurrence rates and the corresponding survival by as much as 20%. Macroscopic pathologic assessment of the completeness of the mesorectum, scored as complete, partially complete, or incomplete, accurately predicts both local recurrence and distant metastasis.

### Coding Instructions

- The American Society of Colon and Rectal Surgeons most recent Practice Parameters for the Management of Rectal Cancer states that total mesorectal excision is used for curative resection of tumors of the middle and lower thirds of the rectum, either as part of low anterior or abdomino-perineal resection. For tumors of the upper third of the rectum, a tumor-specific mesorectal excision should be used with the mesorectum divided ideally no less than 5 cm below the lower margin of the tumor. Pathologic evaluation of the resection specimen has been shown to be a sensitive means of assessing the quality of rectal surgery. Macroscopic pathologic assessment of the completeness of the mesorectum, is scored as complete, partially complete, or incomplete.
- Information for this data item comes from the pathology report only.
- Leave this field blank if primary site is other than C20.9
- Neoadjuvant therapy does not alter coding of this data item
- Code 00 if patient did not have a Total Mesorectal Excision.
- Codes 10, 20, and 30 must be based on pathology report
  - Registrar should not assign codes 10-30 based on criteria used by pathologist to assess completeness status
  - If the pathologist does not indicate incomplete, nearly complete, or complete for a TME specimen assign code 40.

Code	Label
00	Patient did not receive TME
10	Incomplete TME
20	Nearly Complete
30	Complete TME
40	TME performed not specified on pathology report as incomplete, nearly complete, or complete TME performed but pathology report not available Physician statement that TME performed, no mention of incomplete, nearly complete or complete status
99	UNKNOWN if TME performed
BLANK	Site not rectum (C20.9)

---

## Sentinel and Regional Lymph Nodes



## Date of Sentinel Lymph Node Biopsy

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
832	8	1016-1023	CCYYMMDD, Blank	2018+	01/18

### Description

Records the date of the sentinel lymph node(s) biopsy procedure. This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

### Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of the sentinel lymph node biopsy procedure separate from the date of a subsequent regional node dissection procedure, if performed.

### Coding Instructions

- Record the date of the sentinel lymph node biopsy procedure documented in the Sentinel Lymph Node Examined [834].
- This data item documents the date of sentinel node biopsy; do not record the date of lymph node aspiration, fine needle aspiration, fine needle aspiration biopsy, core needle biopsy, or core biopsy.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for ALL sites.
- If the sentinel lymph node biopsy is the first or only surgical procedure performed, record the date documented in this data item in the Date First Surgical Procedure [1200].
- If separate sentinel node biopsy procedure and subsequent regional node dissection procedure are performed, record the date of the sentinel lymph node biopsy in this data item, and record the date the subsequent regional node dissection was performed in the Date Regional Lymph Node Dissection [682].
- If a sentinel lymph node biopsy is performed in the same procedure as the regional node dissection, record the date of the procedure in both this data item and in the Date of Regional Lymph Node Dissection [682] (i.e., the dates should be equal).
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Sentinel Lymph Node Biopsy is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Sentinel Lymph Node Biopsy transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

## Date of Sentinel Lymph Node Biopsy Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
833	2	dateSentinelLymphNodeBiopsyFlag	10-12, Blank	2018+	2021

### Description

This flag explains why there is no appropriate value in the corresponding date data item, *Date of Sentinel Lymph Node Biopsy* [832]. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and melanoma cases only.**

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of Sentinel Lymph Node Biopsy* [832] has a full or partial date recorded.
- Code 10 if it is unknown whether a sentinel lymph node biopsy was performed.
- Code 11 if no sentinel lymph node biopsy was performed.
- Code 12 if the *Date of Sentinel Lymph Node Biopsy* cannot be determined, but a sentinel lymph node biopsy was performed for the patient.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any sentinel lymph node biopsy was performed)
11	No proper value is applicable in this context (for example, no sentinel lymph node biopsy performed; autopsy only cases)
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, sentinel lymph node biopsy performed but date is unknown)
Blank	A valid date value is provided in item <i>Date of Sentinel Lymph Node Biopsy</i> [832]. Case was diagnosed prior to January 1, 2018.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Sentinel Lymph Nodes Examined

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
834	2	1014-1015	00-90, 95, 98, 99, Blank	2018+	01/18, 01/22

### Description

Records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

### Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of lymph nodes biopsied during the sentinel node biopsy procedure separate from the number of lymph nodes dissected during additional subsequent regional node procedures.

### Coding Instructions

- If, during a sentinel node biopsy procedure, a few non-sentinel nodes happen to be sampled, document the **total number of nodes sampled during the sentinel node procedure** in this data item. I.e., record the total number of nodes from the sentinel node biopsy procedure regardless of sentinel node status.
- If a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the total number of nodes biopsied during the sentinel node procedure in this data item, and record the total number of regional lymph nodes biopsied/dissected (**which includes the number of nodes documented in this data item**) in Regional Lymph Nodes Examined [830].
- If a sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, record the total number of nodes biopsied during the sentinel node procedure in this data item, and record the total number of regional lymph nodes biopsied/dissected (**which includes the number of nodes documented in this data item**) in Regional Lymph Nodes Examined [830].
- If aspiration of sentinel lymph node(s) AND a sentinel node biopsy procedure were performed for same patient, record the results for the sentinel node biopsy.
- The number of sentinel lymph nodes examined will typically be found in the pathology report; radiology reports, or documented by the physician. Determination of the exact number of sentinel lymph nodes examined may require assistance from the managing physician for consistent coding.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for ALL sites.
- The number of sentinel nodes should be equal to or less than the number of regional nodes examined recorded in the Regional Lymph Nodes Examined [830] data item.

<b>Code</b>	<b>Label</b>
00	No sentinel nodes were examined
01-90	Sentinel nodes were examined (code the exact number of sentinel lymph nodes examined)
95	No sentinel nodes were removed, but aspiration of sentinel node(s) was performed
98	Sentinel lymph nodes were biopsied, but the number is unknown
99	It is unknown whether sentinel nodes were examined; not applicable or negative; not stated in medical record

## Sentinel Lymph Nodes Positive

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
835	2	1012-1013	00-90, 95, 97-99, Blank	2018+	01/18, 01/22

### Description

Records the exact number of sentinel lymph nodes biopsied by the pathologist and found to contain metastases. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and cutaneous melanoma cases only.**

### Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the number of positive sentinel lymph nodes biopsied separate from the number of positive lymph nodes identified during additional subsequent regional node dissection procedures, if performed.

### Coding Instructions

- If, during a sentinel node biopsy procedure, a few non-sentinel nodes happen to be sampled and are positive, document the **total number of positive nodes identified during the sentinel node procedure** in this data item. I.e., record the total number of positive nodes from the sentinel node biopsy procedure regardless of whether the nodes contain dye or colloidal material (tracer or radiotracer).
- If both a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the total number of **positive sentinel nodes** identified during the sentinel node procedure in this data item, and record the total number of positive regional lymph nodes biopsied/dissected (**which includes the number of sentinel nodes documented in this data item**) in Regional Lymph Nodes Positive [820].
- If a positive aspiration of sentinel lymph node(s) AND a positive sentinel node biopsy procedure were performed for same patient, record the results for the positive sentinel node biopsy procedure.
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for ALL sites.
- **FOR BREAST ONLY:** If a sentinel lymph node biopsy is performed **during the same procedure** as the regional node dissection, use code 97 in this data item, and record the total number of positive regional lymph nodes biopsied/dissected (both sentinel and regional) in Regional Lymph Nodes Positive [820].
- The CAP Protocol for Breast is designed to capture information from the resection (there is no diagnostic protocol for breast). As a result, when the sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, only the overall total number of positive regional nodes (both sentinel and regional) is recorded; the number of positive sentinel nodes is not captured.

- **FOR MELANOMA ONLY:** If a sentinel lymph node biopsy is performed **during the same procedure** as the regional node dissection, record the total number of **positive sentinel nodes** identified in this data item, and record the total number of positive regional lymph nodes identified (**which includes the number of positive sentinel nodes documented in this data item**) in Regional Lymph Nodes Positive [820].
- When the sentinel lymph node biopsy is performed during the same procedure as the regional node dissection the CAP Protocol for Melanoma captures both the number of positive sentinel nodes as well as the number of positive regional nodes (i.e., the number of positive sentinel nodes is captured).
- The number of sentinel lymph nodes biopsied and found positive will typically be found in the pathology report; radiology reports, or documented by the physician. Determination of the exact number of sentinel lymph nodes positive may require assistance from the managing physician for consistent coding.
- The number of sentinel nodes positive should be less than or equal to than the total number of Regional Nodes Positive [820].
- For carcinoma of the breast, if only positive Isolated Tumor Cells (ITC) are identified the sentinel lymph nodes are considered **negative**.
- For melanoma, if only positive Isolated Tumor Cells (ITC) are identified the sentinel lymph nodes are considered **positive**.
- mi (microscopic or micro mets) sentinel lymph nodes are considered positive.

Code	Label
00	All sentinel nodes examined are negative
01-90	Sentinel nodes are positive (code exact number of nodes positive)
95	Positive aspiration of sentinel lymph node(s) was performed
97	Positive sentinel nodes are documented, but the number is unspecified; For breast ONLY: SLN and RLND occurred during the same procedure
98	No sentinel nodes were biopsied
99	It is unknown whether sentinel nodes are positive; not applicable; not stated in medical record

## Date Regional Lymph Node Dissection

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
682	8	1002-1009	CCYMMDD, Blank	2018+	01/18

### Description

Records the date non-sentinel regional node dissection was performed. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

### Rationale

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of regional node dissection separate from the date of sentinel lymph node biopsy if performed.

### Coding Instructions

- Record the date of regional lymph node dissection documented in the Regional Lymph Nodes Examined [830].
- Sentinel node procedures are common for other sites, but data is only collected in these fields for breast and cutaneous melanoma. Use the AJCC N suffix to designate sentinel node procedures for ALL sites.
- **For Breast and Melanoma cases**, if both a sentinel node biopsy procedure and then a subsequent, separate regional node dissection procedure are performed, record the date of the regional lymph node dissection in this data item and record the date of the sentinel node biopsy procedure in the Date of Sentinel Lymph Node Biopsy [832].
  - If a sentinel lymph node biopsy is **performed in the same procedure** as the regional node dissection, record the date of the procedure in both this data item and in the Date of Sentinel Lymph Node Biopsy [832] data item (i.e., the dates should be equal).
- **For all other cases**, record the date of the regional lymph node dissection in this data item.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The interoperable form of Date Regional Lymph Node Dissection transmits in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

## Date Regional Lymph Node Dissection Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
683	2	dateRegionalLNDissectionFlag	10-12, Blank	2018+	2018

### Description

This flag explains why there is no appropriate value in the corresponding date data item, *Date of Regional Lymph Node Dissection* [682]. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of Regional Lymph Node Dissection* [682] has a full or partial date recorded.
- Code 10 if it is unknown whether Regional Lymph Nodes were dissected.
- Code 11 if no Regional Lymph Nodes were dissected.
- Code 12 if the *Date of the Regional Lymph Node Dissection* [682] cannot be determined, but regional lymph nodes were dissected.
- Registrars should enter this date item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any regional lymph node dissection was performed)
11	No proper value is applicable in this context (for example, no regional lymph node dissection was performed; autopsy only cases)
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, regional lymph node dissection was performed but date is unknown)
Blank	A valid date value is provided in item <i>Date of Regional Lymph Node Dissection</i> [682]. Case was diagnosed prior to January 1, 2018

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.



## Regional Lymph Nodes Examined

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
830	2	1000-1001	00–90, 95–99	All Years	09/06, 01/10, 2/21, 01/22

### Description

Records the total number of regional lymph nodes that were removed and examined by the pathologist. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016, use of CS was discontinued, however this data item continued to be required.

### Rationale

This data item serves as a quality measure of the pathologic and surgical evaluation and treatment of the patient.

### Coding Instructions

- **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Distant lymph node information should not be coded in this field.
- This field is **based on pathologic information only.** This field is to be recorded regardless of whether the patient received preoperative treatment.
- **Use of Code 00.** Code 00 may be used in several situations.
  - When the assessment of lymph nodes is clinical.
  - When no lymph nodes are removed and examined.
  - When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.
  - If Regional Nodes Examined is coded 00, Regional Nodes Positive is coded as 98.
- **Cumulative nodes removed and examined.** Record the total number of regional lymph nodes removed and examined by the pathologist.
  - The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment with the exception of aspiration or core biopsies coded to 95.
  - Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined.
  - If the aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Examined.
  - If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Examined.
  - When neither the type of lymph node removal procedure nor the number of lymph nodes examined is known, use code 98.
- **Priority of lymph node counts.** If there is a discrepancy regarding the number of lymph nodes examined, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.

- **Use of code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).
- **Lymph node biopsy.** If a lymph node biopsy was performed, code the number of nodes removed, if known. If the number of nodes removed by biopsy is not known, use code 96.
- **Definition of “sampling” (code 96).** A lymph node “sampling” is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection. Use code 96 when a limited number of nodes are removed but the number is unknown.
- **Definition of “dissection” (code 97).** A lymph node “dissection” is removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, lymph node stripping. Use code 97 when more than a limited number of lymph nodes are removed and the number is unknown.
- **Multiple lymph node procedures.** If both a lymph node sampling and a lymph node dissection are performed and the total number of lymph nodes examined is unknown, use code 97.
- **Use of Code 99.** If it is unknown whether nodes were removed or examined, code as 99.
- **Primary sites always coded 99.** For the following primary sites and histologies, the Regional Nodes Examined field is always coded as 99: C420, C421, C423-C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809.

For the following schemas, the Regional Nodes Examined field is always coded as 99.

Placenta

Brain and Cerebral Meninges

Other Parts of Central Nervous System

Intracranial Gland

Hodgkin and non-Hodgkin Lymphoma

- Excludes cases collected in the following schemas: Lymphoma Ocular Adnexa, Primary Cutaneous Lymphomas and Mycosis Fungoides

Hematopoietic, Reticuloendothelial, Immunoproliferative and Myeloproliferative Neoplasms

Myeloma and Plasma Cell Disorders

- Excludes histology 9734

Other and Ill-Defined Primary Sites

- Excludes Spleen (C422)

Unknown Primary Site

- When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual, use the AJCC definition.

Code	Label
00	No nodes were examined
01-89	1-89 nodes were examined (code the exact number of regional lymph nodes examined)
90	90 or more nodes were examined
95	No regional nodes were removed, but aspiration of regional nodes was performed
96	Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated

Code	Label
97	Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated
98	Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown
99	It is unknown whether nodes were examined; not applicable or negative; not stated in medical record

## Regional Lymph Nodes Positive

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
820	2	998-999	00–99	All Years	09/06, 01/10, 2/21, 01/22

### Description

Records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases. Beginning with cases diagnosed on or after January 1, 2004, this item became a component of the Collaborative Staging System (CS). In 2016, use of CS was discontinued, however this data item continued to be required.

### Rationale

This data item is necessary for pathological staging, and it serves as a quality measure for pathology reports and the extent of the surgical evaluation and treatment of the patient.

### Coding Instructions

- **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Distant lymph node information should not be coded in this field.
- This field is **based** on pathologic information only. This field is to be recorded regardless of whether the patient received preoperative treatment.
- **Cumulative nodes positive.** Record the total number of regional lymph nodes removed and found to be positive by pathologic examination.
  - The number of regional lymph nodes positive is cumulative from all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment.
  - Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Positive when there are positive nodes in the resection. In other words, if there are positive regional lymph nodes in a lymph node dissection, do not count the core needle biopsy or the fine needle aspiration if it is in the same chain. See also Use of Code 95 below.
  - If the aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Positive.
  - If the location of the lymph node that is core-biopsied or aspirated is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Positive.
- **Priority of lymph node counts.** If there is a discrepancy regarding the number of positive lymph nodes, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.
- **Positive Nodes in Multiple Primaries in Same Organ.** If there are multiple primary cancers with different histologic types in the same organ and the pathology report just states the number of nodes positive, the registrar should first try to determine the histology of the metastases in the

nodes and code the nodes as positive for the primary with that histology. If no further information is available, code the nodes as positive for all primaries.

- **Isolated tumor cells (ITCs) in lymph nodes.** For all primary sites except cutaneous melanoma and Merkel cell carcinoma of skin, count only lymph nodes that contain micrometastases or larger (metastases greater than 0.2 millimeters in size). Do not include in the count of lymph nodes positive any nodes that are identified as containing isolated tumor cells (ITCs). If the path report indicates that nodes are positive but the size of metastasis is not stated, assume the metastases are larger than 0.2 mm and count the lymph node(s) as positive.
- **For cutaneous melanoma and Merkel cell carcinoma,** count nodes with ITCs as positive lymph nodes.
- **Use of Code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue). Use code 95 when a positive lymph node is aspirated and there are no surgically resected lymph nodes. Use code 95 when a positive lymph node is aspirated and surgically resected lymph nodes are negative.
- **Definition of Code 97.** Use code 97 for any combination of positive aspirated, biopsied, sampled or dissected lymph nodes if the number of involved nodes cannot be determined on the basis of cytology or histology. Code 97 includes positive lymph nodes diagnosed by either cytology or histology. Note: If the aspirated node is the only one that is microscopically positive, use code 95.
- **Use of Code 98.** Code 98 may be used in several situations. When the assessment of lymph nodes is clinical only. When no lymph nodes are removed and examined. When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination. If Regional Nodes Positive is coded as 98, Regional Nodes Examined is usually coded 00.
- **Use of code 99.** Use code 99 if it is unknown whether regional lymph nodes are positive.
- **Primary sites always coded 99.** For the following primary sites and histologies, the Regional Nodes Positive field is always coded as 99: C420, C421, C423-C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809.

For the following schemas, the Regional Nodes Positive field is always coded as 99.

Placenta

Brain and Cerebral Meninges

Other Parts of Central Nervous System

Intracranial Gland

Hodgkin and non-Hodgkin Lymphoma

- Excludes cases collected in the following schemas: Lymphoma Ocular Adnexa, Primary Cutaneous Lymphomas and Mycosis Fungoides

Hematopoietic, Reticuloendothelial, Immunoproliferative and Myeloproliferative Neoplasms

Myeloma and Plasma Cell Disorders

- Excludes histology 9734

## Other and Ill-Defined Primary Sites

- Excludes Spleen (C422)

## Unknown Primary Site

When definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual use the AJCC definition.

Code	Label
00	All nodes examined are negative
01-89	1-89 nodes are positive (code exact number of nodes positive)
90	90 or more nodes are positive
95	Positive aspiration of lymph node(s) was performed
97	Positive nodes are documented, but the number is unspecified
98	No nodes were examined
99	It is unknown whether nodes are positive; not applicable; not stated in medical record

## **Tumor Size and Mets**

## Tumor Size Clinical

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
752	3	tumorSizeClinical	000-990, 998, 999	2016+	

### Description

This data item records the size of a solid primary tumor **before any treatment** (surgical resection or initiation of any treatment including neoadjuvant). Clinical classification is composed of diagnostic workup prior to first treatment, including physical examination, imaging, pathological findings (gross description and microscopic measurements most likely from a biopsy that did not remove the entire lesion), and surgical exploration without resection.

### Rationale

Clinical tumor size (pre-treatment size) is essential for treatment decision making and prognosis determination for many types of cancer. Tumor size is required for all solid tumors.

### Codes

(Refer to the most recent version of [SEER Program Coding and Staging Manual](#) for additional instructions.)

Code	Label
000	No mass/tumor found
001	1 mm or described as less than 1 mm (0.1 cm or less than 0.1 cm)
002-988	Exact size in millimeters (2 mm to 988 mm) (0.2 cm to 98.8 cm)
989	989 millimeters or larger (98.9 cm or larger)
990	Microscopic focus or foci only and no size of focus is given
998	<p>SITE-SPECIFIC CODES</p> <p>Alternate descriptions of tumor size for specific sites:</p> <p>Familial/multiple polyposis:            Rectosigmoid and rectum (C19.9, C20.9)            Colon (C18.0, C18.2-C18.9)</p> <p><b>If no size is documented:</b></p> <p>Circumferential:            Esophagus (C15.0-C15.5, C15.8-C15.9)</p> <p>Diffuse; widespread: 3/4s or more; linitis plastica:            Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)</p> <p>Diffuse, entire lung or NOS:            Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)</p> <p>Diffuse:            Breast (C50.0-C50.6, C50.8-C50.9)</p>
999	<p>Unknown; size not stated</p> <p>Not documented in patient record</p> <p>Size of tumor cannot be assessed</p> <p>The only measurement(s) describes pieces or chips</p> <p>Not applicable</p>

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute.



## Tumor Size Pathologic

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
754	3	tumorSizePathologic	000-990, 998, 999	2016+	

### Description

This data item records the size of a solid primary tumor that has been resected. Pathologic classification includes operative and pathological findings of the resected specimens before initiation of adjuvant treatment.

### Rationale

Pathologic tumor size is an important prognostic indicator and valuable for clinical practice and research on surgically treated patients for most cancers. Tumor size is required for all solid tumors.

### Codes

(Refer to the most recent version of [SEER Program Coding and Staging Manual](#) for additional instructions.)

Code	Label
000	No mass/tumor found
001	1 mm or described as less than 1 mm (0.1 cm or less than 0.1 cm)
002-988	Exact size in millimeters (2 mm to 988 mm) (0.2 cm to 98.8 cm)
989	989 millimeters or larger (98.9 cm or larger)
990	Microscopic focus or foci only and no size of focus is given
998	<p>SITE-SPECIFIC CODES</p> <p>Alternate descriptions of tumor size for specific sites:</p> <p>Familial/multiple polyposis:            Rectosigmoid and rectum (C19.9, C20.9)            Colon (C18.0, C18.2-C18.9)</p> <p>If no size is documented:            Circumferential:            Esophagus (C15.0-C15.5, C15.8-C15.9)</p> <p>Diffuse; widespread: 3/4s or more; linitis plastica:            Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)</p> <p>Diffuse, entire lung or NOS:            Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)</p> <p>Diffuse:            Breast (C50.0-C50.6, C50.8-C50.9)</p>
999	<p>Unknown; size not stated</p> <p>Not documented in patient record</p> <p>Size of tumor cannot be assessed</p> <p>No excisional biopsy or tumor resection done (See SEER instruction #1)</p> <p>The only measurement(s) describes pieces or chips (See SEER instruction #15)</p> <p>Not applicable</p>

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). [SEER Program Coding and Staging Manual 2022](#). National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute

## Tumor Size Summary

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
756	3	882-884	000-990, 998, 999	2016+	01/16, 2/21, 01/22

### Description

This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen.

### Rationale

Tumor size is one indication of the extent of disease. As such, it is used by both clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

### Coding Instructions

**Note: All measurements should be in millimeters (mm).**

Record size in specified order:

1. Size measured on the surgical resection specimen, when surgery is administered as the first definitive treatment, i.e., no pre-surgical treatment administered.
  - a. If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report (also known as CAP protocol or pathology report checklist). If only a text report is available, use: final diagnosis, microscopic, or gross examination, in that order.
 

*Example:* Chest x-ray shows 3.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 2.8 cm. Record tumor size as 028 (28 mm).

*Example:* Pathology report states lung carcinoma is 2.1 cm x 3.2 cm x 1.4 cm. Record tumor size as 032 (32 mm).
2. If neoadjuvant therapy followed by surgery, do not record the size from the pathologic specimen. Code the largest size of tumor prior to neoadjuvant treatment; if unknown code size as 999.
 

*Example:* Patient has a 2.2 cm mass in the oropharynx; find needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathologic size after total resection is 2.8 cm. Record tumor size as 022 (22mm).
3. If no surgical resection, then largest measurement of the tumor from the imaging, physical exam, or other diagnostic procedures in this order of priority prior to any other form of treatment (See Coding Rules below).
4. If 1, 2, and 3 do not apply, the largest size from all information available within four months of the date of diagnosis, in the absence of disease progression.

## Coding Rules

1. Tumor size is the **diameter** of the tumor, **not the depth or thickness** of the tumor.
2. Recording less than/greater than Tumor Size:
  - a. If tumor size is reported as less than x mm or less than x cm, the reported tumor size should be 1 mm less; for example if size is <10 mm, code size as 009. Often these are given in cm such as < 1 cm which is coded as 009, < 2 cm is coded as 019, < 3 cm is coded as 029, < 4 cm is coded as 039, < 5 cm is coded as 049. If stated as less than 1 mm, use code 001.
  - b. If tumor size is reported as more than x mm or more than x cm, code size as 1 mm more; for example if size is >10 mm, size should be coded as 011. Often these are given in cm such as > 1 cm, which is coded as 011, > 2 cm is coded as 021, > 3 cm is coded as 031, > 4 cm is coded as 041, > 5 cm is coded as 051. If described as anything greater than 989 mm (98.9 cm) code as 989.
  - c. If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two (“between 2 and 3 cm” is coded as 025).
3. **Rounding:** Round the tumor size only if it is described in fractions of millimeters. If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9 mm), record size as 001 (do not round down to 000). If tumor size is greater than 1 millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter, and round tenths of millimeters in the 5-9 range up to the nearest whole millimeter. Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters). For breast cancer, please follow the AJCC 8<sup>th</sup> Edition, Breast Chapter.

*Examples:*

Breast cancer described as 6.5 millimeters in size. Round up *Tumor Size as 007.*

Cancer in polyp described as 2.3 millimeters in size. Round down *Tumor Size as 002.*

Focus of cancer described as 1.4 mm in size. *Round down as 001.*

5.2 mm breast cancer. *Round down to 5 mm and code as 005.*

4. **Priority of imaging/radiographic techniques:** Information on size from imaging/radiographic techniques can be used to code the tumor size when there is no more specific size information from pathology or operative report. It should be taken as a lower priority, but over a physical exam.
5. **Tumor size discrepancies among imaging and radiographic reports:** If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.
6. **Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.** However, if the tumor is described as a “cystic mass,” and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.
7. Record the size of the invasive component, if given.

- a. If both an in situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.  
*Example:* Tumor is mixed in situ and invasive adenocarcinoma, total 3.7 cm in size, of which 1.4 cm is invasive. Record tumor size as 014 (14 mm)
  - b. If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.  
*Example:* A breast tumor with infiltrating duct carcinoma with extensive in situ component; total size 2.3 cm. Record tumor size as 023 (23 mm).  
  
*Example:* Duct carcinoma in situ measuring 1.9 cm with an area of invasive ductal carcinoma. Record tumor size as 019 (19 mm).
8. Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.  
*Example:* Tumor is described as 2.4 x 5.1 x 1.8 cm in size. Record tumor size as 051 (51 mm).
  9. Record the size as stated for purely in situ lesions.
  10. **Disregard microscopic residual or positive surgical margins when coding tumor size.** Microscopic residual tumor does not affect overall tumor size. The status of primary tumor margins may be recorded in a separate data item.
  11. **Do not add the size of pieces or chips together to create a whole;** they may not be from the same location, or they may represent only a very small portion of a large tumor. However, if the pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size), record that size. If the only measurement describes pieces or chips, record tumor size as 999.
  12. **Multifocal/multicentric tumors:** If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all of the tumors are in situ, code the size of the largest in situ tumor.
  13. **Tumor size code 999 is used when size is unknown or not applicable.** Sites/morphologies where tumor size is not applicable are listed here.  
Primary sites: C420, C421, C423-C424, C770-C779 or C809
  - Hematopoietic, Reticuloendothelial, and Myeloproliferative neoplasms: histology codes 9590-9993  
*Excludes* cases collected in the following schemas: Lymphoma Ocular Adnexa, Primary Cutaneous Lymphomas, Mycosis Fungoides and lymphomas that are collected in the Brain, CNS Other and Intracranial Gland Schemas
  - Kaposi Sarcoma
  - Melanoma Choroid
  - Melanoma Ciliary Body  
Melanoma Iris
  14. Tumor size code 000 is used for the following schema:  
Schema is Cervical Lymph Nodes and Unknown Primary 00060  
Occult Cervical Lymph Node (See STORE, Overview of Coding Principles, page 44).
  15. Document the information to support coded tumor size in the appropriate text data item of the abstract.

16. Tumor size is also important for staging for the following sites/schemas and schema IDs:  
**Schema (Schema ID)**

00760	Adrenal Gland
00210	Anus
00260	Bile Duct Distal
00230	Bile Ducts Intrahepat
00381	Bone Appendicular Skeleton
00383	Bone Pelvis
00480	Breast
00076	Buccal Mucosa
00520	Cervix
00650	Conjunctiva
00541	Corpus Sarcoma
00150	Cutaneous Carcinoma of Head and Neck
00074	Floor of Mouth
00430	GIST
00073	Gum
00112	Hypopharynx
00600	Kidney Parenchyma
00690	Lacrimal Gland
00071	Lip
00220	Liver
00360	Lung
00080	Major Salivary Glands
00460	Merkel Cell Skin
00077	Mouth Other
00770	NET Adrenal Gland
00320	NET Appendix
00330	NET Colon and Rectum
00340	NET Pancreas
00290	NET Stomach
00700	Orbital Sarcoma
00111	Oropharynx (p16-)
00100	Oropharynx HPV-Mediated (p16+)
00075	Palate Hard
00280	Pancreas
00812	Primary Cutaneous Lymphomas (excluding Mycosis Fungoides)
00440	Retroperitoneum
00640	Skin Eyelid
00400	Soft Tissues Head and Neck
00410	Soft Tissues Trunk and Extremities
00730	Thyroid
00740	Thyroid Medullary
00072	Tongue Anterior
00510	Vagina
00500	Vulva

Code	Label
000	No mass/tumor found
001	1 mm or described as less than 1 mm
002-988	Exact size in millimeters (2 mm to 988 mm)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus is given
998	<p>SITE-SPECIFIC CODES</p> <p>Alternate descriptions of tumor size for specific sites:</p> <p>Familial/multiple polyposis:  Rectosigmoid and rectum (C19.9, C20.9)  Colon (C18.0, C18.2-C18.9)</p> <p>If no size is documented:  Circumferential:  Esophagus (C15.0-C15.5, C15.8-C15.9)</p> <p>Diffuse; widespread: 3/4s or more; linitis plastica:  Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)</p> <p>Diffuse, entire lung or NOS:  Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)</p> <p>Diffuse:  Breast (C50.0-C50.6, C50.8-C50.9)</p>
999	<p>Unknown; size not stated</p> <p>Not documented in medical record</p> <p>Size of tumor cannot be assessed</p> <p>Not applicable</p>

## Mets at Diagnosis – Bone

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1112	1	870-870	0, 1, 8, 9	2016+	01/16, 02/21, 01/22

### Description

This data item identifies whether bone is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about bone metastases only** (discontinuous or distant metastases to bone) identified at the time of diagnosis. This data item should not be coded for bone marrow involvement.
  - a. Bone involvement may be single or multiple
  - b. Information about bone involvement may be clinical or pathological
  - c. Code this data item for bone metastases even if the patient had any preoperative systemic therapy
  - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has bone metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no bone metastases
    - iii. includes imaging reports that are negative for bone metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but bone is not mentioned as an involved site

*Example:* use code 0 when the patient has lung and liver metastases but not bone
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases and bone is mentioned as an involved site
    - ii. indicates that bone is the primary site and there are metastases in a different bone or bones
      - 1) do not assign code 1 for a bone primary with multifocal bone involvement of the same bone

- iii. indicates that the patient is diagnosed as an unknown primary (C80.9) and bone is mentioned as a distant metastatic site
- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.  
Use code 8 (Not applicable) for benign/borderline brain and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has bone metastases; for example, when there is documentation of carcinomatosis but bone is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include bone.

Code	Label
0	None; no bone metastases
1	Yes; distant bone metastases
8	Not applicable
9	Unknown whether bone is an involved metastatic site Not documented in patient record



## Mets at Diagnosis – Brain

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1113	1	871-871	0, 1, 8, 9	2016+	01/16, 02/21, 01/22

### Description

This data item identifies whether brain is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about brain metastases only** (discontinuous or distant metastases to brain) identified at the time of diagnosis. This data item should not be coded for involvement of spinal cord or other parts of the central nervous system.
  - a. Brain involvement may be single or multiple
  - b. Information about brain involvement may be clinical or pathological
  - c. Code this data item whether or not the patient had any preoperative systemic therapy
  - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has brain metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no brain metastases
    - iii. includes imaging reports that are negative for brain metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but brain is not mentioned as an involved site

*Example:* use code 0 when the patient has lung and liver metastases but not brain
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases and brain is mentioned as an involved site
    - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and brain is mentioned as a distant metastatic site
  - c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

Use code 8 (Not applicable) for benign/borderline brain and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has brain metastases; for example, when there is documentation of carcinomatosis but brain is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include brain.

Code	Label
0	None; no brain metastases
1	Yes; distant brain metastases
8	Not applicable
9	Unknown whether brain is involved metastatic site Not documented in patient record

## Mets at Diagnosis – Distant Lymph Nodes

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1114	1	872-872	0, 1, 8, 9	2016+	01/16, 02/21

### Description

This data item identifies whether distant lymph node(s) are an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about distant lymph node(s) metastases only** (metastases to distant lymph nodes) identified at the time of diagnosis.
  - a. Distant lymph node involvement may be single or multiple
  - b. Information about distant lymph node involvement may be clinical or pathological
  - c. Code this data item whether or not the patient had any preoperative systemic therapy
  - d. This data item should not be coded for regional lymph node involvement with the exception of lymph nodes for placenta which are in the M1 category
  - e. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.
2. **Use of codes.** Assign the code that best describes whether the case has distant lymph node metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no distant lymph node metastases
    - iii. includes imaging reports that are negative for distant lymph node metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but distant lymph node(s) are not mentioned as an involved site

*Example:* use code 0 when the patient has lung and liver metastases but not distant lymph node(s)
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases and distant lymph node(s) are mentioned as an involved site
    - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and distant lymph node(s) are mentioned as a metastatic site

- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.

Use code 8 (Not applicable) for benign/borderline and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9740-9809, 9840-9992	Mast cell, histiocytosis, immunoproliferative, leukemias coded to any site
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C440, C442-C689, C691-C694, C698-C809	9820, 9826, 9831-9834	Mostly lymphoid leukemias coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
C000-C440, C442-C689, C691-C694, C698-C809	9731, 9732, 9734	Plasma cell tumors coded to any site except eyelid, conjunctiva, lacrimal gland, orbit, and eye overlapping and NOS
Any primary site		Lymphoma histologies
C420, C421, C424, C770-C779	Any histology	

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has distant lymph node metastases; for example, when there is documentation of carcinomatosis but distant lymph node(s) are not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include distant lymph node(s).

Code	Label
0	None; no distant lymph node metastases
1	Yes; distant lymph node metastases
8	Not applicable
9	Unknown whether distant lymph node(s) are involved metastatic site Not documented in patient record

## Mets at Diagnosis – Liver

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1115	1	873-873	0, 1, 8, 9	2016+	01/16, 02/21, 01/22

### Description

This data item identifies whether liver is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about liver metastases only** (discontinuous or distant metastases to liver) identified at the time of diagnosis.
  - a. Liver involvement may be single or multiple
  - b. Information about liver involvement may be clinical or pathological
  - c. Code this data item whether or not the patient had any preoperative systemic therapy
  - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has liver metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no liver metastases
    - iii. includes imaging reports that are negative for liver metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but liver is not mentioned as an involved site

*Example:* use code 0 when the patient has lung and brain metastases but not liver
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases and liver is mentioned as an involved site
    - ii. indicates that the patient is diagnosed as an unknown primary (C80.9) and liver is mentioned as a distant metastatic site
  - c. Use code 8 (Not applicable) for the following site/histology/combinations for which a code for distant metastasis is not clinically relevant.  
Use code 8 (Not applicable) for benign/borderline brain and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has liver metastases; for example, when there is documentation of carcinomatosis but liver is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include liver.

Code	Label
0	None; no liver metastases
1	Yes; distant liver metastases
8	Not applicable
9	Unknown whether liver is involved metastatic site Not documented in patient record

## Mets at Diagnosis – Lung

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1116	1	874-874	0, 1, 8, 9	2016+	01/16, 02/21, 01/22

### Description

This data item identifies whether lung is an involved metastatic site. The six Mets at Dx-Metastatic Sites data items provide information on specific metastatic sites for data analysis.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about lung metastases only** (discontinuous or distant metastases to lung) identified at the time of diagnosis. This data item should not be coded for pleural or pleural fluid involvement.
  - a. Lung involvement may be single or multiple
  - b. Information about lung involvement may be clinical or pathological
  - c. Code this data item whether or not the patient had any preoperative systemic therapy
  - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites
2. **Use of codes.** Assign the code that best describes whether the case has lung metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no lung metastases
    - iii. includes imaging reports that are negative for lung metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but lung is not mentioned as an involved site.

*Example:* use code 0 when the patient has liver and brain metastases but not lung
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases and lung is mentioned as an involved site
    - ii. indicates that lung is the primary site and there are metastases in the contralateral lung
      - 1) do not assign code 1 for a lung primary with multifocal involvement of the same lung

- iii. indicates that the patient is diagnosed as an unknown primary (C80.9) and lung is mentioned as a distant metastatic site
- c. Use code 8 (Not applicable) for the following site/histology combinations for which a code for distant metastasis is not clinically relevant.  
Use code 8 (Not applicable) for benign/borderline brain and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

- d. Use code 9 when it cannot be determined from the medical record whether the patient specifically has lung metastases; for example, when there is documentation of carcinomatosis but lung is not specifically mentioned as a metastatic site. In other words, use code 9 when there are known distant metastases but it is not known whether the distant metastases include lung.

Code	Label
0	None; no lung metastases
1	Yes; distant lung metastases
8	Not applicable
9	Unknown whether lung is involved metastatic site Not documented in patient record



## Mets at Diagnosis – Other

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1117	1	875-875	0, 1, 2, 8, 9	2016+	01/16, 01/18, 02/21, 01/22

### Description

The six Mets at Dx-Metastatic Sites fields provide information on metastases for data analysis. This data item identifies any type of distant involvement not captured in the **Mets at Diagnosis – Bone, Mets at Diagnosis – Brain, Mets at Diagnosis – Liver, Mets at Diagnosis – Lung, and Mets at Diagnosis – Distant Lymph Nodes** fields. It includes involvement of other specific sites and more generalized metastases such as carcinomatosis. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum, and skin.

### Rationale

Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient's metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors. CoC requires this data item be recorded in its accredited program cancer registries beginning with cases diagnosed January 1, 2016.

### Coding Instructions

1. **Code information about other metastases only** (discontinuous or distant metastases) identified at the time of diagnosis. This data item should not be coded for bone, brain, liver, lung or distant lymph node metastases.
  - a. Other involvement may be single or multiple
  - b. Information about other involvement may be clinical or pathological.
  - c. Code this data item whether or not the patient had any preoperative (neoadjuvant) systemic therapy
  - d. This data item should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary Site, and Other and Ill-Defined Primary Sites.
2. **Use of codes.** Assign the code that best describes whether the case has other metastases at diagnosis.
  - a. Use code 0 when the medical record
    - i. indicates that there are no distant (discontinuous) metastases at all
    - ii. includes a clinical or pathologic statement that there are no other metastases
    - iii. includes imaging reports that are negative for other metastases
    - iv. indicates that the patient has distant (discontinuous) metastases but other sites are not mentioned as involved

*Example:* use code 0 when the patient has lung and liver metastases only
  - b. Use code 1 when the medical record
    - i. indicates that the patient has distant (discontinuous) metastases in any site(s) other than bone, brain, liver, lung or distant lymph node(s)

- ii. includes but not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum and skin
- c. Use code 8 (Not applicable) for the following site/histology combination for which a code for distant metastasis is not clinically relevant.  
Use code 8 (Not applicable) for benign/borderline brain and CNS tumors.

ICD-O-3 Site	ICD-O-3 Histology	
C000-C809	9671, 9741-9742, 9761-9762, 9800-9809, 9820, 9826, 9831-9834, 9840-9920, 9931-9993	Mast cell, histiocytosis, immunoproliferative, and leukemias
C420, C421, C424	9811-9818, 9823, 9827, 9837	Specific leukemia/lymphoma histologies coded to blood, bone marrow, hematopoietic
C000-C809	9731, 9732, 9734	Plasma cell tumors coded to any site
C420, C421, C424	Any histology	

- d. Use code 9 when it cannot be determined from the medical record whether the patient has metastases other than bone, brain, liver, lung and distant lymph node(s). In other words, use code 9 when there are known distant metastases but it is not known specifically what they are.

Code	Label
0	None; no other metastases
1	Yes; distant metastases in known site(s) other than bone, brain, liver, lung or distant lymph nodes
2	Generalized metastases such as carcinomatosis
8	Not applicable
9	Unknown whether any other metastatic site Not documented in patient record

## Summary Stage 2018

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
764	1	summaryStage2018	0-4, 7-9	2018+	

### Description

This item stores the directly assigned Summary Stage 2018. Effective for cases diagnosed 1/1/2018+. Code summary stage at the initial diagnosis or treatment of the reportable tumor. Summary stage should include all information available through completion of surgery(ies) in the first course of treatment or within 4 months of diagnosis in the absence of disease progression, whichever is longer.

### Rationale

The SEER program has collected staging information on cases since its inception in 1973. Summary Stage groups cases into broad categories of in situ, local, regional, and distant. Summary Stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.

Stage information is important when evaluating the effects of cancer control programs. It is crucial in understanding whether changes over time in incidence rates or outcomes are due to earlier detection of the cancers. In addition, cancer treatment cannot be studied without knowing the stage at diagnosis.

From 2004 through 2015, NHSCR relied on the item *Derived SS2000* [3020] for the value of *SEER Summary Stage 2000* [759] as generated by the Collaborative Staging algorithm. For cases diagnosed in 2016 and 2017, the NHSCR required that directly-coded *SEER Summary Stage 2000* [759] be recorded. Effective with cases diagnosed January 1, 2018 the NHSCR requires that directly-coded *SEER Summary Stage 2018* [764] be recorded.

*Note:* This data item was included in Standards Volume II, Version 16; however, it was not implemented until 2018.

### Coding Instructions

NH-46

- Refer to the site and histology-specific definitions of categories and coding instructions in the *SEER Summary Staging Manual 2018*.
- Use Code 8 for benign and borderline brain/CNS cases.
- Note: For Summary Stage 2018, code 5 for “Regional, NOS” can no longer be coded.

### Codes

Code	Label
0	In situ
1	Localized only
2	Regional by direct extension only
3	Regional lymph nodes only
4	Regional by BOTH direct extension AND lymph node involvement
7	Distant site(s)/node(s) involved
8	Benign/borderline*
9	Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case

\*Applicable for the following SS2018 chapters: Brain, CNS Other, Intracranial Gland.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

**AJCC TNM Stage, Current Edition**

NH-46

## AJCC TNM Clin T

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1001	15	1082-1096	Alphanumeric, Blank	2018+	01/18

### Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known *prior* to the start of any therapy. Detailed site-specific values for the clinical T category as defined by the current AJCC edition.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Codes and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The clinical T category staging data item must be recorded for Class of Case 10-22.
- It is strongly recommended that the clinical T category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigning of clinical T.
- Assign clinical T category as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical T, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for detailed staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Clin T Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1031	4	1097-1100	(m), (s), Blank	2018+	01/18

### Description

Identifies the AJCC TNM clinical T category suffix for the tumor *prior* to the start of any therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Codes and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- Record the clinical T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the suffix when applicable, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC manual, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

## AJCC TNM Clin N

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1002	15	1101-1115	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known **prior** to the start of any therapy. Detailed site-specific values for the clinical N category as defined by the current AJCC edition.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Codes and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The clinical N category staging data item must be assigned for Class of Case 10-22.
- It is strongly recommended that the clinical N category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigned of clinical N category.
- Record clinical N category as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded clinical N, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging Manual, Eighth Edition have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Clin N Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1034	4	1116-1119	(sn), (f), Blank	2018+	01/18

### Description

Identifies the AJCC TNM clinical N category suffix for the tumor *prior* to the start of any therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- To distinguish lymph nodes identified during diagnostic evaluation by sentinel node biopsy or FNA or core needle biopsy from those identified by physical examination and imaging, the following suffixes are used in assigning the clinical N (cN) category.
- If SLN biopsy is performed as part of the diagnostic workup, the cN category should have the sn suffix: for example, cN1(sn).
- If an FNA or a core biopsy is performed on lymph nodes as part of the diagnostic workup, the cN category should have the f suffix: for example, cN1(f).
- If you do not know which procedure was done, leave it blank.
- Record the clinical N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC manual, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(sn)	Sentinel node procedure with or without FNA or core needle biopsy
(f)	FNA or core needle biopsy only
(blank)	No suffix needed or appropriate; not recorded



## AJCC TNM Clin M

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1003	15	1120-1134	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the presence or absence of distant metastasis (M) of the tumor known *prior* to the start of any therapy. Detailed site-specific values for the clinical T category suffix as defined by the current AJCC edition.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The clinical M category staging data item must be assigned for Class of Case 10-22.
- It is strongly recommended that the clinical M category staging data item be recorded for Class of Case 00 cases if the patient's workup at the facility allows assigning of clinical M.
- Record clinical M category as documented by the first treating physician or managing physician in the medical record.
- If the managing physician has not recorded clinical M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Clin Stage Group

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1004	15	1135-1149	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the anatomic extent of disease based on the T, N, and M category data items known **prior** to the start of any therapy. Detailed site-specific values for the clinical stage group as defined by the current AJCC edition.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are still utilized for the stage groups only due to the decision to maintain Arabic numerals in the stage groups. New groups will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- Record the clinical stage group as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the clinical stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical, pathological, post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Clin (yc) T

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1062	15		Alphanumeric, Blank	2021+	02/21

### Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries when the planned post-neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy clin T category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy clin T category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Clin (yc) T Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1063	4		(m), (s), Blank	2021+	02/21

### Description

Identifies the AJCC TNM post therapy clinical T category suffix for the tumor following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries when the planned post-neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- Record the post therapy clin T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy clin T category suffix, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC system, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

## AJCC TNM Post Therapy Clin (yc) N

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1064	15		Alphanumeric, Blank	2021+	02/21

### Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries when the planned post-neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy clin N category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded post therapy clin N category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Clin (yc) N Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1065	4		(sn), (f), Blank	2021+	02/21

### Description

Identifies the AJCC TNM post therapy clinical N suffix for the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries when the planned post-neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the ypN category should have the sn suffix: for example, ypN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the ypN category should have the f suffix: for example, ypN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the post therapy clinical N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC System, leave this data item blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.

Code	Label
(sn)	Sentinel node procedure with or without FNA or core needle biopsy
(f)	FNA or core needle biopsy only
(blank)	No suffix needed or appropriate; not recorded

## AJCC TNM Post Therapy Clin (yc) M

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1066	15		Alphanumeric, Blank	2021+	02/21

### Description

Identifies the presence or absence of distant metastasis (M) of the tumor as known in the clinical stage before initiation of neoadjuvant therapy and records this information following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and before planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries when the planned post-neoadjuvant therapy surgery has been canceled. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy clin M category staging data item must be assigned for *Class of Case* 10-22.
- Assign post therapy clin M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy clin M category, registrars *will* assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current *AJCC Cancer Staging System* for staging rules.
- The valid codes and labels for the *AJCC Cancer Staging System* have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## Grade Post Therapy Clin (yc)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1068	1		1-5, 8, 9, A, B, C, D, E, L, H, M, S, Blank	2021+	02/21

### Description

This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual. Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

For cases diagnosed January 1, 2021 and later, this data item, along with *Grade Clinical* [3843], *Grade Pathological* [3844], and *Grade Post Therapy Path* [3845] replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

### Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Staging System. The AJCC Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

### Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.



## AJCC TNM Path T

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1011	15	1150-1164	Alphanumeric, Blank	2018+	01/18

### Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known **following** the completion of surgical therapy. Detailed site-specific values for the pathological tumor (T) as defined by the current AJCC edition.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The pathological T category staging data item must be assigned for Class of Case 10-22.
- Assign pathological T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathological T category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Path T Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1032	4	1165-1168	(m), (s), Blank	2018+	01/18

### Description

Identifies the AJCC TMN pathological T category suffix for the tumor **following** the completion of surgical therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- Record the pathological stage T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the descriptor, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC system, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)

## AJCC TNM Path N

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1012	15	1169-1183	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known **following** the completion of surgical therapy.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The pathological N category staging data item must be assigned for Class of Case 10-22.
- Assign pathological N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded pathological N category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging Manual, Eighth Edition have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Path N Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1035	4	1184-1187	(sn), (f), Blank	2018+	01/18

### Description

Identifies the AJCC TNM pathological N suffix for the tumor **following** the completion of surgical therapy. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the pN category should have the sn suffix: for example, pN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the pN category should have the f suffix: for example, pN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the pathological N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC System, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
(blank)	No suffix needed or appropriate; not recorded

## AJCC TNM Path M

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1013	15	1188- 1202	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the presence or absence of distant metastasis (M) of the tumor known **following** the completion of surgical therapy.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The pathological M category staging data item must be assigned for Class of Case 10-22.
- Assign pathological M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded pathological M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging Manual, Eighth Edition have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Path Stage Group

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1014	15	1203-1217	Alphanumeric, Blank	2018+	01/18

### Description

Identifies the anatomic extent of disease based on the T, N, and M category data items known **following** the completion of surgical therapy.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- Record the pathological stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the pathological stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical, pathological, post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Path (yp) T

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1021	15	1218-1232	Alphanumeric, Blank	2018+	01/18, 02/21

### Description

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy path T category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path T category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy path T category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC system and for in situ tumors that are not staged according to the current AJCC system. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- For lung, occult carcinoma is assigned TX according to the definition in the current AJCC system
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Path (yp) T Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1033	4	1233-1236	(m), (s), Blank	2018+	01/18, 02/21

### Description

Identifies the AJCC TNM post therapy pathological T category suffix for the tumor following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- Record the post therapy path T category suffix as documented by the first treating physician or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy path T category suffix, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC System, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(blank)	No information available; not recorded
(m)	Multiple synchronous tumors OR Multifocal tumor (differentiated and anaplastic thyroid only)
(s)	Solitary tumor (differentiated and anaplastic thyroid only)



## AJCC TNM Post Therapy Path (yp) N

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1022	15	1237-1251	Alphanumeric, Blank	2018+	01/18, 02/21

### Description

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy path N category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path N category as documented by the treating physician(s) or managing physician in the medical record.
- If the managing physician has not recorded post therapy path N category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site.. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Path (yp) N Suffix

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1036	4	1252-1255	(sn), (f), Blank	2018+	01/18, 02/21

### Description

Identifies the AJCC TNM post therapy pathological N suffix for the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post- neoadjuvant therapy surgical resection**. Stage suffices identify special cases that need separate analysis. Suffices are adjuncts to and do not change the stage group.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- If SLN biopsy is performed in the absence of complete dissection of the nodal basin, the ypN category should have the sn suffix: for example, ypN0(sn).
- If an FNA or a core biopsy is performed in the absence of a complete dissection of the nodal basin, the ypN category should have the f suffix: for example, ypN0(f).
- If you do not know which procedure was done, leave it blank.
- Record the post therapy pathological N category suffix as documented by the managing physician in the medical record.
- If the managing physician has not recorded the suffix, registrars will code this item based on the best available information, without necessarily requiring additional contact with the physician.
- If the tumor is not staged according to the AJCC System, leave this data item blank.
- Refer to the current AJCC Cancer Staging System for staging rules.

Code	Label
(sn)	Sentinel node procedure without resection of nodal basin
(f)	FNA or core needle biopsy without resection of nodal basin
(blank)	No suffix needed or appropriate; not recorded

## AJCC TNM Post Therapy Path (yp) M

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1023	15	1256-1270	Alphanumeric, Blank	2018+	01/18, 02/21

### Description

Identifies the presence or absence of distant metastasis (M) of the tumor as known in the clinical stage before initiation of neoadjuvant therapy and records this information following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires use of the current AJCC Staging System in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

With the implementation of the 8<sup>th</sup> Edition storage codes are no longer utilized. Values and Labels for the different categories are exact matches to what is listed in the current system (except for code 88). The new categories will be used for cases diagnosed in 2018 and later.

### Coding Instructions

- The post therapy path M category staging data item must be assigned for Class of Case 10-22.
- Assign post therapy path M category as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded post therapy path M category, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician.
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## AJCC TNM Post Therapy Path (yp) Stage Group

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1024	15	1271-1285	Alphanumeric, Blank	2018+	01/18, 02/21

### Description

Identifies the anatomic extent of disease based on the T, N, and M category data items of the tumor known following the completion of **neoadjuvant** therapy (satisfying the definition for that disease site) and planned **post-neoadjuvant therapy surgical resection**.

### Rationale

The CoC requires that AJCC TNM staging be used in its accredited cancer programs. The CoC requires that AJCC TNM staging be recorded in its accredited program cancer registries. The AJCC developed this staging system for evaluating trends in the treatment and control of cancer. This staging system is used by physicians to estimate prognosis, plan treatment, evaluate new types of therapy, analyze outcomes, design follow-up strategies, and to assess early detection results.

### Coding Instructions

- Record the post therapy path stage group as documented by the treating physician(s) or the managing physician in the medical record.
- If the managing physician has not recorded the post therapy path stage, registrars will assign this item based on the best available information, without necessarily requiring additional contact with the physician(s).
- Code 88 for clinical and pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition. Code 88, only if the case qualifies, for post therapy clinical or for post therapy pathological T, N, and M as well as stage group if a site/histology combination is not defined in the current AJCC edition and for in situ tumors that are not staged according to the current AJCC edition.
- Code 99 for clinical and pathological or post therapy clinical or post therapy pathological stage group if the TNM combination along with any required prognostic factors does not result in a valid stage group according to the current AJCC system.
- If the value does not fill all 15 characters, then record the value to the left and leave the remaining spaces blank.
- Convert all Roman numerals to Arabic numerals and use upper-case (capital letters) only.
- Refer to the current AJCC Cancer Staging System for staging rules.
- The valid codes and labels for the AJCC Cancer Staging System have been expanded and are now consistent for clarity. They are provided on the AJCC Web site. Refer to the most current list of valid codes and labels: <https://cancerstaging.org/Pages/Vendors.aspx>.

## Grade Post Therapy Path (yp)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3845	1	1288-1288	1-5, 8, 9, A, B, C, D, E, L, H, M, S, Blank	2018+	01/18

### Description

This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. If AJCC staging is being assigned, the tumor must have met the surgical resection requirements in the AJCC manual. Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

For cases diagnosed January 1, 2018 and later, this data item, along with *Grade Clinical* [3843], *Grade Pathological* [3844], and *Grade Post Therapy Clin* [1068] replaces *Grade/Differentiation* [440] as well as SSF's for cancer sites with alternative grading systems (e.g., breast [Bloom-Richardson], prostate [Gleason]).

### Rationale

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the post-neoadjuvant stage group.

For those cases that are eligible AJCC staging, the recommended grading system is specified in the AJCC Staging System. The AJCC Chapter-specific grading systems (codes 1-5, L, H, M, S) take priority over the generic grade definitions (codes A-E, 8, 9). For those cases that are not eligible for AJCC staging, if the recommended grading system is not documented, the generic grade definitions would apply.

### Coding Instructions

- Please see the following URL for detailed coding instructions and site-specific coding rules: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>.

## Text--Staging

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2600	1000	textStaging	Neither carriage return nor line feed characters allowed	All Years	2021

### Description

Additional text area for staging information not already entered in other Text fields.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values.

Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date(s) of procedure(s), including clinical procedures, that provided information for assigning stage
- Organs involved by direct extension
- Size of tumor
- Status of margins
- Number and sites of positive lymph nodes
- Site(s) of distant metastasis
- Physician's specialty and comments

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Staging, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
RxDate Dx/Stg Proc	1280
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
Regional Nodes Positive	820
Regional Nodes Examined	830
RX Hosp--Surg Prim Site	670
RX Summ--Surg Prim Site	1290
RX Hosp--Scope Reg LN Sur	672
RX Summ--Scope Reg LN Sur	1292
RX Hosp--Surg Oth Rg/Dis	674
RX Summ--Surg Oth Reg/Dis	1294
Mult Tum Rpt as One Prim	444
Laterality	410

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Site-Specific Data Items

For cases diagnosed on January 1, 2018 and later, use of the Collaborative Stage (CS) Site-Specific Factors (SSF's) is discontinued, and Site-Specific Data Items (SSDIs) are used for collection of site-specific information.

For cases diagnosed on January 1, 2018 and later, the Site-Specific Data Items in the below table are required by CoC. Data items are listed by their respective NAACCR Data Item Number and Name.

- Please see the SSDI Manual at the following URL for detailed descriptions, rationales, coding instructions and site-specific coding rules: <https://apps.naacr.org/ssdi/list/>
- Five new SSDIs [3938-3942].
- Six SSDIs [3850-3854; 3859] no longer required.

**NH-47**

Item #	Site-Specific Data Item
<a href="#">3801</a>	Chromosome 1p: Loss of Heterozygosity (LOH)
<a href="#">3802</a>	Chromosome 19q: Loss of Heterozygosity (LOH)
<a href="#">3803</a>	Adenoid Cystic Basaloid Pattern
<a href="#">3804</a>	Adenopathy
<a href="#">3805</a>	AFP Post-Orchiectomy Lab Value
<a href="#">3806</a>	AFP Post-Orchiectomy Range
<a href="#">3807</a>	AFP Pre-Orchiectomy Lab Value
<a href="#">3808</a>	AFP Pre-Orchiectomy Range
<a href="#">3809</a>	AFP Pretreatment Interpretation
<a href="#">3810</a>	AFP Pretreatment Lab Value
<a href="#">3811</a>	Anemia
<a href="#">3812</a>	B symptoms
<a href="#">3813</a>	Bilirubin Pretreatment Total Lab Value
<a href="#">3814</a>	Bilirubin Pretreatment Unit of Measure
<a href="#">3815</a>	Bone Invasion
<a href="#">3817</a>	Breslow Tumor Thickness
<a href="#">3818</a>	CA-125 Pretreatment Interpretation
<a href="#">3819</a>	CEA Pretreatment Interpretation
<a href="#">3820</a>	CEA Pretreatment Lab Value
<a href="#">3821</a>	Chromosome 3 Status
<a href="#">3822</a>	Chromosome 8q Status
<a href="#">3823</a>	Circumferential Resection Margin (CRM)
<a href="#">3824</a>	Creatinine Pretreatment Lab Value
<a href="#">3825</a>	Creatinine Pretreatment Unit of Measure
<a href="#">3826</a>	Estrogen Receptor Percent Positive or Range
<a href="#">3827</a>	Estrogen Receptor Summary
<a href="#">3828</a>	Estrogen Receptor Total Allred Score
<a href="#">3829</a>	Esophagus and EGJ Tumor Epicenter
<a href="#">3830</a>	Extranodal Extension Clin (non-Head and Neck)

Item #	Site-Specific Data Item
<a href="#">3831</a>	Extranodal Extension Head and Neck Clinical
<a href="#">3832</a>	Extranodal Extension Head and Neck Pathological
<a href="#">3833</a>	Extranodal Extension Path (non-Head and Neck)
<a href="#">3834</a>	Extravascular Matrix Patterns
<a href="#">3835</a>	Fibrosis Score
<a href="#">3836</a>	FIGO Stage
<a href="#">3837</a>	Gestational Trophoblastic Prognostic Scoring Index
<a href="#">3838</a>	Gleason Patterns Clinical
<a href="#">3839</a>	Gleason Patterns Pathological
<a href="#">3840</a>	Gleason Score Clinical
<a href="#">3841</a>	Gleason Score Pathological
<a href="#">3842</a>	Gleason Tertiary Pattern
<a href="#">3843</a>	Grade Clinical
<a href="#">3844</a>	Grade Pathological
<a href="#">3845</a>	Grade Post Therapy
<a href="#">3846</a>	hCG Post-Orchiectomy Lab Value
<a href="#">3847</a>	hCG Post-Orchiectomy Range
<a href="#">3848</a>	hCG Pre-Orchiectomy Lab Value
<a href="#">3849</a>	hCG Pre-Orchiectomy Range
<a href="#">3855</a>	HER2 Overall Summary
<a href="#">3856</a>	Heritable Trait
<a href="#">3857</a>	High Risk Cytogenetics
<a href="#">3858</a>	High Risk Histologic Features
<a href="#">3860</a>	International Normalized Ratio Prothrombin Time
<a href="#">3861</a>	Ipsilateral Adrenal Gland Involvement
<a href="#">3862</a>	JAK2
<a href="#">3863</a>	Ki-67
<a href="#">3865</a>	KIT Gene Immunohistochemistry



Item #	Site-Specific Data Item	Item #	Site-Specific Data Item
<a href="#">3866</a>	KRAS	<a href="#">3905</a>	Oncotype Dx Risk Level-DCIS
<a href="#">3867</a>	LDH Post-Orchiectomy Range	<a href="#">3906</a>	Oncotype Dx Risk Level-Invasive
<a href="#">3868</a>	LDH Pre-Orchiectomy Range	<a href="#">3907</a>	Organomegaly
<a href="#">3869</a>	LDH Level	<a href="#">3908</a>	Percent Necrosis Post Neoadjuvant
<a href="#">3870</a>	LDH Upper Limits of Normal	<a href="#">3909</a>	Perineural Invasion
<a href="#">3871</a>	LN Assessment Method Femoral-Inguinal	<a href="#">3910</a>	Peripheral Blood Involvement
<a href="#">3872</a>	LN Assessment Method Para-Aortic	<a href="#">3911</a>	Peritoneal Cytology
<a href="#">3873</a>	LN Assessment Method Pelvic	<a href="#">3913</a>	Pleural Effusion
<a href="#">3874</a>	LN Distant Assessment Method	<a href="#">3914</a>	Progesterone Receptor Percent Positive or Range
<a href="#">3875</a>	LN Distant: Mediastinal, Scalene	<a href="#">3915</a>	Progesterone Receptor Summary
<a href="#">3876</a>	LN Head and Neck Levels I-III	<a href="#">3916</a>	Progesterone Receptor Total Allred Score
<a href="#">3877</a>	LN Head and Neck Levels IV-V	<a href="#">3917</a>	Primary Sclerosing Cholangitis
<a href="#">3878</a>	LN Head and Neck Levels VI-VII	<a href="#">3918</a>	Profound Immune Suppression
<a href="#">3879</a>	LN Head and Neck Other	<a href="#">3919</a>	EOD Prostate Pathological Extension
<a href="#">3880</a>	LN Isolated Tumor Cells (ITC)	<a href="#">3920</a>	PSA (Prostatic Specific Antigen) Lab Value
<a href="#">3881</a>	LN Laterality	<a href="#">3921</a>	Residual Tumor Volume Post Cytoreduction
<a href="#">3882</a>	LN Positive Axillary Level I-II	<a href="#">3922</a>	Response to Neoadjuvant Therapy
<a href="#">3883</a>	LN Size	<a href="#">3923</a>	S Category Clinical
<a href="#">3884</a>	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	<a href="#">3924</a>	S Category Pathological
<a href="#">3885</a>	Lymphocytosis	<a href="#">3925</a>	Sarcomatoid Features
<a href="#">3886</a>	Major Vein Involvement	<a href="#">3926</a>	Schema Discriminator 1
<a href="#">3887</a>	Measured Basal Diameter	<a href="#">3927</a>	Schema Discriminator 2
<a href="#">3888</a>	Measured Thickness	<a href="#">3928</a>	Schema Discriminator 3
<a href="#">3889</a>	Methylation of O6-Methylguanine-Methyltransferase	<a href="#">3929</a>	Separate Tumor Nodules
<a href="#">3890</a>	Microsatellite Instability (MSI)	<a href="#">3930</a>	Serum Albumin Pretreatment Level
<a href="#">3891</a>	Microvascular Density	<a href="#">3931</a>	Serum Beta-2 Microglobulin Pretreatment Level
<a href="#">3892</a>	Mitotic Count Uveal Melanoma	<a href="#">3932</a>	LDH Lab Value
<a href="#">3893</a>	Mitotic Rate Melanoma	<a href="#">3933</a>	Thrombocytopenia
<a href="#">3894</a>	Multigene Signature Method	<a href="#">3934</a>	Tumor Deposits
<a href="#">3895</a>	Multigene Signature Results	<a href="#">3935</a>	Tumor Growth Pattern
<a href="#">3896</a>	NCCN International Prognostic Index (IPI)	<a href="#">3936</a>	Ulceration
<a href="#">3897</a>	Number of Cores Examined	<a href="#">3937</a>	Visceral and Parietal Pleural Invasion
<a href="#">3898</a>	Number of Cores Positive	<a href="#">3938</a>	ALK Rearrangement
<a href="#">3899</a>	Number of Examined Para-Aortic Nodes	<a href="#">3939</a>	EGFR Mutational Analysis
<a href="#">3900</a>	Number of Examined Pelvic Nodes	<a href="#">3940</a>	BRAF Mutational Analysis
<a href="#">3901</a>	Number of Positive Para-Aortic Nodes	<a href="#">3941</a>	NRAS Mutational Analysis
<a href="#">3902</a>	Number of Positive Pelvic Nodes	<a href="#">3942</a>	CA 19-9 PreTx Lab Value
<a href="#">3904</a>	Oncotype Dx Recurrence Score-Invasive		

## Text--DX Proc—X-Ray/Scan

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2530	1000	textDxProcXRayScan	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation from all X-rays, scan, and/or other imaging examinations that provide information about staging.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date(s) and type(s) of X-ray/Scan(s)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Distant disease or metastasis

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc—X-Ray/Scan, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Primary Site	400
Laterality	410
Histology (92-00) ICD-O-2	420
Histologic Type ICD-O-3	522
Collaborative Stage variables	2800-2930
SEER Summary Stage 2000	759
SEER Summary Stage 1977	760
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3901-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Op

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2560	1000	textDxProcOp	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of all surgical procedures that provide information for staging.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Dates and descriptions of biopsies and all other surgical procedures from which staging information was derived
- Number of lymph nodes removed
- Size of tumor removed
- Documentation of residual tumor
- Evidence of invasion of surrounding areas
- Reason primary site surgery could not be completed

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Op, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Diagnostic Confirmation	490
Primary Site	400
RX Hosp--Dx/Stg Proc	740
RX Summ--Surg Prim Site	1290
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
Reason for No Surgery	1340
Summary Stage 2018	764
AJCC TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Scopes

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2540	1000	textDxProcScopes	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation from endoscopic examinations that provide information for staging and treatment.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date(s) of endoscopic exam(s)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Record site and type of endoscopic biopsy
- Record positive and negative clinical findings. Record positive results first

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--DX Proc--Scopes, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date of Diagnosis	390
RX Summ--Dx/Stg Proc	1350
Diagnostic Confirmation	490
Primary Site	400
Laterality	410
Histology (92-00) ICD-O-2	420
Histologic Type ICD-O-3	522
Collaborative Stage variables	2800-2930
SEER Summary Stage 1977	760
SEER Summary Stage 2000	759
RX Hosp--Surg Prim Site	670
RX Date Surgery	1200
Summary Stage 2018	764
Ajcc TNM Data Items	1001-1036
EOD Data Items	772-776
Site-specific SSDI Data Items	3801-3937

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## First Course of Treatment



## Date of First Course of Treatment

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1270	8	2104-2111	CCYYMMDD, Blank	2003+	01/10, 01/11

### Description

Records the date on which treatment (surgery, radiation, systemic, or other therapy) of the patient began at any facility.

### Rationale

It is important to be able to measure the delay between diagnosis and the onset of treatment. A secondary use for this date is as a starting point for survival statistics (rather than using the diagnosis date). This date cannot be calculated from the respective first course treatment modality dates if no treatment was given. Therefore, providing the date on which active surveillance is chosen, a physician decides not to treat a patient, or a patient's family or guardian declines treatment is important.

### Coding Instructions

[See Treatment Plan and Time Periods for First Course of Treatment in Section One for further instructions.](#)

- Record the earliest of the following dates: Date of First Surgical Procedure [1200], Date Radiation Started [1210], Date Systemic Therapy Started [3230], or Date Other Treatment Started [1250].
- If active surveillance or watchful waiting is selected as the first course of treatment (RX Summ–Treatment Status [1285] = 2) record the date this decision is made.
- In cases of non-treatment (RX Summ–Treatment Status [1285] = 0), in which a physician decides not to treat a patient, a patient's family or guardian declines all treatment, or patient receives palliative care for pain management only, the date of first course of treatment is the date this decision was made.
- Leave this item blank if the cancer was diagnosed at autopsy and not suspected prior to that.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of First Course of Treatment is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of First Course of Treatment transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

### Examples

Code	Reason
20040214	A patient has a core biopsy on February 12, 2004, and subsequently undergoes an excisional biopsy on February 14, 2004.
20050421	A patient begins receiving preoperative radiation therapy elsewhere on April 21, 2005, and subsequent surgical therapy at this facility on June 2, 2005.

## Date 1<sup>st</sup> Crs Rx CoC Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1271	2	date1stCrsRxCocFlag	10-12, Blank	2010+	2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Course of Treatment* [1270].

Formerly Date of 1st Crs Rx Flag.

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of First Course of Treatment* [1270] has a full or partial date recorded.
- Code 12 if the *Date of First Course of Treatment* cannot be determined at all, but the patient did receive first course treatment.
- Code 12 if a decision not to treat was made, but the date is totally unknown.
- Code 12 if a decision to use active surveillance was made, but the date is totally unknown.
- Code 10 if it is unknown whether any treatment was administered.
- Code 11 if the initial diagnosis was at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (e.g., unknown whether treatment was administered)
11	No proper value is applicable in this context (that is, autopsy only).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (for example, treatment was given but the date is unknown).
Blank	A valid date value is provided in item <i>Date of First Course of Treatment</i> [1270], or the date was not expected to have been transmitted.

Comment: This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Rx Summ – Treatment Status

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1285	1	2224-2224	0-2, 9	2010+	01/11, 02/21

### Description

This data item summarizes whether the patient received any treatment or the tumor was under active surveillance.

### Rationale

This item documents active surveillance (watchful waiting) and eliminates searching each treatment modality to determine whether treatment was given. It is used in conjunction with *Date of First Course of Treatment* [1270] to document whether treatment was or was not given, it is unknown if treatment was given, or treatment was given on an unknown date.

### Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Treatment given after a period of active surveillance is considered subsequent treatment, and it is not coded in this item.
- Use code 0 when treatment is refused or the physician decides not to treat for any reason such as the presence of comorbidities.
- Assign code 0 when the patient does not receive any treatment
  - a. Scope of Regional Lymph Node Surgery may be coded 0, 1-7, or 9
- Assign code 1 when the patient receives treatment collected in any of the following data items
  - a. Surgery of Primary Site
  - b. Surgical Procedure of Other Site
  - c. Radiation Treatment Modality, Phase I, II, III
  - d. Chemotherapy
  - e. Hormone Therapy
  - f. Immunotherapy
  - g. Hematologic Transplant and Endocrine Procedures
  - h. Other Therapy

Code	Label
0	No treatment given
1	Treatment given
2	Active surveillance (watchful waiting)
9	Unknown if treatment was given

### Examples

Code	Reason
0	An elderly patient with pancreatic cancer requested no treatment.

0	Patient is expected to receive radiation, but it has not occurred yet ( <i>Reason for No Radiation</i> [1430] = 8)
2	Treatment plan for a lymphoma patient is active surveillance.

## Surgery Data Items

[See Surgery in Section One for further instructions.](#)

## Date of First Surgical Procedure

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1200	8	2114-2121	CCYYMMDD	<1996, 2002+	01/10, 01/11, 02/21

### Description

Records the earliest date on which any first course surgical procedure was performed. Formerly called "Date of Cancer-Directed Surgery."

### Rationale

This item can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

### Coding Instructions

- Record the date of the first surgical procedure of the types coded as Surgical Procedure of Primary Site [1290], Scope of Regional Lymph Node Surgery [1292] (excluding code 1) or Surgical Procedure/Other Site [1294] performed at this or any facility.
- The date in this item may be the same as that in Date of Most Definitive Surgical Resection of the Primary Site [3170], if the patient received only one surgical procedure and it was a resection of the primary site.
- If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item Date of First Course Treatment [1270].
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of First Surgical Procedure is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of First Surgical Procedure transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The Rx Date–Surgery Flag [1201] is used to explain why Date of First Surgical Procedure is not a known date. See Rx Date–Surgery Flag for an illustration of the relationships among these items.

### Examples

Code	Reason
20080323	A melanoma patient had an excisional biopsy on March 23, 2008, then a wide excision on March 28, 2008.
20091116	The patient had a small (0.5 cm) lump removed from her breast on November 16, 2009.
20070327	The patient's primary tumor was treated with radiation beginning on April 16, 2007, after a distant metastasis was removed surgically on March 27, 2007.

## Rx Date–Surgery Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1201	2	2122-2123	10-12, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Surgical Procedure* [1200].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if Date of First Surgical Procedure [1200] has a full or partial date recorded.
- Code 12 if the Date of First Surgical Procedure cannot be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed).
11	No proper value is applicable in this context (for example, no surgery performed).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgery was performed but the date is unknown).
(blank)	A valid date value is provided in item <i>Date of First Surgical Procedure</i> [1200].

## Date of Most Definitive Surgical Resection of the Primary Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3170	8	2124-2131	CCYYMMDD	2003+	09/08, 01/10, 01/11

### Description

Records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment.

### Rationale

This item is used to measure the lag time between diagnosis and the most definitive surgery of the primary site. It is also used in conjunction with *Date of Surgical Discharge* [3180] to calculate the duration of hospitalization following the most definitive primary site surgical procedure. This can then be used to evaluate treatment efficacy.

### Coding Instructions

- Record the date on which the surgery described by *Surgical Procedure of Primary Site* [1290] was performed at this or any facility.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Most Definitive Surgical Resection of the Primary Site is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Most Definitive Surgical Resection of the Primary Site transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.



## Rx Date Most Defn Srg Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
3171	2	rxDateMostDefinSurgFlag	10-12, Blank	2010+	2011

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Most Definitive Surgical Resection of the Primary Site* [3170].

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of Most Definitive Surgical Resection of the Primary Site* [3170] has a full or partial date recorded.
- Code 12 if the *Date of Most Definitive Surgical Resection of the Primary Site* cannot be determined, but the patient did receive first course surgery.
- Code 10 if it is unknown whether any surgery was performed.
- Code 11 if no surgical procedure was performed.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave blank for cases diagnosed prior to January 1, 2003.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery of the primary site was performed).
11	No proper value is applicable in this context (for example, no surgical resection of the primary site was performed and for cases diagnosed at autopsy).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, surgical procedure of the primary site was performed but the date is unknown).
Blank	A valid date value is provided in item <i>Date of Most Definitive Surgical Resection of the Primary Site</i> [3170]. Case was diagnosed prior to January 1, 2003.

Comment: This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Surgical Procedure of Primary Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1290	2	2225-2226	00, 10-80, 90, 98, 99	<1996, 2002+	06/05, 01/10, 01/12, 01/15, 02/21

### Description

Records the surgical procedure(s) performed to the primary site.

### Rationale

This data item can be used to compare the efficacy of treatment options.

### Coding Instructions

- Site-specific codes for this data item are found in [Appendix A](#).
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes 80 and 90 only if more precise information about the surgery is not available.
- Code 98 for any case coded to primary site C420, C421, C423, C424, C760-C768, C809
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* [1290].
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in [Appendix A](#).
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Code	Label	Definition
00	None	No surgical procedure of primary site. Diagnosed at autopsy.
10–19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.
20–80	Site-specific codes; resection	Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.

Code	Label	Definition
90	Surgery, NOS	A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided.
98	Site-specific codes; special	<p>Special code. Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.</p> <p>Code 98 for the following sites/schema unless the case is death certificate only:</p> <p>a. Any case coded to primary site C420, C421, C423, C424, C760-C768, C809</p> <p>When Surgery of Primary Site is coded 98</p> <ol style="list-style-type: none"> <li>1. Code Surgical Margins of the Primary Site (#1320) to 9</li> <li>2. Code Reason for No Surgery of Primary Site (#1340) to 1</li> </ol>
99	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.

## Surgical Procedure of Primary Site at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
670	2	795-796	00, 10-80, 90, 98, 99	All Years	09/04, 01/10, 01/12, 01/15, 02/21

### Description

Records the surgical procedure(s) performed to the primary site at this facility.

### Rationale

This data item can be used to compare the efficacy of treatment options.

### Coding Instructions

- Site-specific codes for this data item are found in [Appendix A](#).
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows multiple procedures to be collected, this item refers to the most invasive surgical procedure for the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes 80 and 90 only if more precise information about the surgery is not available.
- Code 98 for any case coded to primary site C420, C421, C423, C424, C760-C768, C809
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- If a needle biopsy precedes an excisional biopsy or more extensive surgery, and upon the excisional biopsy or more extensive surgery the surgical margins are clear (i.e., no tumor remains), DO NOT consider the needle biopsy to be an excisional biopsy. The needle biopsy should be recorded as such in the *Surgical Diagnostic and Staging Procedure* [1350] and the excisional biopsy or more extensive surgery in the *Surgical Procedure of the Primary Site* [1290].
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].

Code	Label	Definition
00	None	No surgical procedure of primary site. Diagnosed at autopsy.
10–19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.
20–80	Site-specific codes; resection	Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.
90	Surgery, NOS	A surgical procedure to primary site was done, but no information on the type of surgical procedure is provided.

Code	Label	Definition
98	Site-specific codes; special	<p>Special code. Refer to <a href="#">Appendix A</a> for the correct site-specific code for the procedure.</p> <p>Code 98 for the following sites/schema unless the case is death certificate only:</p> <p>a. Any case coded to primary site C420, C421, C423, C424, C760-C768, C809</p> <p>When Surgery of Primary Site is coded 98</p> <ol style="list-style-type: none"> <li>1. Code Surgical Margins of the Primary Site (#1320) to 9</li> <li>2. Code Reason for No Surgery of Primary Site (#1340) to 1</li> </ol>
99	Unknown	<p>Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.</p>

## Rx Hosp—Surg Breast

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
10104	4		B000, B200-B990, Alphanumeric, Blank	2022	New

### Description

Records the surgical procedure performed of the primary site **at this facility**. This data item is required for date of diagnosis 2022 breast cases only.

### Rationale

Field study for updating the surgery codes in Appendix A, to support the Synoptic Operative Reporting and to allow for more descriptive surgery codes. This data item can be used to compare the efficacy of treatment options.

### Coding Instructions

- Review the operative report or procedure note to code the appropriate surgical code.
- Code the surgical resection code for Breast primaries performed at this facility with diagnosis date  $\geq$  1/1/2022 through 12/31/2022.
- Code the most definitive surgical procedure for the primary site performed at this facility.
- Reconstruction performed immediately after the surgical resection (codes B200-B900) at this facility should be coded in the Rx Hosp – Recon Breast [Item# 10106] site specific data item.
- For codes B200 to B760, code in order of hierarchy, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes B800 and B900 only if more precise information about the surgery performed at this facility is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item using code 210.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site.
- If contralateral breast reveals a second primary, each breast is abstracted separately.
- This data item is effective for Breast cases diagnosed 2022 only.
- Leave this data item blank for:
  - Breast cases diagnosed in any year except for 2022
  - All other sites

## Codes and Code Definitions

B000	None; no surgery of primary site; autopsy ONLY
B200	Partial mastectomy; less than total mastectomy; lumpectomy, segmental mastectomy, quadrantectomy, tylectomy, with or without nipple resection
B210	Excisional breast biopsy - Diagnostic excision, no pre-operative biopsy proven diagnosis of cancer
<p><b>NOTE:</b> An excisional biopsy can occur when the nodule was previously not expected to be cancer.</p> <p><b>Example:</b> Use code B210, when a surgeon removes the mass and it comes back cancer and there is no biopsy (either core or FNA) done prior to the mass being removed.</p>	
B215	Excisional breast biopsy, for atypia
<p><b>NOTE:</b> An excisional breast biopsy removes the entire tumor and/or leave only microscopic margins. This surgical code was added to collect code when atypia tissue is excised and found to be reportable. Approx. 10-15% of excised atypia are cancer and reportable.</p> <p><b>Example:</b> Use code B215 when patient has biopsy that shows atypical ductal hyperplasia, an excision is then performed, and pathology shows in situ or invasive cancer. The excisional breast biopsy for the ADH diagnosed the cancer, not the core biopsy.</p>	
B240	Re-excision of margins from primary tumor site for gross or microscopic residual disease when less than total mastectomy performed.
B290	Central lumpectomy, only performed for a prior diagnosis of cancer, which includes removal of the nipple areolar complex
<p><b>Note:</b> A central lumpectomy removes the nipple areolar complex, whereas a lumpectomy does not. Central lumpectomy and central portion lumpectomy, central portion excision, central partial mastectomy are interchangeable terms.</p> <p><b>Example:</b> Use code B290, when patients with Paget's disease or cancer directly involving the nipple areolar complex, where the nipple areolar complex needs to be removed.</p>	
B300	Skin-sparing mastectomy
B310	WITHOUT removal of uninvolved contralateral breast
B320	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> A skin sparing mastectomy removes all breast tissue and the nipple areolar complex and preserves native breast skin to cover the immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B400	Nipple-sparing mastectomy
B410	WITHOUT removal of uninvolved contralateral breast
B420	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> A nipple sparing mastectomy removes all breast tissue but preserves the nipple areolar complex and breast skin and is performed with immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B500	Areolar-sparing mastectomy
B510	WITHOUT removal of uninvolved contralateral breast
B520	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> An areolar sparing mastectomy removes all breast tissue and the nipple but preserves the areola and breast skin and is performed with immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B600	Total (simple) mastectomy
B610	WITHOUT removal of uninvolved contralateral breast

B620	WITH removal of uninvolved contralateral breast
<b>NOTE:</b> A total (simple) mastectomy removes all breast tissue, the nipple areolar complex and breast skin and is not performed with reconstruction. It is performed with and without sentinel node biopsy or ALND.	
B700	Radical mastectomy, NOS
B710	WITHOUT removal of uninvolved contralateral breast
B720	WITH removal of uninvolved contralateral breast
<b>NOTE:</b> A radical mastectomy removes all breast tissue, the nipple areolar complex, breast skin, and pectoralis muscle and is not performed with reconstruction. It is performed with level I-III ALND.	
B760	Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma
B800	Mastectomy, NOS (including extended radical mastectomy)
B900	Surgery, NOS
B990	Unknown if surgery was performed; death certificate ONLY



## Rx Summ-- Surg Breast

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
10105	4		B000, B200-B990, Alphanumeric, Blank	2022	New

### Description

Records the surgical procedure performed of the primary site performed at **any facility**. This data item is required for 2022 breast cases only.

### Rationale

Field study for updating the surgery codes in Appendix A to support the Synoptic Operative Reporting and allow for more descriptive surgery codes. This data item can be used to compare the efficacy of treatment options.

### Coding Instructions

- Review the operative report or procedure note to code the appropriate surgical code.
- Code the surgical resection code for Breast primaries performed at any facility with diagnosis date  $\geq$  1/1/2022 through 12/31/2022.
- Code the most definitive surgical procedure for the primary site performed at any facility.
- Reconstruction that is performed immediately after surgical resection (codes B200-B900) at any facility should be coded in the Rx Summ – Recon Breast [Item # 10107] site specific data item.
- For codes B200 to B760, code in order of hierarchy, the response positions are hierarchical. Last-listed responses take precedence over responses written above.
- Use codes B800 and B900 only if more precise information about the surgery performed at any facility is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item using code 210.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are
- removed in continuity with the primary site.
- If contralateral breast reveals a second primary, each breast is abstracted separately.
- This data item is effective for Breast cases diagnosed 2022 only.
- Leave this data item blank for:
  - Breast cases diagnosed in any year except for 2022
  - All other sites

## Codes and Code Definitions

B000	None; no surgery of primary site; autopsy ONLY
B200	Partial mastectomy; less than total mastectomy; lumpectomy, segmental mastectomy, quadrantectomy, tylectomy, with or without nipple resection
B210	Excisional breast biopsy - Diagnostic excision, no pre-operative biopsy proven diagnosis of cancer
<p><b>NOTE:</b> An excisional biopsy can occur when the nodule was previously not expected to be cancer.</p> <p><b>Example:</b> Use code B210, when a surgeon removes the mass and it comes back cancer and there is no biopsy (either core or FNA) done prior to the mass being removed.</p>	
B215	Excisional breast biopsy, for atypia
<p><b>NOTE:</b> An excisional breast biopsy removes the entire tumor and/or leave only microscopic margins. This surgical code was added to collect code when atypia tissue is excised and found to be reportable. Approx. 10-15% of excised atypia are cancer and reportable.</p> <p><b>Example:</b> Use code B215 when patient has biopsy that shows atypical ductal hyperplasia, an excision is then performed, and pathology shows in situ or invasive cancer. The excisional breast biopsy for the ADH diagnosed the cancer, not the core biopsy.</p>	
B240	Re-excision of margins from primary tumor site for gross or microscopic residual disease when less than total mastectomy performed.
B290	Central lumpectomy, only performed for a prior diagnosis of cancer, which includes removal of the nipple areolar complex
<p><b>Note:</b> A central lumpectomy removes the nipple areolar complex, whereas a lumpectomy does not. Central lumpectomy and central portion lumpectomy, central portion excision, central partial mastectomy are interchangeable terms.</p> <p><b>Example:</b> Use code B290, when patients with Paget's disease or cancer directly involving the nipple areolar complex, where the nipple areolar complex needs to be removed.</p>	
B300	Skin-sparing mastectomy
B310	WITHOUT removal of uninvolved contralateral breast
B320	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> A skin sparing mastectomy removes all breast tissue and the nipple areolar complex and preserves native breast skin to cover the immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B400	Nipple-sparing mastectomy
B410	WITHOUT removal of uninvolved contralateral breast
B420	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> A nipple sparing mastectomy removes all breast tissue but preserves the nipple areolar complex and breast skin and is performed with immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B500	Areolar-sparing mastectomy
B510	WITHOUT removal of uninvolved contralateral breast
B520	WITH removal of uninvolved contralateral breast
<p><b>NOTE:</b> An areolar sparing mastectomy removes all breast tissue and the nipple but preserves the areola and breast skin and is performed with immediate reconstruction. It is performed with and without sentinel node biopsy or ALND.</p>	
B600	Total (simple) mastectomy
B610	WITHOUT removal of uninvolved contralateral breast

B620	WITH removal of uninvolved contralateral breast
<b>NOTE:</b> A total (simple) mastectomy removes all breast tissue, the nipple areolar complex and breast skin and is not performed with reconstruction. It is performed with and without sentinel node biopsy or ALND.	
B700	Radical mastectomy, NOS
B710	WITHOUT removal of uninvolved contralateral breast
B720	WITH removal of uninvolved contralateral breast
<b>NOTE:</b> A radical mastectomy removes all breast tissue, the nipple areolar complex, breast skin, and pectoralis muscle and is not performed with reconstruction. It is performed with level I-III ALND.	
B760	Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma
B800	Mastectomy, NOS (including extended radical mastectomy)
B900	Surgery, NOS
B990	Unknown if surgery was performed; death certificate ONLY

## Rx Hosp-- Recon Breast

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
10106	4		A000, A100-A640, A900-A980, A990, Alphanumeric, Blank	2022	New

### Description

Records the reconstruction procedure immediately following resection performed **at this facility**. This data item is required for 2022 breast cases only.

### Rationale

Breast reconstruction was previously collected within the breast surgery codes. CoC will collect these data items to support the Synoptic Operative Reports and allow for more descriptive reconstruction codes. This is being collected in anticipation for a 2023 Site Specific Disease Item.

### Coding Instructions

- Code the breast reconstruction code for Breast primaries performed at this facility with diagnosis date  $\geq$  1/1/2022 through 12/31/2022.
- Code only the ipsilateral breast reconstruction.
- Immediate reconstruction is defined as reconstruction performed during the same operative session as the operative procedure coded in Data item Rx Hosp—Surg Breast [Item # 10104]
- One surgeon can perform the surgical resection to primary site and another surgeon can perform the reconstruction during the same day procedure. As long as reconstruction was done during the same day as the surgical resection, an immediate reconstruction code should be assigned.
- Reconstruction performed on a different day than the breast primary definitive resection is not collected/coded.
- For Codes, A600-A900, information for this data item may be found in the Breast Plastic Reconstructive operative report.
- Oncoplastic surgery is typically coded by the surgeon but sometimes found in the plastics operative note. Oncoplastic surgery is defined as rebuilding the breast tissue after breast cancer resection and is a way to reconstruct and reshape the breast after a lumpectomy or mastectomy and involves rearrangement of breast tissue to correct a defect.
- Oncoplastic surgery and breast tissue rearrangement, mastopexy, batwing mastopexy, crescent mastopexy, donut mastopexy, mammoplasty, and breast reduction are interchangeable terms.
- Direct to implant placement is found in the operative report. This is when the surgeon places an implant and does not state placement of a tissue expander.
- Breast resection procedure at this facility should be coded in the Rx Hosp—Surg Breast [Item # 10104] data item.
- Leave this data item blank if primary site is not breast or breast primary not diagnosed in 2022.
- Leave this data item blank for:
  - Breast cases diagnosed in any year except for 2022
  - All other sites

## Codes and Code Definitions

A000	No Reconstruction
<b>NOTE:</b> Code A000 when no immediate reconstruction was performed at any facility.	
A100	Tissue expander placement
<b>NOTE:</b> Code A100 when tissue expanders were placed without implant or tissue placement.	
A200	Direct to implant placement
<b>NOTE:</b> Code A200 when a permanent implant is placed immediately following resection. <b>Example:</b> A mastectomy is performed by the breast surgeon and an implant is placed at the same time by a plastic surgeon (some general /breast surgeons may place implants, but most are placed by plastics).	
A300	Oncoplastic tissue rearrangement (not a formal mastopexy/reduction)
A400	Oncoplastic reduction and/or mastopexy
<b>NOTE:</b> Code A400 when patient has breast conserving resection and a breast reduction/lift is performed.	
A500	Oncoplastic reconstruction with regional tissue flaps
<b>NOTE:</b> Code A500 when patient has breast conserving resection and reconstruction is performed with skin flaps.	
A600	Mastectomy reconstruction with autologous tissue, source not specified
A610	WITH abdominal tissue
A620	WITH thigh tissue
A630	WITH gluteal tissue
A640	WITH back tissue
<b>NOTE:</b> Code A600 when patient's autologous tissue source is unknown or not specified.	
A900	Reconstruction performed, method unknown
<b>NOTE:</b> Code A900 when reconstruction is done, but the type of reconstruction is not known.	
A970	Implant based reconstruction, NOS
A980	Autologous tissue-based reconstruction, NOS
A990	Unknown if reconstruction performed
<b>NOTE:</b> Code A990 when it's unknown if immediate reconstruction was performed.	

## Rx Summ-- Recon Breast

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
10107	4		A000, A100-A640, A900-A980, A990, Alphanumeric, Blank	2022	New

### Description

Records the reconstruction procedure immediately following resection performed **at any facility**. This data item is required for 2022 breast cases only.

### Rationale

Breast reconstruction was previously collected within the breast surgery codes. CoC will collect these data items to support the Synoptic Operative Reports and allow for more descriptive reconstruction codes. This is being collected in anticipation for a 2023 Site Specific Disease Item.

### Coding Instructions

- Code the breast reconstruction code for Breast primaries performed at any facility with diagnosis date  $\geq$  1/1/2022 through 12/31/2022.
- Code only the ipsilateral breast reconstruction.
- Immediate reconstruction is defined as reconstruction performed during same day the operative procedure coded in Data items RX Summ—Surg Breast [Item # 10105].
- One surgeon can perform the surgical resection to primary site and another surgeon can perform the reconstruction during the same day procedure. As long as reconstruction was done during the same day as the surgical resection, an immediate reconstruction code should be assigned.
- Reconstruction performed on a different day than the breast primary definitive resection is not collected/coded.
- For Codes, A600-A900, information for this data item may be found in the Breast Plastic Reconstructive operative report.
- Oncoplastic surgery is typically coded by the surgeon but sometimes found in the plastics operative note. Oncoplastic surgery is defined as rebuilding the breast tissue after breast cancer resection and is a way to reconstruct and reshape the breast after a lumpectomy or mastectomy and involves rearrangement of breast tissue to correct a defect.
- Oncoplastic surgery and breast tissue rearrangement, mastopexy, batwing mastopexy, crescent mastopexy, donut mastopexy, mammoplasty, and breast reduction are interchangeable terms.
- Direct to implant placement is found in the operative report. This is when the surgeon places an implant and does not state placement of a tissue expander.
- Breast resection procedure performed same day as definitive breast resection should be coded in the Rx Hosp—Surg Breast [Item # 10105] data item.
- Leave this data item blank if primary site is not breast or breast primary not diagnosed in 2022.
- Leave this data item blank for:
  - Breast cases diagnosed in any year except for 2022
  - All other sites

## Codes and Code Definitions

A000	No Reconstruction
NOTE: Code A000 when no immediate reconstruction was performed at any facility.	
A100	Tissue expander placement
NOTE: Code A100 when tissue expanders were placed without implant or tissue placement.	
A200	Direct to implant placement
NOTE: Code A200 when a permanent implant is placed immediately following resection. Example: A mastectomy is performed by the breast surgeon and an implant is placed at the same time by a plastic surgeon (some general /breast surgeons may place implants, but most are placed by plastics).	
A300	Oncoplastic tissue rearrangement (not a formal mastopexy/reduction)
A400	Oncoplastic reduction and/or mastopexy
NOTE: Code A400 when patient has breast conserving resection and a breast reduction/lift is performed.	
A500	Oncoplastic reconstruction with regional tissue flaps
NOTE: Code A500 when patient has breast conserving resection and reconstruction is performed with skin flaps.	
A600	Mastectomy reconstruction with autologous tissue, source not specified.
A610	WITH abdominal tissue
A620	WITH thigh tissue
A630	WITH gluteal tissue
A640	WITH back tissue
NOTE: Code A600 when patient's tissue autologous source is unknown or not specified.	
A900	Reconstruction performed, method unknown
NOTE: Code A900 when reconstruction is done, but the type of reconstruction is not known.	
A970	Implant based reconstruction, NOS
A980	Autologous tissue-based reconstruction, NOS
A990	Unknown if reconstruction performed
NOTE: Code A990 when it's unknown if immediate reconstruction was performed.	

## Approach - Surgery of the Primary Site at this Facility (RxHospSurgApp 2010)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
668	1	794-794	0-5, 9	2010+	05/10, 01/11, 01/13, 01/15, 02/21

### Description

This item is used to describe the surgical method used to approach the primary site for patients undergoing surgery of the primary site at this facility.

### Rationale

This item is used to monitor patterns and trends in the adoption and utilization of minimally-invasive surgical techniques.

### Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- If the patient has multiple surgeries of the primary site, this item describes the approach used for the most invasive, definitive surgery.
- For ablation procedures, assign code 3.
- Assign code 2 or 4 if the surgery began as robotic assisted or endoscopic and was converted to open.
- If both robotic and minimally invasive (for example, endoscopic or laparoscopic) surgery are used, code to robotic (codes 1 or 2).
- This item should not be confused with the obsolete item published in Registry Operations and Data Standards (ROADS), Surgical Approach [1310].

Code	Label
0	No surgical procedure of primary site at this facility; Diagnosed at autopsy
1	Robotic assisted
2	Robotic converted to open
3	Minimally invasive (such as endoscopic or laparoscopic)
4	Minimally invasive (endoscopic or laparoscopic) converted to open.
5	Open or approach unspecified
9	When Surgical Procedure of Primary Site [1290] and Surgical Procedure of Primary Site at this Facility [670] is coded to 98; Unknown whether surgery was performed at this facility



## Examples

Code	Reason
0	Patient received radiation at this facility after having surgery elsewhere
3	Endoscopic surgery was performed
3	Patient treated with RFA of kidney
5	The surgical report described conventional open surgery, but did not use the term "open"

## Surgical Margins of the Primary Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1320	1	2232-2232	0-3, 7-9	All Years	08/02, 01/10, 02/10, 01/13, 02/21

### Description

Records the final status of the surgical margins after resection of the primary tumor.

### Rationale

This data item serves as a quality measure for pathology reports and is used for staging, and may be a prognostic factor in recurrence.

### Coding Instructions

- Record the margin status as it appears in the pathology report.
- Codes 0–3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- Code 7 if the pathology report indicates the margins could not be determined.
- If no surgery of the primary site was performed, code 8.
- Code 9 if the pathology report makes no mention of margins or no tissue was sent to pathology.
- Code 9 if the Surgery of Primary Site (#1290) is coded to 98 (not applicable)
- Code 9 for:
  - Any cases coded to primary sites C420, C421, C423, C424, C760-C768, C770-C779, C809

Code	Label	Definition
0	No residual tumor	All margins are grossly and microscopically negative.
1	Residual tumor, NOS	Involvement is indicated, but not otherwise specified.
2	Microscopic residual tumor	Cannot be seen by the naked eye.
3	Macroscopic residual tumor	Gross tumor of the primary site which is visible to the naked eye.
7	Margins not evaluable	Cannot be assessed (indeterminate).
8	No primary site surgery	No surgical procedure of the primary site. Diagnosed at autopsy.
9	Unknown or not applicable	It is unknown whether a surgical procedure to the primary site was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

**Example**

Code	Reason
3	(C18-Colon) The pathology report from a colon resection describes the proximal margin as grossly involved with tumor (code 3) and the distal margin as microscopically involved (code 2). Code macroscopic involvement (code 3).

## Scope of Regional Lymph Node Surgery

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1292	1	2227-2227	0-7, 9	All Years	01/04, 09/08, 02/10, 01/11, 01/12, 04/12, 01/13, 01/15, 02/21, 01/22

### Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

### Rationale

This data item can be used to compare and evaluate the extent of surgical treatment.

### Coding Instructions

The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.

- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose or stage disease in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* [1270] and/or *Date of First Surgical Procedure* [1200] if applicable.
- Record the date of this procedure in *Date of Sentinel Lymph Node Biopsy* [832] and/or *Date Regional Lymph Node Dissection* [682], if applicable.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.
- Code 9 for:
  - Any Schema ID with primary site: C420, C421, C423, C424, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, C809)
  - Lymphoma (excluding CLL/SLL, Schema ID 00790)
  - Lymphoma (CLL/SLL, Schema ID 00795)
  - Plasmacytoma, bone (9731/3)

Do not code *distant* lymph nodes remove during surgery to the primary site for this data item. Distant nodes are coded in the data field *Surgical Procedure/Other Site* [1294].

- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms,

to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].

**Note:** One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

## Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. It is important to distinguish between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes.

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
		Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.	Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary lymph node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and an ALND.
0	No regional lymph node surgery	No regional lymph node surgery.	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
1	Biopsy or aspiration of regional lymph node(s)	Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed, and it did not include the use of dye or tracer for a SLNBx procedure (code 2). If additional procedures were performed on the lymph nodes, use the appropriate code 2-7.	Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7.
2	Sentinel Lymph Node Biopsy	<ul style="list-style-type: none"> <li>• The operative report states that a SLNBx was performed.</li> <li>• Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination.</li> <li>• When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes are palpably abnormal and selectively removed (or harvested) as part of the SLNBx procedure by the surgeon or may be discovered by the pathologist. Code this as a SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6.</li> </ul>	<ul style="list-style-type: none"> <li>• If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND).</li> <li>• Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items Regional Lymph Nodes Examined [830] and Regional Lymph Nodes Positive [820].</li> </ul>

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
Codes 3 -5 are used for regional lymph node dissection/removal; these do NOT include sentinel lymph node biopsy (SLNBx).			
3	Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS	<p>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure).</p> <ul style="list-style-type: none"> <li>Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7).</li> </ul>	Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).
4	1-3 regional lymph nodes removed	<ul style="list-style-type: none"> <li>Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only.</li> </ul>	
5	4 or more regional lymph nodes removed	<ul style="list-style-type: none"> <li>Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7).</li> </ul> <p>Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</p>	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed.</li> <li>• Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</li> <li>• Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6.</li> </ul>	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed.</li> <li>• Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an ALND was performed.</li> </ul>
7	Sentinel node biopsy and code 3, 4, or 5 at different times	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events.</li> <li>• Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</li> </ul>	<ul style="list-style-type: none"> <li>• Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND was performed.</li> </ul>



Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
9	Unknown or not applicable	<ul style="list-style-type: none"><li data-bbox="505 237 976 373">• The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded 19-90 in the data item <i>Surgery of Primary Site</i> [1290]. Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code.</li></ul>	

## Examples

Code	Reason
0	No effort was made to locate sentinel lymph nodes, and no nodes were found in pathologic analysis.
2	(C50.1-Breast) There was an attempt at sentinel lymph node dissection, but no lymph nodes were found in the pathological specimen.
1	(C14.0-Pharynx) Aspiration of regional lymph node to confirm histology of widely metastatic disease.
2	(C44.5-Skin of Back) Patient has melanoma of the back. A sentinel lymph node dissection was done with the removal of one lymph node. This node was negative for disease.
3	(C61.9-Prostate) Bilateral pelvic lymph node dissection for prostate cancer.
6	(C50.3-Breast) Sentinel lymph node biopsy (SLNBx) of right axilla, followed by right axillary lymph node dissection (ALND) during the same surgical event.
7	(50.4-Breast) Sentinel lymph node biopsy (SLNBx) of left axilla, followed in a second procedure 5 days later by a left axillary lymph node dissection (ALND).
9	(C34.9-Lung) Patient was admitted for radiation therapy following surgery for lung cancer. There is no documentation on the extent of lymph node surgery in patient record.

## Scope of Regional Lymph Node Surgery at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
672	1	797-797	0-7, 9	All Years	01/04, 09/08, 02/10, 01/12, 02/21

### Description

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event at this facility.

### Rationale

This item can be used to compare and evaluate the extent of surgical treatment.

### Coding Instructions

The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.

- If a surgical procedure which aspirates, biopsies, or removes regional lymph nodes to diagnose or stage this cancer, record the scope of regional lymph nodes surgery in this data item. Record the date of this surgical procedure in data item *Date of First Course of Treatment* [1270] and/or *Date of First Surgical Procedure* [1200] as appropriate.
- Record the date of this procedure in *Date of Sentinel Lymph Node Biopsy* [832] and/or *Date Regional Lymph Node Dissection* [682], if applicable.
- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.

If two or more surgical procedures of regional lymph nodes are performed, the codes entered in the registry for each subsequent procedure must include the cumulative effect of all preceding procedures. For example, a sentinel lymph node biopsy followed by a regional lymph node dissection at a later time is coded 7. Do not rely on registry software to determine the cumulative code.

- Code 9 for:
  - Any Schema ID with primary site: C420, C421, C423, C424, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, C809)
  - Lymphoma (excluding CLL/SLL, Schema ID 00790)
  - Lymphoma (CLL/SLL, Schema ID 00795)
  - Plasmacytoma, bone (9731/3)

Do not code *distant* lymph nodes removed during surgery to the primary site for this data item. They are coded in the data field *Surgical Procedure/Other Site* [1294].

- Refer to the current *AJCC Cancer Staging Manual* for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].

**Note:** One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment with previously published treatment based on former codes, or to data unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. However, it is *very important* to note that the distinction between codes 4 and 5 is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than 4 lymph nodes was not reflected in surgery codes. *It is not intended to reflect clinical significance* when applied to a particular surgical procedure. It is important to *avoid inferring, by data presentation or other methods, that one category is preferable to another within the intent of these items.*

## Codes and Labels

The following instructions should be applied to all surgically treated cases for all types of cancers. It is important to distinguish between sentinel lymph node biopsies (SLNBx) and more extensive dissection of regional lymph nodes.

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
		Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.	Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary lymph node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon's planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and an ALND.
0	No regional lymph node surgery	No regional lymph node surgery.	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
1	Biopsy or aspiration of regional lymph node(s)	Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed, and it did not include the use of dye or tracer for a SLNBx procedure (code 2). If additional procedures were performed on the lymph nodes, use the appropriate code 2-7.	Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report of to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7.
2	Sentinel Lymph Node Biopsy	<ul style="list-style-type: none"> <li>• The operative report states that a SLNBx was performed.</li> <li>• Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination.</li> <li>• When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes are palpably abnormal and selectively removed (or harvested) as part of the SLNBx procedure by the surgeon or may be discovered by the pathologist. Code this as a SLNBx (code 2). If review of the operative report confirms that a regional lymph node dissection followed the SLNBx, code these cases as 6.</li> </ul>	<ul style="list-style-type: none"> <li>• If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND).</li> <li>• Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made and a node exploration was conducted. Patients undergoing SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items Regional Lymph Nodes Examined [830] and Regional Lymph Nodes Positive [820].</li> </ul>

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
Codes 3 -5 are used for regional lymph node dissection/removal; these do NOT include sentinel lymph node biopsy (SLNBx).			
3	Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS	<p>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure).</p> <ul style="list-style-type: none"> <li>Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7).</li> </ul>	Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).
4	1-3 regional lymph nodes removed	<ul style="list-style-type: none"> <li>Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only.</li> </ul>	
5	4 or more regional lymph nodes removed	<ul style="list-style-type: none"> <li>Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes was examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes was examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7).</li> </ul> <p>Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</p>	

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
6	Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed.</li> <li>• Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However it is possible for these procedures to harvest only a few nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</li> <li>• Infrequently, a SLNBx is attempted and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6.</li> </ul>	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, look for a report to the Operating Room (OR) by the pathologist on the SLNBx results prior to the regional node dissection. If the SLNBx shows positive nodes, then a dissection may be done. If the nodes are negative, it is rare that a node dissection is performed.</li> <li>• Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However it is possible for these procedures to harvest fewer (or more) nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an ALND was performed.</li> </ul>
7	Sentinel node biopsy and code 3, 4, or 5 at different times	<ul style="list-style-type: none"> <li>• SLNBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events.</li> <li>• Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</li> </ul>	<ul style="list-style-type: none"> <li>• Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes.</li> <li>• If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND was performed.</li> </ul>

Code	Label	General Instructions Applying to All Sites	Additional Notes Specific to Breast (C50.x)
9	Unknown or not applicable	<ul style="list-style-type: none"><li>The status of regional lymph node evaluation should be known for surgically-treated cases (i.e., cases coded 19-90 in the data item <i>Surgery of Primary Site</i> [1290]. Review surgically treated cases coded 9 in <i>Scope of Regional Lymph Node Surgery</i> to confirm the code.</li></ul>	



## Surgical Procedure/Other Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1294	1	2228-2228	0-5, 9	All Years	01/04, 09/08, 01/10, 02/10, 01/12, 01/13, 02/21

### Description

Records the surgical removal of *distant lymph nodes* or other tissue(s) or organ(s) removed beyond the primary site.

### Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

### Coding Instructions

- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific *Surgical Procedure of the Primary Site* [1290 or 670] code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code. Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 for:
  - Any case coded to primary site C420, C421, C423, C424, C760-C768, C770-C779, C809 Excluding cases coded to the Cervical Lymph Nodes and Unknown Primary 00060
  - When the involved contralateral breast is removed for a single primary breast cancer. Note: See also notes and codes in Appendix A, Breast surgery codes.
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care* [3270].

Code	Label	Definition
0	None	No surgical procedure of non-primary site was performed. Diagnosed at autopsy.
1	Non-primary surgical procedure performed	Non-primary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.

Code	Label	Definition
2	Non-primary surgical procedure to other regional sites	Resection of regional site.
3	Non-primary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> .
4	Non-primary surgical procedure to distant site	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only.

### Examples

Code	Reason
0	(C18.1–Colon) The incidental removal of the appendix during a surgical procedure to remove a primary malignancy in the right colon.
1	Surgical removal of metastatic lesion from liver; unknown primary.
2	(C18.3–Colon) Surgical ablation of solitary liver metastasis, hepatic flexure primary.
4	(C34.9–Lung) Removal of solitary brain metastasis.
5	(C21.0–Anus) Excision of solitary liver metastasis and one large hilar lymph node.

## Surgical Procedure/Other Site at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
674	1	798-798	0-5, 9	All Years	01/04, 01/10, 02/10, 01/12, 02/21

### Description

Records the surgical removal of *distant lymph nodes* or other tissue(s)/organ(s) beyond the primary site at this facility.

### Rationale

The removal of non-primary tissue documents the extent of surgical treatment and is useful in evaluating the extent of metastatic involvement.

### Coding Instructions

- If other tissue or organs are removed during primary site surgery that are not specifically defined by the site-specific Surgical Procedure of the Primary Site [1290 or 670] code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Assign the highest numbered code that describes the surgical resection of *distant lymph node(s)*.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- If multiple first course surgical procedures coded in this item are performed for a single primary, the code should represent the cumulative effect of those surgeries. Do not rely on registry software to perform this task for you.
- *Surgical Procedure/Other Site* is collected for each surgical event even if surgery of the primary site was not performed.
- Code 1 for:
  - Any case coded to primary site C420, C421, C423, C424 C760-C768, C770-C779, C809 Excluding cases coded to the Cervical Lymph Nodes and Unknown Primary 00060
  - When the involved contralateral breast is removed for a single primary breast cancer. Note: See also notes and codes in Appendix A, Breast surgery codes.
- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item *Palliative Care at This Facility* [3280].

Code	Label	Definition
0	None	No non-primary surgical site resection was performed. Diagnosed at autopsy.
1	Non-primary surgical procedure performed	Non-primary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
2	Non-primary surgical procedure to other regional sites	Resection of regional site.
3	Non-primary surgical procedure to <i>distant lymph node(s)</i>	Resection of <i>distant lymph node(s)</i> .
4	Non-primary surgical procedure to distant site	Resection of distant site.
5	Combination of codes	Any combination of surgical procedures 2, 3, or 4.
9	Unknown	It is unknown whether any surgical procedure of a non-primary site was performed. Death certificate only.

## Date of Surgical Discharge

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3180	8	2134-2141	CCYYMMDD	2003+	01/10, 01/11

### Description

Records the date the patient was discharged following primary site surgery. The date corresponds to the event recorded in *Surgical Procedure of Primary Site* [1290], and *Date of Most Definitive Surgical Resection* [3170].

### Rationale

Length of stay is an important quality of care and financial measure among hospital administrations, those who fund public and private health care, and public health users. This date, in conjunction with the data item *Date of Most Definitive Surgical Resection* [3170], will allow for the calculation of a patient's length of hospitalization associated with primary site surgery.

### Coding Instructions

- Record the date the patient was discharged from the hospital following the event recorded in *Surgical Procedure of Primary Site* [1290].
- If the patient died following the event recorded in *Surgical Procedure of Primary Site* [1290], but before being discharged from the treating facility, then the *Date of Surgical Discharge* is the same as the date recorded in the data item *Date of Last Contact or Death* [1750].
- If the patient received out-patient surgery, then the date of surgical discharge is the same as the date recorded in the data item *Date of Most Definitive Surgical Resection of the Primary Site* [3170].
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for *Date of Surgical Discharge* is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of *Date of Surgical Discharge* transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

## Readmission to the Same Hospital within 30 Days of Surgical Discharge

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3190	1	2276-2276	0-3, 9	2003+	06/15, 01/10, 01/18

### Description

Records a readmission to the same hospital, for the same illness, within 30 days of discharge following hospitalization for surgical resection of the primary site.

### Rationale

This data item provides information related to the quality of care. A patient may have a readmission related to the primary diagnosis on discharge if the length of stay was too short, and then he/she needed to return due to problems or complications. A patient may also need to be readmitted if discharge planning and/or follow-up instructions were ineffective. It is important to distinguish a planned from an unplanned readmission, since a planned readmission is not an indicator of quality of care problems.

### Coding Instructions

- Consult patient record or information from the billing department to determine if a readmission to the same hospital occurred within 30 days of the date recorded in the item *Date of Surgical Discharge* [3180].
- Only record a readmission related to the treatment of this cancer.
- Review the treatment plan to determine whether the readmission was planned.
- If there was an unplanned admission following surgical discharge, check for an ICD-9-CM “E” code and record it, space allowing, as an additional *Comorbidities and Complications* [3110, 3120, 3130, 3140, 3150, 3160, 3161, 3162, 3163, 3124] for cases diagnosed between 2003 and 2017. For cases diagnosed January 1, 2018 and later, check for an ICD-10-CM “Y” codes and record it, space allowing, as an additional *Secondary Diagnosis 1-10* [3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.

Code	Label
0	No surgical procedure of the primary site was performed, or the patient was not readmitted to the same hospital within 30 days of discharge.
1	A patient was surgically treated and was readmitted to the same hospital within 30 days of being discharged. This readmission was unplanned.
2	A patient was surgically treated and was then readmitted to the same hospital within 30 days of being discharged. This readmission was planned (chemotherapy port insertion, revision of colostomy, etc.)
3	A patient was surgically treated and, within 30 days of being discharged, the patient had both a planned and an unplanned readmission to the same hospital.
9	It is unknown whether surgery of the primary site was recommended or performed. It is unknown whether the patient was readmitted to the same hospital within 30 days of discharge. Death certificate only.

**Examples**

<b>Code</b>	<b>Reason</b>
0	A patient does not return to the hospital following a local excision for a Stage I breast cancer.
0	A patient was surgically treated and, upon discharge from acute hospital care, was admitted/transferred to an extended care ward of the hospital.
1	A patient is readmitted to the hospital three weeks (21 days) following a colon resection due to unexpected perirectal bleeding.
2	Following surgical resection the patient returns to the hospital for the insertion of a chemotherapy port.

## Reason for No Surgery of Primary Site

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1340	1	2234-2234	0-2, 5-9	2002+	01/04, 01/13, 02/21

### Description

Records the reason that no surgery was performed on the primary site.

### Rationale

This data item provides information related to the quality of care and describes why primary site surgery was not performed.

### Coding Instructions

- If *Surgical Procedure of Primary Site* [1290] is coded 00, then record the reason based on documentation in the patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient.
- Code 1 if *Surgical Procedure of Primary Site* [1290] is coded 98.
  - Any case coded to primary sites C420, C421, C423, C424, C760-C768, C809
- Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any was provided.

Code	Label
0	Surgery of the primary site was performed.
1	Surgery of the primary site was not performed because it was not part of the planned first course treatment. Diagnosed at autopsy.
2	Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc.)
5	Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.
6	Surgery of the primary site was not performed; it was recommended by the patient’s physician, but was not performed as part of the first course of therapy. No reason was noted in patient record.
7	Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in patient record.
8	Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.



9	It is unknown whether surgery of the primary site was recommended or performed. Death certificate only.
---	--

## Examples

Code	Reason
2	A patient with a primary tumor of the liver is not recommended for surgery due to advanced cirrhosis.
8	A patient is referred to another facility for recommended surgical resection of a gastric carcinoma, but further information from the facility to which the patient was referred is not available.

## Text--Surgery

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2610	1000	rxTextSurgery	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for information describing all surgical procedures performed as part of treatment.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date of each procedure.
- Type(s) of surgical procedure(s), including excisional biopsies and surgery to other and distant sites.
- Lymph nodes removed.
- Regional tissues removed.
- Metastatic sites.
- Facility where each procedure was performed.
- Record positive and negative findings. Record positive findings first.
- Other treatment information, e.g., planned procedure aborted; unknown if surgery performed.

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Surgery, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Date Surgery	1200
RX Summ--Surg Prim Site	1290
RX Hosp--Surg Prim Site	670
RX Summ--Scope Reg LN Sur	1292
RX Hosp--Scope Reg LN Sur	672
RX Summ--Surg Oth Reg/Dis	1294
RX Hosp--Surg Oth Reg/Dis	674
Reason for No Surgery	1340
RX Summ--Surgical Margins	1320
RX Hosp--Palliative Proc	3280
RX Summ--Palliative Proc	3270
Text--Place of Diagnosis	2690
RX Summ--Surg/Rad Seq	1380
RX Summ--Systemic/Sur Seq	1639

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Radiation Data Items

[See \*Radiation Therapy\* in Section One for overview of coding principles.](#)

## Date Radiation Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1210	8	2144-2151	CCYMMDD	All Years	06/05, 01/10, 01/11

### Description

Records the date on which the first radiation therapy for this diagnosis began at any facility that is part of the first course of treatment.

### Rationale

It is important to be able to sequence the use of multiple treatment modalities and to evaluate the time intervals between the treatments. For some diseases, the sequence of radiation and surgical therapy is important when determining the analytic utility of pathological stage information.

### Coding Instructions

- Date radiation started will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the date radiation started may require assistance from the radiation oncologist for consistent coding.
- If radiation therapy is the first or only treatment administered to the patient, then the date radiation started should be the same as the date entered into the item Date of First Course of Treatment [1270].
- The date when treatment started will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Radiation Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Radiation Started transmits in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

### Examples

Code	Reason
20031215	A patient has external beam radiation on December 15, 2003.
20031012	A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on October 12, 2003.
20030602	A patient enters the facility for interstitial radiation boost for prostate cancer that is performed on August 6, 2003. Just prior to this, the patient had external beam therapy to the lower pelvis that was started on June 2, 2003 at another facility.

## Rx Date Radiation Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1211	2	rxDateRadiationFlag	10-12, Blank	2010+	2010, 2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Started* [1210].

Formerly RX Date--Radiation Flag.

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date Radiation Started* [1210] has a full or partial date recorded.
- Code 12 if the *Date Radiation Started* cannot be determined, but the patient did receive first course radiation.
- Code 10 if it is unknown whether any radiation was given.
- Code 11 if no radiation is planned or given.
- Code 15 if radiation is planned but has not yet started and the start date is not yet available. Follow this patient for radiation treatment and update this item, *Date Radiation Started*, and all other radiation items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given).
11	No proper value is applicable in this context (for example, no radiation given; autopsy only case).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (for example, radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).
Blank	A valid date value is provided in item <i>Date Radiation Started</i> [1210].

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Location of Radiation Treatment

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1550	1	2263-2263	0-4, 8, 9	2003+	01/04, 01/12, 01/18, 02/21

### Description

Identifies the location of the facility where radiation therapy was administered during the first course of treatment.

### Rationale

This data item provides information useful to understanding the referral patterns for radiation therapy services and for assessing the quality and outcome of radiation therapy by delivery site.

### Coding Instructions

- Location of radiation treatment will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the location of radiation treatment may require assistance from the radiation oncologist for consistent coding.
- If the radiation treatment was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the radiation administered in the items Palliative Care [3270] and/or Palliative Care at This Facility [3280], as appropriate.
- In this context, "regional" is used to distinguish from "boost" or "cone down"; it does not refer to "regional" as used to identify stage or disease spread. In general, regional treatment will correspond to the phase in which the treatment fields had their largest dimension. In most, but not all, cases this will be phase I.
- For cases diagnosed January 1, 2018 and later, the first phase (regional treatment) may be commonly referred to as an initial plan and a subsequent phase may be referred to as a boost or cone down, and would be recorded as Phase II, Phase III, etc. accordingly.

Code	Label	Definition
0	No radiation treatment	No radiation therapy was administered to the patient. Diagnosed at autopsy.
1	All radiation treatment at this facility	All radiation therapy was administered at the reporting facility.
2	Regional treatment at this facility, boost elsewhere	Regional treatment was administered at the reporting facility; a boost dose was administered elsewhere.
3	Boost radiation at this facility, regional elsewhere	Regional treatment was administered elsewhere; a boost dose was administered at the reporting facility.
4	All radiation treatment elsewhere	All radiation therapy was administered elsewhere.
8	Other	Radiation therapy was administered, but the pattern does not fit the above categories.

Code	Label	Definition
9	Unknown	Radiation therapy was administered, but the location of the treatment facility is unknown or not stated in patient record; or it is unknown whether radiation therapy was administered, or diagnosis was by Death certificate only.

### Examples

Code	Reason
2	A patient received radiation therapy to the entire head and neck region at the reporting facility and is then referred to another facility for a high-dose-rate (HDR) intracavitary boost.
3	A patient was diagnosed with breast cancer at another facility and received surgery and regional radiation therapy at that facility before being referred to the reporting facility for boost dose therapy.
8	Regional treatment was initiated at another facility and midway through treatment the patient was transferred to the reporting facility to complete the treatment regime.
9	Patient is known to have received radiation therapy, but records do not define the facility or facility(s) where the treatment was administered.



## Phase I-II-III Radiation Primary Treatment Volume

Item #	Phase	Length	Column #	Allowable Values	Required Status	Date Revised
1504	I	2	2281-2282	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-99, Blank	All Years	01/18, 02/21, 01/22
1514	II	2	2303-2304	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-99, Blank	All Years	01/18, 02/21
1524	III	2	2325-2326	00-07, 09-14, 20-26, 29-32, 39-42, 50-68, 70-73, 80-86, 88, 90-96, 98-99, Blank	2018+	01/18, 02/21

### Description

Identifies the primary treatment volume or primary anatomic target treated during phase I-II-III of radiation therapy during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

### Rationale

This data items provides information describing the anatomical structure targeted by radiation therapy during the phases of radiation treatment and can be used to determine whether the site of the primary disease was treated with radiation or if other regional or distant sites were targeted. This information is useful in evaluating the patterns of care within a facility and on a regional or national basis.

### Coding Instructions

- Phase I [1504] data item should be used to indicate the primary target volume, which is typically the primary tumor or tumor bed. If the primary tumor or primary tumor bed was not targeted, record the other regional or distant site that was targeted.
- Phase II-III of radiation treatment also commonly includes draining lymph node regions that are associated with the primary tumor or tumor bed. The draining lymph nodes are recorded in the Phase II Radiation to Draining Lymph Nodes [1515, 1525].
- Subsequent phase may be referred to as a boost or cone down, and would be recorded in fields with subsequent phases recorded as Phase II [1514], Phase III [1524], etc. accordingly. If one or more discrete volumes are treated and one of those includes the primary site, record the Phase II -III treatment to the primary site in this data item.
- Draining lymph nodes may also be concurrently targeted during the first phase. Whether draining lymph nodes were targeted and which ones were targeted will be identified in a separate data item Phase I-II-III Radiation to Draining Lymph Nodes [1505, 1515, 1525].
- When the primary volume is lymph nodes, draining lymph nodes are not targeted. Record code 88 in the Phase I-II-III Radiation to Draining Lymph Nodes [1505, 1515, 1525]. Use codes 01 to 09 only when the lymph nodes are the primary target, for example, in lymphomas.
- Note that for many of the treatment volumes, the same code should be used when the anatomic structure is targeted or when the surgical bed of the resected anatomical structure is targeted. For example, when prostate cancer is treated with radiation alone, code 64 will be the Primary Treatment Volume. Similarly, when prostate cancer is treated with radiation after radical prostatectomy, code 64 will be the Primary Treatment Volume. There is an exception to the rule for breast cancer. In patients with breast cancer, code 41 (Breast- partial) in patients who have had a lumpectomy and were treated with partial breast irradiation (sometimes called accelerated partial breast irradiation

- (APBI)), code 40 (Breast – whole) in patients who had a lumpectomy and whole breast radiation, and code 42 (chest wall) in patients who had a mastectomy and post-mastectomy radiation.
- A new paradigm of treatment called on-line adaptive (or on-table) adaptive radiation may be a source of confusion when coding the Primary Treatment Volume. New linear accelerators may now be attached to such high-quality imaging devices that they can function as both simulation scanners for planning and radiation delivery systems. If a new radiation plan is created while the patient is on the radiation delivery table to take into account that day’s anatomy, this is referred to “on-line” (or “on-table”) adaptive radiation. If a new radiation plan is created while the patient is not on the delivery table, then it is referred to as “off-line” (or “off-table”) adaptive therapy. Off-line adaptive therapy treatments are relatively common, but MR-guided and CT-guided on-line adaptive therapy treatments are just emerging. In adaptive therapy, new radiation plans are created to account for changes in the position or shape of a target volume, but this does NOT mean that there has been a change in “phase”. When the adaptive therapy paradigm is being used, a new phase should be documented only when there has been a change in the conceptual anatomic target volume (for example, a change from whole prostate to partial prostate) or if there has been a change in the draining lymph node target, dose per fraction, modality or planning technique.
  - Code 00 if the tumor was diagnosed at autopsy.
  - This data item, in conjunction with Phase I-II-III Radiation to Draining Lymph Nodes [1505, 1515, 1525], replaces the Radiation Treatment Volume [1540] and includes converted historical values. Conversion took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.
  - If the patient received just one phase of treatment, code the phase II Radiation Treatment Volume to “00” (No treatment). All other phase II and phase III data fields should be left blank.
  - If the patient received just two phases of treatment, code the phase III Radiation Treatment Volume to “00” and leave all other phase III data fields blank.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient. Diagnosed at autopsy.
01	Neck lymph node regions	The primary treatment is directed at lymph node regions of the neck. Example situations include treatment of lymphoma or lymph node recurrence (in the absence of primary site failure) following definitive surgery of the primary tumor. If radiation to the neck lymph nodes includes the supraclavicular region use code 03.
02	Thoracic lymph node regions	Radiation therapy is directed to some combination of hilar, mediastinal, and supraclavicular lymph nodes without concurrent treatment of a visceral organ site. Example situations include mantle or mini-mantle for lymphomas, and treatment of lymphatic recurrence after complete surgical excision of a thoracic primary. Note that the supraclavicular region may be part of a head and neck lymph node region. Use code 03 for treatments directed at neck nodes and supraclavicular nodes with a head and neck primary. Use code 04 if supraclavicular lymph nodes are part of breast treatment.

Code	Label	Definition
03	Neck and thoracic lymph node regions	Treatment is directed to lymph nodes in the neck and thoracic region without concurrent treatment of a primary visceral tumor. This code might apply to some mantle or mini-mantle fields used in lymphoma treatments or some treatments for lymphatic recurrences following definitive treatment for tumors of the head and neck or thoracic regions.
04	Breast/ Chest wall lymph node regions	Radiation is directed primarily to some combination of axillary, supraclavicular, and/or internal mammary lymph node sites WITHOUT concurrent treatment of the breast or chest wall. If the breast AND lymph nodes are being treated, then code the Primary Treatment Volume to Breast (codes 40 or 41) and Breast/chest wall lymph nodes (code 04) in Radiation to Draining Lymph Nodes.
05	Abdominal lymph nodes	Treatment is directed to some combination of the lymph nodes of the abdomen, including retro-crural, peri-gastric, peri-hepatic, portocaval and para-aortic nodes. Possible situations might include seminoma, lymphoma or lymph node recurrence following surgical resection of the prostate, bladder or uterus.
06	Pelvic lymph nodes	Treatment is directed to some combination of the lymph nodes of the pelvis, including the common, internal and external iliac, obturator, inguinal and peri-rectal lymph nodes. This might be done for lymphoma or lymph node recurrence following definitive surgery for a pelvic organ.
07	Abdominal and pelvic lymph nodes	Treatment is directed to a combination of lymph nodes in both the abdomen and pelvis. This code includes extended fields ("hockey stick", "dog-leg", "inverted Y", etc.) utilized to treat seminomas and lymphomas or recurrence of a solid tumor.
09	Lymph node region, NOS	This category should be used to code treatments directed at lymph node regions that are not adequately described by codes 01-07.
10	Eye/orbit/optic nerve	Treatment is directed at all or a portion of the eye, orbit and/or optic nerve.
11	Pituitary	Treatment is directed at the pituitary gland.
12	Brain	Treatment is directed at all the brain and its meninges ("Whole brain").
13	Brain (Limited)	Treatment is directed at one or more sub-sites of the brain but not the whole brain. Chart may describe "SRS", "Stereotactic Radiosurgery", "Gamma Knife®".
14	Spinal cord	Treatment is directed at all or a portion of the spinal cord or its meninges.
20	Nasopharynx	Treatment is directed at all or a portion of the nasopharynx.
21	Oral Cavity	Treatment is directed at all or a portion of the oral cavity, including the lips, gingiva, alveolus, buccal mucosa, retromolar trigone, hard palate, floor of mouth and oral tongue.
22	Oropharynx	Treatment is directed at all or a portion of the oropharynx, including the soft palate, tonsils, base of tongue and pharyngeal wall.
23	Larynx (glottis) or hypopharynx	Treatment is directed at all or a portion of the larynx and/or hypopharynx.

Code	Label	Definition
24	Sinuses/Nasal tract	Treatment is directed at all or a portion of the sinuses and nasal tract, including the frontal, ethmoid, sphenoid and maxillary sinuses.
25	Parotid or other salivary glands	Treatment is directed at the parotid or other salivary glands, including the submandibular, sublingual and minor salivary glands.
26	Thyroid	Treatment is directed at all or a portion of the thyroid. Code 98 when the thyroid is treated with I-131 radioisotope.
29	Head and neck (NOS)	The treatment volume is directed at a primary tumor of the head and neck, but the primary sub-site is not a head and neck organ identified by codes 20-26 or it is an "unknown primary".
30	Lung or bronchus	Treatment is directed at all or a portion of the lung or bronchus.
31	Mesothelium	Treatment is directed to all or a portion of the mesothelium. This code should be used for mesothelioma primaries, even if a portion of the lung is included in the radiation field.
32	Thymus	Treatment is directed to all or a portion of the thymus.
39	Chest/lung (NOS)	The treatment is directed at a primary tumor of the chest, but the primary sub-site is unknown or not identified in codes 30-32. For example, this code should be used for sarcomas arising from the mediastinum.
40	Breast - whole	Treatment is directed at all the intact breast. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy.
41	Breast - partial	Treatment is directed at a portion of the intact breast but not the whole breast. The chart may have terms such as "Mammosite", "interstitial (seed) implant)", or "(accelerated) partial breast irradiation". Consider the possibility of partial breast irradiation when "IMRT" is documented in the record.
42	Chest wall	Treatment encompasses the chest wall (following mastectomy).
50	Esophagus	Treatment is directed at all or a portion of the esophagus. Include tumors of the gastro-esophageal junction.
51	Stomach	Treatment is directed at all or a portion of the stomach.
52	Small bowel	Treatment is directed at all or a portion of the small bowel.
53	Colon	Treatment is directed at all or a portion of the colon.
54	Rectum	Treatment is directed at all or a portion of the rectum.
55	Anus	Treatment is directed at all or a portion of the anus.
56	Liver	Treatment is directed at all or a portion of the liver.
57	Biliary tree or gallbladder	Treatment is directed at all or a portion of the biliary tree or gallbladder.
58	Pancreas or hepatopancreatic ampulla	Treatment is directed at all or a portion of the pancreas or the hepatopancreatic ampulla. Hepatopancreatic ampulla tumors are sometimes referred to as periampullary tumors.
59	Abdomen (NOS)	The treatment volume is directed at a primary tumor of the abdomen, but the primary sub-site is not an abdominal organ defined by codes 50-58 or it is considered to be an "unknown primary". For example, this code should be used for sarcomas arising from the abdominal retroperitoneum.

Code	Label	Definition
60	Bladder - whole	Treatment is directed at all the bladder.
61	Bladder - partial	Treatment is directed at a portion of the bladder but not the whole bladder.
62	Kidney	Treatment is directed at all or a portion of the kidney.
63	Ureter	Treatment is directed at all or a portion of the ureter.
64	Prostate - whole	Treatment is directed at all the prostate with/without seminal vesicles. Use this code even if seminal vesicles are not explicitly targeted.
65	Prostate - partial	Treatment is directed at a portion of the prostate but not the whole prostate.
66	Urethra	Treatment is directed at all or a portion of the urethra.
67	Penis	Treatment is directed at all or a portion of the penis. Treatments of urethral primaries should be coded as 'urethra' (code 66).
68	Testicle or scrotum	Treatment is directed at all or a portion of the testicle and/or scrotum.
70	Ovaries or fallopian tubes	Treatment is directed at all or a portion of the ovaries or fallopian tubes.
71	Uterus or Cervix	Treatment is directed at all or a portion of the uterus, endometrium or cervix.
72	Vagina	Treatment is directed at all or a portion of the vagina. Treatments of urethral primaries should be coded as 'urethra' (code 66).
73	Vulva	Treatment is directed at all or a portion of the vulva. Treatments of urethral primaries should be coded as 'urethra' (code 66).
80	Skull	Treatment is directed at all or a portion of the bones of the skull. Any brain irradiation is a secondary consequence.
81	Spine/vertebral bodies	Treatment is directed at all or a portion of the bones of the spine/vertebral bodies, including the sacrum. Spinal cord malignancies should be coded using 'spinal cord' (code 14).
82	Shoulder	Treatment is directed to all or a portion of the proximal humerus, scapula, clavicle, or other components of the shoulder complex.
83	Ribs	Treatment is directed at all or a portion of one or more ribs.
84	Hip	Treatment is directed at all or a portion of the proximal femur or acetabulum.
85	Pelvic bones	Treatment is directed at all or a portion of the bones of the pelvis other than the hip or sacrum.
86	Pelvis (NOS, non-visceral)	The treatment volume is directed at a primary tumor of the pelvis, but the primary sub-site is not a pelvic organ or is not known or indicated. For example, this code should be used for sarcomas arising from the pelvis.
88	Extremity bone, NOS	Treatment is directed at all or a portion of the bones of the arms or legs. This excludes the proximal femur (Hip, code 84). This excludes the proximal humerus (Shoulder, code 82).

Code	Label	Definition
90	Skin	Treatment is directed at all or a portion of the skin. The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastases are usually subcutaneous and should be coded as a soft tissue site.
91	Soft tissue	This category should be used to code primary or metastatic soft tissue malignancies not fitting other categories.
92	Hemibody	A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer.
93	Whole body	Treatment is directed to the entire body included in a single treatment.
94	Mantle, mini-mantle (obsolete after 2017)	For conversion of historical data only
95	Lower extended field (obsolete after 2017)	For conversion of historical data only
96	Inverted Y (obsolete after 2017)	For conversion of historical data only
97	Invalid historical FORDS value	Conversion to new STORE data item could not take place due to an invalid FORDS Volume code
98	Other	Radiation therapy administered; treatment volume other than those previously categorized by codes 01-93.
99	Unknown	This category should be used to code treatments for which there is no information available about the treatment volume, or it is unknown if radiation treatment was administered.

## Examples

Code	Reason
00	An elderly man with mild fatigue is found to have an elevated lymphocyte count on CBC. Bone marrow biopsy in your facility confirms a diagnosis of chronic lymphocytic leukemia. Physician and patient agree that no treatment is indicated at this time. Record Phase I Radiation Primary Treatment Volume as 00 (No radiation treatment).
98	A man with a history of prostate cancer and prior radical prostatectomy is treated with SBRT to 3500cGy in five fractions to a recurrent tumor in a remnant right seminal vesicle. Record Phase I Radiation Primary Treatment Volume as 98 because there is no specific code for seminal vesicles.
93	A woman with advanced multiple myeloma is referred for total body irradiation and is treated twice daily for three consecutive days in a total body stand at extended distance with open rectangular photon fields, 200cGy to mid-body per treatment. Record Phase I Radiation Primary Treatment Volume as 93 (Whole body).

## Phase I-II-III Radiation to Draining Lymph Nodes

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1505	2	2283-2284	00-08, 88, 99, Blank	All Years	01/18, 02/21, 01/22
1515	2	2305-2306	00-08, 88, 99, Blank	All Years	01/18, 02/21
1525	2	2327-2328	00-08, 88, 99, Blank	2018+	01/18, 02/21

### Description

Identifies the draining lymph nodes treated (if any) during the phase I-II-III of radiation therapy delivered to the patient during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

### Rationale

The first phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the first phase of radiation to the primary site.

The second and third phase of radiation treatment commonly targets both the primary tumor (or tumor bed) and draining lymph nodes as a secondary site. This data item should be used to indicate the draining regional lymph nodes, if any, that were irradiated during the second and third phase of radiation to the primary site.

### Coding Instructions

- When the primary volume is lymph nodes, draining lymph nodes are not targeted. Record code 88 in the Phase I-II-III Radiation to Draining Lymph Nodes [1505,1515,1525]. Use codes 01 to 09 only when the lymph nodes are the primary target, for example, in lymphomas.
- Code 00 if the tumor was diagnosed at autopsy for all Phases Radiation to Draining Lymph Nodes.
- Phase I data item, in conjunction with Phase I Radiation Primary Treatment Volume [1504], replaces the Radiation Treatment Volume [1540] and includes converted historical values. Conversion took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.
- Phase II and III radiation treatment includes primary tumor or tumor bed in addition to the draining lymph node regions that are associated with the primary tumor or tumor bed. The primary tumor or tumor bed is recorded in the Phase II-III Radiation Primary Treatment Volume [1514, 1524].
- Note: When the Phase II Primary Treatment Volume is lymph nodes, draining lymph nodes are not targeted. Record code 88 in this data item.
- Blanks allowed only for Phase II or III if no radiation treatment administered.
- Phase II data item may include converted historical values. For conversion of historical values, this data item includes a mapped value of 99 when Rad--Boost RX Modality [3200] was administered. Conversion took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.



Code	Label
00	No radiation treatment to draining lymph nodes. Diagnosed at autopsy.
01	Neck lymph node regions
02	Thoracic lymph node regions
03	Neck and thoracic lymph node regions
04	Breast/Chest wall lymph node regions
05	Abdominal lymph nodes
06	Pelvic lymph nodes
07	Abdominal and pelvic lymph nodes
08	Lymph node region, NOS
88	Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes
99	Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered

## Examples

Code	Reason
04	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions. Axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Radiation to Draining Lymph Nodes as 04 (Breast/Chest wall lymph node regions).
88	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. Record the Phase I Radiation to Draining Lymph Nodes as 88 because Phase I Radiation Primary Treatment Volume is lymph nodes.
06	Prostate cancer patient declines surgery for management of his prostate cancer, and opts for EBRT. The treatment summary states that pelvis/prostate were targeted on phase 1 with 180 cGy X 25 fx= 45 Gy. Record Phase I Radiation to Draining Lymph Nodes as 06 because when the pelvis is specifically mentioned in the treatment summary, we can assume that regional lymph nodes were targeted.



## Phase I-II-III Radiation Treatment Modality

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1506	2	2285-2286	00-16, 98-99, Blank	All Years	01/18, 02/21
1516	2	2307-2308	00-16, 98-99, Blank	All Years	01/18, 02/21
1526	2	2319-2324	00-16, 98-99, Blank	2018+	01/18, 02/21

### Description

Identifies the radiation modality administered during phase I-II-III of radiation treatment delivered during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

### Rationale

Radiation modality reflects whether a treatment was external beam, brachytherapy, a radioisotope as well as their major subtypes, or a combination of modalities. These data items should be used to indicate the radiation modality administered during phase I-II-III of radiation.

Historically, the previously-named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of radiation modality and external beam radiation treatment planning techniques is to clarify this information and implement mutually exclusive categories. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end of treatment summaries.

### Coding Instructions

- Radiation treatment modality will typically be found in the radiation oncologist's treatment summary for the first course of treatment. Segregation of treatment components into Phases and determination of the respective treatment modality may require assistance from the radiation oncologist to ensure consistent coding.
- For purposes of this data item, photons, x-rays and gamma-rays are equivalent.
- Use code 13 - Radioisotopes, NOS for radioembolization procedures, e.g. intravascular Yttrium-90 for cases diagnosed January 1, 2018 or later. For cases diagnosed prior January 1, 2018, use code 07-Brachytherapy, NOS.
- This data item intentionally does not include reference to various MV energies because this is not a clinically important aspect of technique. A change in MV energy (e.g., 6MV to 12MV) is not clinically relevant and does not represent a change in treatment technique. It is rare for change in MV energy to occur during any phase of radiation therapy.
- If this data item is coded to any of the External beam codes (01-06 or 12), the planning technique must be recorded in the data item Phase I-II-III External Beam Radiation Planning Technique [1502, 1512, 1522].
- If Radiation Treatment Modality is coded to any of the Brachytherapy or Radioisotopes codes (07-16) the code of 88 must be recorded in the data item Phase I-II-III External Beam Radiation Planning Technique [1502, 1512, 1522].
- Note: Do not confuse a radioiodine scan with treatment. Only treatment is recorded in this item.

- This data item, in conjunction with Phase I-II Radiation External Beam Planning Technique [1502, 1512], replaces the Rad--Regional RX Modality [1570], Rad--Boost RX Modality [3200] and includes converted historical values. Conversion took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.
- Phase I must be coded however blanks allowed for Phase II-III if no treatment administered.

Code	Label
00	No radiation treatment
01	External beam, NOS
02	External beam, photons
03	External beam, protons
04	External beam, electrons
05	External beam, neutrons
06	External beam, carbon ions
07	Brachytherapy, NOS
08	Brachytherapy, intracavitary, LDR
09	Brachytherapy, intracavitary, HDR
10	Brachytherapy, Interstitial, LDR
11	Brachytherapy, Interstitial, HDR
12	Brachytherapy, electronic
13	Radioisotopes, NOS
14	Radioisotopes, Radium-223
15	Radioisotopes, Strontium-89
16	Radioisotopes, Strontium-90
98	Radiation treatment administered; modality unknown
99	Unknown if radiation treatment administered

## Examples

Code	Reason
13	A patient with follicular carcinoma of the thyroid is treated with post-operative injection of radioiodine (I-131) for a total dose of 150 millicuries. Record Phase I Radiation Treatment Modality as 13 (Radioisotopes, NOS).
02	A woman with multiple myeloma is treated using locally opposed conformal 15Mv photons to a total dose of 2000cGy in 5 fractions. Record Phase I Radiation Treatment Modality as 13 (External beam, photons).

## Phase I-II-III External Beam Radiation Planning Technique

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1502	2	2287-2288	00-10, 88, 98, 99, Blank	All Years	01/18, 02/21, 01/22
1512	2	2309-2310	00-10, 88, 98, 99, Blank	All Years	01/18, 02/21
1522	2	2331-2332	00-10, 88, 98, 99, Blank	2018+	01/18, 02/21

### Description

Identifies the external beam radiation planning technique used to administer the first phase of radiation treatment during the first course of treatment. This data item is required for CoC accredited facilities as of 01/01/2018.

### Rationale

External beam radiation is the most commonly-used radiation modality in North America. In this data item we specified the planning technique for external beam treatment. Identifying the radiation technique is of interest for patterns of care and comparative effectiveness studies.

Historically, the previously-named *Regional Treatment Modality* [1570] utilized codes that were not mutually exclusive. Rather, it included codes describing a mix of modalities, treatment planning techniques, and delivery techniques that are commonly utilized by radiation oncologists. However, every phase of radiation treatment will include a specified modality, planning technique, and delivery technique. The goal of the 2018 implementation of separate phase-specific data items for the recording of *Phase I-II-III Radiation Treatment Modality* [1506,1516,1526], and *Phase I-II-III External Beam Radiation Planning Technique* [1502,1512, 1522] is to clarify this information and implement mutually exclusive categories. Note that Planning Technique details are not being captured for non-External Beam modalities. A separate data item for delivery technique has not been implemented because this information is not consistently reported in end treatment summaries.

### Coding Instructions

- A new paradigm of treatment called on-line adaptive (or on-table) adaptive radiation may be the source of confusion when coding External Beam Radiation Planning Technique. New linear accelerators are attached to such high-quality imaging devices that they can function as both simulation scanners for planning and radiation delivery systems. If a new radiation plan is created while the patient is on the radiation delivery table to take into account that day's anatomy, this is referred to "on-line" (or "on-table") adaptive radiation. If a new radiation plan is created while the patient is not on the delivery table, then it is referred to as "off-line" (or "off-table") adaptive therapy. Off-line adaptive therapy treatments are relatively common, but MR-guided and CT-guided online adaptive therapy treatments are just emerging. If treatment is described as both MR-guided (or CT-Guided) on-line adaptive as well as another external beam planning technique (e.g. IMRT, SBRT, etc) code as MR-guided (or CT-Guided) online adaptive therapy. On-line adaptive techniques are the most complex and usually include IMRT and/or SBRT techniques within them, so the on-line adaptive component is most important to capture.
- If a treatment is described as off-line adaptive then the on-line adaptive codes should NOT be used to describe the phase planning technique.
- Code 00, no radiation treatment, when diagnosed at autopsy.
- Code 05 for Intensity Modulated Therapy (IMT) or Intensity Modulated Radiation Therapy (IMRT).
- Code 04 for Conformal or 3-D Conformal Therapy whenever either is explicitly mentioned.

- When code 98 is recorded, document the planning technique in the appropriate text data item.
- This data item, in conjunction with Phase I-II Radiation Treatment Modality [1506, 1516], replaces the Rad--Regional RX Modality [1570] and includes converted historical values. Conversion took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.
- Phase I must be coded however blanks are allowed for Phase II-III.

Code	Label	Definition
00	No radiation treatment	Radiation therapy was not administered to the patient. Diagnosed at autopsy.
01	External beam, NOS	The treatment is known to be by external beam, but there is insufficient information to determine the specific planning technique.
02	Low energy x-ray/photon therapy	External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Energies are typically expressed in units of kilovolts (kV). These types of treatments are sometimes referred to as electronic brachytherapy or orthovoltage or superficial therapy. Clinical notes may refer to the brand names of low energy x-ray delivery devices, e.g. Axxent®, INTRABEAM®, or Esteya®.
03	2-D therapy	An external beam planning technique using 2-D imaging, such as plain film x-rays or fluoroscopic images, to define the location and size of the treatment beams. Should be clearly described as 2-D therapy. This planning modality is typically used only for palliative treatments.
04	Conformal or 3-D conformal therapy	An external beam planning technique using multiple, fixed beams shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.
05	Intensity modulated therapy	An external beam planning technique where the shape or energy of beams is optimized using software algorithms. Any external beam modality can be modulated but these generally refer to photon or proton beams. Intensity modulated therapy can be described as intensity modulated radiation therapy (IMRT), intensity modulated x-ray or proton therapy (IMXT/IMPT), volumetric arc therapy (VMAT) and other ways. If a treatment is described as IMRT with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning.
06	Stereotactic radiotherapy or radiosurgery, NOS	Treatment planning using stereotactic radiotherapy/radiosurgery techniques, but the treatment is not described as Cyberknife® or Gamma Knife®. These approaches are sometimes described as SBRT (stereotactic body radiation), SABR (stereotactic ablative radiation), SRS (stereotactic radiosurgery), or SRT (stereotactic radiotherapy). If the treatment is described as robotic radiotherapy (e.g. Cyberknife®) or Gamma Knife®, use stereotactic radiotherapy subcodes below. If a treatment is described as stereotactic radiotherapy or radiosurgery with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning.

Code	Label	Definition
07	Stereotactic radiotherapy or radiosurgery, robotic.	Treatment planning using stereotactic radiotherapy/radiosurgery techniques which is specifically described as robotic (e.g. Cyberknife®).
08	Stereotactic radiotherapy or radiosurgery, Gamma Knife®	Treatment planning using stereotactic radiotherapy/radiosurgery techniques which uses a Cobalt-60 gamma ray source and is specifically described as Gamma Knife®. This is most commonly used for treatments in the brain.
09	CT-guided online adaptive therapy	An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient's tumor or normal anatomy radiation using a CT or cone beam CT (CBCT) scan obtained at the treatment machine (online). These approaches are sometimes described as CT-guided online re- optimization or online re-planning. If a treatment technique is described as both CT-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as CT-guided online adaptive therapy. If a treatment is described as "adaptive" but does not include the descriptor "online", this code should not be used. Clinic notes may refer to the brand name of a linear accelerator called Ethos.
10	MR-guided online adaptive therapy	An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient's tumor or normal anatomy radiation using an MRI scan obtained at the treatment machine (online). These approaches are sometimes described as MR-guided online re-optimization or online re-planning. If a treatment technique is described as both MR-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as MR-guided online adaptive therapy. If a treatment is described as "adaptive" but does not include the descriptor "online", this code should not be used. Clinic notes may refer to an MR-Linac or the brand name of an MR-Linac called MRlidian or Unity.
88	Not Applicable	Treatment not by external beam.
98	Other, NOS	Other radiation, NOS; Radiation therapy administered, but the treatment modality is not specified or is unknown.
99	Unknown	It is unknown whether radiation therapy was administered.

## Examples

Code	Reason
04	A man with prostate cancer is initially treated with whole pelvis RT using a four-field approach, all fields shaped conformally to pelvic anatomy. He then was treated with an IMRT boost. Record the Phase I External Beam Radiation Planning Technique as 04 (Conformal or 3-D conformal therapy)
03	A woman with advanced multiple myeloma is referred for total body irradiation and is treated twice daily for three consecutive days in a total body stand at extended distance with open rectangular photon fields, 200cGy to mid-body per treatment. Record the Phase I External Beam Radiation Planning Technique as 03 (2-D therapy)
88	Record 88 as the Phase I External Beam Radiation Planning Technique for any phase uses radioisotopes or brachytherapy (e.g. I-131 radioiodine for thyroid cancer, brachytherapy for prostate cancer).

## Phase I-II-III Dose per Fraction

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1501	5	2289-2293	00000-99999, Blank	All Years	01/18, 02/21, 01/22
1511	5	2311-2315	00000-99999, Blank	All Years	01/18, 02/21
1521	5	2333-2337	00000-99999, Blank	2018+	01/18, 02/21

### Description

Records the dose per fraction (treatment session) delivered to the patient in the first phase of radiation during the first course of treatment. The unit of measure is centi-Gray (cGy). This data item is required for CoC-accredited facilities as of 01/01/2018.

### Rationale

Radiation therapy is delivered in one or more phases with identified dose per fraction. It is necessary to capture information describing the dose per fraction to evaluate patterns of radiation oncology care.

### Coding Instructions

- In general, (Phase Dose per Fraction x Phase Number of Fractions = Phase Total Dose). But, there may be inconsistencies in rounding of dose or the way the dose is automatically measured in a treatment which will result in slight inconsistencies in the math. That is, in some radiation treatment summaries, Phase Dose per Fraction x Phase Number of Fractions  $\approx$  Phase Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGE units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGE = 1 Gy = 100 cGy. For a Phase Total Dose, you would need to multiply dose in CGE by 100 to get dose in cGy.).
- Note that dose is still occasionally specified in “rads”. 1 rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy.
- Code 99998 when radioisotopes were administered to the patient (codes 13-16) for Phase I -I-III Radiation Treatment Modality [1506, 1516, 1526].
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I-II-III Treatment Modality [1506, 1516, 1526]). If the dose is not available/provided in cGy for a brachytherapy procedure, code 99999.
- Record the actual dose delivered (NOT the initially prescribed dose) as documented in the treatment summary.
- This data item replaces the Rad--Regional Dose: cGy [1510] and Rad--Boost Dose cGy [3210] and may include mapped historical values. 1-1 mapping took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.

Code	Label
00000	No radiation treatment
00001-99997	Record the actual Phase I dose delivered in cGy

99998	Not applicable, radioisotopes administered to the patient
99999	Regional radiation therapy was administered but dose is unknown; Unknown whether radiation therapy was administered; Death Certificate only

## Examples

Code	Reason
00200	A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy over 25 fractions followed by a Phase II (boost) prostate irradiation to 7,000 cGy. Record the Phase I dose per fraction as 00200 (5000/25).
00150	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region over 40 fractions. The dose is calculated at the prescribed depth of 3cm. A secondary calculation shows a Dmax dose of 6,450 cGy. Record the Phase I dose per fraction as 00150 (6000/40).
00180	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record phase I dose per fraction as 00180 (4500/25). See a detailed discussion of this example in the "CTR Guide to Coding Radiation Therapy Treatment in the STORE"



## Phase I-II-III Number of Fractions

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1503	3	2294-2296	000-999, Blank	All Years	01/18, 02/21, 01/22
1513	3	2316-2318	000-999, Blank	All Years	01/18, 02/21
1523	3	2338-2340	000-999, Blank	2018+	01/18, 02/21

### Description

Records the total number of fractions (treatment sessions) delivered to the patient in the first phase of radiation during the first course of treatment. This data item is required for CoC-accredited facilities as of 01/01/2018.

### Rationale

Radiation therapy is delivered in one or more phases with each phase spread out over a number of fractions (treatment sessions). It is necessary to capture information describing the number of fraction(s) to evaluate patterns of radiation oncology care.

### Coding instructions

- Although a fraction or treatment session may include several treatment beam positions delivered within a relatively confined period of time-usually a few minutes to a few hours-it is still considered one session. However, multiple fractions may be delivered in a single day. This may be documented as BID treatment or twice daily treatment. Usually multiple fractions in a single day are separated by at least 4 hours.
- Count each separate administration of brachytherapy or implant as a single fraction or treatment.
- Record the actual number of fractions delivered (NOT initially prescribed), as documented in the treatment summary.
- Code 999 for Death Certificate Only (DCO) cases.
- Phase I data item replaced the *Rad--No of Treatment Vol* [1520] and includes mapped values for historical cases. Phase II data item includes a mapped value of 999 when Rad--Boost RX Modality [3200] was administered. 1-1 mapping took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year.
- Phase I must be coded however blanks allowed for Phase II-III if no radiation treatment administered.

Code	Label
000	No radiation treatment
001-998	Number of fractions administered to the patient during the first phase of radiation therapy
999	Phase I Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered

## Examples

Code	Reason
025	A patient with breast carcinoma had treatment sessions in which treatment was delivered to the chest wall and encompassing the ipsilateral supraclavicular region for a total of three fraction portals. Twenty-five treatment sessions were given. Record 25 fractions as 025.
050	A patient with advanced head and neck cancer was treated using “hyper-fractionation.” Three fields were delivered in each session; two sessions were given each day, six hours apart, with each session delivering a total dose of 150 cGy. Treatment was given for a total of 25 days. The total course dose was 7500cGy. Record 50 fractions as 050.
010	The patient was given Mammosite® brachytherapy, repeated in 10 separate sessions. Record 10 fractions as 010.
001	Prostate cancer patient treated with a single administration of seeds. Record 1 fraction as 001.

## Phase I-II-III Total Dose

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1507	6	2297-2302	000000-999999, Blank	All Years	01/18, 02/21, 01/22
1517	6	2319-2324	000000-999999, Blank	All years	01/18, 02/21
1527	6	2341-2346	000000-999999, Blank	2018+	01/18, 02/21

### Description

Identifies the total radiation dose delivered to the patient during phase I-II-III of radiation treatment during the first course of treatment. Each phase is meant to reflect the delivered radiation prescription. The unit of dose is centi-Gray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed as of 01/01/2018.

### Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed dose of Phase I-II-III radiation to the patient during the first course of treatment.

### Coding instructions

- Record the actual total dose delivered (NOT initially prescribed), as documented in the radiation treatment summary. The value recorded for this data item should NOT be auto-calculated within the registry abstraction software. In general, (Phase Dose per Fraction x Phase Number of Fractions = Phase Total Dose). But, there may be inconsistencies in rounding of dose or the way the dose is automatically measured in a treatment which will result in slight inconsistencies in the math. That is, in some radiation treatment summaries, Phase Dose per Fraction x Phase Number of Fractions  $\approx$  Phase Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGE units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGE = 1 Gy = 100 cGy. For a Phase Total Dose, you would need to multiply dose in CGE by 100 to get dose in cGy.)
- Note that dose is still occasionally specified in "rads". 1 rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy. A dose of Code 99998 when radioisotopes were administered to the patient (codes 13-16 for Phase I-II-III Treatment Modality [1506, 1516, 1526]).
- Code 000000, radiation therapy not administered, when diagnosed at autopsy.
- Code 999998 when radioisotopes are administered to the patient (codes 13-16 recorded in the Phase I-II-III Treatment Modality [1506, 1516, 1526]).
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I-II-III Treatment Modality [1506, 1516, 1526]). If only one fraction of brachytherapy was delivered, then then the Phase I Dose per Fraction and the Phase I Total Dose will be the same.
- Code 999999 for Death Certificate Only (DCO) cases.
- Phase I data item is an all new data item in 2018 includes mapped values for historical cases. Mapping took place upon upgrade to NAACCR v18-compliant software; as of 2018 this data item is required for all cases regardless of diagnosis year. Phase II data item may include mapped values for historical cases. This data item includes a mapped value of 999999 when Rad--Boost RX Modality [3200] was administered

- Phase I must be coded however blanks are allowed for Phase II-III if no radiation treatment was administered.

Code	Label
000000	No radiation treatment. Diagnosed at autopsy.
000001-999997	Record the actual total dose delivered in cGy
999998	Not applicable, radioisotopes administered to the patient
999999	Radiation therapy was administered, but the total dose is unknown; it is unknown whether radiation therapy was administered, or diagnosed by Death Certificate Only

## Examples

Code	Reason
005000	A patient with Stage III prostate carcinoma received pelvic irradiation of 5,000 cGy in 25 fractions during Phase I Radiation Treatment. Record the Phase I Total Dose of 5,000 cGy as 005000.
006000	A patient with a left supraclavicular metastasis from a gastric carcinoma received 6,000 cGy to the left supraclavicular region. Record the Phase I Total Dose of 6,000 cGy as 006000.
004500	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Total Dose of 4500 cGy as 004500. See a detailed discussion of this example in the "CTR Guide to Coding Radiation Therapy Treatment in the STORE".

## Number of Phases of Radiation Treatment

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1532	2	2347-2348	00-98, 99	2018+	01/18

### Description

A course of radiation is made up of one or more phases and each phase reflects a distinct delivered prescription. The STORE has fields for up to 3 phases of a radiation course to be documented. This field identifies the actual number of distinct radiation phases in a course so that it is clear when only a portion of the course is being captured in the phase summary sections.

### Rationale

The number of phases of radiation treatment is used to flag cases where only a subset of phase data is being captured.

### Coding Instructions

Code	Label
00	No radiation treatment
01-98	Record the actual number of phases in the radiation course
99	Unknown number of phases; Unknown if radiation therapy administered.

### Examples

Code	Reason
00	Radiation therapy was not administered.
01	A patient with advanced head and neck cancer was treated using "hyper-fractionation." Three fields were delivered in each session; two sessions were given each day, six hours apart, with each session delivering a total fractional dose of 150 cGy. Treatment was given for a total of 25 days. The total course dose was 7500cGy. Record the Number of Phases of Radiation Treatment as 01.
03	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions, but axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record 03 as the Number of Phases of Radiation Treatment. See a detailed discussion of this example in the "CTR Guide to Coding Radiation Therapy Treatment in the STORE"

## Radiation Treatment Discontinued Early

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1531	2	2349-2350	00-07, 99	2018+	01/18

### Description

This field is used to identify patients/tumors whose radiation treatment course was discontinued earlier than initially planned. That is, the patients/tumors received fewer treatment fractions (sessions) than originally intended by the treating physician. This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later.

### Rationale

Currently, the total dose of radiation reflects what was actually delivered rather than what was intended. When a patient does not complete a radiation course as initially intended this is typically commented on within the radiation treatment summary. By flagging these patients within the cancer registry database, these patients can be excluded from analyses attempting to describe adherence to radiation treatment guidelines or patterns of care analyses.

### Coding Instructions

- Use code 01 when there is no indication in the record that radiation therapy was discontinued or completed early.
- Use code 02-07 when there is an indication in the record that the radiation therapy discontinued or was completed early.
- Use code 99 when radiation therapy was administered, but it is not clear if the treatment course was discontinued early, or if it is unknown whether radiation therapy was administered, or it is a death certificate only case.

Code	Label
00	No radiation treatment
01	Radiation treatment completed as prescribed
02	Radiation treatment discontinued early - toxicity
03	Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)
04	Radiation treatment discontinued early - patient decision
05	Radiation discontinued early - family decision
06	Radiation discontinued early - patient expired
07	Radiation discontinued early - reason not documented
99	Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered. Death Certificate only.

## Examples

Code	Reason
01	A patient with Stage III prostate carcinoma received pelvic irradiation to 5,000 cGy over 25 fractions followed by a Phase II (boost) prostate irradiation to 7,000 cGy. Record Radiation Treatment Discontinued Early field as 01.
03	A patient with a metastasis from a gastric carcinoma at the L1 vertebral body was planned to receive 3000 cGy over 10 fractions. However, after 5 fractions, the patient developed cord compression symptoms and imaging evidence of compression and was taken for urgent surgical resection of the mass at L1. He did not resume radiotherapy. Record Radiation Treatment Discontinued Early field as 03 because there was clear evidence of progression.
02	A patient with muscle-invasive bladder cancer was being treated with radiation to the whole bladder. The initial plan was to treat the whole bladder to 6480cGy in 36 fractions but after 23 fractions he developed severe radiation enteritis and unrelenting diarrhea requiring a prolonged hospital admission. He discontinued treatment early after a total dose of 4140cGy. Record Radiation Treatment Discontinued Early field as 02 because treatment was stopped early due to treatment toxicity.

## Radiation Course Total Dose

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1533	6	2351-2356	000000-999999	2018+	01/18

### Description

Identifies the total cumulative radiation dose administered to the patient across all phases during the first course of treatment to the same body site. The unit of measure is centi-Gray (cGy). This data item is required for CoC-accredited facilities for cases diagnosed 01/01/2018 and later.

### Rationale

To evaluate the patterns of radiation care, it is necessary to capture information describing the total delivered prescribed total dose of radiation during the first course of treatment. Outcomes are strongly related to the dose delivered.

### Coding Instructions

- If the total dose for the course is not documented, then add the dose from each of the sequential phases (I, II, III, or IV or more) that target the same body site and document the total cumulative dose. Note when calculating the Radiation Course Total Dose, all of the phases should be used, not just the first three.
- Doses should ONLY be summed across phases to create a Total Dose when all of the phases were delivered *sequentially* to the *same body site*. If phases were delivered to multiple body sites (e.g. simultaneous treatment to multiple metastatic sites), then code the Radiation Course Total Dose as the dose to the body site that received the highest dose. Examples are provided in the “CTR Guide to Coding Radiation Therapy Treatment in the STORE”.
- Doses should ONLY be summed across phases to create a Total Dose when all of the phases were delivered *using the same modality*. If phases were delivered using two or more different modalities (e.g. external beam and brachytherapy to the same body site), then code 999998, Not applicable.
- Doses *can* be summed across phases even if the fraction size of phases is different. That is, if phase I to the whole prostate and seminal vesicles is 180 cGy x 28 = 5040 cGy, Phase II to a partial prostate volume is 200 cGy x 15 = 3000cGy, and these phases are delivered sequentially, then record 8040 cGy as the Radiation Course Total Dose.
- For proton treatment, dosage may occasionally be specified as in CGE units (Cobalt Gray Equivalent) rather than Gy or cGy. 1 CGE = 1 Gy = 100 cGy. For a Phase Total Dose, you would need to multiply dose in CGE by 100 to get dose in cGy.)
- Note that dose is still occasionally specified in “rads”. 1 rad = 1cGy.
- If dose is documented in the medical record includes a fraction of a cGy (e.g. 180.3), round to the nearest cGy. For example, 180.5 cGy should be rounded up to 181 cGy and 180.4 cGy should be rounded down to 180cGy. A dose of Code 99998 when radioisotopes were administered to the patient (codes 13-16 for *Phase I Treatment Modality* [1506]).
- Code 999998 when radioisotopes are administered to the patient (codes 13-16 recorded in the Phase I, Phase II, or Phase III Treatment Modality [1506, 1516, 1526] data items).
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12 for Phase I Treatment Modality [1506]).



Code	Label
000000	No radiation treatment. Diagnosed at autopsy.
000001-999997	Record the actual total dose delivered in cGy
999998	Not applicable, radioisotopes administered to the patient, or the patient was treated with a mixed modalities (e.g. external beam and brachytherapy).
999999	Radiation therapy was administered, but the total dose is unknown; it is unknown whether radiation therapy was administered

## Examples

Code	Reason
006040	A patient with breast cancer was treated with whole breast RT, 5040 cGy in 28 fractions. Axillary and supraclavicular (SC) nodes treated concurrently with an anterior field covering both regions and a posterior field (PAB) added to the axilla. The medial portion of the anterior field was blocked for the last three treatments to hold the SC region to a maximum of 4500cGy to minimize the risk of brachial plexus injury. Subsequently, the surgical bed received an electron boost of 1000cGy in 5 fractions using fields shaped to surround surgical bed with 1.5 cm margins. Record the Phase I Total Dose as 004500. Record the Phase II Total Dose as 000540. Record the Phase III Total Dose as 001000. Record the Radiation Course Total Dose as 006040.
008040	A patient with Stage III prostate carcinoma received 5,040 cGy to his pelvic nodes, prostate and seminal vesicles over 28 fractions using IMRT followed by a Phase II (boost) of 3000 cGy in 30 fractions using proton therapy. Record the Phase I Total Dose as 005040. Record the Phase II Total Dose as 003000. Record the Radiation Course Total Dose as 008040.
999998	A patient with Stage III prostate carcinoma received 4600cGy to his pelvic nodes, prostate and seminal vesicles over 23 fractions using IMRT followed by a Phase II (boost) of 11500 cGy using a low dose rate (LDR) brachytherapy implant. Record the Phase I Total Dose as 004600. Record the Phase II Total Dose as 011500. Record the Radiation Course Total Dose as 999998 because it is a mixed modality course.

## Radiation/Surgery Sequence

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1380	1	2240-2240	0, 2-7, 9	2003+	01/04, 01/10, 01/11, 01/12, 02/21

### Description

Records the sequencing of radiation and surgical procedures given as part of the first course of treatment.

### Rationale

The sequence of radiation and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

### Coding Instructions

- For the purpose of coding the data item Radiation Sequence with Surgery, 'Surgery' is defined as a Surgical Procedure of Primary Site (codes 10-90) or Scope of Regional Lymph Node Surgery (codes 2-7) or Surgical Procedure of Other Site (codes 1-5).
- Surgical procedures include *Surgical Procedure of Primary Site* [1290]; *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1); *Surgical Procedure/Other Site* [1294]. If all these procedures are coded 0, or it is not known whether the patient received both surgery and radiation, then this item should be coded 0.
- If the patient received both radiation therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of Primary Site*, *Regional Lymph Node Surgery* (excluding code 1), or *Surgical Procedure/Other Site*, then code this item 2–9, as appropriate. Assign codes 2-9 when first course of therapy includes both cancer-directed surgery and radiation therapy.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies. Assign code 4 when there are at least two courses, episodes, or fractions of radiation therapy given before and at least two more after surgery to the primary site, scope of regional lymph node surgery (excluding code 1), surgery to other regional site(s), distant site(s), or distant lymph node(s).

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s) or it is unknown whether any surgery given.
2	Radiation therapy before surgery	Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).

Code	Label	Definition
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
4	Radiation therapy both before and after surgery	At least two courses of radiation therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
5	Intraoperative radiation therapy	Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative radiation therapy with other therapy administered before or after surgery	Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s).
7	Surgery both before and after radiation	Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of the treatment is not stated in the patient record.

## Examples

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	A large lung lesion received radiation therapy prior to resection.
3	A patient received a wedge resection of a right breast mass with axillary lymph node dissection followed by radiation to right breast.
4	Preoperative radiation therapy was given to a large, bulky vulvar lesion and was followed by a lymph node dissection. This was then followed by radiation therapy to treat positive lymph nodes.
5	A cone biopsy of the cervix was followed by intracavitary implant for IIIB cervical carcinoma.
6	Stage IV vaginal carcinoma was treated with 5,000 cGy to the pelvis followed by a lymph node dissection and 2,500 cGy of intracavitary brachytherapy.
9	An unknown primary of the head and neck was treated with surgery and radiation prior to admission, but the sequence is unknown. The patient enters for chemotherapy.

## Date Radiation Ended

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3220	8	2154-2161	CCYMMDD	2003+	06/05, 01/10, 01/11, 01/12

### Description

The date on which the patient completes or receives the last radiation treatment at any facility.

### Rationale

The length of time over which radiation therapy is administered to a patient is a factor in tumor control and treatment morbidity. It is useful to evaluate the quality of care and the success of patient support programs designed to maintain continuity of treatment.

### Coding Instructions

- Date radiation ended will typically be found in the radiation oncologist's summary letter for the first course of treatment. Determination of the date radiation ended may require assistance from the radiation oncologist for consistent coding.
- The date when treatment ended will typically be found in the radiation oncologist's summary letter for the first course of treatment.
- For brachytherapy if the treatment is applied only once, this date will be the same as Date Radiation Started [1210].
- There may be times when the first course of treatment information is incomplete. Therefore, it is important to continue follow-up efforts to be certain the complete treatment information is collected.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Radiation Ended is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Radiation Ended transmits in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

### Examples

Code	Reason
20050104	A patient starts IMRT radiation treatment on December 15, 2004 and treatment continues until January 4, 2005.
20091002	A patient receives one radiation treatment on October 2, 2009, then refuses further treatments.
20060404	A patient with a primary tumor of the brain undergoes stereotactic radiosurgery using a Gamma Knife on April 4, 2006.

## Reason for No Radiation

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1430	1	2250-2250	0-2, 5-9	2003+	09/04, 01/13

### Description

Records the reason that no regional radiation therapy was administered to the patient.

### Rationale

When evaluating the quality of care, it is useful to know the reason that various methods of therapy were not used, and whether the failure to provide a given type of therapy was due to the physician's failure to recommend that treatment, or due to the refusal of the patient, a family member, or the patient's guardian.

### Coding Instructions

- If *Number of Phases of Radiation Treatment to this Volume* [1532] is coded 00, *Phase I Radiation Primary Treatment Volume* [1504] is coded 00, *Radiation Treatment Discontinued Early* [1531] is coded 00, and *Total Dose* [1533] is coded 000000, then record the reason based on documentation in patient record.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include radiation therapy.
- Code 7 if the patient refused recommended radiation therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 8 if it is known that a physician recommended radiation treatment, but no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a radiation oncologist was made and the registry should follow to determine whether radiation was administered. If follow-up to the specialist or facility determines the patient was never there and no other documentation can be found, code 1.
- Cases coded 8 should be followed and updated to a more definitive code as appropriate.
- Code 9 if the treatment plan offered multiple alternative treatment options, but it is unknown which treatment, if any, was provided. Death Certificate only.

Code	Label
0	Radiation therapy was administered.
1	Radiation therapy was not administered because it was not part of the planned first course treatment. Diagnosed at autopsy.
2	Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).
5	Radiation therapy was not administered because the patient died prior to planned or recommended therapy.

Code	Label
6	Radiation therapy was not administered; it was recommended by the patient's physician, but was not administered as part of first course treatment. No reason was noted in patient record.
7	Radiation therapy was not administered; it was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in patient record.
8	Radiation therapy was recommended, but it is unknown whether it was administered.
9	It is unknown if radiation therapy was recommended or administered. Death certificate cases only.

### Examples

Code	Reason
1	A patient with Stage I prostate cancer is offered either surgery or brachytherapy to treat his disease. The patient elects to be surgically treated.

## Text--Radiation (Beam)

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2620	1000	rxTextRadiation	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with beam radiation.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date radiation treatment began
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of beam radiation, e.g., Orthovoltage, Cobalt 60, MV X-rays, Electrons, Mixed modalities
- Other treatment information, e.g., patient discontinued after 5 treatments; unknown if radiation was given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Radiation (Beam), cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Summ--Radiation	1360
RX Summ--Surg/Rad Seq	1380
Reason For No Radiation	1430
RX Date Radiation	1210
Rad Regional RX Modality	1570
RX Hosp--Radiation	690
RX Date Rad Ended	3220
RX Summ--Rad to CNS	1370
Rad--No of Treatment Vol	1520
Rad--Regional Dose cGy	1510
Rad Treatment Volume	1540
Rad Location of RX	1550
Rad Boost RX Modality	3200
Rad Boost Dose cGy	3210
Phase I dose per Fraction	1501
Phase II dose per Fraction	1511
Phase III dose per Fraction	1521
Phase I Number of Fractions	1503
Phase II Number of Fractions	1513
Phase III Number of Fractions	1523
Phase I Radiation Treatment Modality	1506
Phase II Radiation Treatment Modality	1516
Phase III Radiation Treatment Modality	1526

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Text--Radiation Other

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2630	1000	rxTextRadiationOther	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding treatment of the tumor being reported with radiation other than beam radiation. This includes brachytherapy and systemic radiation therapy.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of nonbeam radiation, e.g., High Dose rate brachytherapy, seed implant, Radioisotopes (I-131)
- Other treatment information, e.g., unknown if radiation was given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Radiation Other, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1st Crs RX CoC	1270
RX Summ--Radiation	1360
RX Summ--Surg/Rad Seq	1380
Reason For No Radiation	1430
RX Date Radiation	1210
Rad Regional RX Modality	1570
RX Hosp--Radiation	690
RX Date Rad Ended	3220
RX Summ--Rad to CNS	1370
Rad--No of Treatment Vol	1520
Rad--Regional Dose cGy	1510
Rad Treatment Volume	1540
Rad Location of RX	1550
Rad Boost RX Modality	3200
Rad Boost Dose cGy	3210
Phase I dose per Fraction	1501
Phase II dose per Fraction	1511
Phase III dose per Fraction	1521
Phase I Number of Fractions	1503
Phase II Number of Fractions	1513
Phase III Number of Fractions	1523
Phase I Radiation Treatment Modality	1506
Phase II Radiation Treatment Modality	1516
Phase III Radiation Treatment Modality	1526

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Systemic Therapy Data Items

[See \*Systemic Therapy\* in Section One for overview of coding principles.](#)

## Date Systemic Therapy Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3230	8	2164-2171	CCYYMMDD	2003+	01/10, 01/11

### Description

Records the date of initiation for systemic therapy that is part of the first course of treatment. Systemic therapy includes the administration of chemotherapy agents, hormonal agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

### Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

- Record the first or earliest date on which systemic therapy was administered. Systemic therapy includes *Chemotherapy* [1390], *Hormone Therapy* [1400], *Immunotherapy* [1410], and *Hematologic Transplant and Endocrine Procedures* [3250].
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Systemic Therapy Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Systemic Therapy Started transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

### Examples

Code	Reason
20031215	A patient with breast cancer begins her regimen of chemotherapy on December 15, 2003, and is subsequently given Tamoxifen on January 20, 2004.
20030602	A patient with Stage IV prostate cancer has an orchiectomy on June 2, 2003. He is then started on a regime of hormonal agents on June 9, 2003.

## Rx Date Systemic Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
3231	2	rxDateSystemicFlag	10-12, Blank	2010+	2012, 2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Systemic Therapy Started* [3230].

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date Systemic Therapy Started* [3230] has a full or partial date recorded.
- Code 12 if the *Date Systemic Therapy Started* cannot be determined, but the patient did receive first course systemic therapy.
- Code 10 if it is unknown whether any systemic therapy was given.
- Code 11 if no systemic therapy is planned or given.
- Code 15 if systemic therapy is planned, but not yet started. Follow this patient for systemic therapy and update this item, *Date Systemic Therapy Started*, and all relevant systemic therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any systemic therapy was given).
11	No proper value is applicable in this context (for example, no systemic therapy given; autopsy only case).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, systemic therapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, systemic therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
Blank	A valid date value is provided in item <i>Date Systemic Therapy Started</i> [3230].

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Chemotherapy

## Date Chemotherapy Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1220	8	2174-2181	CCYYMMDD	1996- 2002, 2010+	01/11

### Description

Records the date of initiation of chemotherapy that is part of the first course of treatment.

### Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

- Record the first or earliest date on which chemotherapy was administered by any facility. This date corresponds to administration of the agents coded in *Chemotherapy* [1390].
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Chemotherapy Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Chemotherapy Started transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The RX Date–Chemo Flag [1221] is used to explain why Date Chemotherapy Started is not a known date. See RX Date–Chemo Flag for an illustration of the relationships among these items.

## Rx Date–Chemo Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1221	2	2182-2183	10-12, 15, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Chemotherapy Started* [1220].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if Date Chemotherapy Started [1220] has a full or partial date recorded.
- Code 12 if the Date Chemotherapy Started cannot be determined, but the patient did receive first course chemotherapy.
- Code 10 if it is unknown whether any chemotherapy was given.
- Code 11 if no chemotherapy is planned or given.
- Code 15 if chemotherapy is planned, but not yet started. Follow this patient for chemotherapy and update this item, Date Chemotherapy Started, and the relevant chemotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 (inclusive) if this facility did not collect Date Chemotherapy Started at that time.

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any chemotherapy was given).
11	No proper value is applicable in this context (for example, no chemotherapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, chemotherapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, chemotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Chemotherapy Started</i> [1220]. Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Chemotherapy Started</i> [1220] at that time.



## Chemotherapy

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1390	2	2243-2244	00-03, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/15

### Description

Records the type of chemotherapy administered as first course treatment at this and all other facilities. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

### Coding Instructions

- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer. Diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Code 88 to indicate referral was made to a medical oncologist and the registry must follow to determine whether it was given. If follow-up with the specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered. Death Certificate only.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and *only the original agent or regimen is recorded as*

*first course therapy.*

- Refer to the *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer.
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care [3270].

**Important information affecting classification of some systemic therapies.** The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER\*Rx Interactive Drug Database*.

Drug Name(s)	Category Prior to 2013	Category 2013 +
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuxumab/Erbitux	Chemotherapy	BRM/Immunotherapy

Code	Label
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy.
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age progression of tumor prior to administration, etc.).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.

Code	Label
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

### Examples

Code	Reason
01	A patient with primary liver cancer is known to have received chemotherapy; however, the name(s) of agent(s) administered is not stated in patient record.
02	A patient with Stage III colon cancer is treated with a combination of fluorouracil and levamisole. Code the administration of fluorouracil as single agent chemotherapy, and levamisole as an immunotherapeutic agent.
02	A patient with non-Hodgkin's lymphoma is treated with fludarabine.
03	A patient with early stage breast cancer receives chemotherapy. The patient chart indicates that a regimen containing doxorubicin is to be administered.
86	After surgical resection of an ovarian mass the following physician recommends chemotherapy. The patient record states that chemotherapy was not subsequently administered to the patient, but the reason why chemotherapy was not administered is not given.

## Chemotherapy at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
700	2	802-803	00-03, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/12, 01/13, 01/15

### Description

Records the type of chemotherapy administered as first course treatment at this facility. If chemotherapy was not administered, then this item records the reason it was not administered to the patient.

Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of chemotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if chemotherapy was not administered.

### Coding Instructions

- Record only chemotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer. Diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include chemotherapy or if the option of “no treatment” was accepted by the patient.
- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration
- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.
- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered. Death Certificate only.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and only the original agent or regimen is recorded as first course therapy.

- Refer to the SEER\*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) for a list of chemotherapeutic agents.
- If chemotherapy was provided as a radiosensitizer or radioprotectant DO NOT code as chemotherapy treatment. When chemotherapy is given for radiosensitization or radioprotection it is given in low doses that do not affect the cancer.
- If chemotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the chemotherapy administered in the item Palliative Care at This Facility [3280].

**Important information affecting classification of some systemic therapies.** The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER\*Rx Interactive Drug Database*.

Drug Name(s)	Category Prior to 2013	Category 2013 +
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuxumab/Erbitux	Chemotherapy	BRM/Immunotherapy

Code	Label
00	None, chemotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Chemotherapy administered as first course therapy; but the type and number of agents is not documented in patient record.
02	Single-agent chemotherapy administered as first course therapy.
03	Multiagent chemotherapy administered as first course therapy
82	Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to planned administration).
85	Chemotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Chemotherapy was recommended, but it is unknown if it was administered.

---

Code	Label
99	It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

## Text--Chemo

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2640	1000	rxTextChemo	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding chemotherapy treatment of the reported tumor.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date chemotherapy began
- Where treatment was given, e.g., at this facility, at another facility
- Type of chemotherapy, e.g., name of agent(s) or protocol
- Other treatment information, e.g., treatment cycle incomplete, unknown if chemotherapy was given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022

## Text—Chemo, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 <sup>st</sup> Crs RX CoC	1270
RX Hosp--Chemo	700
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--Chemo	1390
RX Date Chemo	1220
RX Summ--Systemic/Sur Seq	1639

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Hormone Therapy

## Date Hormone Therapy Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1230	8	2184-2191	CCYYMMDD	1996-2002, 2010+	01/11, 01/12

### Description

Records the date of initiation of hormone therapy that is part of the first course of treatment.

### Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

- Record the first or earliest date on which hormone therapy was administered by any facility. This date corresponds to administration of the agents coded in *Hormone Therapy* [1400].
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Hormone Therapy Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Hormone Therapy Started transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The RX Date–Hormone Flag [1231] is used to explain why Date Hormone Therapy Started is not a known date. See RX Date–Hormone Flag for an illustration of the relationships among these items.

## Rx Date–Hormone Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1231	2	2192-2193	10-12, 15, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Hormone Therapy Started* [1230].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if Date Hormone Therapy Started [1230] has a full or partial date recorded.
- Code 12 if the Date Hormone Therapy Started cannot be determined, but the patient did receive first course hormone therapy.
- Code 10 if it is unknown whether any hormone therapy was given.
- Code 11 if no hormone therapy is planned or given.
- Code 15 if hormone therapy is planned, but not yet started. Follow this patient for hormone therapy and update this item, Date Hormone Therapy Started, and the relevant hormone therapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect Date Hormone Therapy Started at that time.

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any hormone therapy was given).
11	No proper value is applicable in this context (for example, no hormone therapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, hormone therapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, hormone therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Hormone Therapy Started</i> [1230]. Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Hormone Therapy Started</i> [1230] at that time.

## Hormone Therapy (Hormone/Steroid Therapy)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1400	2	2245-2246	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13

### Description

Records the type of hormone therapy administered as first course treatment at this and all other facilities. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

### Coding Instructions

- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer. Diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of "no treatment" was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate the patient was referred to a medical oncologist and the registry should follow the case for hormone therapy. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why

not.

- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered. Death certificate only.
- Refer to the *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* [3270].

Code	Label
00	None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

## Examples

Code	Reason
00	A patient has advanced lung cancer with multiple metastases to the brain. The physician orders Decadron to reduce the edema in the brain and relieve the neurological symptoms. Decadron is not coded as hormonal therapy.
00	A patient with breast cancer may be treated with aminoglutethimide (Cytadren, Elipten), which suppresses the production of glucocorticoids and mineralocorticoids. This patient must take glucocorticoid (hydrocortisone) and may also need a mineralocorticoid (Florinef) as a replacement therapy.
00	A patient with advanced disease is given prednisone to stimulate the appetite and improve nutritional status. Prednisone is not coded as hormone therapy.
01	A patient with metastatic prostate cancer is administered flutamide (an antiestrogen).
87	A patient with metastatic prostate cancer declines the administration of Megace (a progestational agent) and the refusal is noted in the patient record.

## Hormone Therapy at this Facility (Hormone/Steroid Therapy)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
710	2	804-805	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13

### Description

Records the type of hormone therapy administered as first course treatment at this facility. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of hormonal agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if hormone therapy was not administered.

### Coding Instructions

- Record only hormone therapy received at this facility. Do not record procedures done at other facilities.
- Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).
- Do not code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.
- Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer. Diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include hormone therapy or if the option of "no treatment" was accepted by the patient.
- Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.
- If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.
- Cases coded 88 should be followed to determine whether they received hormone therapy or why

not.

- Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered. Death certificate only.
- Refer to the *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) for a list of hormonal agents.
- If hormone therapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hormone therapy administered in the item *Palliative Care* [3270].

Code	Label
00	None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Hormone therapy administered as first course therapy.
82	Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
86	Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hormone therapy was recommended, but it is unknown if it was administered.
99	It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

## Text--Hormone

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2650	1000	rxTextHormone	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for information about hormonal treatment.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values**.

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of hormone or antihormone, e.g., Tamoxifen
- Type of endocrine surgery or radiation, e.g., orchiectomy
- Other treatment information, e.g., treatment cycle incomplete; unknown if hormones were given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Text--Hormone, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 <sup>st</sup> Crs RX CoC	1270
RX Hosp--Hormone	710
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--Hormone	1400
RX Date Hormone	1230
RX Summ--Systemic/Sur Seq	1639

## **Immunotherapy**

## Date Immunotherapy Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1240	8	2194-2201	CCYYMMDD	1996- 2002, 2010+	01/11

### Description

Records the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment.

### Rationale

Collecting dates for each treatment modality allows the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

- Record the first or earliest date on which immunotherapy or a biologic response modifier was administered by any facility. This date corresponds to administration of the agents coded in *Immunotherapy* [1410].
- This item was required in the past but discontinued in FORDS as a required item in 2003. If the date was not collected between 2003 and 2009, this field may be left blank. However, if it was collected for cases diagnosed in those years, it should be retained in this field.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Immunotherapy Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Immunotherapy Started transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. The RX Date–BRM Flag [1241] is used to explain why Date Immunotherapy Started is not a known date. See RX Date–BRM Flag for an illustration of the relationships among these items.

## Rx Date–BRM Flag

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1241	2	2202-2203	10-12, 15, Blank	2010+	01/10

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Immunotherapy Started* [1240].

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if Date Immunotherapy Started [1240] has a full or partial date recorded.
- Code 12 if the Date Immunotherapy Started cannot be determined, but the patient did receive first course immunotherapy or a biologic response modifier.
- Code 10 if it is unknown whether any immunotherapy or a biologic response modifier was given.
- Code 11 if no immunotherapy or biologic response modifier is planned or given.
- Code 15 if immunotherapy or a biologic response modifier is planned, but not yet started. Follow this patient for immunotherapy and update this item, Date Immunotherapy Started, and the relevant immunotherapy items.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.
- Leave this item blank for diagnoses between 2003 and 2009 if this facility did not collect Date Immunotherapy Started at that time.

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any immunotherapy was given).
11	No proper value is applicable in this context (for example, no immunotherapy given).
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, immunotherapy was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (that is, immunotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).
(blank)	A valid date value is provided in item <i>Date Immunotherapy Started</i> [1240]. Case was diagnosed between 2003 and 2009 and the facility did not record <i>Date Immunotherapy Started</i> [1240] at that time.

## Immunotherapy

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1410	2	2247-2248	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13, 01/15

### Description

Records the type of immunotherapy administered as first course treatment at this and all other facilities. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason if immunotherapy was not administered.

### Coding Instructions

- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of "no treatment" was accepted by the patient.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed and the code updated as appropriate. Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the SEER\*Rx Interactive Drug Database (<https://seer.cancer.gov/tools/seerrx/>) for immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item Palliative Care [3270].

**Important information affecting classification of some systemic therapies.** The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding

instructions related to this change have been added to the remarks field for the applicable drugs in *SEER\*Rx Interactive Drug Database*.

Drug Name(s)	Category Prior to 2013	Category 2013 +
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuxumab/Erbix	Chemotherapy	BRM/Immunotherapy

Code	Label
00	None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

## Examples

Code	Reason
01	A patient with malignant melanoma is treated with interferon.
85	Before recommended immunotherapy could be administered, the patient died from cancer.

## Immunotherapy at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
720	2	806-807	00, 01, 82, 85-88, 99	All Years	06/05, 09/08, 01/10, 01/13, 01/15

### Description

Records the type of immunotherapy administered as first course treatment at this facility. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells.

### Rationale

Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. In addition, when evaluating the quality of care, it is useful to know the reason immunotherapy was not administered.

### Coding Instructions

- Record only immunotherapy received at this facility. Do not record agents administered at other facilities.
- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
- Code 00 if the treatment plan offered multiple alternative treatment options, and the patient selected treatment that did not include immunotherapy or if the option of "no treatment" was accepted by the patient.
- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended the patient receive immunotherapy but no further documentation is available yet to confirm its administration.
- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.
- Cases coded 88 should be followed to determine whether they received immunotherapy or why not.
- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.
- Refer to the *SEER\*Rx Interactive Drug Database* (<https://seer.cancer.gov/tools/seerrx/>) for a list of immunotherapeutic agents.
- If immunotherapy was provided to prolong a patient's life by controlling symptoms, to alleviate

pain, or to make the patient more comfortable, then also record the immunotherapy administered in the item *Palliative Care at This Facility* [3280].

**Important information affecting classification of some systemic therapies.** The six drugs listed in the table below were previously classified as Chemotherapy and are now classified as BRM/Immunotherapy. **This change is effective for cases diagnosed January 1, 2013, and forward.** For cases diagnosed prior to January 1, 2013, registrars have been instructed to continue coding these drugs as Chemotherapy. Coding instructions related to this change have been added to the remarks field for the applicable drugs in *SEER\*Rx Interactive Drug Database*.

Drug Name(s)	Category Prior to 2013	Category 2013 +
Alemtuzumab/Campath	Chemotherapy	BRM/Immunotherapy
Bevacizumab/Avastin	Chemotherapy	BRM/Immunotherapy
Rituximab	Chemotherapy	BRM/Immunotherapy
Trastuzumab/Herceptin	Chemotherapy	BRM/Immunotherapy
Pertuzumab/Perjeta	Chemotherapy	BRM/Immunotherapy
Cetuxumab/Erbitux	Chemotherapy	BRM/Immunotherapy

Code	Label
00	None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.



## Text--BRM

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2660	1000	rxTextBrm	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding the treatment of the tumor being reported with biological response modifiers or immunotherapy.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized (see Appendix G).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date treatment began
- Where treatment was given, e.g., at this facility, at another facility
- Type of BRM agent, e.g., Interferon, BCG
- BRM procedures, e.g., bone marrow transplant, stem cell transplant
- Other treatment information, e.g., treatment cycle incomplete; unknown if BRM was given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--BRM, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 <sup>st</sup> Crs RX CoC	1270
RX Hosp--BRM	720
RX Date Systemic	3230
RX Summ--Tranplnt/Endocr	3250
RX Summ--BRM	1410
RX Date BRM	1240
RX Summ--Systemic/Sur Seq	1639

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Hematologic Transplant and Endocrine Procedures

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3250	2	2241-2242	00, 10-12, 20, 30, 40, 82, 85-88, 99	All Years	06/05, 01/10, 01/12, 01/13

### Description

Identifies systemic therapeutic *procedures* administered as part of the first course of treatment at this and all other facilities. If none of these *procedures* were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

### Rationale

This data item allows the evaluation of patterns of treatment which involve the alteration of the immune system or change the patient's response to tumor cells but does not involve the administration of antineoplastic agents. In addition, when evaluating the quality of care, it is useful to know the reason if these *procedures* were not performed.

### Coding Instructions

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.
- Code 00 if a transplant or endocrine procedure was not administered to the patient, and it is known that these procedures are not usually administered for this type and stage of cancer. Diagnosed at autopsy.
- Code 00 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include a transplant or endocrine procedure or if the option of "no treatment" was accepted by the patient.
- If it is known that a transplant or endocrine procedure is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
- Code 87 if the patient refused a recommended transplant or endocrine procedure, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.
- Code 88 if it is known that a physician recommended a hematologic transplant or endocrine procedure, but no further documentation is available yet to confirm its administration.
- Code 88 to indicate referral to a specialist for hematologic transplant or endocrine procedures and the registry should follow the case. If follow-up to the specified specialist or facility determines the

patient was never there, code 00.

- Use code 88 if a bone marrow or stem cell harvest was undertaken, but was not followed by a rescue or re-infusion as part of first course treatment.
- Cases coded 88 should be followed to determine whether they were given a hematologic transplant or endocrine procedure or why not.
- Code 99 if it is not known whether a transplant or endocrine procedure is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered. Death certificate only.
- If the hematologic transplant or endocrine procedure coded in this item was provided to prolong a patient's life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the hematologic transplant or endocrine procedure provided in the items *Palliative Care* [3270] and/or *Palliative Care at This Facility* [3280], as appropriate.

Code	Label
00	No transplant procedure or endocrine therapy was administered as part of first course therapy. Diagnosed at autopsy.
10	A bone marrow transplant procedure was administered, but the type was not specified.
11	Bone marrow transplant—autologous.
12	Bone marrow transplant—allogeneic.
20	Stem cell harvest and infusion. Umbilical cord stem cell transplant, with blood from one or multiple umbilical cords
30	Endocrine surgery and/or endocrine radiation therapy.
40	Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.)
82	Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of disease prior to administration, etc.).
85	Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.
86	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.
87	Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record.
88	Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.
99	It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only.

## Systemic/Surgery Sequence

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1639	1	2273-2273	0, 2-7, 9	2006+	01/10, 01/11, 01/12, 02/21

### Description

Records the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment.

### Rationale

The sequence of systemic therapy and surgical procedures given as part of the first course of treatment cannot always be determined using the date on which each modality was started or performed. This data item can be used to more precisely evaluate the timing of delivery of treatment to the patient.

### Coding Instructions

For the purpose of coding the data item Systemic Sequence with Surgery, 'Surgery' is defined as a Surgical Procedure of Primary Site (codes 10-90) or Scope of Regional Lymph Node Surgery (codes 2-7) or Surgical Procedure of Other Site (codes 1-5).

- *Systemic/Surgery Sequence* is to be used for patients diagnosed on or after January 1, 2006.
- Code the administration of systemic therapy in sequence with the first surgery performed, described in the item *Date of First Surgical Procedure* [1200].
- If none of the following surgical procedures were performed: *Surgical Procedure of Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1) , *Surgical Procedure/Other Site* [1294], then this item should be coded 0.
- If the patient received both systemic therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of the Primary Site* [1290], *Scope of Regional Lymph Node Surgery* [1292] (excluding code 1) , or *Surgical Procedure/Other Site* [1294], then code this item 2-9, as appropriate.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies. For example: the sequence, chemo then surgery then hormone therapy then surgery is coded 4 for "chemo then surgery then hormone".

Code	Label	Definition
0	No systemic therapy and/or surgical procedures	No systemic therapy was given; and/or no surgical procedure of primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s); or no reconstructive surgery was performed. It is unknown whether both surgery and systemic treatment were provided.
2	Systemic therapy before surgery	Systemic therapy was given before surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.

Code	Label	Definition
3	Systemic therapy after surgery	Systemic therapy was given after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
4	Systemic therapy both before and after surgery	At least two courses of systemic therapy were given before and at least two more after a surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
5	Intraoperative systemic therapy	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s).
6	Intraoperative systemic therapy with other systemic therapy administered before or after surgery	Intraoperative systemic therapy was given during surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) with other systemic therapy administered before or after surgical procedure of primary site; scope of regional lymph node surgery; surgery to other regional site(s), distant site(s), or distant lymph node(s) was performed.
7	Surgery both before and after systemic therapy	Systemic therapy was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s).
9	Sequence unknown	Both surgery and systemic therapy were provided, but the sequence is unknown.

## Examples

Code	Reason
0	Due to other medical conditions surgery was not performed. The patient received palliative radiation therapy to alleviate pain.
2	Patient with prostate cancer received hormone therapy prior to a radical prostatectomy.
3	Patient underwent a colon resection followed by a 5-FU based chemotherapy regimen.
4	Patient with breast cancer receives pre-operative chemotherapy followed by post-operative Tamoxifen.
5	Patient with an intracranial primary undergoes surgery at which time a glial wafer is implanted into the resected cavity.
6	Patient with metastatic colon cancer receives intraoperative chemotherapy to the liver.
9	An unknown primary of the head and neck was treated with surgery and chemotherapy prior to admission, but the sequence is unknown. The patient enters for radiation therapy.

## Other Treatment

[See \*Other Treatment\* in Section One for overview of coding principles.](#)

## Date Other Treatment Started

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1250	8	2204-2211	CCYMMDD	All Years	01/10, 01/11

### Description

Records the date on which other treatment began at any facility.

### Rationale

Collecting dates for each treatment modality allows for the sequencing of multiple treatments and aids in the evaluation of time intervals from diagnosis to treatment and from treatment to recurrence.

### Coding Instructions

- Record the date on which the care coded as *Other Treatment* [1420] was initiated.
- If other treatment is the first or only treatment administered to the patient, then the date other treatment started should be the same as the *Date of First Course of Treatment* [1270].
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date Other Treatment Started is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date Other Treatment Started transmits in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

### Examples

Code	Reason
20100316	A patient with metastatic disease was started on an experimental therapy on March 16, 2010.
20090801	Alcohol was used as an embolizing agent for a patient on August 1, 2009
20080917	A polycythemia vera patient was given several phlebotomies, the first being on September 17, 2008



## Rx Date Other Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1251	2	rxDateOtherFlag	10-12, Blank	2010+	2015, 2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date Other Treatment Started* [1250].

Formerly RX Date--Other Flag.

### Rationale

As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date Other Treatment Started* [1250] has a full or partial date recorded.
- Code 12 if the *Date Other Treatment Started* cannot be determined, but the patient did receive first course other treatment.
- Code 10 if it is unknown whether any other treatment was given (*Other Treatment* [1420] is 9).
- Code 11 if no other treatment is planned or given (*Other Treatment* [1420] is 0, 7 or 8).
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any Other Treatment was given).
11	No proper value is applicable in this context (for example, no Other Treatment given; autopsy only cases)
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, Other Treatment was given but the date is unknown).
15	Information is not available at this time, but it is expected that it will be available later (for example, Other therapy is planned as part of the first course of treatment, but had not been started at the time of the most recent follow-up.)
Blank	A valid date value is provided in item <i>Date Other Treatment Started</i> [1250]

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: [Standards for Oncology Registry Entry \(v2018\)](#). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Other Treatment

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1420	1	2249-2249	0-3, 6-9	All Years	06/05, 09/08, 01/10, 01/11, 01/12, 01/15

### Description

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

### Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

### Coding Instructions

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care* [3270].
- Code 8 if it is known that a physician recommended treatment coded as Other Treatment, and no further documentation is available yet to confirm its administration
- Code 8 to indicate referral to a specialist for Other Treatment and the registry should follow. If follow-up with the specialist or facility determines the patient was never there, code 0.
- Code 0 when diagnosed at autopsy.
- Code 9 for Death Certificate Only (DCO) cases.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy).
2	Other–Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other–Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other–Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient's family member, or the patient’s guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

## Other Treatment at this Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
730	1	808-808	0-3, 6-9	All Years	01/04, 09/08, 01/10, 01/12, 01/15

### Description

Identifies other treatment given at this facility that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

### Rationale

Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

### Coding Instructions

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue.
- Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases ONLY. Consult the most recent version of the **Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual** for instructions for coding care of specific hematopoietic neoplasms in this item
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Do not code presurgical embolization that given for a purpose to shrink the tumor.
- A complete description of the treatment plan should be recorded in the text field for “Other Treatment” on the abstract.
- If other treatment was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record the other treatment administered in the item *Palliative Care at This Facility* [3280].
- Code 8 if it is known that a physician recommended the patient receive treatment coded as Other Treatment, but no further documentation is available yet to confirm its administration.
- Code 0 when diagnosed at autopsy.
- Code 9 for Death Certificate Only (DCO) cases.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.

Code	Label	Definition
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy). Use this code for treatment unique to hematopoietic diseases.
2	Other–Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other–Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other–Unproven	Cancer treatments administered by nonmedical personnel.
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.
8	Recommended; unknown if administered	Other treatment was recommended, but it is unknown whether it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

## Text--Other

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2670	1000	rxTextOther	Neither carriage return nor line feed characters allowed	All Years	

### Description

Text area for manual documentation of information regarding the treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments (when the mechanism of action for a drug is unknown), and blinded clinical trials. If the mechanism of action for the experimental drug is known, code to the appropriate treatment field.

### Rationale

Text documentation is an essential component of a complete electronic report and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The text field must contain a description that has been entered by the reporter independently from the code(s). If software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record **and should not be generated electronically from coded values.**

### Instructions

- Prioritize entered information in the order of the fields listed below.
- Text automatically generated from coded data is not acceptable.
- NAACCR-approved abbreviations should be utilized ([see Appendix G](#)).
- Do not repeat information from other text fields.
- Additional comments can be continued in empty text fields, including Remarks. For text documentation that is continued from one text field to another, use asterisks or other symbols to indicate the connection with preceding text.
- If information is missing from the record, state that it is missing.
- Do not include irrelevant information.
- Do not include information that the registry is not authorized to collect.

*Note:* For software that allows unlimited text, NAACCR recommends that the software indicate to the reporter the portion of the text that will be transmitted to the central registry.

### Suggestions for text:

- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of other treatment, e.g., blinded clinical trial, hyperthermia
- Other treatment information, e.g., treatment cycle incomplete; unknown if other treatment was given

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Text--Other, cont.

### Data Item(s) to be verified/validated using the text entered in this field

After manual entry of the text field, ensure that the text entered both agrees with the coded values and clearly justifies the selected codes in the following fields:

Item name	Item number
Date Initial RX SEER	1260
Date 1 <sup>st</sup> Crs RX CoC	1270
RX Summ--Other	1420
RX Date Other	1250
RX Hosp--Other	730

## Neoadjuvant Therapy

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1632	1	neoadjuvantTherapy	0-3, 9	2021+	

### Description

This data item records whether the patient had neoadjuvant therapy prior to planned definitive surgical resection of the primary site.

### Rationale

This data item provides information related to the quality of care and describes whether a patient had neoadjuvant therapy.

For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine / hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy before intended or performed surgical resection to improve local therapy and long term outcomes.

### Codes

Code	Label
0	No neoadjuvant therapy, no treatment before surgery, surgical resection not part of first course of treatment plan; Autopsy only
1	Neoadjuvant therapy completed according to treatment plan and guidelines
2	Neoadjuvant therapy started, but not completed OR unknown if completed
3	Limited systemic exposure when the intent was not neoadjuvant; treatment did not meet the definition of neoadjuvant therapy
9	Unknown if neoadjuvant therapy performed; Death Certificate only (DCO)

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Neoadjuvant Therapy--Clinical Response

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1633	1	neoadjuvTherapyClinicalResponse	0-9	2021+	

### Description

This data item records the clinical outcomes of neoadjuvant therapy prior to planned surgical resection.

### Rationale

This data item provides information related to the quality of care and describes the clinical outcomes after neoadjuvant therapy. This data item provides prognostically relevant information by quantifying the extent of therapy-induced tumor regression. Therefore, this item can provide a better risk stratification for patients who received neoadjuvant therapy. In addition, this data item can contribute to assessments of cancer care quality.

This data item records the clinical outcomes of neoadjuvant therapy as determined by the managing physician (oncologic surgeon, radiation oncologist or medical oncologist).

For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine / hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy given to shrink a tumor before surgical resection.

### Codes

Code	Label
0	Neoadjuvant therapy not given
1	Complete clinical response (CR)(per managing/treating physician statement)
2	Partial clinical response (PR) (per managing/treating physician statement)
3	Progressive disease (PD)(per managing/treating physician statement)
4	Stable disease (SD)(per managing/treating physician statement)
5	No response (NR) (per managing/treating physician statement; Not stated as progressive disease (PD) or stable disease (SD)
6	Neoadjuvant therapy done, managing/treating physician interpretation not available, treatment response inferred from imaging, biomarkers, or yc stage
7	Complete clinical response based on pathology report (per pathologist assessment)
8	Neoadjuvant therapy done, response not documented or unknown
9	Unknown if neoadjuvant therapy performed; Death Certificate only (DCO)

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Neoadjuvant Therapy--Treatment Effect

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1634	1	neoadjuvTherapyTreatmentEffect	0-4, 6, 7, 9	2021+	

### Description

This data item records the pathologist's statement of neoadjuvant treatment effect on the primary tumor from the surgical pathology report. Whenever treatment effect definitions are recommended by or available in CAP Cancer Protocols, this data item follows the CAP definitions indicating absent or present effect. When specific CAP definitions are not available, registrars should use treatment effect general use categories.

### Rationale

This data item provides information related to the quality of care and describes the pathological outcomes after neoadjuvant therapy. This data item provides prognostically relevant information by quantifying the extent of therapy-induced tumor regression. Therefore, this item can provide a better risk stratification for patients who received neoadjuvant therapy. In addition, this data item can contribute to assessments of cancer care quality.

### Codes

Code	Label
0	Neoadjuvant therapy not given/no known presurgical therapy
1-4	Site-specific code; type of response
6	Neoadjuvant therapy completed and surgical resection performed, response not documented or unknown; Cannot be determined
7	Neoadjuvant therapy completed and planned surgical resection not performed
9	Unknown if neoadjuvant therapy performed Unknown if planned surgical procedure performed after completion of neoadjuvant therapy Death Certificate only (DCO)

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Palliative Care (Palliative Procedure)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3270	1	2237-2237	0-7, 9	All Years	01/04, 01/10

### Description

Identifies any care provided in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

### Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

[See Palliative Care in Section One for overview of coding principles.](#)

### Coding Instructions

- Record the type of palliative care provided.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded palliative care and as first course therapy if that procedure removes or modifies either primary or metastatic malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

Code	Label
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for painmanagement therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

## Examples

Code	Reason
0	No palliative care was given.
1	A patient undergoes palliative surgical removal of brain metastasis. [Surgery recorded in <i>Surgical Procedure/Other Site</i> [1294]
1	A patient with unresectable pancreatic carcinoma (no surgical procedure of the primary site is performed) receives bypass surgery to alleviate jaundice and pain.
2	A patient is diagnosed with Stage IV prostate cancer. His only symptoms are painful bony metastases in his right hip and lower spine. XRT is given to those areas. (Record all radiotherapy items also).
2	A patient with lung cancer with a primary tumor extending into the spine is treated with XRT to shrink tumor away from spine/nerves to provide pain relief. (Record all radiotherapy items also).
3	A patient is given palliative chemotherapy for Stage IIIB lung cancer. (Record all chemotherapy items also).
4	A 93-year old patient is diagnosed with multiple myeloma and enters a pain management clinic to treat symptoms. No other therapy is planned due to other medical problems.
5	A patient is diagnosed with widely disseminated small cell lung cancer. A palliative resection of a solitary brain metastasis is performed followed by XRT to the lower spine for painful bony metastasis. There is no known pain management. (Record all surgery and radiotherapy items also).
6	A patient diagnosed with colon cancer receives bypass surgery to alleviate symptoms and XRT to the liver for metastasis, and then enters a pain management clinic for treatment for unremitting abdominal pain. (Record all radiotherapy items also).
7	A patient enters the facility with a clinical diagnosis of unresectable carcinoma of the pancreas. A stent was inserted into the bile duct to relieve obstruction and improve the bile duct flow.

## Palliative Care at this Facility (Palliative Procedure at this Facility)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3280	1	811-811	0-7, 9	All Years	01/04, 01/10

### Description

Identifies care provided at this facility in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy (chemotherapy, hormone therapy, or other systemic drugs), and/or other pain management therapy.

### Rationale

This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

### Coding Instructions

- Record only the type of palliative care at this facility.
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable at this facility should be coded as palliative care and as first course therapy if that procedure removes or modifies either primary or secondary malignant tissue.
- Palliative care is not used to diagnose or stage the primary tumor.
- Do not code routine pain management following surgery or other treatment; do code first course pain management for persistent pain.

Code	Label
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery (which may involve a bypass procedure) to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
3	Chemotherapy, hormone therapy, or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made.
4	Patient received or was referred for pain management therapy with no other palliative care.
5	Any combination of codes 1, 2, and/or 3 without code 4.
6	Any combination of codes 1, 2, and/or 3 with code 4.
7	Palliative care was performed or referred, but no information on the type of procedure is available in the patient record. Palliative care was provided that does not fit the descriptions for codes 1–6.
9	It is unknown if palliative care was performed or referred; not stated in patient record.

## Outcomes

NH-48

## Date of First Recurrence

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1860	8	2867-2874	CCYMMDD	All Years	06/05, 01/10, 01/11, 01/12

### Description

Records the date of the first recurrence.

### Rationale

This data item is used to measure the efficacy of the first course of treatment.

### Coding Instructions

- Record the date the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of First Recurrence is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of First Recurrence transmits in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

## Recurrence Date--1st Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1861	2	recurrenceDate1stFlag	10-12, Blank	2010+	2010, 2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Recurrence* [1860].

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of First Recurrence* [1860] has a full or partial date recorded.
- Code 12 if the *Date of First Recurrence* cannot be determined, but the patient did have a recurrence following a disease-free period.
- Code 10 if it is unknown whether the patient had a recurrence.
- Code 11 if the patient was never disease free, became disease free but had no recurrence, or was initially diagnosed at autopsy.
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if the patient was ever disease-free or had a first recurrence)
11	No proper value is applicable in this context (that is, patient became disease-free after treatment and never had a recurrence; or patient was never disease-free; autopsy only case)
12	A proper value is applicable but not known (that is, there was a recurrence, but the date is unknown)
Blank	A valid date value is provided in item <i>Date of First Recurrence</i> [1860].

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.



## Type of First Recurrence

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1880	2	2877-2878	00, 04, 06, 10, 13-17, 20-22, 25-27, 30, 36, 40, 46, 51-59, 60, 62, 70, 88, 99	All Years	06/05, 01/10, 01/11, 01/13, 01/15, 01/18

### Description

Identifies the type of first recurrence after a period of documented disease-free intermission or remission.

### Rationale

This item is used to evaluate treatment efficacy and as a long-term prognostic factor.

### Coding Instructions

- Code the type of first recurrence. First recurrence may occur well after completion of the first course of treatment or after subsequent treatment.
- Check the *SEER Multiple Primary and Histology Coding Rules Manual* or the 2018 Solid Tumor Rules to determine which subsequent tumors should be coded as recurrences.
- If the patient has never been disease-free (code 70), continue to track for disease-free status which may occur after subsequent treatment has been completed.
- If the patient is disease-free (code 00), continue to track until a recurrence occurs. First recurrence may occur well after completion of the first course of treatment.
- Once a recurrence has been recorded (code 04-62 or 88), subsequent recurrences are NOT to be recorded.
- Codes 00 through 70 are hierarchical; record the highest-numbered applicable response, with the following limits. The first time a patient converts from disease status (70) to disease-free, change the code to 00. Then the first time a patient converts from 00 to a recurrence, then record the proper code for the recurrence. No further changes (other than corrections) should be made.
- If the tumor was originally diagnosed as in situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only. Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51–59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or “seeding”) within the distant location.
- Code lymphomas or leukemias that are in remission 00. If the patient relapses, then code recurrence as 59. If one of these is controlled by drugs (for example, Gleevec for CML), the patient is in remission.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor. If the recurrent primary is identified later, revise the codes appropriately.

Code	Label
00	Patient became disease-free after treatment and has not had a recurrence.
04	In situ recurrence of an invasive tumor.
06	In situ recurrence of an in situ tumor.

Code	Label
10	Local recurrence, and there is insufficient information available to code to 13–17. Local recurrence includes recurrence confined to the remnant of the organ of origin, to the organ of origin, to the anastomosis, or to scar tissue where the organ previously existed.
13	Local recurrence of an invasive tumor.
14	Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery.
15	Both local and trocar recurrence of an invasive tumor (both 13 and 14).
16	Local recurrence of an in situ tumor, NOS
17	Both local and trocar recurrence of an in situ tumor.
20	Regional recurrence, and there is insufficient information available to code to 21–27.
21	Recurrence of an invasive tumor in adjacent tissue or organ(s) only.
22	Recurrence of an invasive tumor in regional lymph nodes only.
25	Recurrence of an invasive tumor in adjacent tissue or organ(s) and in regional lymph nodes (both 21 and 22) at the same time.
26	Regional recurrence of an in situ tumor, NOS.
27	Recurrence of an in situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time.
30	Both regional recurrence of an invasive tumor in adjacent tissue or organs(s) and/or regional lymph nodes (20–25) and local and/or trocar recurrence (10, 13, 14, or 15).
36	Both regional recurrence of an in situ tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17).
40	Distant recurrence, to a site not listed in 46–62 or there is insufficient information available to code to 46–62.
46	Distant recurrence of an in situ tumor.
51	Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid.
52	Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura.
53	Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid.
54	Distant recurrence of an invasive tumor in the liver only.
55	Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site.
56	Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye.
57	Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site.
58	Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site.
59	Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease.

Code	Label
60	Distant recurrence of an invasive tumor in a single distant site (51–58) and local, trocar and/or regional recurrence (10–15, 20–25, or 30).
62	Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51–59).
70	Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated.
88	Disease has recurred, but the type of recurrence is unknown.
99	It is unknown whether the disease has recurred or if the patient was ever disease-free.

### Examples

Code	Reason
52	Distant recurrence in the lung.
62	Recurrence in liver, lung and bone

## Date of Last Cancer (tumor) Status

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1772	8	2788-2795	CCYMMDD, Blank	2018+	01/18

### Description

This data item documents the date of last cancer (tumor status) of the patient's malignant or non-malignant tumor. Record in CCYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later.

### Rationale

This information is used for patient follow-up and outcomes studies.

### Coding Instructions

- Record the last date on which the patient's cancer status (Cancer Status [1770]) was known to be updated.
- Cancer Status is based on information from the patient's physician or other official source such as a death certificate.
- The patient's Cancer Status should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other non-physician, then Cancer Status is not updated.
- Cancer Status changes if the patient has a recurrence or relapse.
- This data item differs from the Date of Last Contact or Death [1750] as it is a tumor-level data item. If a patient has multiple primaries, each primary could have a different Date of Last Cancer (tumor) Status [1772].

## Date of Last Cancer (Tumor) Status Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1773	2	dateOfLastCancerStatusFlag	12, Blank	2018+	

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Last Cancer (tumor) Status* [1772].

### Rationale

This information is used for patient follow-up and outcomes studies. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of Last Cancer (tumor) Status* [1772] has a full or partial date recorded.
- Code 12 if the *Date of Last Cancer (tumor) Status* [1772] cannot be determined
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, the <i>Date of Last Cancer (tumor) Status</i> is unknown)
Blank	A valid date value is provided in item <i>Date of Last Cancer (tumor) Status</i> [1772]

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary*, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.

## Cancer Status

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1770	1	2787-2787	1, 2, 9	All Years	01/04, 01/18

### Description

Records the presence or absence of clinical evidence of the patient's malignant or non-malignant tumor as of the *Date of Last Cancer (tumor) Status* [1772].

### Rationale

This information is used for patient follow-up and outcomes studies.

### Coding Instructions

- *Cancer Status* is based on information from the patient's physician or other official source such as a death certificate.
- The patient's *Cancer Status* should be changed **only** if new information is received from the patient's physician or other official source. If information is obtained from the patient, a family member, or other non-physician, then cancer status is not updated.
- *Cancer Status* changes if the patient has a recurrence or relapse.
- If a patient has multiple primaries, each primary could have a different cancer status.

Code	Label
1	No evidence of this tumor
2	Evidence of this tumor
9	Unknown, indeterminate whether this tumor is present; not stated in patient record

### Examples

Code	Reason
1	Patient with hematopoietic disease who is in remission.
1	A patient is seen by the physician on February 2, 2004 with no evidence of this tumor. The patient did not return to the physician. The patient was then called by the registry on August 29, 2005. The <i>Date of Last Contact or Death</i> [1750] is updated, but the cancer status is not.
2	A patient with prostate cancer is diagnosed with bone metastasis in April 2003. The registrar finds an obituary documenting the patient's death in a nursing home in June 2003.

## Date of Last Contact or Death

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1750	8	2775-2782	CCYYMMDD	All Years	06/05, 01/10, 01/11, 01/15

### Description

Records the date of last contact with the patient or the date of death.

### Rationale

This information is used for patient follow-up and outcomes studies.

### Coding Instructions

- Record the last date on which the patient was known to be alive or the date of death.
- Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same date of last contact.
- As of January 1, 2006, the CoC does not require *Class of Case 00* cases to be followed.
- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely accepted outside of the registry setting. However, this does not necessarily mean that the way dates are entered in any particular registry software product has changed. Software providers can provide the best information about data entry in their own systems. The traditional format for Date of Last Contact or Death is MMDDCCYY, with 99 identifying unknown month or day, and 99999999 representing an entirely unknown date. The interoperable form of Date of Last Contact or Death transmits in CCYYMMDD form, where blank spaces are used for unknown trailing portions of the date or where a date is not applicable.

## Date of Last Contact Flag

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1751	2	dateOfLastContactFlag	12, Blank	2010+	2010, 2021

### Description

This flag explains why there is no appropriate value in the corresponding date field, *Date of Last Contact or Death* [1750].

### Rationale

Before Version 12 (through 2009 diagnosis), date fields included codes that provided information other than dates. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

### Coding Instructions

- Leave this item blank if *Date of Last Contact or Death* [1750] has a full or partial date recorded.
- Code 12 if the *Date of Last Contact or Death* cannot be determined
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

### Codes

Code	Label
12	A proper value is applicable but not known. This event occurred, but the date is unknown (that is, the date of last contact is unknown).
Blank	A valid date value is provided in item <i>Date of Last Contact or Death</i> [1750].

*Comment:* This is part of the initiative of the transformation from the old NAACCR date standards to interoperable dates.

Source 1: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

Source 2: *Standards for Oncology Registry Entry* (v2018). Available at <https://www.facs.org/Quality-Programs/Cancer/NCDB/call-for-data/cocmanuals>.



## Vital Status

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1760	1	2785-2785	0, 1	All Years	01/15

### Description

Records the vital status of the patient as of the date entered in *Date of Last Contact or Death* [1750].

### Rationale

This information is used for patient follow-up and outcomes studies.

### Coding Instructions

- This item is collected during the follow-up process with *Date of Last Contact or Death* [1750].
- Note that failure to find a patient on a list of deceased individuals does not constitute evidence that the patient is alive. *Vital Status* is not changed, but neither is the *Date of Last Contact or Death* changed. Unless more information is located, follow up of this patient has failed.
- If a patient has multiple primaries, all records should have the same vital status.

Code	Label
0	Dead
1	Alive

### Examples

Code	Reason
0	Death clearance information obtained from a state central registry confirms the death of the patient within the past year.
1	In response to a follow-up letter to a patient's following physician, it is learned the patient is alive.

## Cause of Death

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1910	4	causeOfDeath	Valid ICD-7, ICD-8, ICD-9, and ICD-10 codes; also 0000, 7777, 7797	All Years	

### Description

Official cause of death as coded from the death certificate in valid ICD-7, ICD-8, ICD-9, and ICD-10 codes.

### Rationale

Cause of death is used for calculation of adjusted survival rates by the life table method. The adjustment corrects for deaths other than from the diagnosed cancer.

*Note:* This data item is no longer supported by CoC (as of January 1, 2003).

### Special codes in addition to ICD-7, ICD-8, ICD-9, and ICD-10

(Refer to [SEER Program Code Manual](#) for additional instructions.)

Code	Label
0000	Patient alive at last contact
7777	State death certificate not available
7797	State death certificate available but underlying cause of death is not coded

*Source:* Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Place of Death--State

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1942	2	placeOfDeathState	USPS or CanadaPost 2-character codes; CD, US, XX, YY, ZZ, Blank	2013+	

### Description

State or Province where the patient died and where certificate of death is filed. This data item became part of the NAACCR transmission record effective with Volume II, Version 13 in order to include country and state for each geographic item and to use interoperable codes. It supplements the item *Place of Death--Country* [1944]. It replaces the use of *Place of Death* [1940].

### Rationale

This field also helps carry out death clearance. When a reporting facility reports a place of death, the information can help in death certificate matching. It can also signal an out-of-state death for which the death certificate is to be requested.

### Codes

Code	Label
Blank	Not applicable, patient alive

See Appendix D for numeric and alphabetic lists of places and codes (also see Appendix B of the *SEER Program Code Manual* at [seer.cancer.gov/tools/codingmanuals/index.html](http://seer.cancer.gov/tools/codingmanuals/index.html)).

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Place of Death--Country

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1944	2	placeOfDeathCountry	USPS or CanadaPost 2-character codes; CD, US, XX, YY, ZZ, Blank	2013+	

### Description

Code for the country in which the patient died and where certificate of death is filed. If the patient has multiple tumors, all records should contain the same code. This data item became part of the NAACCR transmission record effective with Volume II, Version 13 in order to include country and state for each geographic item and to use interoperable codes. It supplements the item *Place of Death--State* [1942]. It replaces the use of *Place of Death* [1940].

### Rationale

Place of death is helpful for carrying out death clearance. When a reporting facility reports a place of death that is outside of the registry's country, the information can signal a death for which the death certificate will not be available from another state or through the NDI linkage.

### Codes

Use the International Standards Organization (ISO) 3166-1 Country Three Character Codes, whenever possible, augmented by custom codes. See [Appendix D](#) for complete list of country names and corresponding three character alpha codes.

Code	Label
ZZN	Not applicable, patient alive
ZZC	Central America NOS
ZZS	South America NOS
ZZP	Pacific NOS
ZZE	Europe NOS
ZZF	Africa NOS
ZZA	Asia NOS
ZZX	Non-US NOS
ZZU	Unknown

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Place of Death--Country, cont.

Code	Label
Custom codes for historic use only	
XNI	North American Islands
ZCB	Other Caribbean Islands
XEN	England, Channel Islands, Isle of Man
XSC	Scandinavia
XGR	Germanic Countries
XSL	Slavic Countries
CSK	Czechoslovakia (former)
YUG	Yugoslavia (former)
XUM	Ukraine and Moldova
XNF	North Africa
XSD	Sudanese Countries
XWF	West Africa
XSF	South Africa
XEF	East Africa
XIF	African Islands
XET	Ethiopia and Eritrea
XAP	Arabian Peninsula
XIS	Israel and Palestine
XCR	Caucasian Republics of former USSR
XOR	Other Asian Republics of former USSR
XSE	Southeast Asia
XMS	Malaysia, Singapore, Brunei
XCH	China, NOS
XML	Melanesian Islands
XMC	Micronesian Islands
XPL	Polynesian Islands
Blank	Not applicable, patient alive

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Follow-Up Source

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1790	1	2801-2801	0-5, 7-9	All Years	

### Description

Records the source from which the latest follow-up information was obtained.

### Rationale

This data item is used by registries to identify the most recent follow-up source.

### Coding Instructions

Code	Label	Definition
0	Reported hospitalization	Hospitalization at another institution/hospital or first admission to the reporting facility.
1	Readmission	Hospitalization or outpatient visit at the reporting facility.
2	Physician	Information from a physician.
3	Patient	Direct contact with the patient.
4	Department of Motor Vehicles	The Department of Motor Vehicles confirmed the patient has a current license.
5	Medicare/Medicaid file	The Medicare or Medicaid office confirmed the patient is alive.
7	Death certificate	Information from the death certificate only.
8	Other	Friends, relatives, employers, other registries, or any sources not covered by other codes.
9	Unknown; not stated in patient record	The follow-up source is unknown or not stated in patient record.

## Next Follow-Up Source (Next Follow-Up Method)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1800	1	2802-2802	0-5, 8, 9	All Years	01/10

### Description

Identifies the method planned for the next follow-up.

### Rationale

This data item is used by registries to identify the method planned for the next follow-up.

### Coding Instructions

- Registries in CoC-accredited cancer programs are not required to follow foreign residents.
- As of January 1, 2006, the CoC does not require Class of Case 00 cases to be followed.

Code	Label
0	Chart requisition
1	Physician letter
2	Contact letter
3	Phone call
4	Other hospital contact
5	Other, NOS
8	Foreign residents (not followed)
9	Not followed. Other cases for which follow-up is not required.

## Case Administration



## Abstracted By

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
570	3	756-758	Alphanumeric	1996+	

### Description

Records the initials or assigned code of the individual abstracting the case.

### Rationale

This item can be used for quality control and management in multistaffed registries.

### Coding Instructions **NH-49**

- Code the initials of the abstractor.

Code	Label
(fill spaces)	Initials or code of abstractor.

## Facility Identification Number (FIN)

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
540	10	715-724	10 digits	All Years	09/08, 01/12

### Description

Identifies the facility reporting the case.

### Rationale

Each facility's identification number (FIN) is unique. The number is essential to the National Cancer Database (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

### Coding Instructions

- Facility Identification Number is automatically coded by the software provider.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific FIN in their data for submission to the National Cancer Database.
- Facilities that merge are legally a single hospital. Consult NCDB for instructions for recording the FIN for newly-merged programs.

### Examples

Code	Reason
0006439999	6439999, General Hospital, Anytown, Illinois
0010000099	10000099, Anytown Medical Center, Anytown, Illinois

## NPI–Reporting Facility

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
545	10	704-714	10 digits, Blank	2008+	04/07, 09/08, 01/10, 01/12

### Description

Identifies the facility whose data are in the record.

### Rationale

Each facility's NPI is unique. The number is essential to the National Cancer Database (NCDB) for monitoring data submissions, ensuring the accuracy of data, and for identifying areas for special studies.

*NPI–Reporting Facility* is the NPI equivalent of *Facility Identification Number* [540]. Both are required during a period of transition.

### Coding Instructions

- NPI–Reporting Facility is automatically coded by the software provider.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- The facility's NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number in their data for submission to the National Cancer Database.
- Facilities that merge are legally a single hospital. Use the NPI number for the merged hospital.
- NPI may be blank for cases diagnosed on or before December 31, 2007.

### Examples

Code	Reason
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

## Archive FIN

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3100	10	735-744	10 digits	2003+	01/10, 01/12

### Description

Identifies the facility that originally abstracted the case.

### Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

### Coding Instructions

- Archive FIN is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- For facilities that have not merged, the Archive FIN and FIN [540] will be the same.
- If facilities merged after January 1, 2003, a new FIN was assigned to represent the merged facility. This new FIN was assigned to all cases in the merged registry, but the Archive FIN for cases from each registry prior to the merger does not change.
- If a merged program continues to operate multiple campuses, the Archive FIN is the historic FIN for the respective facilities that are now separate campuses of the same hospital.
- Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific FIN for the Archive FIN in their data for submission to the National Cancer Database.
- Programs that are not part of a merged facility or an INCP will use their hospital's FIN as the Archive FIN.
- For facilities with seven-digit FINs in the range of 6020009–6953290 that were assigned by the CoC before January 1, 2001, the coded FIN will consist of three leading zeros followed by the full seven-digit number. The Archive FIN must be recorded similarly.
- For facilities with eight-digit FINs greater than or equal to 10000000 that were assigned by the CoC after January 1, 2001, the coded FIN will consist of two leading zeros followed by the full eight-digit number. The Archive FIN must be recorded similarly.

## Examples

Code	Reason
0006439999	General Hospital, Anytown, Illinois (FIN: 6439999). Original diagnosis was made at this facility; both the FIN and the Archive FIN are the same.
0006439999 or 0006430000	<p>General Hospital (FIN: 6439999) and Anytown Medical Center (FIN: 6430000) in Anytown IL merged; the two cancer registries were combined and now report as Anytown Medical Center. The new FIN for this reporting facility is 10000099.</p> <p>All cases from the merged General Hospital and Anytown Medical Center registry have the new FIN (0010000099) assigned to them. In addition, either the General Hospital Archive FIN (0006439999) or the Anytown Medical Center Archive FIN (0006430000) is retained in each record depending on which registry originally accessioned the case.</p>

## NPI–Archive FIN

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
3105	10	725-734	10 digits, Blank	2008+	01/10, 01/12

### Description

Identifies the facility that originally abstracted the case.

### Rationale

It is essential for hospital registries to have the ability to distinguish cases originally accessioned by each registry of the merged unit. This enables the CoC to manage the receipt of historical data and to appropriately attribute these data.

*NPI–Archive FIN* is the NPI equivalent of *Archive FIN* [3100]. Both are required during a period of transition.

### Coding Instructions

- NPI–Archive FIN is automatically coded by the software provider.
- This data item never changes and must be included as part of the patient record when data are submitted to the NCDB.
- The facility’s NPI can be obtained from the billing or accounting department, or searched at <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>.
- For facilities that have not merged, the NPI–Archive FIN and the NPI–Reporting Facility [545] will be the same. Facilities that are part of an Integrated Network Cancer Program (INCP) must use the hospital-specific NPI number for the NPI–Archive FIN in their data for submission to the National Cancer Database.
- If the facility has more than one NPI number assigned, use the “umbrella” number that applies to the entire facility.
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- NPI may be blank for cases diagnosed on or before December 31, 2007.

### Examples

Code	Reason
(fill spaces)	10-digit NPI number for the facility.
(leave blank)	NPI for the facility is unknown or not available.

## Date Case Completed – CoC

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2092	8	2656-2663	CCYYMMDD	≥2010	01/12

### Description

This data item identifies the date that specified items are completed, based on the *Class of Case*, and those items pass the relevant edits. Follow-up information, including delayed treatment received elsewhere, may be coded after the *Date Case Completed–CoC*. This item should be autocoded by the registry software. The CoC specifications will not necessarily be the same as those used for *Date Case Completed* [NAACCR Item #2090], which CoC does not require.

NH-50

### Rationale

This item was created to measure abstracting timeliness of information that should be available when the facility's main involvement in the patient's first course care is completed, based on *Class of Case*. This may also be used as part of CoC Standard 6.1 Cancer Registry Quality Control for timeliness determined by the program.

### Coding Instructions

- This item may be left blank for cases diagnosed prior to 2010.
- Follow-up information, information about delayed treatment received elsewhere, and information about multiple tumors diagnosed later may be coded after the *Date Case Completed – CoC*.
- Corrections and updates may be made after the *Date Case Completed – CoC*.
- Information can be found on the [NCDB Call for Data](#) Webpage under Layouts, NAACCR 18.0 & 21.0 Record Layout and Items to Be Submitted.
- After all required items identified below for the patient's *Class of Case* have been abstracted, the registrar should run the current NAACCR edit set "Hosp: CoC Required - All" using the registry software. The registry software will record the *Date Case Completed – CoC* when those items are abstracted and the case passes all edits in that set.

Class of Case	Description	Items that Must Be Completed by Date Case Completed - CoC
00-22	All analytic cases	Identification, demographic, diagnostic
10-22	Patient received part or all first course treatment from facility	Staging, hospital-specific treatment

<b>Class of Case</b>	<b>Description</b>	<b>Items that Must Be Completed by Date Case Completed - CoC</b>
10, 12, 14, 20, 22	Patient received all first course treatment from facility, or unspecified whether all or part	Summary treatment (treatment at any facility)
00	Patient diagnosed at facility, received all treatment elsewhere	NPI number for the facility the patient was referred to or a treating physician
20-22	Patient diagnosed elsewhere, received part or all of treatment from facility	NPI number for the facility the patient was referred to or from OR the physician who diagnosed or treated the patient



## Override Site/TNM-Stage Group

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1989	1	2578-2578	1, Blank	All Years	09/04, 09/08, 01/10, 01/12

### Description

Used with the EDITS software to override the edits of the type *Primary Site, AJCC Stage Group*, for AJCC staging editions 6 and later.

### Rationale

This override flag allows identification of pediatric cancers that were staged according to a system other than the **AJCC** staging manual (which is predominantly directed toward adult staging) if they are not also **AJCC**-staged. In that situation an otherwise-stageable case may be coded 88 (not applicable) for all **AJCC** items.

### EDITS Use

Edits of the type, *Primary Site, AJCC Stage Group*, check that the pathological and clinical AJCC stage group codes are valid for the site and histology group according to the applicable *AJCC Cancer Staging Manual*, using the codes described for the items *Clinical Stage Group* [970] and *Pathological Stage Group* [910]. Combinations of site and histology not represented in any AJCC schema must be coded 88. Unknown codes must be coded 99. Blanks are not permitted.

Since pediatric cancers whose sites and histologies have an AJCC scheme may be coded according to a pediatric scheme instead, use *Override Site/TNM-Stage Group* to indicate the case was coded according to a pediatric staging system if it was not also coded according to the AJCC manual. Pediatric stage groups should *not* be recorded in the *Clinical Stage Group* or *Pathological Stage Group* items. When neither clinical nor pathological AJCC staging is used for pediatric cases, code all AJCC items 88. When any AJCC component is used to stage a pediatric case, follow the instructions for coding AJCC items and leave *Override Site/TNM-Stage Group* blank.

[See EDITS Overrides in Section One for overview of coding principles.](#)

### Coding Instructions

- Leave blank if the EDITS program does not generate an error message for the edits of the type, Primary Site, AJCC Stage Group.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if the case is confirmed to be a pediatric case that was coded using a pediatric coding system.

Code	Label
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed and confirmed as reported.

## Over-ride Age/Site/Morph

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
1990	1	overRideAgeSiteMorph	1-3 or blank		2007, 2008, 2010, 2021

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Age, Primary Site, Morphology ICDO2 (SEER IF15)
- Age, Primary Site, Morphology ICDO3 (SEER IF15)
- Age, Primary Site, Morph ICDO3--Adult (SEER)
- Age, Primary Site, Morph ICDO3--Pediatric (NPCR)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Some cancers occur almost exclusively in certain age groups.

Edits of the type Age, Primary Site, Morphology require review if a site/morphology combination occurs in an age group for which it is extremely rare. The edit Age, Primary Site, Morph ICDO3--Adult (SEER) edits cases with an Age at Diagnosis of 15 and older. The edit Age, Primary Site, Morph ICDO3--Pediatric (NPCR) edits cases with an Age at Diagnosis of less than 15. The edits Age, Primary Site, Morphology ICDO2 (SEER IF15) and Age, Primary Site, Morphology ICDO3 (SEER IF15) contain logic for all ages.

### Coding Instructions

- Leave blank if the program does not generate an error message (and if the case was not diagnosed in utero) for the edits of the type Age, Primary Site, Morphology.
- Correct any errors for the case if an item is discovered to be incorrect.
- Code 1 or 3 as indicated if review of items in the error or warning message confirms that all are correct.

### Codes

Code	Label
1	Reviewed and confirmed that age/site/histology combination is correct as reported
2	Reviewed and confirmed that case was diagnosed in utero
3	Reviewed and confirmed that conditions 1 and 2 both apply
Blank	Not reviewed or reviewed and corrected.

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Over-ride Surg/DXConf

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2020	1	overRideSurgDxconf	1 or blank		2006, 2008

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- RX Summ--Surg Prim Site, Diag Conf (SEER IF76)
- RX Summ--Surg Site 98-02, Diag Conf (SEER IF106)
- RX Summ--Surgery Type, Diag Conf (SEER IF46)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Edits of the type RX Summ--Surg Prim Site, Diag Conf check that cases with a primary site surgical procedure coded 20-90 are histologically confirmed. If the patient had a surgical procedure, most likely there was a microscopic examination of the cancer. Verify the surgery and diagnostic confirmation codes, and correct any errors. Sometimes there are valid reasons why no microscopic confirmation is achieved with the surgery; for example, the tissue removed may be inadequate for evaluation.

### Coding Instructions

- Leave blank if the program does not generate an error message for edits of the type, RX Summ--Surg Prim Site, Diag Conf.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review confirms that they are correct. The patient had surgery, but the tissue removed was not sufficient for microscopic confirmation.

### Codes

Code	Label
Blank	Not reviewed or reviewed and corrected.
1	Reviewed and confirmed as reported

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Override Site/Type

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
2030	1	2586-2586	1, Blank	All Years	09/06, 09/08, 01/10

### Description

Used with the EDITS software to override edits of the type *Primary Site, Morphology-Type and Primary Site, Morphology-Type, Behavior ICDO3*.

### Rationale

Some edits in the EDITS software package check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the override flag is used to skip the edit on future runs of the EDITS package.

### EDITS Use

There are multiple versions of edits of the type, *Primary Site, Morphology-Type*, which check for “usual” combinations of site and ICD-O-2 or ICD-O-3 histology. The SEER version of the edit is more restrictive than the CoC edit, and thus uses a different override flag. The CoC version of the edit will accept *Override CoC-Site/Type* or *Override Site/Type* as equivalent.

- The Site/Histology Validation List (available on the SEER website) contains those histologies commonly found in the specified primary site. Histologies that occur only rarely or never are not included. These edits require review of all combinations not listed.
- Since basal and squamous cell carcinomas of non-genital skin sites are not reportable to SEER, these site/histology combinations do not appear on the SEER validation list. For the CoC version of the edit, if Primary Site [400] is in the range C440-C449 (skin), and the ICD-O-3 histology is in the range 8000-8005 (neoplasms, malignant, NOS), 8010-8046 (epithelial carcinomas), 8050-8084 (papillary and squamous cell carcinomas), or 8090-8110 (basal cell carcinomas), no further editing is done. No override is necessary for these cases in the CoC version of the edit.

Review of these cases requires investigating whether the combination is biologically implausible or there are cancer registry coding conventions that would dictate different codes for the diagnosis (See *Cancer Identification* in Section I). Review of these rare combinations often results in changes to the primary site and/or morphology, rather than a decision that the combination is correct.

### Coding Instructions

- Leave blank if the EDITS program does not generate an error message for edits of the type Primary Site, Morphology-Type.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of all items in the error or warning message confirms that all are correct.

Code	Label
(leave blank)	Not reviewed; or reviewed and corrected.
1	Reviewed, confirmed as reported.

## Over-ride Histology

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2040	1	overRideHistology	1-3 or blank		2007, 2008

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Diagnostic Confirmation, Behavior ICDO2 (SEER IF31)
- Diagnostic Confirmation, Behavior ICDO3 (SEER IF31)
- Morph (1973-91) ICD-O-1 (SEER MORPH)
- Morphology--Type/Behavior ICDO2 (SEER MORPH)
- Morphology--Type/Behavior ICDO3 (SEER MORPH)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Edits of the type Diagnostic Confirmation, Behavior differ in the use of ICD-O-2 or ICD-O-3 and check that, for *in situ* cases (Behavior = 2), Diagnostic Confirmation specifies microscopic confirmation (1, 2, or 4).

The distinction between *in situ* and invasive is very important to a registry, since prognosis is so different. Since the determination that a neoplasm has not invaded surrounding tissues, i.e., *in situ*, is made microscopically, cases coded *in situ* in behavior should have a microscopic confirmation code. However, very rarely, a physician will designate a case noninvasive or *in situ* without microscopic evidence.

If an edit of the type, Diagnostic Confirmation, Behavior, gives an error message or warning, check that Behavior and Diagnostic Confirmation have been coded correctly. Check carefully for any cytologic or histologic evidence that may have been missed in coding.

Edits of the type, Morphology--Type/Behavior, perform the following check:

1. Codes listed in ICD-O-2 or ICD-O-3 with behavior codes of only 0 or 1 are considered valid, since the behavior matrix of ICD-O-2 and ICD-O-3 allows for the elevation of the behavior of such histologies when the tumor is *in situ* or malignant. This edit forces review of these rare cases to verify that they are indeed *in situ* or malignant.
2. The following histologies are generally not accepted as *in situ*: ICD-O-2 histologies 8000-8004, 8020, 8021, 8331, 8332, 8800-9054, 9062, 9082, 9083, 9110-9491, 9501-9989, ICD-O-3 histologies 8000-8005, 8020, 8021, 8331, 8332, 8800-9055, 9062, 9082, 9083, 9110-9493, 9501-9989. This edit forces review of these cases.

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

3. If a Morphology-Type/Behavior edit produces an error or warning message and the case is one in which the 4-digit morphology code is one that appears in ICD-O-2 or ICD-O-3 only with behavior codes of 0 or 1, or the case is one in which the 4-digit morphology code is not generally accepted with a behavior code of 2, verify the coding of morphology and that the behavior should be coded malignant or *in situ*. The registrar may need to consult a pathologist or medical advisor in problem cases.

Exceptions:

If year of Date of Diagnosis > 2000, then a behavior code of 1 is valid for the following ICD-O-2 histologies and no over-ride flag is needed: 8931, 9393, 9538, 9950, 9960-9962, 9980-9984, and 9989. Similarly, the following ICD-O-3 histologies are valid with a behavior code of 1: 8442, 8451, 8462, 8472, and 8473. If year of Date of Diagnosis > 2003, the following ICD-O-3 benign histologies will pass without review: 8146, 8271, 8861, 8897, 9121, 9122, 9131, 9161, 9350, 9351, 9352, 9360, 9361, 9383, 9384, 9394, 9412, 9413, 9444, 9492, 9493, 9506, 9531, 9532, 9533, 9534, 9537, 9541, 9550, 9562, and 9570.

4. Grade 5-8 with histologies not in the range of 9590-9948 is impossible.
5. Some terms in ICD-O-2 and ICD-O-3 carry an implied statement of grade. These histologies must be reported with the correct grade as stated below. An error of this type cannot be over-ridden.

**ICD-O-2**

8020/34 Carcinoma, undifferentiated  
 8021/34 Carcinoma, anaplastic  
 8331/31 Follicular adenocarcinoma, well differentiated  
 8851/31 Liposarcoma, well differentiated  
 9062/34 Seminoma, anaplastic  
 9082/34 Malignant teratoma, undifferentiated  
 9083/32 Malignant teratoma, intermediate type  
 9401/34 Astrocytoma, anaplastic  
 9451/34 Oligodendroglioma, anaplastic  
 9511/31 Retinoblastoma, differentiated  
 9512/34 Retinoblastoma, undifferentiated

**ICD-O-3**

8020/34 Carcinoma, undifferentiated  
 8021/34 Carcinoma, anaplastic  
 8331/31 Follicular adenocarcinoma, well differentiated  
 9082/34 Malignant teratoma, undifferentiated  
 9083/32 Malignant teratoma, intermediate type  
 9401/34 Astrocytoma, anaplastic  
 9451/34 Oligodendroglioma, anaplastic  
 9511/31 Retinoblastoma, differentiated  
 9512/34 Retinoblastoma, undifferentiated

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Coding Instructions

- Leave blank if the program does not generate an error message for edits of the types, Diagnostic Confirmation, Behav Code or Morphology--Type/Behavior.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1, 2, or 3 as indicated if review of all items in the error or warning message confirms that all are correct.

## Codes

Code	Label
1	Reviewed and confirmed that the pathologist states the primary to be " <i>in situ</i> " or "malignant" although the behavior code of the histology is designated as "benign" or "uncertain" in ICD-O-2 or ICD-O-3
2	Reviewed and confirmed that the behavior code is " <i>in situ</i> ," but the case is not microscopically confirmed
3	Reviewed and confirmed that conditions 1 and 2 both apply
Blank	Not reviewed or reviewed and corrected

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Over-ride Leuk, Lymphoma

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2070	1	overRideLeukLymphoma	1 or blank		2006, 2008, 2010, 2021

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Diagnostic Confirmation, Histology ICDO2 (SEER IF48)

Diagnostic Confirmation, Histology ICDO3 (SEER IF48)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Edits of the type Diagnostic Confirmation, Histology differ in use of ICD-O-2 or ICD-O-3 and check the following:

1. Since lymphoma and leukemia are almost exclusively microscopic diagnoses, this edit forces review of any cases of lymphoma that have diagnostic confirmation of direct visualization or clinical, and any leukemia with a diagnostic confirmation of direct visualization.
2. If histology = 9590-9717 for ICD-O-2 or 9590-9729 for ICD-O-3 (lymphoma) then Diagnostic Confirmation cannot be 6 (direct visualization) or 8 (clinical).
3. If histology = 9720-9941 for ICD-O-2 or 9731-9948 for ICD-O-3 (leukemia and other) then Diagnostic Confirmation cannot be 6 (direct visualization).

### Coding Instructions

- Leave blank if the program does not generate an error message for edits of the type Diagnostic Confirmation, Histology.
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- If the edit produces an error or warning message, verify that the ICD-O-2 or ICD-O-3 histology and diagnostic confirmation are correctly coded. Remember that positive hematologic findings and bone marrow specimens are included as histologic confirmation (code 1 in Diagnostic Confirmation) for leukemia. Code 1 indicates that a review has taken place and histologic type and diagnostic confirmation are correctly coded.

### Codes

Code	Label
Blank	Not reviewed or reviewed and corrected.
1	Reviewed and confirmed as reported

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.



## Over-ride Site/Behavior

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2071	1	overRideSiteBehavior	1 or blank	1997+	2006, 2008

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

- Primary Site, Behavior Code ICDO2 (SEER IF39)
- Primary Site, Behavior Code ICDO3 (SEER IF39)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Edits of the type, Primary Site, Behavior Code, require review of the following primary sites with a behavior of *in situ* (ICD-O-2 or ICD-O-3 behavior = 2):

- C269            Gastrointestinal tract, NOS
- C399            Ill-defined sites within respiratory system
- C559            Uterus, NOS
- C579            Female genital tract, NOS
- C639            Male genital organs, NOS
- C689            Urinary system, NOS
- C729            Nervous system, NOS
- C759            Endocrine gland, NOS
- C760-C768      Ill-defined sites
- C809            Unknown primary site

Since the designation of *in situ* is very specific and almost always requires microscopic confirmation, ordinarily specific information should also be available regarding the primary site. Conversely, if inadequate information is available to determine a specific primary site, it is unlikely that information about a cancer being *in situ* is reliable.

If an *in situ* diagnosis is stated, try to obtain a more specific primary site. A primary site within an organ system can sometimes be identified based on the diagnostic procedure or treatment given or on the histologic type. If no more specific site can be determined, it is usually preferable to code a behavior code of 3. In the exceedingly rare situation in which it is certain that the behavior is *in situ* and no more specific site code is applicable, set Over-ride Site/Behavior to 1.

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Over-ride Site/Behavior, cont.

### Coding Instructions

- Leave blank if the program does not generate an error message for the edit Primary Site, Behavior Code ICDO2 (SEER IF39) and/or the edit Primary Site, Behavior Code ICDO3 (SEER IF39).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of site and behavior verifies that the patient has an *in situ* cancer of a nonspecific site and no further information about the primary site is available.

### Codes

Code	Label
Blank	Not reviewed or reviewed and corrected
1	Reviewed and confirmed as reported

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## Over-ride Site/Lat/Morph

Item #	Length	XML NAACCR ID	Allowable Values	Required Status	Date Revised
2074	1	overrideSiteLatMorph	1 or blank		2006, 2008, 2021

### Description

Some computer edits identify errors. Others indicate possible errors that require manual review for resolution. To eliminate the need to review the same cases repeatedly, over-ride flags have been developed to indicate that data in a record (or records) have been reviewed and, while unusual, are correct.

This over-ride is used with the following edits in the NAACCR Metafile of the EDITS software:

Laterality, Primary Site, Morph ICDO2 (SEER IF42)

Laterality, Primary Site, Morph ICDO3 (SEER IF42)

### Rationale

Some edits check for code combinations that are possible, but quite rare. If the code combination generates an error message and review of the case indicates that the codes are correct for the case, then the over-ride flag is used to skip the edit in the future. See Chapter IV, Recommended Data Edits and Software Coordination of Standards.

### Over-ride Flag as Used in the EDITS Software Package

Edits of the type Laterality, Primary Site, Morph differ in use of ICD-O-2 or ICD-O-3 morphology and do the following:

1. If the Primary Site is a paired organ and ICD-O-2 or ICD-O-3 behavior is *in situ* (2), then laterality must be 1, 2, or 3.
2. If diagnosis year less than 1988 and ICD-O-2 or ICD-O-3 histology = 9590, no further editing is performed.
3. If diagnosis year greater than 1987 and ICD-O-2 or ICD-O-3 histology = 9140, 9700, 9701, 9590-9980, no further editing is performed.

The intent of this edit is to force review of *in situ* cases for which laterality is coded 4 (bilateral) or 9 (unknown laterality) as to origin. In rare instances when the tumor is truly midline (9) or the rare combination is otherwise confirmed correct, enter a code 1 for Override Site/Lat/Morph.

### Coding Instructions

- Leave blank if the program does not generate an error message for the edit Laterality, Primary site, Morph ICDO2 (SEER IF 42) and/or the edit Laterality, Primary site, Morph ICDO3 (SEER IF42).
- Leave blank and correct any errors for the case if an item is discovered to be incorrect.
- Code 1 if review of site, laterality and morphology verifies that the case had behavior code of “*in situ*” and laterality is not stated as “right: origin of primary;” “left: origin of primary;” or “only one side involved, right or left origin not specified”.

### Codes

Code	Label
Blank	Not reviewed or reviewed and corrected
1	Reviewed and confirmed as reported

Source: Thornton ML, (ed). [Standards for Cancer Registries Volume II: Data Standards and Data Dictionary](#), Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022.

## TNM Edition Number

Item #	Length	Column #	Allowable Values	Required Status	Date Revised
1060	1	1046-1047	00–08, 88, 99	1996+	01/04, 01/10, 01/18

### Description

Identifies the edition of the *AJCC Cancer Staging Manual* used to stage the case.

### Rationale

AJCC stage and component T, N, and M codes and rules have changed over time. This item enables the analysis of cases grouped by edition number.

### Coding Instructions

- This item is autocoded by the software provider.

Code	Label
00	Not staged (cases that have an AJCC staging scheme and staging was not done).
01	First Edition
02	Second Edition
03	Third Edition
04	Fourth Edition
05	Fifth Edition
06	Sixth Edition
07	Seventh Edition
08	Eighth Edition
09	Ninth Edition
88	Not applicable (cases that do not have an AJCC staging scheme)
99	Staged, but the edition is unknown

## APPENDIX A: Site-Specific Surgery Codes

**Note: The histologies specified in this section apply only to cases diagnosed in 2010 or later. Please consult *FORDS: Revised for 2009* for applicable histologies for cases diagnosed prior to that date.**

## ORAL CAVITY

**Lip C00.0–C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0–C02.9,  
Gum C03.0–C03.9, Floor of Mouth C04.0–C04.9, Palate C05.0–C05.9,  
Other Parts of Mouth C06.0–C06.9**

### Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

### No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision
- 30 Wide excision, NOS
 

**Code 30 includes:**

  - Hemiglossectomy
  - Partial glossectomy
- 40 Radical excision of tumor, NOS
  - 41 Radical excision of tumor ONLY
  - 42 Combination of 41 WITH resection in continuity with mandible (marginal, segmental, hemi-, or total resection)
  - 43 Combination of 41 WITH resection in continuity with maxilla (partial, subtotal, or total resection)

**Codes 40–43 include:**

  - Total glossectomy
  - Radical glossectomy

### Specimen sent to pathology from surgical events 20–43.

- 90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 12/4/02, 01/10, 02/10, 01/16, 02/21,  
01/22)

## PAROTID AND OTHER UNSPECIFIED GLANDS

### Parotid Gland C07.9, Major Salivary Glands C08.0–C08.9

#### Codes

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

#### No specimen sent to pathology from surgical events 10–14.

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
  - Any combination of 20 or 26–27 WITH
    - 21 Photodynamic therapy (PDT)
    - 22 Electrocautery
    - 23 Cryosurgery
    - 24 Laser ablation
  - 25 Laser excision
  
- 30 Less than total parotidectomy, NOS; less than total removal of major salivary gland, NOS
  - 31 Facial nerve spared
  - 32 Facial nerve sacrificed
  - 33 Superficial lobe ONLY
    - 34 Facial nerve spared
    - 35 Facial nerve sacrificed
  - 36 Deep lobe (Total)
    - 37 Facial nerve spared
    - 38 Facial nerve sacrificed
  
- 40 Total parotidectomy, NOS; total removal of major salivary gland, NOS
  - 41 Facial nerve spared
  - 42 Facial nerve sacrificed
  
- 50 Radical parotidectomy, NOS; radical removal of major salivary gland, NOS
  - 51 WITHOUT removal of temporal bone
  - 52 WITH removal of temporal bone
  - 53 WITH removal of overlying skin (requires graft or flap coverage)



80 Parotidectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**PHARYNX****Tonsil C09.0–C09.9, Oropharynx C10.0–C10.9, Nasopharynx C11.0–C11.9****Pyramiform Sinus C12.9, Hypopharynx C13.0–C13.9, Pharynx C14.0****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Stripping

**No specimen sent to pathology from surgical events 10–15.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision
- 28 Stripping
- 30 Pharyngectomy, NOS
  - 31 Limited/partial pharyngectomy; tonsillectomy, bilateral tonsillectomy
  - 32 Total pharyngectomy
- 40 Pharyngectomy WITH laryngectomy OR removal of contiguous bone tissue, NOS (does NOT include total mandibular resection)
  - 41 WITH Laryngectomy (laryngopharyngectomy)
  - 42 WITH bone
  - 43 WITH both 41 and 42
- 50 Radical pharyngectomy (includes total mandibular resection), NOS
  - 51 WITHOUT laryngectomy
  - 52 WITH laryngectomy

**Specimen sent to pathology from surgical events 20–52.**

- 90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**ESOPHAGUS****C15.0–C15.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

**No specimen sent to pathology from surgical events 10–14.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
  - Any combination of 20 or 26–27 WITH
    - 21 Photodynamic therapy (PDT)
    - 22 Electrocautery
    - 23 Cryosurgery
    - 24 Laser ablation
  - 25 Laser excision
  
- 30 Partial esophagectomy
  
- 40 Total esophagectomy, NOS
  
- 50 Esophagectomy, NOS WITH laryngectomy and/or gastrectomy, NOS
  - 51 WITH laryngectomy
  - 52 WITH gastrectomy, NOS
  - 53 Partial gastrectomy
  - 54 Total gastrectomy
  - 55 Combination of 51 WITH any of 52–54
  
- 80 Esophagectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

- 90 Surgery, NOS
  
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**STOMACH****C16.0–C16.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

**No specimen sent to pathology from surgical events 10–14.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision
- 30 Gastrectomy, NOS (partial, subtotal, hemi-)
  - 31 Antrectomy, lower (distal-less than 40% of stomach)\*\*\*
  - 32 Lower (distal) gastrectomy (partial, subtotal, hemi-)
  - 33 Upper (proximal) gastrectomy (partial, subtotal, hemi-)

**Code 30 includes:**

- Partial gastrectomy, including a sleeve resection of the stomach
- Billroth I: anastomosis to duodenum (duodenostomy)
- Billroth II: anastomosis to jejunum (jejunostomy)

- 40 Near-total or total gastrectomy, NOS
    - 41 Near-total gastrectomy
    - 42 Total gastrectomy
- A total gastrectomy may follow a previous partial resection of the stomach.**

- 50 Gastrectomy, NOS WITH removal of a portion of esophagus
    - 51 Partial or subtotal gastrectomy
    - 52 Near total or total gastrectomy
- Codes 50–52 are used for gastrectomy resection when only portions of esophagus are included in procedure.**

- 60 Gastrectomy with a resection in continuity with the resection of other organs, NOS\*\*\*
- 61 Partial or subtotal gastrectomy, in continuity with the resection of other organs\*\*\*
- 62 Near total or total gastrectomy, in continuity with the resection of other organs\*\*\*
- 63 Radical gastrectomy, in continuity with the resection of other organs\*\*\*

**Codes 60–63 are used for gastrectomy resections with organs other than esophagus. Portions of esophagus may or may not be included in the resection.**

- 80 Gastrectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

---

\*\*\* Incidental splenectomy NOT included

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**COLON****C18.0–C18.9**

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

**No specimen sent to pathology from surgical events 10–12.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy, NOS
  - 27 Excisional biopsy
  - 28 Polypectomy-endoscopic
  - 29 Polypectomy-surgical excision
  - Any combination of 20 or 26–29 WITH
    - 22 Electrocautery
- 30 Partial colectomy, segmental resection
  - 32 Plus resection of contiguous organ; example: small bowel, bladder
- 40 Subtotal colectomy/hemicolectomy (total right or left colon and a portion of transverse colon)
  - 41 Plus resection of contiguous organ; example: small bowel, bladder
- 50 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)
  - 51 Plus resection of contiguous organ; example: small bowel, bladder
- 60 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)
  - 61 Plus resection of contiguous organ; example: small bowel, bladder
- 70 Colectomy or coloproctectomy with resection of contiguous organ(s), NOS (where there is not enough information to code 32, 41, 51, or 61)
 

**Code 70 includes:** Any colectomy (partial, hemicolectomy, or total) WITH a resection of any other organs in continuity with the primary site. Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.
- 80 Colectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)



**RECTOSIGMOID****C19.9**

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

**No specimen sent to pathology from surgical events 10–12.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
 Combination of 20 or 26–27 WITH
  - 22 Electrocautery
- 30 Segmental resection; partial proctosigmoidectomy, NOS
  - 31 Plus resection of contiguous organs; example: small bowel, bladder

**Procedures coded 30 include, but are not limited to:**

- Anterior resection
- Hartmann's operation
- Low anterior resection (LAR)
- Partial colectomy, NOS
- Rectosigmoidectomy, NOS
- Sigmoidectomy

- 40 Pull through WITH sphincter preservation (colo-anal anastomosis)
- 50 Total proctectomy
- 51 Total colectomy
- 55 Total colectomy WITH ileostomy, NOS
  - 56 Ileorectal reconstruction
  - 57 Total colectomy WITH other pouch; example: Koch pouch
- 60 Total proctocolectomy, NOS
  - 65 Total proctocolectomy WITH ileostomy, NOS
  - 66 Total proctocolectomy WITH ileostomy and pouch

**Removal of the colon from cecum to the rectosigmoid or a portion of the rectum.**

- 70 Colectomy or proctocolectomy resection in continuity with other organs; pelvic exenteration
- 80 Colectomy, NOS; Proctectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**RECTUM****C20.9**

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site* (NAACCR Item #1294).

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

**No specimen sent to pathology from surgical events 10-12**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
- Any combination of 20 or 26–27 WITH
  - 22 Electrocautery
  - 28 Curette and fulguration

- 30 Segmental resection; partial proctectomy, NOS

**Procedures coded 30 include, but are not limited to:**

- Anterior resection
- Hartmann's operation
- Low anterior resection (LAR)
- Transsacral rectosigmoidectomy

- 40 Pull through WITH sphincter preservation (coloanal anastomosis)

- 50 Total proctectomy

**Procedure coded 50 includes, but is not limited to:**

- Abdominoperineal resection

- 60 Total proctocolectomy, NOS

- 70 Proctectomy or proctocolectomy with resection in continuity with other organs; pelvic exenteration

- 80 Proctectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 05/10, 01/16, 02/21, 01/22)

**ANUS****C21.0–C21.8****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
- 15 Thermal Ablation

**No specimen sent to pathology from surgical events 10, 12 and 15.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
- Any combination of 20 or 26–27 WITH
  - 22 Electrocautery
  
- 60 Abdominal perineal resection, NOS (APR)
  - 61 APR and sentinel node excision
  - 62 APR and unilateral inguinal lymph node dissection
  - 63 APR and bilateral inguinal lymph node dissection

**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**

**Specimen sent to pathology from surgical events 20–63.**

- 90 Surgery, NOS
  
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**LIVER AND INTRAHEPATIC BILE DUCTS****C22.0–C22.1****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Alcohol (Percutaneous Ethanol Injection-PEI)
  - 16 Heat-Radio-frequency ablation (RFA)
  - 17 Other (ultrasound, acetic acid)

**No specimen sent to pathology from surgical events 10–17.**

- 20 Wedge or segmental resection, NOS
  - 21 Wedge resection
  - 22 Segmental resection, NOS
    - 23 One
    - 24 Two
    - 25 Three
  - 26 Segmental resection AND local tumor destruction
  
- 30 Lobectomy, NOS
  - 36 Right lobectomy
  - 37 Left lobectomy
  - 38 Lobectomy AND local tumor destruction
  
- 50 Extended lobectomy, NOS (extended: resection of a single lobe plus a segment of another lobe)
  - 51 Right lobectomy
  - 52 Left lobectomy
  - 59 Extended lobectomy AND local tumor destruction
  
- 60 Hepatectomy, NOS
  - 61 Total hepatectomy and transplant
  
- 65 Excision of a bile duct (for an intra-hepatic bile duct primary only)
  - 66 Excision of an intrahepatic bile duct PLUS partial hepatectomy
  
- 75 Extrahepatic bile duct and hepatectomy WITH transplant

**Specimen sent to pathology from surgical events 20–75.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

Revised 01/10, 02/10, 01/11, 01/16, 02/21, 01/22)

**PANCREAS****C25.0–C25.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 25 Local excision of tumor, NOS
  
- 30 Partial pancreatectomy, NOS; example: distal
  
- 35 Local or partial pancreatectomy and duodenectomy
  - 36 WITHOUT distal/partial gastrectomy
  - 37 WITH partial gastrectomy (Whipple)
  
- 40 Total pancreatectomy
  
- 60 Total pancreatectomy and subtotal gastrectomy or duodenectomy
  
- 70 Extended pancreatoduodenectomy
  
- 80 Pancreatectomy, NOS
  
- 90 Surgery, NOS
  
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)



**LARYNX****C32.0–C32.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Stripping

**No specimen sent to pathology from surgical events 10–15.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
  - Any combination of 20 or 26–27 WITH
    - 21 Photodynamic therapy (PDT)
    - 22 Electrocautery
    - 23 Cryosurgery
    - 24 Laser ablation
  - 25 Laser excision
  - 28 Stripping
  
- 30 Partial excision of the primary site, NOS; subtotal/partial laryngectomy NOS; hemilaryngectomy NOS
  - 31 Vertical laryngectomy
  - 32 Anterior commissure laryngectomy
  - 33 Supraglottic laryngectomy
  
- 40 Total or radical laryngectomy, NOS
  - 41 Total laryngectomy ONLY
  - 42 Radical laryngectomy ONLY
  
- 50 Pharyngolaryngectomy
  
- 80 Laryngectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

- 90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**LUNG****C34.0–C34.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS  
**Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).**
- 15 Local tumor destruction, NOS  
 12 Laser ablation or cryosurgery  
 13 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)  
**No specimen sent to pathology from surgical events 12–13 and 15.**
- 20 Excision or resection of less than one lobe, NOS  
 23 Excision, NOS  
 24 Laser excision  
 25 Bronchial sleeve resection ONLY  
 21 Wedge resection  
 22 Segmental resection, including lingulectomy
- 30 Resection of lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)  
 33 Lobectomy WITH mediastinal lymph node dissection  
**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**
- 45 Lobe or bilobectomy extended, NOS  
 46 WITH chest wall  
 47 WITH pericardium  
 48 WITH diaphragm
- 55 Pneumonectomy, NOS  
 56 WITH mediastinal lymph node dissection (radical pneumonectomy)  
**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**
- 65 Extended pneumonectomy  
 66 Extended pneumonectomy plus pleura or diaphragm
- 70 Extended radical pneumonectomy  
**The lymph node dissection should also be coded under *Scope of Regional Lymph Node Surgery* (NAACCR Item #1292) or *Scope of Regional Lymph Node Surgery at This Facility* (NAACCR Item #672).**

80 Resection of lung, NOS  
**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**HEMATOPOIETIC/RETICULOENDOTHELIAL/****IMMUNOPROLIFERATIVE/MYELOPROLIFERATIVE DISEASE**

C42.0, C42.1, C42.3, C42.4 (with any histology)

**Code**

98 All hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment.

**Surgical procedures for hematopoietic/reticuloendothelial/immunoproliferative/ myeloproliferative primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).**

(Revised 01/04, 01/10, 02/10, 01/16, 01/22)

**BONES, JOINTS, AND ARTICULAR CARTILAGE****C40.0–C41.9****PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM****C47.0–C47.9****CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES****C49.0–C49.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

**Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).**

15 Local tumor destruction

**No specimen sent to pathology from surgical event 15.**

25 Local excision

26 Partial resection

30 Radical excision or resection of lesion WITH limb salvage

40 Amputation of limb

41 Partial amputation of limb

42 Total amputation of limb

50 Major amputation, NOS

51 Forequarter, including scapula

52 Hindquarter, including ilium/hip bone

53 Hemipelvectomy, NOS

54 Internal hemipelvectomy

**Specimen sent to pathology from surgical events 25–54.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 8/17/02, 01/10, 02/10, 01/16, 02/21, 01/22)

**SPLEEN****C42.2****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

**Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).**

- 21 Partial splenectomy
- 22 Total splenectomy
- 80 Splenectomy, NOS

**Specimen sent to pathology for surgical events 21-80.**

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**SKIN****C44.0–C44.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
  
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser ablation

**No specimen sent to pathology from surgical events 10–14.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsyAny combination of 20 or 26–27 WITH
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  
- 25 Laser excision
  
- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
  - 31 Shave biopsy followed by a gross excision of the lesion
  - 32 Punch biopsy followed by a gross excision of the lesion
  - 33 Incisional biopsy followed by a gross excision of the lesion
  - 34 Mohs surgery, NOS
  - 35 Mohs with 1-cm margin or less
  - 36 Mohs with more than 1-cm margin
  
- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS.  
**Margins MUST be microscopically negative.**
  - 46 WITH margins more than 1 cm and less than or equal to 2 cm
  - 47 WITH margins greater than 2 cm**If the excision or reexcision has microscopically confirmed negative margins less than 1 cm OR the margins are 1cm or more but are not microscopically confirmed; use the appropriate code, 20–36.**
  
- 60 Major amputation



**Specimen sent to pathology from surgical events 20–60.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/15, 01/16, 02/21, 01/22)

**BREAST****C50.0–C50.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction, NOS

**No specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).**

20 Partial mastectomy, NOS; less than total mastectomy, NOS

21 Partial mastectomy WITH nipple resection

22 Lumpectomy or excisional biopsy

23 Reexcision of the biopsy site for gross or microscopic residual disease

**24 Segmental mastectomy (including wedge resection, quadrantectomy, tylectomy)**

**Procedures coded 20–24 remove the gross primary tumor and some of the breast tissue (breast-conserving or preserving). There may be microscopic residual tumor.**

30 Subcutaneous mastectomy

**A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. Cases coded 30 may be considered to have undergone breast reconstruction.**

40 Total (simple) mastectomy

41 WITHOUT removal of uninvolved contralateral breast

43 With reconstruction NOS

44 Tissue

45 Implant

46 Combined (Tissue and Implant)

42 WITH removal of uninvolved contralateral breast

47 With reconstruction NOS

48 Tissue

49 Implant

75 Combined (Tissue and Implant)

**A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done, but sentinel lymph nodes may be removed.**

**For single primaries, involving both breasts use code 76.**

**If the contralateral breast reveals a second primary, each breast is abstracted separately. The surgical procedure is coded 41 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.**

**Reconstruction that is planned as part of first course treatment is coded 43-49 or 75, whether it is done at the time of mastectomy or later.**

- 76 Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma.
- 50 Modified radical mastectomy
- 51 WITHOUT removal of uninvolved contralateral breast
- 53 Reconstruction, NOS
- 54 Tissue
- 55 Implant
- 56 Combined (Tissue and Implant)
- 52 WITH removal of uninvolved contralateral breast
- 57 Reconstruction, NOS
- 58 Tissue
- 59 Implant
- 63 Combined (Tissue and Implant)

**Removal of all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin in continuity with the axilla. The specimen may or may not include a portion of the pectoralis major muscle**

**If contralateral breast reveals a second primary, it is abstracted separately. The surgical procedure is coded 51 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.**

**For single primaries only, code removal of contralateral breast under the data item *Surgical Procedure/Other Site (NAACCR Item #1294)* or *Surgical Procedure/Other Site at This Facility (NAACCR Item #674)*.**

- 60 Radical mastectomy, NOS
- 61 WITHOUT removal of uninvolved contralateral breast
- 64 Reconstruction, NOS
- 65 Tissue
- 66 Implant
- 67 Combined (Tissue and Implant)
- 62 WITH removal of uninvolved contralateral breast
- 68 Reconstruction, NOS
- 69 Tissue
- 73 Implant
- 74 Combined (Tissue and Implant)
- 70 Extended radical mastectomy
- 71 WITHOUT removal of uninvolved contralateral breast
- 72 WITH removal of uninvolved contralateral breast

80 Mastectomy, NOS

**Specimen sent to pathology for surgical events coded 20-80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 05/10, 01/11, 01/13, 01/16, 02/21, 01/22)

**CERVIX UTERI****C53.0–C53.9**

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Loop Electrocautery Excision Procedure (LEEP)
  - 16 Laser ablation
  - 17 Thermal ablation

**No specimen sent to pathology from surgical events 10–17.**

- 20 Local tumor excision, NOS
  - 26 Excisional biopsy, NOS
  - 27 Cone biopsy
  - 24 Cone biopsy WITH gross excision of lesion
  - 29 Trachelectomy; removal of cervical stump; cervicectomy
  - Any combination of 20, 24, 26, 27 or 29 WITH
    - 21 Electrocautery
    - 22 Cryosurgery
    - 23 Laser ablation or excision
  - 25 Dilatation and curettage; endocervical curettage (for in situ only)
  - 28 Loop electrocautery excision procedure (LEEP)
- 30 Total hysterectomy (simple, pan-) WITHOUT removal of tubes and ovaries  
**Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.**
- 40 Total hysterectomy (simple, pan-) WITH removal of tubes and/or ovary  
**Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.**
- 50 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
  - 51 Modified radical hysterectomy
  - 52 Extended hysterectomy

- 53 Radical hysterectomy; Wertheim procedure
- 54 Extended radical hysterectomy
  
- 60 Hysterectomy, NOS, WITH or WITHOUT removal of tubes and ovaries
  - 61 WITHOUT removal of tubes and ovaries
  - 62 WITH removal of tubes and ovaries
  
- 70 Pelvic exenteration
  - 71 Anterior exenteration  
**Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.**
  
  - 72 Posterior exenteration  
**Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.**
  
  - 73 Total exenteration  
**Includes removal of all pelvic contents and pelvic lymph nodes.**
  
  - 74 Extended exenteration  
**Includes pelvic blood vessels or bony pelvis.**

**Specimen sent to pathology from surgical events 20–74.**

- 90 Surgery, NOS
  
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**CORPUS UTERI****C54.0–C55.9**

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure* (NAACCR Item #1350).

**Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

**Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).**

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Loop Electocautery Excision Procedure (LEEP)

16 Thermal ablation

**No specimen sent to pathology from surgical events 10–16.**

20 Local tumor excision, NOS; simple excision, NOS

24 Excisional biopsy

25 Polypectomy

26 Myomectomy

Any combination of 20 or 24–26 WITH

21 Electrocautery

22 Cryosurgery

23 Laser ablation or excision

30 Subtotal hysterectomy/supracervical hysterectomy/fundectomy WITH or WITHOUT removal of tube(s) and ovary(ies).

31 WITHOUT tube(s) and ovary(ies)

32 WITH tube(s) and ovary(ies)

40 Total hysterectomy (simple, pan-) WITHOUT removal of tube(s) and ovary(ies)

**Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.**

50 Total hysterectomy (simple, pan-) WITH removal of tube(s) and/or ovary(ies)

**Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.**

- 60 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
  - 61 Modified radical hysterectomy
  - 62 Extended hysterectomy
  - 63 Radical hysterectomy; Wertheim procedure
  - 64 Extended radical hysterectomy
  
- 65 Hysterectomy, NOS, WITH or WITHOUT removal of tube(s) and ovary(ies)
  - 66 WITHOUT removal of tube(s) and ovary(ies)
  - 67 WITH removal of tube(s) and ovary(ies)
  
- 75 Pelvic exenteration
  - 76 Anterior exenteration  
**Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.**
  
  - 77 Posterior exenteration  
**Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.**
  
  - 78 Total exenteration  
**Includes removal of all pelvic contents and pelvic lymph nodes.**
  
  - 79 Extended exenteration  
**Includes pelvic blood vessels or bony pelvis.**

**Specimen sent to pathology from surgical events 20–79.**

- 90 Surgery, NOS
  
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)



**OVARY****C56.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

17 Local tumor destruction, NOS

**No specimen sent to pathology from surgical event 17.**

25 Total removal of tumor or (single) ovary, NOS

26 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done

27 WITHOUT hysterectomy

28 WITH hysterectomy

35 Unilateral (salpingo-)oophorectomy; unknown if hysterectomy done

36 WITHOUT hysterectomy

37 WITH hysterectomy

50 Bilateral (salpingo-)oophorectomy; unknown if hysterectomy done

51 WITHOUT hysterectomy

52 WITH hysterectomy

55 Unilateral or bilateral (salpingo-)oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done

56 WITHOUT hysterectomy

57 WITH hysterectomy

60 Debulking; cytoreductive surgery, NOS

61 WITH colon (including appendix) and/or small intestine resection (not incidental)

62 WITH partial resection of urinary tract (not incidental)

63 Combination of 61 and 62

**Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.**

70 Pelvic exenteration, NOS

71 Anterior exenteration

**Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.**

72 Posterior exenteration

**Specimen sent to pathology from surgical events 25–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**PROSTATE****C61.9**

**Do not code** an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item *Hematologic Transplant and Endocrine Procedures* (NAACCR Item #3250).

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 18 Local tumor destruction or excision, NOS
- 19 Transurethral resection (TURP), NOS, and no specimen sent to pathology or unknown if sent

**Unknown whether a specimen was sent to pathology for surgical events coded 18 or 19 (principally for cases diagnosed prior to January 1, 2003).**

- 10 Local tumor destruction, NOS
  - 14 Cryoprostatectomy
  - 15 Laser ablation
  - 16 Hyperthermia
  - 17 Other method of local tumor destruction

**No specimen sent to pathology from surgical events 10–17.**

- 20 Local tumor excision, NOS
  - 21 Transurethral resection (TURP), NOS, with specimen sent to pathology
  - 22 TURP—cancer is incidental finding during surgery for benign disease
  - 23 TURP—patient has suspected/known cancer
 Any combination of 20–23 WITH
  - 24 Cryosurgery
  - 25 Laser
  - 26 Hyperthermia
- 30 Subtotal, segmental, or simple prostatectomy, which may leave all or part of the capsule intact
- 50 Radical prostatectomy, NOS; total prostatectomy, NOS
 

**Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.**
- 70 Prostatectomy WITH resection in continuity with other organs; pelvic exenteration
 

**Surgeries coded 70 are any prostatectomy WITH resection in continuity with any other organs. The other organs may be partially or totally removed. Procedures may include, but are not limited to, cystoprostatectomy, radical cystectomy, and prostatectomy.**

80 Prostatectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 12/4/02, 01/10, 02/10, 1/11, 01/16, 02/21, 01/22)

**TESTIS****C62.0–C62.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

12 Local tumor destruction, NOS

**No specimen sent to pathology from surgical event 12.**

20 Local or partial excision of testicle

30 Excision of testicle WITHOUT cord

40 Excision of testicle WITH cord or cord not mentioned (radical orchiectomy)

80 Orchiectomy, NOS (unspecified whether partial or total testicle removed)

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**KIDNEY, RENAL PELVIS, AND URETER****Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Thermal ablation

**No specimen sent to pathology from this surgical event 10–15.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
 Any combination of 20 or 26–27 WITH
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision

- 30 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial ureterectomy (ureter)

**Procedures coded 30 include, but are not limited to:**

- Segmental resection
- Wedge resection

- 40 Complete/total/simple nephrectomy—for kidney parenchyma  
Nephroureterectomy

**Includes bladder cuff for renal pelvis or ureter.**

- 50 Radical nephrectomy

**May include removal of a portion of vena cava, adrenal gland(s), Gerota's fascia, perinephric fat, or partial/total ureter.**

- 70 Any nephrectomy (simple, subtotal, complete, partial, simple, total, radical) in continuity with the resection of other organ(s) (colon, bladder)

**The other organs, such as colon or bladder, may be partially or totally removed.**

- 80 Nephrectomy, NOS

Ureterectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/16, 02/21, 01/22)

**BLADDER****C67.0–C67.9****Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Intravesical therapy
  - 16 Bacillus Calmette-Guerin (BCG) or other immunotherapy

**Also code the introduction of immunotherapy in the immunotherapy items. If immunotherapy is followed by surgery of the type coded 20-80 code that surgery instead and code the immunotherapy only as immunotherapy.**

**No specimen sent to pathology from surgical events 10–16.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
  - Combination of 20 or 26–27 WITH
    - 21 Photodynamic therapy (PDT)
    - 22 Electrocautery
    - 23 Cryosurgery
    - 24 Laser ablation
  - 25 Laser excision
- 30 Partial cystectomy
- 50 Simple/total/complete cystectomy
- 60 Complete cystectomy with reconstruction
  - 61 Radical cystectomy PLUS ileal conduit
  - 62 Radical cystectomy PLUS continent reservoir or pouch, NOS
  - 63 Radical cystectomy PLUS abdominal pouch (cutaneous)
  - 64 Radical cystectomy PLUS in situ pouch (orthotopic)

**When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).**
- 70 Pelvic exenteration, NOS
  - 71 Radical cystectomy including anterior exenteration



**For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).**

72 Posterior exenteration

**For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.**

73 Total exenteration

**Includes all tissue and organs removed for an anterior and posterior exenteration.**

74 Extended exenteration

**Includes pelvic blood vessels or bony pelvis.**

80 Cystectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/12, 01/16, 02/21, 01/22)

**BRAIN****Meninges C70.0–C70.9, Brain C71.0–C71.9,****Spinal Cord, Cranial Nerves and Other Parts of Central Nervous System C72.0–C72.9****Do not code** laminectomies for spinal cord primaries.**Codes**

00 None; no surgery of primary site; autopsy ONLY

10 Tumor destruction, NOS

**No specimen sent to pathology from surgical event 10.****Do not record stereotactic radiosurgery (SRS), Gamma knife, Cyber knife, or Linac radiosurgery as surgical tumor destruction. All of these modalities are recorded in the radiation treatment fields.**

20 Local excision of tumor, lesion or mass; excisional biopsy

21 Subtotal resection of tumor, lesion or mass in brain

22 Resection of tumor of spinal cord or nerve

30 Radical, total, gross resection of tumor, lesion or mass in brain

40 Partial resection of lobe of brain, when the surgery cannot be coded as 20-30.

55 Gross total resection of lobe of brain (lobectomy)

**Codes 30 - 55 are not applicable for spinal cord or spinal nerve primary sites.****Specimen sent to pathology from surgical events 20–55.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**THYROID GLAND****C73.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

13 Local tumor destruction, NOS

**No specimen sent to pathology from surgical event 13.**

25 Removal of less than a lobe, NOS

26 Local surgical excision

27 Removal of a partial lobe ONLY

20 Lobectomy and/or isthmectomy

21 Lobectomy ONLY

22 Isthmectomy ONLY

23 Lobectomy WITH isthmus

30 Removal of a lobe and partial removal of the contralateral lobe

40 Subtotal or near total thyroidectomy

50 Total thyroidectomy

80 Thyroidectomy, NOS

**Specimen sent to pathology from surgical events 20–80.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 01/10, 02/10, 01/15, 01/16, 02/21, 01/22)

**LYMPH NODES****C77.0–C77.9****Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

**Unknown whether a specimen was sent to pathology for surgical events coded to 19 (principally for cases diagnosed prior to January 1, 2003).**

15 Local tumor destruction, NOS

**No specimen sent to pathology from surgical event 15.**

25 Local tumor excision, NOS

**Less than a full chain, includes an excisional biopsy of a single lymph node.**

30 Lymph node dissection, NOS

31 One chain

32 Two or more chains

40 Lymph node dissection, NOS PLUS splenectomy

41 One chain

42 Two or more chains

50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)

51 One chain

52 Two or more chains

60 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) PLUS splenectomy (Includes staging laparotomy for lymphoma.)

61 One chain

62 Two or more chains

**Specimen sent to pathology for surgical events 25-62.**

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

(Revised 09/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**ALL OTHER SITES**

**C14.2–C14.8, C17.0–C17.9, C23.9, C24.0–C24.9, C26.0–C26.9, C30.0–C 30.1, C31.0–C31.9, C33.9, C37.9, C38.0–C38.8, C39.0–C39.9, C48.0–C48.8, C51.0–C51.9, C52.9, C57.0–C57.9, C58.9, C60.0–C60.9, C63.0–C63.9, C68.0–C68.9, C69.0–C69.9, C74.0–C74.9, C75.0–C75.9**

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

**No specimen sent to pathology from surgical events 10–14.**

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy
  - Any combination of 20 or 26–27 WITH
    - 21 Photodynamic therapy (PDT)
    - 22 Electrocautery
    - 23 Cryosurgery
    - 24 Laser ablation
  - 25 Laser excision
- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation
  - 41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be “debulking”
- 60 Radical surgery
 

**Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.**

**Specimen sent to pathology from surgical events 20–60.**

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

**UNKNOWN AND ILL-DEFINED PRIMARY SITES****C76.0–C76.8, C80.9****Code**

98 All unknown and ill-defined disease sites, WITH or WITHOUT surgical treatment.

**Surgical procedures for unknown and ill-defined primaries are to be recorded using the data item *Surgical Procedure/Other Site* (NAACCR Item #1294) or *Surgical Procedure/Other Site at This Facility* (NAACCR Item #674).**

(Revised 01/04, 01/10, 02/10, 01/16, 02/21, 01/22)

## APPENDIX B: ICD-O-3 Eligibility Reporting Table

ICD-O Code	Term	Required and collected by CoC	Remarks
8033/3	Carcinoma with sarcomatoid component	Y	New related term
8085/3	Squamous cell carcinoma, HPV-associated	Y	New term for uterine cervix
8086/3	Squamous cell carcinoma, HPV-independent	Y	New term for uterine cervix
8144/2	Intestinal-type adenoma, high grade (C16.0 – C16.9, C17.0 -C17.9)	Y Reportable for Stomach and Small Intestine only	Term is reportable for stomach and small intestines ONLY beginning 1/1/2022
8213/2	Serrated dysplasia, high grade (C16.0 – C16.9, C17.0 -C17.9)	Y for Stomach and Small Intestine	Term is reportable for stomach and small intestines ONLY beginning 1/1/2022
8243/3	Goblet cell adenocarcinoma	Y	New preferred term
8262/3	Adenoma-like adenocarcinoma	Y	New term
8310/3	Adenocarcinoma, HPV-independent, clear cell type	Y	New term for uterine cervix
8455/2	Intraductal oncocytic papillary neoplasm, NOS	Y	New ICD-O code/term
8455/3	Intraductal oncocytic papillary neoplasm with associated invasive carcinoma	Y	New ICD-O code/term
8480/2	Low-grade appendiceal mucinous neoplasm (LAMN)	Y	New behavior/term
8480/3	Low-grade appendiceal mucinous neoplasm (LAMN)	Y	New behavior/term
8480/2	High grade appendiceal mucinous neoplasm (HAMN)	Y	New behavior/term
8480/3	Appendiceal mucinous neoplasm with extra-appendiceal spread	Y	New behavior/term
8482/3	Adenocarcinoma, HPV-independent, gastric type	Y	New term

8483/3	Adenocarcinoma, HPV-associated	Y	New ICD-O code/term
8484/3	Adenocarcinoma, HPV-independent, NOS	Y	New ICD-O code/term
8503/2	Ductal carcinoma in situ, papillary	Y	New preferred term
8509/3	Tall cell carcinoma with reversed polarity	Y	New preferred term
8859/3	Myxoid pleomorphic liposarcoma	Y	New ICD-O code/term
8912/3	Congenital spindle cell rhabdomyosarcoma with VGLL2/NCOA2/CITED2 rearrangements	Y	New term
8912/3	MYOD1-mutant spindle cell/sclerosing rhabdomyosarcoma	Y	New term
8912/3	Intraosseous spindle cell rhabdomyosarcoma with TFCEP2/NCOA2 rearrangements	Y	New term
8976/3	Gastroblastoma (C16.0 – C16.9)	Y	New ICD-O code/term
9110/3	Adenocarcinoma, HPV-independent, mesonephric type	Y	New preferred term
9111/3	Mesonephric-like adenocarcinoma	Y	New ICD-O code/term for ovary and corpus uterus
9120/3	Post radiation angiosarcoma of the breast	Y	New term
9133/3	Epithelioid hemangioendothelioma with WWTR1-CAMTA1 fusion	Y	New term
9133/3	Epithelioid hemangioendothelioma with YAP1-TFE3 fusion	Y	New term
9222/3	Chondrosarcoma, grade 1	Y	Behavior change. Reportable 1/1/2022 forward
9366/3	Round cell sarcoma with EWSR1-non-ETS fusions	Y	New ICD-O code/term
9367/3	CIC-rearranged sarcoma	Y	New ICD-O code/term
9368/3	Sarcoma with BCOR genetic alterations	Y	New ICD-O code/term



## APPENDIX C: Country and State Codes

Geographic Area	Country Code	State or Province Code
<b>Preferred: Specific Codes for Use Where the Detail is Known</b>		
United States (state and armed forces codes)		
Alabama	USA	AL
Alaska	USA	AK
Arizona	USA	AZ
Arkansas	USA	AR
Armed Forces Americas	USA	AA
Armed Forces Canada, Europe, Middle East, Africa	USA	AE
Armed Forces Pacific	USA	AP
California	USA	CA
Colorado	USA	CO
Connecticut	USA	CT
Delaware	USA	DE
District of Columbia	USA	DC
Florida	USA	FL
Georgia	USA	GA
Hawaii	USA	HI
Idaho	USA	ID
Illinois	USA	IL
Indiana	USA	IN
Iowa	USA	IA
Kansas	USA	KS
Kentucky	USA	KY
Louisiana	USA	LA
Maine	USA	ME
Maryland	USA	MD
Massachusetts	USA	MA
Michigan	USA	MI
Minnesota	USA	MN
Mississippi	USA	MS
Missouri	USA	MO
Montana	USA	MT
Nebraska	USA	NE
Nevada	USA	NV
New Hampshire	USA	NH

Geographic Area	Country Code	State or Province Code
<b>Preferred: Specific Codes for Use Where the Detail is Known</b>		
New Jersey	USA	NJ
New Mexico	USA	NM
New York	USA	NY
North Carolina	USA	NC
North Dakota	USA	ND
Ohio	USA	OH
Oklahoma	USA	OK
Oregon	USA	OR
Pennsylvania	USA	PA
Rhode Island	USA	RI
South Carolina	USA	SC
South Dakota	USA	SD
Tennessee	USA	TN
Texas	USA	TX
Utah	USA	UT
Vermont	USA	VT
Virginia	USA	VA
Washington	USA	WA
West Virginia	USA	WV
Wisconsin	USA	WI
Wyoming	USA	WY
Canada (province and territory codes)		
Alberta	CAN	AB
British Columbia	CAN	BC
Manitoba	CAN	MB
New Brunswick	CAN	NB
Newfoundland and Labrador	CAN	NL
Northwest Territories	CAN	NT
Nova Scotia	CAN	NS
Nunavut	CAN	NU
Ontario	CAN	ON
Prince Edward Island	CAN	PE
Quebec	CAN	QC
Saskatchewan	CAN	SK
Yukon Territory	CAN	YT
Afghanistan	AFG	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Africa, NOS	ZZF	YY
Alabama	USA	AL
Aland Islands	ALA	XX
Alaska	USA	AK
Albania	ALB	XX
Alberta	CAN	AB
Algeria	DZA	XX
American Samoa	ASM	AS
Andorra	AND	XX
Angola	AGO	XX
Anguilla	AIA	XX
Antarctica	ATA	XX
Antigua and Barbuda	ATG	XX
Argentina	ARG	XX
Arizona	USA	AZ
Arkansas	USA	AR
Armed Forces Americas	USA	AA
Armed Forces Canada, Europe, Middle East, Africa	USA	AE
Armed Forces Pacific	USA	AP
Armenia	ARM	XX
Aruba	ABW	XX
Asia, NOS	ZZA	YY
Australia	AUS	XX
Austria	AUT	XX
Azerbaijan	AZE	XX
Bahamas	BHS	XX
Bahrain	BHR	XX
Bangladesh	BGD	XX
Barbados	BRB	XX
Belarus	BLR	XX
Belgium	BEL	XX
Belize	BLZ	XX
Benin	BEN	XX
Bermuda	BMU	XX
Bhutan	BTN	XX
Bolivia	BOL	XX
Bonaire, Saint Eustatius and Saba	BES	XX
Bosnia and Herzogovina	BIH	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Botswana	BWA	XX
Bouvet Island	BVT	XX
Brazil	BRA	XX
British Columbia	CAN	BC
British Indian Ocean Territory	IOT	XX
British Virgin Islands	VGB	XX
Brunei	BRN	XX
Bulgaria	BGR	XX
Burkina Faso	BFA	XX
Burundi	BDI	XX
California	USA	CA
Cambodia	KHM	XX
Cameroon	CMR	XX
Canada	CAN	CD
Cape Verde	CPV	XX
Cayman Islands	CYM	XX
Central African Republic	CAF	XX
Central America, NOS	ZZC	YY
Chad	TCD	XX
Chile	CHL	XX
China	CHN	XX
Christmas Island	CXR	XX
Cocos (Keeling) Islands	CCK	XX
Colombia	COL	CO
Colorado	USA	XX
Comoros	COM	XX
Congo	COG	XX
Congo, Democratic Republic of	COD	XX
Connecticut	USA	CT
Cook Islands	COK	XX
Costa Rica	CRI	XX
Cote d'Ivoire	CIV	XX
Croatia	HRV	XX
Cuba	CUB	XX
Curacao	CUW	XX
Cyprus	CYP	XX
Czech Republic	CZE	XX
Czechoslovakia	CSK	YY

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Delaware	USA	DE
Denmark	DNK	XX
District of Columbia	USA	DC
Djibouti	DJI	XX
Dominica	DMA	XX
Dominican Republic	DOM	XX
Ecuador	ECU	XX
Egypt	EGY	XX
El Salvador	SLV	XX
England	ENG	XX
Equatorial Guinea	GNQ	XX
Eritrea	ERI	XX
Estonia	EST	XX
Ethiopia	ETH	XX
Europe, NOS	ZZE	YY
Falkland Islands	FLK	XX
Faroe Islands	FRO	XX
Fiji	FJI	XX
Finland	FIN	XX
Florida	USA	FL
France	FRA	XX
French Guiana	GUF	XX
French Polynesia	PYF	XX
French Southern Territories	ATF	XX
Gabon	GAB	XX
Gambia	GMB	XX
Georgia	USA	GA
Georgia	GEO	XX
Germany	DEU	XX
Ghana	GHA	XX
Gibraltar	GIB	XX
Greece	GRC	XX
Greenland	GRL	XX
Grenada	GRD	XX
Guadeloupe	GLP	XX
Guam	GUM	GU
Guatemala	GTM	XX
Guernsey	GGY	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Guinea	GIN	XX
Guinea Bissau	GNB	XX
Guyana	GUY	XX
Haiti	HTI	XX
Hawaii	USA	HI
Heard Island and McDonald Islands	HMD	XX
Honduras	HND	XX
Hong Kong	HKG	XX
Hungary	HUN	XX
Iceland	ISL	XX
Idaho	USA	ID
Illinois	USA	IL
India	IND	XX
Indiana	USA	IN
Indonesia	IDN	XX
Iowa	USA	IA
Iran	IRN	XX
Iraq	IRQ	XX
Ireland	IRL	XX
Isle of Man	IMN	XX
Israel	ISR	XX
Italy	ITA	XX
Jamaica	JAM	XX
Japan	JPN	XX
Jersey	JEY	XX
Jordan	JOR	XX
Kazakhstan	KAZ	XX
Kentucky	USA	KY
Kenya	KEN	XX
Kiribati	KIR	XX
Korea	KOR	XX
Kuwait	KWT	XX
Kyrgyzstan	KGZ	XX
Laos	LAO	XX
Latvia	LVA	XX
Lebanon	LBN	XX
Lesotho	LSO	XX
Liberia	LBR	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Libya	LBY	XX
Liechtenstein	LIE	XX
Lithuania	LTU	XX
Louisiana	US	LA
Luxembourg	LUX	XX
Macao	MAC	XX
Macedonia	MKD	XX
Madagascar	MDG	XX
Maine	USA	ME
Malawi	MWI	XX
Malaysia	MYS	XX
Maldives	MDV	XX
Mali	MLI	XX
Malta	MLT	XX
Manitoba	CAN	MB
Marshall Islands	MHL	MH
Martinique	MTQ	XX
Maryland	USA	MD
Massachusetts	USA	MA
Mauritania	MRT	XX
Mauritius	MUS	XX
Mayotte	MYT	XX
Mexico	MEX	XX
Michigan	USA	MI
Micronesia	FSM	FM
Minnesota	USA	MN
Mississippi	USA	MS
Missouri	USA	MO
Moldova	MDA	XX
Monaco	MCO	XX
Mongolia	MNG	XX
Montana	USA	MT
Montenegro	MNE	XX
Montserrat	MSR	XX
Morocco	MAR	XX
Mozambique	MOZ	XX
Myanmar	MMR	XX
Namibia	NAM	XX
Nauru	NRU	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Nepal	NPL	XX
Netherlands	NLD	XX
Nevada	USA	NV
New Brunswick	CAN	NB
New Caledonia	NCL	XX
New Hampshire	USA	NH
New Jersey	USA	NJ
New Mexico	USA	NM
New York	USA	NY
New Zealand	NZL	XX
Newfoundland and Labrador	CAN	NL
Nicaragua	NIC	XX
Niger	NER	XX
Nigeria	NGA	XX
Niue	NIU	XX
Non-US/Canada NOS	ZZX	YY
Norfolk Island	NFK	XX
North America, NOS	ZZN	YY
North Carolina	USA	NC
North Dakota	USA	ND
North Korea	PRK	XX
Northern Ireland	NIR	XX
Northern Mariana Islands	MNP	MP
Northwest Territories	CAN	NT
Norway	NOR	XX
Nova Scotia	CAN	NS
Nunavut	CAN	NU
Ohio	USA	OH
Oklahoma	USA	OK
Oman	OMN	XX
Ontario	CAN	ON
Oregon	USA	OR
Pacific, NOS	ZZP	YY
Pakistan	PAK	XX
Palau	PLW	PW
Palestine	PSE	XX
Panama	PAN	XX
Papua New Guinea	PNG	XX
Paraguay	PRY	XX



Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Pennsylvania	USA	PA
Peru	PER	XX
Philippines	PHL	XX
Pitcairn Islands	PCN	XX
Poland	POL	XX
Portugal	PRT	XX
Prince Edward Island	CAN	PE
Puerto Rico	PRI	PR
Qatar	QAT	XX
Quebec	CAN	QC
Republic of South Africa	ZAF	XX
Réunion	REU	XX
Rhode Island	USA	RI
Romania	ROU	XX
Russia	RUS	XX
Rwanda	RWA	XX
Saint-Martin (French part)	MAF	XX
Samoa	ASM	XX
San Marino	SMR	XX
Sao Tome & Principe	STP	XX
Saskatchewan	CAN	SK
Saudi Arabia	SAU	XX
Scotland	SCT	XX
Senegal	SEN	XX
Serbia	SRB	XX
Seychelles	SYC	XX
Sierra Leone	SLE	XX
Singapore	SGP	XX
Sint-Maarten	SXM	XX
Slovakia	SVK	XX
Slovenia	SVN	XX
Solomon Islands	SLB	XX
Somalia	SOM	XX
South America, NOS	ZZS	YY
South Carolina	USA	SC
South Dakota	USA	SD
South Georgia and the South Sandwich Islands	SGS	XX
South Korea	KOR	XX
South Sudan	SSD	XX

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Spain	ESP	XX
Sri Lanka	LKA	XX
St Pierre and Miquelon	SPM	XX
St. Barthelemy	BLM	XX
St. Helena	SHN	XX
St. Kitts and Nevis	KNA	XX
St. Lucia	LCA	XX
St. Vincent and the Grenadines	VCT	XX
Sudan	SDN	XX
Suriname	SUR	XX
Svalbard and Jan Mayen	SJM	XX
Swaziland	SWZ	XX
Sweden	SWE	XX
Switzerland	CHE	XX
Syria	SYR	XX
Taiwan	TWN	XX
Tajikistan	TJK	XX
Tanzania	TZA	XX
Tennessee	USA	TN
Texas	USA	TX
Thailand	THA	XX
Timor-Leste	TLS	XX
Togo	TGO	XX
Tokelau Islands	TKL	XX
Tonga	TON	XX
Trinidad and Tobago	TTO	XX
Tunisia	TUN	XX
Turkey	TUR	XX
Turkmenistan	TKM	XX
Turks and Caicos	TCA	XX
Tuvalu	TUV	XX
U.S Minor Outlying Islands	UMI	UM
U.S. Virgin Islands	VIR	VI
Uganda	UGA	XX
Ukraine	UKR	XX
United Arab Emirates	ARE	XX
United Kingdom	GBR	XX
United States	USA	US
Unknown	ZZU	ZZ

Geographic Area	Country Code	State or Province Code
Preferred: Specific Codes for Use Where the Detail is Known		
Uruguay	URY	XX
Utah	USA	UT
Uzbekistan	UZB	XX
Vanuatu	VUT	XX
Vatican City	VAT	XX
Venezuela	VEN	XX
Vermont	USA	VT
Vietnam	VNM	XX
Virginia	USA	VA
Wales	WLS	XX
Wallis and Fotuna	WLF	XX
Washington	USA	WA
West Virginia	USA	WV
Western Sahara	ESH	XX
Wisconsin	USA	WI
Wyoming	USA	WY
Yemen	YEM	XX
Yugoslavia	YUG	YY
Yukon Territory	CAN	YT
Zambia	ZMB	XX
Zimbabwe	ZWE	XX

## General

Geographic Area	Country Code	State or Province Code
<b>General: Codes to Use In the Absence of More Specific Information</b>		
United States, NOS	USA	US
Canada, NOS	CAN	CD
Africa, NOS (Central, Equatorial)	ZZF	YY
Asia, NOS	ZZA	YY
Asian and Arab Countries	ZZA	YY
Atlantic/Caribbean Area	ZZN	YY
Baltic Republic(s), NOS (Baltic States, NOS)	ZZE	YY
Central America	ZZC	YY
Czechoslovakia	CSK	YY
East Asia	ZZA	YY
Europe, NOS (Central, Eastern, Northern, Southern, Western)	ZZE	YY
Latin America, NOS	ZZU	YY
Near East	ZZA	YY
North America, NOS	ZZN	YY
Other Atlantic/Caribbean Area (not on detailed list)	ZZN	YY
Other Mainland Europe (not on detailed list)	ZZE	YY
Other Mediterranean Isles (not on detailed list)	ZZE	YY
Other Pacific Area (not on first list)	ZZP	YY
Pacific Area, NOS	ZZP	YY
Pacific Islands, NOS	ZZP	YY
Romance-Language Countries	ZZE	YY
South America, NOS	ZZS	YY
South American Islands	ZZS	YY
United Kingdom, NOS	GBR	XX
Yugoslavia	YUG	YY
Not U.S., but no other information	ZZX	YY
Unknown, no mention in patient record	ZZU	ZZ

## Obsolete

Geographic Area	Country Code	State or Province Code
<b>Obsolete: State/Province or Country Codes That Must Not Be Used for Current Coding (May have been assigned during conversion, so may be present in pre-2013 data)</b>		
New England and New Jersey	USA	NN
Maritime Provinces (New Brunswick, Newfound, Nova Scotia, PE)	CAN	MM
Northwest Territories, Yukon Territory	CAN	YN
Prairie Provinces (Alberta, Manitoba, Saskatchewan)	CAN	PP
African Coastal Islands (previously in South Africa, NOS)	XIF	YY
Arabian Peninsula	XAP	YY
Caucasian Republics of the USSR	XCR	YY
China, NOS	XCH	YY
East Africa	XEF	YY
England, Channel Islands, Isle of Man	XEN	XX
Ethiopia (Abyssinia), Eritrea	XET	YY
Germanic Countries	XGR	YY
Indochina	XSE	YY
Israel and former Jewish Palestine	XIS	YY
Malaysia, Singapore, Brunei	XMS	YY
Melanesian Islands, Solomon Islands	XML	YY
Micronesian Islands	XMC	YY
North Africa	XNF	YY
North American Islands	XNI	YY
Other Asian Republics of the USSR	XOR	YY
Other Caribbean Islands	XCB	YY
Other West African Countries	XWF	YY
Polynesian Islands	XPL	YY
Republic of South Africa, Botswana, Lesotho, Namibia, Swaziland	XSF	YY
Scandinavia	XSC	YY
Slavic Countries	XSL	XX
South Africa, NOS	XSF	YY
Southeast Asia	XSE	YY
Sudanese Countries	XSD	YY
Ukraine and Moldavia	XUM	YY
West Africa, NOS (French Africa, NOS)	XWF	YY

## APPENDIX D: NEW HAMPSHIRE TOWN/COUNTY & ZIP CODES

The city, town, and village zip codes with county were taken from the website of the New Hampshire Hospital Association (<http://www.nhha.org/>) and reformatted by NHSCR to reflect the required county names and codes to be used by reporting registries.

[Coding instructions for \*City/Town at Diagnosis\*](#)

[Coding instructions for \*State at Diagnosis\*](#)

[Coding instructions for \*Postal Code at Diagnosis\*](#)

If the town you are looking for is not in "Town Name" column, check the "Zip Name" column, which is sorted by the town's zip code name.

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
ACWORTH,NH	ACWORTH,NH	03601	Sullivan	019
ACWORTH,NH	SOUTH ACWORTH, NH	03607	Sullivan	019
ALBANY,NH	CONWAY,NH	03818	Carroll	003
ALEXANDRIA,NH	BRISTOL,NH	03222	Grafton	009
ALLENSTOWN,NH	SUNCOOK,NH	03275	Merrimack	013
ALSTEAD,NH	ALSTEAD,NH	03602	Cheshire	005
ALTON BAY,NH	ALTON BAY,NH	03810	Belknap	001
ALTON,NH	ALTON,NH	03809	Belknap	001
AMHERST,NH	AMHERST,NH	03031	Hillsborough	011
ANDOVER,NH	ANDOVER,NH	03216	Merrimack	013
ANTRIM,NH	ANTRIM,NH	03440	Hillsborough	011
ASHLAND,NH	ASHLAND,NH	03217	Grafton	009
ASHUELOT,NH	ASHUELOT,NH	03441	Cheshire	005
ATKINSON & GILMANTON,NH	ERROL,NH	03579	Coos	007
ATKINSON,NH	ATKINSON,NH	03811	Rockingham	015
AUBURN,NH	AUBURN,NH	03032	Rockingham	015
BARNSTEAD,NH	BARNSTEAD,NH	03218	Belknap	001
BARRINGTON,NH	BARRINGTON,NH	03825	Strafford	017
BARTLETT,NH	BARTLETT,NH	03812	Carroll	003
BATH,NH	BATH,NH	03740	Grafton	009
BEANS PURCHASE,NH	GORHAM,NH	03581	Coos	007
BEDFORD,NH	BEDFORD,NH	03110	Hillsborough	011
BEEBE RIVER,NH	BEEBE RIVER,NH	03219	Grafton	009
BELMONT,NH	BELMONT,NH	03220	Belknap	001
BENNINGTON,NH	BENNINGTON,NH	03442	Hillsborough	011
BENTON,NH	WOODSVILLE,NH	03785	Grafton	009
BERLIN,NH	BERLIN,NH	03570	Coos	007
BETHLEHEM,NH	BETHLEHEM,NH	03574	Grafton	009
BLODGETT'S LANDING,NH	NEWBURY,NH	03255	Merrimack	013
BLOOMFIELD, VT	NORTH STRATFORD, NH	03590	Grafton	009
BOSCAWEN,NH	CONCORD,NH	03303	Merrimack	013
BOW,NH	BOW,NH	03304	Merrimack	013
BRADFORD,NH	BRADFORD,NH	03221	Merrimack	013
BRENTWOOD,NH	EXETER,NH	03833	Rockingham	015
BRETTON WOODS,NH	BRETTON WOODS,NH	03575	Coos	007
BRIDGEWATER,NH	BRISTOL,NH	03222	Grafton	009
BRISTOL,NH	BRISTOL,NH	03222	Grafton	009
BROOKFIELD,NH	SANBORNVILLE,NH	03872	Carroll	003
BROOKLINE,NH	BROOKLINE,NH	03033	Hillsborough	011
BURKEHAVEN,NH	SUNAPEE,NH	03782	Carroll	003
CAMBRIDGE,NH	MILAN,NH	03588	Coos	007
CAMPTON,NH	CAMPTON,NH	03223	Grafton	009
CANAAN,NH	CANAAN,NH	03741	Grafton	009

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
CANDIA,NH	CANDIA,NH	03034	Rockingham	015
CANTERBURY,NH	CANTERBURY,NH	03224	Merrimack	013
CARROLL,NH	WHITEFIELD,NH	03598	Coos	007
CASCADE,NH	GORHAM,NH	03581	Coos	007
CENTER BARNSTEAD,NH	CTR BARNSTEAD,NH	03225	Belknap	001
CENTER HARBOR,NH	CENTER HARBOR,NH	03226	Belknap	001
CENTER OSSIPEE,NH	CTR OSSIPEE,NH	03814	Carroll	003
CENTER SANDWICH,NH	CTR SANDWICH,NH	03227	Carroll	003
CENTER STRAFFORD,NH	CTR STRAFFORD,NH	03815	Strafford	017
CENTER TUFTONBORO,NH	CTR TUFTNBORO,NH	03816	Carroll	003
CHARLESTOWN,NH	CHARLESTOWN,NH	03603	Sullivan	019
CHATHAM,NH	CENTER CONWAY,NH	03813	Carroll	003
CHESTER,NH	CHESTER,NH	03036	Rockingham	015
CHESTERFIELD,NH	CHESTERFIELD,NH	03443	Cheshire	005
CHICHESTER,NH	CHICHESTER,NH	03258	Merrimack	013
CHOCORUA,NH	CHOCORUA,NH	03817	Carroll	003
CLAREMONT,NH	CLAREMONT,NH	03743	Sullivan	019
CLARKSVILLE,NH	PITTSBURG,NH	03592	Coos	007
COLEBROOK,NH	COLEBROOK,NH	03576	Coos	007
COLUMBIA,NH	COLEBROOK,NH	03576	Coos	007
CONCORD,NH	CONCORD,NH	03301	Merrimack	013
CONCORD,NH	CONCORD,NH	03302	Merrimack	013
CONCORD,NH	CONCORD,NH	03304	Merrimack	013
CONCORD,NH	CONCORD,NH	03305	Merrimack	013
CONCORD,NH	CONCORD,NH	03306	Merrimack	013
CONTOOCCOOK,NH	CONTOOCCOOK,NH	03229	Merrimack	013
CONWAY,NH	CONWAY,NH	03818	Carroll	003
CORNISH FLAT,NH	CORNISH FLAT,NH	03746	Sullivan	019
CORNISH,NH	CORNISH,NH	03745	Sullivan	019
GROYDON,NH	NEWPORT,NH	03773	Sullivan	019
CRYSTAL,NH	GROVETON,NH	03582	Coos	007
DALTON,NH	WHITEFIELD,NH	03598	Coos	007
DANBURY,NH	DANBURY,NH	03230	Merrimack	013
DANVILLE, NH	S DANVILLE, NH	03881	Rockingham	015
DANVILLE,NH	DANVILLE,NH	03819	Rockingham	015
DEERFIELD,NH	DEERFIELD,NH	03037	Rockingham	015
DEERING,NH	HILLSBORO,NH	03244	Hillsborough	011
DERRY,NH	DERRY,NH	03038	Rockingham	015
DIXVILLE,NH	COLEBROOK,NH	03576	Coos	007
DORCHESTER,NH	RUMNEY,NH	03266	Grafton	009
DOVER,NH	DOVER,NH	03820	Strafford	017
DOVER,NH	DOVER,NH	03821	Strafford	017
DOVER,NH	DOVER,NH	03822	Strafford	017
DREWSVILLE,NH	DREWSVILLE,NH	03604	Cheshire	005
DUBLIN,NH	DUBLIN,NH	03444	Cheshire	005



TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
DUMMER,NH	MILAN,NH	03588	Coos	007
DUNBARTON,NH	DUNBARTON,NH	03046	Merrimack	013
DURHAM,NH	DURHAM,NH	03824	Strafford	017
EAST ANDOVER,NH	EAST ANDOVER,NH	03231	Merrimack	013
EAST CANDIA,NH	EAST CANDIA,NH	03040	Rockingham	015
EAST DERRY,NH	EAST DERRY,NH	03041	Rockingham	015
EAST HAMPSTEAD,NH	EAST HAMPSTEAD,NH	03826	Rockingham	015
EAST HEBRON,NH	EAST HEBRON,NH	03232	Grafton	009
EAST KINGSTON,NH	EAST KINGSTON,NH	03827	Rockingham	015
EAST LEMPSTER,NH	EAST LEMPSTER,NH	03605	Sullivan	019
EAST ROCHESTER,NH	EAST ROCHESTER,NH	03868	Strafford	017
EAST SWANZEY,NH	EAST SWANZEY,NH	03446	Cheshire	005
EAST WAKEFIELD,NH	EAST WAKEFIELD,NH	03830	Carroll	003
EASTON,NH	FRANCONIA,NH	03580	Grafton	009
EATON,NH	EATON CENTER,NH	03832	Carroll	003
EFFINGHAM,NH	SOUTH EFFINGHAM,NH	03882	Carroll	003
ELKINS,NH	ELKINS,NH	03233	Merrimack	013
ELLSWORTH,NH	PLYMOUTH,NH	03264	Grafton	009
ENFIELD CENTER,NH	ENFIELD CTR,NH	03749	Grafton	009
ENFIELD,NH	ENFIELD,NH	03748	Grafton	009
EPPING,NH	EPPING,NH	03042	Rockingham	015
EPSOM,NH	EPSOM,NH	03234	Merrimack	013
ERROL,NH	ERROL,NH	03579	Coos	007
ERVINGS LOCATION,NH	COLEBROOK,NH	03576	Coos	007
ETNA,NH	ETNA,NH	03750	Grafton	009
EXETER,NH	EXETER,NH	03833	Rockingham	015
FARMINGTON,NH	FARMINGTON,NH	03835	Strafford	017
FITZWILLIAM,NH	FITZWILLIAM,NH	03447	Cheshire	005
FRANCESTOWN,NH	FRANCESTOWN,NH	03043	Hillsborough	011
FRANCONIA,NH	FRANCONIA,NH	03580	Grafton	009
FRANKLIN,NH	FRANKLIN,NH	03235	Merrimack	013
FREEDOM,NH	FREEDOM,NH	03836	Carroll	003
FREMONT,NH	FREMONT,NH	03044	Rockingham	015
GEORGES MILLS,NH	GEORGES MILLS,NH	03751	Sullivan	019
GERRISH,NH	CONCORD,NH	03303	Merrimack	013
GILFORD,NH	GILFORD,NH	03249	Belknap	001
GILMANTON IRON WORKS,NH	GLMTN IRN WKS,NH	03837	Belknap	001
GILMANTON,NH	GILMANTON,NH	03237	Belknap	001
GILSUM,NH	GILSUM,NH	03448	Cheshire	005
GLEN,NH	GLEN,NH	03838	Carroll	003
GLENCLIFF (HOME FOR,NH	WOODSVILLE,NH	03785	Grafton	009
GLENCLIFF,NH	GLENCLIFF,NH	03238	Grafton	009
GOFF'S FALLS,NH	MANCHESTER,NH	03103	Hillsborough	011
GOFFSTOWN,NH	GOFFSTOWN,NH	03045	Hillsborough	011
GONIC,NH	GONIC,NH	03839	Strafford	017

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
GOSHEN,NH	GOSHEN,NH	03752	Sullivan	019
GOSSVILLE,NH	EPSOM,NH	03234	Merrimack	013
GRAFTON,NH	GRAFTON,NH	03240	Grafton	009
GRANTHAM,NH	GRANTHAM,NH	03753	Sullivan	019
GRASMERE,NH	GOFFSTOWN,NH	03045	Hillsborough	011
GREENFIELD,NH	GREENFIELD,NH	03047	Hillsborough	011
GREENLAND,NH	GREENLAND,NH	03840	Rockingham	015
GREENS GRANT,NH	GORHAM,NH	03581	Coos	007
GREENVILLE,NH	GREENVILLE,NH	03048	Hillsborough	011
GROTON,NH	HEBRON,NH	03241	Grafton	009
GROVETON,NH	GROVETON,NH	03582	Coos	007
GUILD,NH	GUILD,NH	03754	Sullivan	019
HAMPSTEAD,NH	HAMPSTEAD,NH	03841	Rockingham	015
HAMPTON FALLS,NH	HAMPTON FALLS,NH	03844	Rockingham	015
HAMPTON,NH	HAMPTON,NH	03842	Rockingham	015
HAMPTON,NH	HAMPTON	03843	Rockingham	015
HANCOCK,NH	HANCOCK,NH	03449	Hillsborough	011
HANOVER,NH	HANOVER,NH	03755	Grafton	009
HANOVER,NH	HANOVER,NH	03756	Grafton	009
HARRISVILLE(CHESHAM)	CHESHAM	03455	Cheshire	005
HARRISVILLE,NH	HARRISVILLE,NH	03450	Cheshire	005
HARTS LOCATION,NH	BARTLETT,NH	03812	Carroll	003
HAVERHILL,NH	HAVERHILL,NH	03765	Grafton	009
HEBRON,NH	HEBRON,NH	03241	Grafton	009
HEDDING,NH	EPPING,NH	03042	Rockingham	015
HENNIKER,NH	HENNIKER,NH	03242	Merrimack	013
HILL,NH	HILL,NH	03243	Merrimack	013
HILLSBORO, HILLSBORO,NH	HILLSBORO,NH	03244	Hillsborough	011
HINSDALE,NH	HINSDALE,NH	03451	Cheshire	005
HOLDERNESS,NH	HOLDERNESS,NH	03245	Grafton	009
HOLLIS,NH	HOLLIS,NH	03049	Hillsborough	011
HOOKSETT,NH	MANCHESTER,NH	03106	Merrimack	013
HOPKINTON,NH	CONTOOCOOK,NH	03229	Merrimack	013
HUDSON,NH	HUDSON,NH	03051	Hillsborough	011
INTERVALE,NH	INTERVALE,NH	03845	Carroll	003
JACKSON,NH	JACKSON,NH	03846	Carroll	003
JAFFREY CENTER,NH	JAFFREY CTR,NH	03454	Cheshire	005
JAFFREY,NH	JAFFREY,NH	03452	Cheshire	005
JEFFERSON,NH	JEFFERSON,NH	03583	Coos	007
KEARSARGE,NH	KEARSARGE,NH	03847	Carroll	003
KEENE STATE COLLEGE, NH	KEENE STATE COLLEGE, NH	03435	Cheshire	005
KEENE,NH	KEENE,NH	03431	Cheshire	005
KELLYVILLE,NH	NEWPORT,NH	03773	Sullivan	019
KENSINGTON,NH	EXETER,NH	03833	Rockingham	015
KILKENNY TOWNSHIP,NH	BERLIN,NH	03570	Coos	007

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
KINGSTON,NH	KINGSTON,NH	03848	Rockingham	015
LACONIA P.O.,NH	LACONIA,NH	03247	Belknap	001
LACONIA,NH	LACONIA,NH	03246	Belknap	001
LAKEPORT,NH	LACONIA,NH	03246	Belknap	001
LANCASTER,NH	LANCASTER,NH	03584	Coos	007
LANDAFF,NH	LISBON,NH	03585	Grafton	009
LANGDON,NH	ALSTEAD,NH	03602	Sullivan	019
LEBANON,NH	LEBANON,NH	03766	Grafton	009
LEE,NH	DOVER,NH	03820	Strafford	017
LEMPSTER,NH	LEMPSTER,NH	03606	Sullivan	019
LINCOLN,NH	LINCOLN,NH	03251	Grafton	009
LISBON,NH	LISBON,NH	03585	Grafton	009
LITCHFIELD,NH	LITCHFIELD,NH	03052	Hillsborough	011
LITTLETON,NH	LITTLETON,NH	03561	Grafton	009
LIVERMORE,NH	BARTLETT,NH	03812	Grafton	009
LOCHMERE,NH	LOCHMERE,NH	03252	Belknap	001
LONDONDERRY,NH	LONDONDERRY,NH	03053	Rockingham	015
LOUDON,NH	LOUDON, NH	03307	Merrimack	013
LYMAN,NH	LISBON,NH	03585	Grafton	009
LYME CENTER,NH	LYME CENTER,NH	03769	Grafton	009
LYME,NH	LYME,NH	03768	Grafton	009
LYNDEBOROUGH, LYNDEB,NH	LYNDEBOROUGH,NH	03082	Hillsborough	011
MADBURY,NH	DOVER,NH	03820	Strafford	017
MADISON,NH	MADISON,NH	03849	Carroll	003
MANCHESTER,NH	MANCHESTER,NH	03101	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03102	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03103	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03104	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03105	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03107	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03108	Hillsborough	011
MANCHESTER,NH	MANCHESTER,NH	03109	Hillsborough	011
MARLBORO, MARLBOROUG,NH	MARLBOROUGH,NH	03455	Cheshire	005
MARLOW,NH	MARLOW,NH	03456	Cheshire	005
MARTINS LOCATION,NH	GORHAM,NH	03581	Coos	007
MASCOMA,NH	LEBANON,NH	03766	Grafton	009
MASON,NH	GREENVILLE,NH	03048	Hillsborough	011
MEADOWS,NH	MEADOWS,NH	03587	Coos	007
MELVIN MILLS,NH	WARNER,NH	03278	Merrimack	013
MELVIN VILLAGE,NH	MELVIN VLG,NH	03850	Carroll	003
MEREDITH,NH	MEREDITH,NH	03253	Belknap	001
MERIDEN,NH	MERIDEN,NH	03770	Sullivan	019
MERRIMACK,NH	MERRIMACK,NH	03054	Hillsborough	011
MIDDLETON,NH	UNION,NH	03887	Strafford	017
MILAN,NH	MILAN,NH	03588	Coos	007

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
MILFORD,NH	MILFORD,NH	03055	Hillsborough	011
MILLSFIELD,NH	ERROL,NH	03579	Coos	007
MILTON MILLS,NH	MILTON MILLS,NH	03852	Strafford	017
MILTON,NH	MILTON,NH	03851	Strafford	017
MIRROR LAKE,NH	MIRROR LAKE,NH	03853	Carroll	003
MONROE,NH	MONROE,NH	03771	Grafton	009
MONT VERNON,NH	MONT VERNON,NH	03057	Hillsborough	011
MOULTONBORO,NH	MOULTONBORO,NH	03254	Carroll	003
MOULTONVILLE,NH	CTR OSSIPEE,NH	03814	Carroll	003
MOUNT SUNAPEE,NH	MOUNT SUNAPEE,NH	03772	Merrimack	013
MOUNT WASHINGTON,NH	MT WASHINGTON,NH	03589	Coos	007
MUNSONVILLE,NH	MUNSONVILLE,NH	03457	Cheshire	005
NASHUA,NH	NASHUA,NH	03060	Hillsborough	011
NASHUA,NH	NASHUA,NH	03061	Hillsborough	011
NASHUA,NH	NASHUA,NH	03062	Hillsborough	011
NASHUA,NH	NASHUA,NH	03063	Hillsborough	011
NASHUA,NH	NASHUA,NH	03064	Hillsborough	011
NELSON,NH	MUNSONVILLE,NH	03457	Cheshire	005
NEW BOSTON,NH	NEW BOSTON,NH	03070	Hillsborough	011
NEW CASTLE,NH	NEW CASTLE,NH	03854	Rockingham	015
NEW DURHAM,NH	NEW DURHAM,NH	03855	Strafford	017
NEW HAMPTON,NH	NEW HAMPTON,NH	03256	Belknap	001
NEW IPSWICH,NH	NEW IPSWICH,NH	03071	Hillsborough	011
NEW LONDON,NH	NEW LONDON,NH	03257	Merrimack	013
NEWBURY,NH	NEWBURY,NH	03255	Merrimack	013
NEWFIELDS,NH	NEWFIELDS,NH	03856	Rockingham	015
NEWINGTON,NH	PORTSMOUTH,NH	03801	Rockingham	015
NEWMARKET,NH	NEWMARKET,NH	03857	Rockingham	015
NEWPORT,NH	NEWPORT,NH	03773	Sullivan	019
NEWTON JUNCTION,NH	NEWTON JCT,NH	03859	Rockingham	015
NEWTON,NH	NEWTON,NH	03858	Rockingham	015
NORTH CONWAY,NH	NORTH CONWAY,NH	03860	Carroll	003
NORTH HAMPTON,NH	NORTH HAMPTON,NH	03862	Rockingham	015
NORTH HAVERHILL,NH	NORTH HAVERHILL,NH	03774	Grafton	009
NORTH SALEM,NH	NORTH SALEM,NH	03073	Rockingham	015
NORTH SANDWICH,NH	NORTH SANDWICH,NH	03259	Carroll	003
NORTH SUTTON,NH	NORTH SUTTON,NH	03260	Merrimack	013
NORTH WALPOLE,NH	NORTH WALPOLE,NH	03609	Cheshire	005
NORTH WOODSTOCK,NH	NORTH WOODSTOCK,NH	03262	Grafton	009
NORTHFIELD,NH	TILTON,NH	03276	Merrimack	013
NORTHUMBERLAND,NH	GROVETON,NH	03582	Coos	007
NORTHWOOD,NH	NORTHWOOD,NH	03261	Rockingham	015
NOTTINGHAM,NH	NOTTINGHAM,NH	03290	Rockingham	015
ODELL,NH	COLEBROOK,NH	03576	Coos	007
ORANGE,NH	CANAAN,NH	03741	Grafton	009

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
ORFORD,NH	ORFORD,NH	03777	Grafton	009
ORFORDVILLE,NH	ORFORD,NH	03777	Grafton	009
OSSIPEE,NH	OSSIPEE,NH	03864	Carroll	003
PELHAM,NH	PELHAM,NH	03076	Hillsborough	011
PEMBROKE,NH	SUNCOOK,NH	03275	Merrimack	013
PENACOOK,NH	CONCORD,NH	03303	Merrimack	013
PERCY,NH	GROVETON,NH	03582	Coos	007
PETERBOROUGH, NH	PETERBOROUGH,NH	03458	Hillsborough	011
PETERBOROUGH, NH	PETERBOROUGH, NH	03460	Hillsborough	011
PIERMONT,NH	PIERMONT,NH	03779	Grafton	009
PIKE,NH	PIKE,NH	03780	Grafton	009
PINKHAMS GRANT,NH	GORHAM,NH	03581	Coos	007
PITTSBURG,NH	PITTSBURG,NH	03592	Coos	007
PITTSFIELD,NH	PITTSFIELD,NH	03263	Merrimack	013
PLAINFIELD,NH	PLAINFIELD,NH	03781	Sullivan	019
PLAISTOW,NH	PLAISTOW,NH	03865	Rockingham	015
PLYMOUTH,NH	PLYMOUTH,NH	03264	Grafton	009
PORTSMOUTH,NH	PORTSMOUTH,NH	03801	Rockingham	015
PORTSMOUTH,NH	PORTSMOUTH,NH	03802	Rockingham	015
PORTSMOUTH,NH	PORTSMOUTH,NH	03803	Rockingham	015
PORTSMOUTH,NH	PORTSMOUTH,NH	03804	Rockingham	015
POTTER PLACE,NH	POTTER PLACE,NH	03265	Merrimack	013
QUINCY,NH	RUMNEY,NH	03266	Grafton	009
RANDOLPH,NH	BERLIN,NH	03570	Coos	007
RAYMOND,NH	RAYMOND,NH	03077	Rockingham	015
REDSTONE,NH	CENTER CONWAY,NH	03813	Carroll	003
REEDS FERRY,NH	MERRIMACK,NH	03054	Hillsborough	011
RICHMOND,NH	WINCHESTER,NH	03470	Cheshire	005
RINDGE,NH	RINDGE,NH	03461	Cheshire	005
RIVERHILL,NH	CONCORD,NH	03303	Merrimack	013
RIVERSIDE,NH	COLEBROOK,NH	03576	Coos	007
RIVERTON,NH	JEFFERSON,NH	03583	Coos	007
ROCHESTER,NH	ROCHESTER	03866	Strafford	017
ROCHESTER,NH	ROCHESTER,NH	03867	Strafford	017
ROLLINSFORD,NH	ROLLINSFORD,NH	03869	Strafford	017
ROXBURY,NH	KEENE,NH	03431	Cheshire	005
RUMNEY,NH	RUMNEY,NH	03266	Grafton	009
RYE BEACH,NH	RYE BEACH,NH	03871	Rockingham	015
RYE,NH	RYE,NH	03870	Rockingham	015
SALEM,NH	SALEM,NH	03079	Rockingham	015
SALISBURY,NH	SALISBURY,NH	03268	Merrimack	013
SALMON FALLS,NH	ROLLINSFORD,NH	03869	Strafford	017
SANBORNTON,NH	SANBORNTON,NH	03269	Belknap	001
SANBORNVILLE,NH	SANBORNVILLE,NH	03872	Carroll	003
SANDOWN,NH	SANDOWN,NH	03873	Rockingham	015

TOWN NAME	ZIP NAME	ZIP CODE	NHSCR Residence Code	
			County	Code
SANDWICH,NH	SANDWICH,NH	03270	Carroll	003
SEABROOK,NH	SEABROOK,NH	03874	Rockingham	015
SHARON,NH	PETERBOROUGH,NH	03458	Hillsborough	011
SHELBURNE,NH	GORHAM,NH	03581	Coos	007
SHORT FALLS,NH	EPSOM,NH	03234	Merrimack	013
SILVER LAKE,NH	SILVER LAKE,NH	03875	Carroll	003
SMITHTOWN,NH	SEABROOK,NH	03874	Rockingham	015
SNOWVILLE,NH	MADISON,NH	03849	Carroll	003
SOMERSWORTH,NH	SOMERSWORTH,NH	03878	Strafford	017
SOUTH EFFINGHAM,NH	SOUTH EFFINGHAM,NH	03882	Carroll	003
SOUTH HAMPTON,NH	EAST KINGSTON,NH	03827	Rockingham	015
SOUTH NEWBURY,NH	SOUTH NEWBURY,NH	03272	Merrimack	013
SOUTH SUTTON,NH	SOUTH SUTTON,NH	03273	Merrimack	013
SOUTH TAMWORTH,NH	SOUTH TAMWORTH,NH	03883	Carroll	003
SPOFFORD,NH	SPOFFORD,NH	03462	Cheshire	005
SPRINGFIELD,NH	WEST SPRINGFIELD,NH	03284	Sullivan	019
STARK,NH	GROVETON,NH	03582	Coos	007
STATELINE,NH	FITZWILLIAM,NH	03447	Cheshire	005
STATELINE,NH	FITZWILLIAM,NH	03447	Cheshire	005
STEWARTSTOWN,NH	COLEBROOK,NH	03576	Coos	007
STINSON LAKE,NH	STINSON LAKE,NH	03274	Grafton	009
STODDARD,NH	STODDARD,NH	03464	Cheshire	005
STRAFFORD,NH	STRAFFORD,NH	03884	Strafford	017
STRATFORD,NH	NORTH STRATFORD,NH	03590	Coos	007
STRATHAM,NH	STRATHAM,NH	03885	Rockingham	015
STRAWBERRY BANKE,NH	PORTSMOUTH,NH	03801	Rockingham	015
SUCCESS, SUCCESS TOW,NH	MILAN,NH	03588	Coos	007
SUGAR HILL,NH	LISBON,NH	03585	Grafton	009
SULLIVAN,NH	EAST SULLIVAN,NH	03445	Cheshire	005
SUNAPEE,NH	SUNAPEE,NH	03782	Sullivan	019
SUNCOOK,NH	SUNCOOK,NH	03275	Merrimack	013
SURRY,NH	KEENE,NH	03431	Cheshire	005
SUTTON,NH	BRADFORD,NH	03221	Merrimack	013
SWANZEY,NH	WINCHESTER,NH	03470	Cheshire	005
TAMWORTH,NH	TAMWORTH,NH	03886	Carroll	003
TEMPLE,NH	TEMPLE,NH	03084	Hillsborough	011
THORNTON,NH	CAMPTON,NH	03223	Grafton	009
TILTON,NH	TILTON,NH	03276	Belknap	001
TROY,NH	TROY,NH	03465	Cheshire	005
TUFTONBORO,NH	OSSIPEE,NH	03864	Carroll	003
TWIN MOUNTAIN,NH	TWIN MOUNTAIN,NH	03595	Coos	007
UNION,NH	UNION,NH	03887	Carroll	003
UNITY,NH	CHARLESTOWN,NH	03603	Sullivan	019
WAKEFIELD,NH	SANBORNVILLE,NH	03872	Carroll	003
WALPOLE,NH	WALPOLE,NH	03608	Cheshire	005



# ***NEW HAMPSHIRE STATE CANCER REGISTRY*** ***DATA COLLECTION MANUAL***

Supplement to

**S**Tandards for **O**ncology **R**egistry **E**ntry  
STORE 2022

Effective for cases diagnosed January 1, 2022



**NEW HAMPSHIRE STATE CANCER REGISTRY**  
**P.O. BOX 186, Hanover, NH 03755**  
**(603)653-6265**



## Summary of Changes 2022

### New Data Items (STORE 2022, p29)

1. There are five new SSDIs added to capture information to prognosis and/or treatment planning and reflect changes in clinical guidelines. All new SSDI information is incorporated into the Staging APIs. Please see the SSDI Manual, Version 2.1 (<https://apps.naacr.org/ssdi/list/>) for additional definition and coding information.<sup>1</sup>
  - 3955 Derived Rai Stage
  - 3956 p16
  - 3957 LN Status Pelvic
  - 3958 LN Status Para-Aortic
  - 3959 LN Status Femoral-Inguinal
2. The four tobacco data items previously required are now replaced with the new data item *Tobacco Use Smoking Status* [Item #344] effective with cases diagnosed January 1, 2022 and forward only.

### Data Items with Changes (STORE 2022, p29)

3. Some SSDI codes and code descriptions were changed to reflect changes in clinical management and/or staging and to improve clarity or to address questions that were raised in the various forums. Code changes for SSDIs are applicable to cases diagnosed January 1, 2018 forward, but registrars will not be required to update previously coded information. All changes are available on the [2022 NAACCR Implementation Guidelines and Recommendations](#) and incorporated into the [SSDI Manual](#).

### Reportability Change (STORE 2022, p31)

4. Reportability for cases diagnosed in 2022 is based on the ICD-O Third Edition, Second Revision Morphology (ICD-O-3.2) plus the ICD-O-3.2 updates posted on the [NAACCR website](#). The 2022 ICD-O update tables have columns for each standard setter (SEER, NPCR, CoC, and Canada) to indicate reportability for each of the new codes, terms, etc.<sup>1</sup> Note that NHSCR reporting requirements follow NPCR requirements.

### Reportability Change (STORE 2022, p33 and p38)

5. 8210/3 Adenomatous polyp, high grade dysplasia is reportable for stomach and small intestines ONLY beginning 01/01/2022.

## Section One: Case Eligibility

### Case Eligibility (STORE 2022, p38)

6. NHSCR requires registries in accredited programs to accession and abstract required tumors diagnosed and/or treated at the abstracting facility. NHSCR does not conduct follow-up activities for reportable cancers after the diagnosis and complete first-course treatment has been reported. NHSCR collects analytic cases (Class of Case 00-22) as well as most non-analytic cases (Class of Case 30-43). ([See NH-20](#))

### Required Tumors (STORE 2022, p38)

7. Examples of reportable and non-reportable cancers are provided on pages [E-5 – E-10](#) of this supplement.
8. Cases diagnosed clinically are reportable. In the absence of a histologic or cytologic confirmation of a reportable neoplasm, accession a case based on the **clinical diagnosis** (when a recognized medical practitioner says the patient has a cancer, carcinoma, malignant neoplasm, or reportable neoplasm). A clinical diagnosis may be recorded in the discharge diagnosis on the face sheet or other parts of the medical record.<sup>2</sup>

**Note:** A pathology report normally takes precedence over a clinical diagnosis. If the patient has a negative biopsy, the case would **not** be reported.

#### Exceptions

1. Patient receives **treatment** for cancer. Accession the case.

**Note:** Standard treatments for cancer may be given for non-malignant conditions. Follow back with the physician to clarify if needed.

2. It has been **six months or longer** since the negative biopsy, and the physician continues to call this a reportable disease. Accession the case.
9. Intraepithelial neoplasia, grade III, for all sites are reportable, EXCEPT carcinoma in situ of cervix (CIS, CIN III) and of the prostate (PIN III).
10. A brain or a CNS neoplasm identified only by diagnostic imaging is reportable.<sup>3</sup>
    - **Neoplasm** and **tumor** are **reportable** terms for brain and CNS because they are listed in ICD-O-3 with behavior codes of /0 and /1.
    - **Mass** and **lesion** are not reportable terms for brain and CNS because they are not listed in ICD-O-3 with behavior codes of /0 or /1.

#### Reportable-by-Agreement Cases (STORE 2022, p38)

11. Reportable-by-agreement cases that fall outside the NHSCR's reportable list should not be transferred to the NHSCR.

#### Reportable-by-Agreement Cases (STORE 2022, p39)

12. NHSCR requires the reporting of most nonanalytic cases. ([See NH-21](#))

#### Ambiguous Terms at Diagnosis (STORE 2022, p39)

13. The use of ambiguous terminology is further defined on pages [E-11 – E-12](#) of this supplement.
    - a. Report cases that use the words on the list or an equivalent word such as “favored” rather than “favor(s).” Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable. Do not substitute “likely” for “most likely.”
    - b. There may be ambiguous terms preceded by a modifier, such as “mildly” suspicious. In general, ignore modifiers or other adjectives and accept the reportable ambiguous term.<sup>2</sup>
14. “Suspicious cytology” means any cytology report diagnosis that uses an ambiguous term, including ambiguous terms that are listed as reportable in this manual.<sup>2</sup>
15. Cases with a final diagnosis using any of the non-diagnostic terms are reportable if cancer-directed treatment is given or if the physician states the final diagnosis is a malignancy. ([See NH-10 above](#))

#### Class of Case (STORE 2022, p41)

16. NHSCR requires the staging of all cases, including Class of Case 00 and 30-43.
17. NHSCR requires the collection of most non-analytic cases (Class of Case 30-43). ([See NH-21](#))

**Date of First Contact (STORE 2022, p42)**

18. NHSCR requires the reporting of pathology-only cases.
19. Facilities that have agreements with staff physicians to collect cases seen off site are to abstract as physician-only cases.
20. NHSCR requires NH reporting facilities to accession and abstract all cases seen with evidence of a reportable cancer or for cancer-directed treatment, on or after the NHSCR reference date (June 1986) only IF the case has not been reported by the diagnosing or treating facility. Refer to Appendix G: NHSCR Non-Analytic Tracking Form for procedure to determine which non-analytic cases do not need to be collected.
21. Non-analytic cases include patients receiving transient care, patients with active cancer admitted for medical conditions other than cancer, patients with a history of cancer that are now undergoing cancer-directed treatment, as well as pathology-only, physician-only, and consult-only cases (i.e. class case 30-99). NHSCR does not require the reporting of historical cases when they do not have active disease. Place of diagnosis, residence, and class of case are not determining factors for reportability.

## Reportable Examples

As referenced in the Reportability instructions of the 2022 SEER Program Coding and Staging Manual.<sup>2</sup>

<b>Reportable Malignant Examples</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
1	Atypical fibroxanthoma (superficial malignant fibrous histiocytoma)	The information in parentheses provides more detail and confirms a reportable malignancy.
2	Positive histology from needle biopsy followed by negative resection	This case is reportable based on positive needle biopsy.
3	Biopsy-proven squamous cell carcinoma of the nipple with a subsequent areolar resection showing foreign body granulomatous reaction to suture material and no evidence of residual malignancy in the nipple	This case is reportable. The fact that no residual malignancy was found in the later specimen does not disprove the malignancy diagnosed by the biopsy.
4	Ulcerated histologically malignant spindle cell neoplasm, consistent with atypical fibroxanthoma; an exhaustive immunohistochemical work-up shows no melanocytic, epithelial or vascular differentiation	Atypical fibroxanthoma is a superficial form of a malignant fibrous histiocytoma. This case is reportable. The pathologist has the final say on behavior for a particular case. In this case, the pathologist states that this tumor is malignant.
5	Aggressive adult granulosa cell tumor with one of two lymph nodes positive for malignant metastatic granulosa cell tumor	This case is reportable because malignant granulosa cell tumor is reportable. The lymph node metastases prove malignancy.
6	Carcinoid of the appendix found on appendectomy	Carcinoid tumor, NOS is reportable (8240/3).
7	Microcarcinoid tumors of the stomach	Microcarcinoid and carcinoid tumors are reportable. The ICD-O-3.2 histology code is 8240/3. Microcarcinoid is a designation for neuroendocrine tumors of the stomach when they are less than 0.5 cm. in size. Neuroendocrine tumors of the stomach are designated carcinoid when they are 0.5 cm or larger. The term microcarcinoid tumor is not equivalent to carcinoid tumorlet.
8	Ovarian mucinous borderline tumor with foci of intraepithelial carcinoma	This case is reportable because there are foci of intraepithelial carcinoma (carcinoma in situ).
9	Squamous cell carcinoma of the anus, NOS	Squamous cell carcinoma of the anus (C210) is reportable. <b>Note:</b> Squamous cell carcinoma of the perianal skin (C445) is <b>not</b> reportable.
10	Mature teratoma of the testis when diagnosed after puberty (malignant)	For testis: Mature teratoma in adults is malignant (9080/3). <b>Note:</b> Do not report when diagnosed in a child (benign). Do not report mature teratoma of the testis when it is not known whether the patient is prepubescent or postpubescent. Pubescence can take place over a number of years; review physical history and do not rely only on age.

<b>Reportable Malignant Examples, cont.</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
11	Well-differentiated neuroendocrine tumor (NET) of the stomach	The WHO classification of digestive system tumors uses the term NET G1 (grade 1) as a synonym for carcinoid and well-differentiated NET, 8240/3.
12	Cystic pancreatic endocrine neoplasm (CPEN)	Assign 8150/3 unless specified as a neuroendocrine tumor, Grade 1 (8240/3) or neuroendocrine tumor, Grade 2 (8249/3).
13	Solid pseudopapillary neoplasm of the pancreas	Assign 8452/3.
14	Liver cases with an LI-RADS category LR-4 or LR-5	Report based on the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) <a href="#">definitions</a> . Use the date of the LR-4 (probable HCC; high probability but not 100% certainty observation is HCC) or LR-5 (definitely HCC; 100% certainty observation is HCC) scan as the date of diagnosis when it is the earliest confirmation of the malignancy. If there is no statement of the LI-RADS score but there is reference that a lesion is in the Organ Procurement and Transplantation Network (OPTN) 5 category, report based on the OPTN class of 5. OPTN class 5 indicates that a nodule meets radiologic criteria for hepatocellular carcinoma.
15	Mammary analogue secretory carcinoma (MASC)	MASC is a tumor that predominantly arises in the parotid gland. If the primary site is submandibular gland, assign C080. Assign 8502/3. Override any edits triggered by the combination of C080 and 8502/3.
16	Malignant perivascular epithelioid cell tumor (PEComa)	Assign 8714/3 to malignant PEComa. Some PEComas such as angiomyolipoma and lymphangiomyomatosis have specific ICD-O codes and their <b>malignant</b> counterparts may be coded to 8860/3 and 9174/3, respectively. There are no separate ICD-O codes for other specific PEComas, e.g., clear cell sugar tumor of lung, clear cell myomelanocytic tumor of the falciform ligament, and some unusual clear cell tumors occurring in other organs or for PEComa, NOS. These PEComas may therefore be coded to 8005 as clear cell tumors NOS; in other words, clear cell tumors are not clear cell variants of carcinomas, sarcomas, or other specific tumor type.
		<b>Note:</b> PEComa is non-specific as to behavior. Unless the pathologist states that it is malignant, the default code is 8005/1 (non-reportable).
17	Noninvasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia	For neoplasms of the pancreas, MCN with high grade dysplasia is the preferred term and mucinous cystadenocarcinoma, noninvasive is a related term (8470/2).
18	Noninvasive low grade (micropapillary) serous carcinoma (MPSC) of the ovary	Assign code 8460/2, applying the ICD-O-3 matrix concept to this noninvasive carcinoma. Noninvasive can be used as a synonym for in situ, ICD-O-3 behavior code /2. See page 66 in ICD-O-3.

<b>Reportable Malignant Examples, cont.</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
19	Prostate cancer cases with an PI-RADS category 4 or 5	Report based on the American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS) <a href="#">definitions</a> . PI-RADS categories 4 (high-clinically significant cancer is likely to be present) and 5 (very high-clinically significant cancer is highly likely to be present) are reportable, unless there is other information to the contrary.
20	Early or evolving melanoma, in situ or invasive	As of 1/1/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
21	Low-grade appendiceal mucinous neoplasm (LAMN)	Report LAMN beginning with January 1, 2022 diagnoses. LAMN is assigned a behavior of /2 or /3 making it reportable. LAMNs are slow-growing neoplasms that have the potential for peritoneal spread and can result in patient death. LAMNs demonstrate an interesting biology in that they do not have hematogenous dissemination risk, but risk for appendiceal perforation, which can result in peritoneal dissemination, repeated recurrences after surgery and even death.
22	Clear cell papillary renal cell carcinoma	Clear cell papillary renal cell carcinoma (8323/3) is reportable.

<b>Reportable Non-Malignant Examples</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
23	Hemangioma, NOS (9120/0) and cavernous hemangioma (9121/0)	Report the CNS site in which the hemangioma originates. <b>Note:</b> For cavernous sinus hemangioma, report the site as cerebral meninges C700.
24	Dermoid cyst of the brain	This condition is reportable for cases diagnosed 2004 and later. Assign 9084/0.
25	Tectal plate lipoma	This is a reportable brain tumor. It is a benign neoplasm (lipoma) of the mid brain (brain stem) as noted by the location "tectal plate."
26	Lhermitte-Duclos disease	The WHO classification for CNS tumors lists this entity as dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) signifying that the terms are used synonymously. Assign C716, 9493/0.
27	Rathke pouch tumor (C751, 9350/1)	Rathke pouch tumor is a reportable neoplasm for cases diagnosed 2004 and later. Rathke cleft cyst and Rathke pouch tumor are different conditions. <b>Note:</b> Rathke cleft cyst is not reportable.

## Non-Reportable Examples

As referenced in the Reportability instructions of the 2022 SEER Program Coding and Staging Manual.<sup>2</sup>

<b>Non-Reportable Malignant Examples</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
1	Sclerosing hemangioma of the lung with multiple regional lymph nodes involved with sclerosing hemangioma.	The lymph node involvement is non-malignant. According to the WHO Classification of Lung Tumors, 4th edition, sclerosing hemangioma "behaves in a clinically benign fashion...Reported cases with hilar or mediastinal lymph node involvement do not have a worse prognosis."
2	High grade squamous intraepithelial lesion (HGSIL or HSIL), carcinoma in situ (CIS), and AIN III (8077) arising in perianal <b>skin</b> (C445)	HGSIL or HSIL, CIS, and AIN III arising in perianal <b>skin</b> are not reportable. Refer to the Reportability Section of the main manual.
3	Squamous cell carcinoma of the perianal <b>skin</b> (C445)	Squamous cell carcinoma of sites in C44 is not reportable. Squamous cell carcinoma of the anus (C210) <b>is</b> reportable.
4	Squamous cell carcinoma of the canthus (C441)	Squamous cell carcinoma in sites coded to C44 is not reportable.
5	Breast cases designated BIRADS 4, 4A, 4B, 4C or BIRADS 5 without any additional information	The American College of Radiology defines Category 4 as "Suspicious." The descriptions in categories 4, 4a, 4b, and 4c are not diagnostic of malignancy. They all represent a percentage of likelihood, the highest being 4c which is greater than 50% but less than 95% likelihood of malignancy. The ACR states "This category is reserved for findings that do not have the classic appearance of malignancy but are sufficiently suspicious to justify a recommendation for biopsy." Category 5 is "Highly Suggestive of Malignancy." "Suggestive" is not reportable ambiguous terminology. ACR states that Category 5 has a "very high probability" of malignancy, but again, it is not diagnostic.
6	Lung cases designated "Lung-RADS 4A," 4B, or 4X	Lung: Do <b>not</b> use the ACR Lung Imaging Reporting and Data System (Lung-RADS™) to determine reportability. Look for reportable terminology from the managing physician or other sources.
7	Liver cases based only on an LI-RADS category of LR-3	Do <b>not</b> report liver cases based only on an LI-RADS category of LR-3.
8	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)	DIPNECH is a generalized proliferation of scattered single cells, small nodules (neuroendocrine bodies) or linear proliferation of pulmonary neuroendocrine cells (PNCs) according to the WHO classification of lung tumors.
9	Basal cell carcinoma (BCC) with neuroendocrine differentiation of the <b>skin</b>	BCC in sites coded to C44 is not reportable to SEER.
10	Lentiginous melanocytic lesion	Not reportable.

<b>Non-Reportable Malignant Examples, cont.</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
11	Intraductal papillary mucinous neoplasms with <b>low</b> or <b>moderate</b> grade dysplasia (also called IPMN adenomas)	Not reportable.
12	Noninvasive mucinous cystic neoplasm (MCN) of the pancreas with <b>low</b> or <b>intermediate</b> grade dysplasia	Not reportable.
13	Subdural hygroma	Subdural hygroma is not a neoplasm; it is a collection of cerebrospinal fluid in the subdural space. It may be related to a head injury.
14	Brain lesions associated with multiple sclerosis	These brain lesions are not neoplastic; they are part of the disease process of multiple sclerosis.
15	Mature teratoma of the testis when diagnosed before puberty (benign, 9084/0).	Pubescence can take place over a number of years; review history and physical information and do not rely only on age. Do not report mature teratoma when it is not known whether the patient is pre- or post-pubescent.
16	Mature teratoma of the ovary (9080/0)	Not reportable.
17	Venous angiomas (9122/0)	The primary site for venous (hem)angioma arising in the brain is blood vessel (C490). The combination of 9122/0 and C490 is not reportable. This is a venous abnormality. Previously called venous angiomas, these are currently referred to as developmental venous anomalies (DVA).
18	Multilocular cystic renal neoplasm of low malignant potential	Previously called multilocular cystic renal cell carcinoma, this diagnosis became non-reportable beginning with the new designation in 2016. Refer to the Solid Tumor Tumor Coding Rules, Kidney Equivalent Terms and Definitions, for histology/morphology information.
19	Lymphangioma of the brain or CNS	Lymphangioma is a malformation of the lymphatic system. Even though it has an ICD-O code, do not report it.
20	Carcinoid heart disease based on clinical information	Carcinoid heart disease is not reportable but this diagnosis indicates that the patient likely has a carcinoid tumor which may be reportable. Obtain further information.
21	Carcinoid tumorlet of the lung	Not reportable.
22	Pulmonary benign metastasizing leiomyoma (BML) (8898/1)	According to WHO, this resembles a typical leiomyoma but it is found in the lungs of women with a history of typical uterine leiomyomas. A recent article states that because of the hormone-sensitive characteristics of BML, treatments are based on hormonal manipulation along with either surgical or medical oophorectomy. Tamoxifen treatment is in keeping with the BML diagnosis.



<b>Non-Reportable Malignant Examples, cont.</b>		
<b>#</b>	<b>Diagnosis/Condition</b>	<b>Notes</b>
23	Colloid cyst at the foramen of Monro	Colloid cysts are endodermal congenital malformations and do not have an ICD-O-3 code. See the glossary for registrars at: <a href="#">Colloid cyst</a>
24	Mammary fibromatosis	Mammary fibromatosis is not reportable. The WHO classification for breast tumors assigns mammary fibromatosis a behavior code of /1. According to WHO, mammary fibromatosis is a locally infiltrative lesion without metastatic potential.
25	Thalamic amyloidoma	Amyloidoma (tumoral amyloidosis, amyloid tumor) is a tumor-like deposit of amyloid. It is not neoplastic. Amyloid is a protein derived substance deposited in various clinical settings.
26	Pseudotumor cerebri	Pseudotumor cerebri is not a neoplasm. The pressure inside the skull is increased and the brain is affected in a way that appears to be a tumor, but it is not a tumor.
27	Conjunctival primary acquired melanosis (PAM) with atypia	According to our expert pathologist consultant, there has been a lot of debate in the literature about the diagnostic criteria, terminology, and natural history of PAM. The main issue is whether PAM with atypia should be regarded as melanoma in situ. In most studies it appears that PAM with no atypia or mild atypia does not progress to melanoma, and only a small percentage of those with severe atypia do so. PAM, even with atypia, is not melanoma in situ, and should not be reported. For further information, see this article for a review of a large number of patients: Shields, Jerry A, Shields, Carol L, et al. Primary Acquired Melanosis of the Conjunctiva: Experience with 311 Eyes. Trans. Am Ophthalmol Soc 105:61-72, Dec 2007.
28	Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2)	Genetic disease that produces non-malignant tumors in skin, brain, CNS, and other sites. The brain and CNS tumors spawned by NF1 or NF2 are reportable, the genetic disease is not.
29	Ovarian mucinous borderline tumor with microinvasion	For an ovarian mucinous borderline tumor, the term "microinvasion" is not an indication of malignancy. Low malignant potential/borderline ovarian tumors are defined by the pathology of the primary tumor and are not affected by microinvasion or invasion in implants. Though a case may be staged, this does not mean it is reportable.
30	Rathke cleft cyst	Rathke cleft cyst, also called pars intermedia cyst of the parotid gland, is not reportable; whereas, Rathke pouch tumor is reportable.
31	Colon atypical hyperplasia	Not reportable.
32	High grade dysplasia in colorectal and esophageal primary sites	Not reportable.

## How to Use Ambiguous Terminology for Case Ascertainment<sup>2</sup>

### 1. In Situ and Invasive (Behavior codes /2 and /3)

- a. If any of the reportable **ambiguous terms precede** a word that is **synonymous** with an in situ or invasive tumor (e.g., cancer, carcinoma, malignant neoplasm, etc.), accession the case.

**Example:** The pathology report says: Prostate biopsy with markedly abnormal cells that are typical of adenocarcinoma. Accession the case.

**Negative Example:** The final diagnosis on the outpatient report reads: Rule out pancreatic cancer. Do not accession the case.

### b. Discrepancies

- i. Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record

1. Do **not** accession a case when the original source document used a **non-reportable** ambiguous term and subsequent documents refer to history of cancer

**Example:** Report from the dermatologist is “possible melanoma.” Patient admitted later for unrelated procedure and physician listed history of melanoma. Give priority to the information from the dermatologist and do not report this case. “Possible” is **not** a reportable ambiguous term. The later information is less reliable in this case.

- ii. Accept the reportable term and accession the case when there is a single report in which both reportable and non-reportable terms are used

**Example:** Abdominal CT reveals a 1 cm liver lesion. “The lesion is consistent with hepatocellular carcinoma” appears in the discussion section of the report. The final diagnosis is “1 cm liver lesion, possibly hepatocellular carcinoma.” Accession the case. “Consistent with” is a reportable ambiguous term. Accept “consistent with” over the non-reportable term “possibly.”

### c. Do **not** accession a case based ONLY on **suspicious** cytology

**Note:** “Suspicious cytology” means any cytology report diagnosis that uses an ambiguous term, including ambiguous terms that are listed as reportable on the preceding page.

Follow back on cytology diagnoses using ambiguous terminology is strongly recommended.

Cytology refers to the microscopic examination of cells in body fluids obtained from aspirations, washings, scrapings, and smears; usually a function of the pathology department.

**Important:** Accession cases with cytology diagnoses that are **positive** for malignant cells.

- d. Use the reportable ambiguous terms when **screening** diagnoses on pathology reports, operative reports, scans, mammograms, and other diagnostic testing with the exception of tumor markers

- i. Do not accession a case when resection, excision, biopsy, cytology, or physician’s statement proves the ambiguous diagnosis is not reportable

**Example 1:** Mammogram shows calcifications suspicious for intraductal carcinoma. The biopsy of the area surrounding the calcifications is negative for malignancy. Do not accession the case.

**Example 2:** CT report states “mass in the right kidney, highly suspicious for renal cell carcinoma.” CT-guided needle biopsy with final diagnosis “Neoplasm suggestive of oncocytoma. A malignant neoplasm cannot be excluded.” Discharged back to the nursing home and no other information is available. Do not accession the case. The suspicious CT finding was biopsied and not proven to be malignant. “Suggestive of” is not a reportable ambiguous term.

**Example 3:** Stereotactic biopsy of the left breast is “focally suspicious for DCIS” and is followed by a negative needle localization excisional biopsy. Do not accession the case. The needle localization excisional biopsy was performed to further evaluate the suspicious stereotactic biopsy finding. The suspicious diagnosis was proven to be false.

**Example 4:** Esophageal biopsy with diagnosis of “focal areas suspicious for adenocarcinoma in situ.” Diagnosis on partial esophagectomy specimen “with foci of high grade dysplasia; no invasive carcinoma identified.” Do not accession the case. The esophagectomy proved that the suspicious biopsy result was false.

2. **Benign and borderline primary intracranial and CNS tumors**
  - a. Use the “Ambiguous terms that are reportable” list above to identify benign and borderline primary intracranial and CNS tumors that are reportable
  - b. **Neoplasm and tumor are reportable** terms for brain and CNS because they are listed in ICD-O-3 with behavior codes of /0 and /1
  - c. Accession the case when any of the reportable **ambiguous terms precede** either the word “**tumor**” or the word “**neoplasm**”

**Example:** The mass on the CT scan is consistent with pituitary tumor. Accession the case.
  - d. **Mass and lesion are not reportable terms for brain and CNS because they are not listed in ICD-O-3 with behavior codes of /0 or /1**
  - e. **Discrepancies**
    - i. Accession the case based on the reportable ambiguous term when there are reportable and non-reportable ambiguous terms in the medical record
      1. Do not accession a case when subsequent documents refer to history of tumor and the original source document used a **non-reportable** ambiguous term
    - ii. Accept the reportable term and accession the case when there is a single report and one section of a report uses a reportable term such as “apparently” and another section of the same report uses a term that is not on the reportable list

**Exception:** Do not accession a case based ONLY on ambiguous **cytology** (the reportable term is preceded by an ambiguous term such as apparently, appears, compatible with, etc.).
  - f. Use these terms when **screening** diagnoses on pathology reports, scans, ultrasounds, and other diagnostic testing other than tumor markers
    - i. Do not accession the case when resection, excision, biopsy, cytology or physician’s statement proves the ambiguous diagnosis is not reportable

## Section One: Overview of Coding Principles (STORE 2022, p43)

### Unique Patient Identifier Codes (STORE 2022, p43)

22. When assigning sequence numbers, only count cases that are reportable to NHSCR. If your facility collects non-reportable cancers (e.g. CIS, PIN, etc.), assign the sequence pertinent to your facility after the case has been transmitted. See [Determining Multiple Primaries](#) for additional instructions.

### National Provider Identifier (STORE 2022, p43)

23. NHSCR requires the collection and transmission of the National Provider Identifier—Reporting Facility and National Provider Identifier—Managing Physician when available.

### Cancer Identification, Primary Site (STORE 2022, p44)

24. The current Solid Tumor Rules contain additional coding instructions for some primary sites, including Head and Neck, Lung, and Urinary.<sup>2</sup>

*Note:* Continue to use ICD-O-3 for assigning topography codes. ICD-O-3.2 did not change any of the topography codes.

### Revising the Original Diagnosis (STORE 2022, p47)

25. If a completed definitive case is revised as a result of additional information becoming available, submit a revised abstract to the NHSCR with a notation referencing the revision. Additional instructions are provided on [page E-15](#) of this supplement.

### Patient Address and Residency Rules (STORE 2022, p48-50)

26. *Current Address* is not required by NHSCR.

27. Use residency information from a death certificate only when the residency from other sources is coded as unknown. Review each case carefully and apply the U.S. Census Bureau/SEER rules for determining residence.

**Example:** The death certificate may give the person's previous home address rather than the nursing home address as the place of residence. If the person was a resident of a nursing home at diagnosis, use the nursing home address as the place of residence.

28. For *Address at Diagnosis*, collect the street address of usual residence as stated by the patient. When PO Box is the only address available, record UNKNOWN for address at diagnosis, and record the PO Box address in the *Address at Diagnosis-Supplemental* data field.

### In utero Diagnosis and Treatment (STORE 2022, p50 and p126)

29. NHSCR follows NPCR and SEER<sup>2</sup> guidelines for in utero diagnosis and treatment:

**Diagnosis Prior to Birth.** SEER reportability requirements apply to diagnoses made in utero. Diagnoses made in utero are reportable only when the pregnancy results in a live birth. In the absence of documentation of stillbirth, abortion or fetal death, assume there was a live birth and report the case.

**Disease Regression.** When a reportable diagnosis is confirmed prior to birth and disease is not evident at birth due to regression, accession the case based on the pre-birth diagnosis.

**Cases Diagnosed Before Birth.** Record the actual date of diagnosis for diagnoses made in utero even though this date will precede the date of birth.

*Example:* Fetal intrahepatic mass consistent with hepatoblastoma diagnosed via ultrasound at 39 weeks gestation (01/30/2022). Live birth by C-section 02/04/2022. Code the date of diagnosis as 01/30/2022. **Note:** Prenatal diagnoses are reportable when there is a live birth.

**Comorbidities and Complications/Secondary Diagnoses (STORE 2022, p50)**

30. The recording of *Comorbidities and Complications* is required for cases diagnosed January 1, 2010 – September 30, 2015; *Secondary Diagnosis* is required effective for cases diagnosed October 1, 2015 forward, when ICD-10-CM was implemented.

**Stage of Disease at Initial Diagnosis (STORE 2022, p51)**

31. NHSCR requires the following staging on all reportable cancers:

DX Year	Staging System(s)
≤ 2003	AJCC and SEER Summary Stage
2004 - 2015	Collaborative Stage
2015 - present	AJCC and SEER Summary Stage
2011 Breast and Colorectal only	AJCC and SEER Summary Stage

**First Course Treatment, Leukemias (STORE 2022, p53)**

32. For information regarding first course of therapy for hematopoietic and lymphoid neoplasms, refer to the NCI SEER Hematopoietic and Lymphoid Neoplasm Coding Manual.

**Surgery (STORE 2022, p54)**

33. NHSCR collects ALL surgical procedures of a primary site. Registries with software allowing for multiple treatments to be coded are to code all surgical procedures performed at their facility and elsewhere.

**Outcomes (STORE 2022, p64)**

34. NHSCR does not conduct follow-up activities for reportable cancers after the diagnosis and complete first-course treatment has been reported. ([See NH-6](#))

**Administrative Tracking (STORE 2022, p65)**

35. In registries with more than one abstractor, *Abstracted By* should reflect the abstractor who completed the case.

**EDITS Overrides (STORE 2022, p66)**

36. NHSCR highly recommends that data be put through edits before submission. The use of overrides depends on how and whether the standard NAACCR edits and/or the EDITS software have been integrated into the registry software.

## Changing Information on the Abstract<sup>2</sup>

The information originally collected on the abstract should be changed or modified under the following circumstances

1. To **correct** coding or abstracting **errors** (for example, errors found during quality control activities)
2. **When clarifications or rule changes** retroactively affect data item code  
*Example:* SEER adds codes to a data item and asks the registries to review a set of cases and update using the new codes.
3. **When better information** is available later  
*Example 1:* Consults from specialty labs, pathology report addenda or comments or other information have been added to the chart. Reports done during the diagnostic workup and placed on the chart after the registrar abstracted the information may contain valuable information. Whenever these later reports give better information about the histology, grade of tumor, primary site, etc., change the codes to reflect the better information.  
*Example 2:* The primary site was recorded as unknown at the time of diagnosis. At a later date, the physician determines that the cancer is primary to the testis. Change the primary site from unknown to testis.  
*Example 3:* The original diagnosis was in situ. Metastases are diagnosed at a later date. Change the behavior code for the original diagnosis from in situ to invasive when **no new primary has been diagnosed** in the interim.  
*Example 4:* Patient seen in Hospital A. The pathologic diagnosis was negative for malignancy. Patient goes to Hospital B and the slides from Hospital A are re-read. The diagnosis at Hospital B is reportable. Hospital B sends their slide report back to Hospital A. Hospital A reports the case based on the info from Hospital B. Enter supporting documentation in a text field.
4. **When the date of diagnosis is confirmed in retrospect to be earlier than the original date abstracted**  
*Example:* Patient has surgery for a benign argentaffin carcinoid (8240/1) of the sigmoid colon in May 2021. In January 2022, the patient is admitted with widespread metastasis consistent with malignant argentaffin carcinoid. The registrar accessions the malignant argentaffin carcinoid as a 2022 diagnosis. Two months later, the pathologist reviews the slides from the May 2021 surgery and concludes that the carcinoid diagnosed in 2021 was malignant. Change the date of diagnosis to May 2021 and histology to 8241 and the behavior code to malignant (/3).

## Section Two: Instructions for Coding

37. At a minimum, reporting facilities must collect the NHSCR required data items.

([See Appendix I: Table of Required Data Items](#))

### Patient Identification

#### [Age at Diagnosis \(STORE 2022, p83\)](#)

38. Registry software automatically calculates the *Age at Diagnosis*. When the diagnosis date is unknown, confirm that *Age at Diagnosis* is recorded as 999.

#### [Sex \(STORE 2022, p87\)](#)

39. See *Sex: Definitions and Additional Coding Instructions* on [page E-17](#) of this supplement.

#### [Primary Payer at Diagnosis \(STORE 2022, p88\)](#)

40. Additional coding instructions for *Primary Payer at Diagnosis*<sup>2</sup>

1. Code the type of insurance reported on the patient's admission record
2. Code the **first** insurance mentioned when multiple insurance carriers are listed on one admission record
3. Code the type of insurance reported **closest to the date of diagnosis** when there are multiple insurance carriers reported for multiple admissions and/or multiple physician encounters
4. Code the patient's insurance at the time of **initial diagnosis and/or treatment**. Do not change the insurance information based on subsequent information
5. Use code **02** when the only information available is "self-pay"
6. Use code **10** for prisoners when no further information is available
7. Assign code **99** for death certificate only (DCO) cases when the primary payer at diagnosis is unknown

### Cancer Identification

#### [Class of Case \(STORE 2022, p117-120\)](#)

41. Certain nonanalytic cases are required by the NHSCR. ([See NH-21](#))

42. CIS, CIN III, and PIN III are not reportable to NHSCR. ([See NH-11](#))

43. Non-analytic cases are required by NHSCR to be abstracted and reported by New Hampshire reporting facilities only IF the case has not been reported by the diagnosing or treating facility. ([See Appendix G: NHSCR Non-Analytic Tracking Form](#)) ([See NH-21](#))

44. DCO cases are accessioned only by NHSCR.

45. [Grade Post Therapy Path \(yp\)](#) [3845] can be found in the AJCC TNMS Stage section.

## Sex: Definitions and Additional Coding Instructions<sup>2</sup>

### Definitions

**Intersex:** A person born with ambiguous reproductive or sexual anatomy; chromosomal [genotype](#) and sexual [phenotype](#) other than [XY-male and XX-female](#). An example is 45,X/46,XY mosaicism, also known as X0/XY mosaicism.

**Transsexual:** A person who was assigned one gender at birth based on physical characteristics but who self-identifies psychologically and emotionally as the other gender.

### Coding Instructions

1. Assign code **3** for
  - a. Intersexed (persons with sex chromosome abnormalities)
  - b. Hermaphrodite

**Note:** Hermaphrodite is an outdated term.
2. Codes 5 and 6 may be used for cases diagnosed prior to 2015
3. Codes 5 and 6 have priority over codes 1 and 2
4. Assign code **5** for transsexuals who are natively male or transsexuals with primary site of C600-C639
5. Assign code **6** for transsexuals who are natively female or transsexuals with primary site of C510-C589
6. Assign code **4** for transsexuals with unknown natal sex and primary site is not C510-C589 or C600-C639
7. When gender is not known
  - a. Assign code **1** when the primary site is C600-C639
  - b. Assign code **2** when the primary site is C510-C589
  - c. Assign code **9** for primary sites not included above



## Stage of Disease at Diagnosis

### SEER Summary Stage and AJCC TNM (STORE 2022, p139)

46. NHSCR requires both AJCC and SEER Summary Stage on all cases. ([See NH-32](#))

- Direct staging for cases diagnosed prior to year 2004 and 2015+.
- Collaborative Staging is used for cases diagnosed 2004-2015.
- NHSCR also requires AJCC staging for breast and colorectal cancer diagnosed in year 2011.
- Staging is required for ALL cases, including non-analytic cases. If there is insufficient information to assign stage, leave blank or code to unknown. ([See NH-17 and NH-18](#))

### Site-specific Data Items (STORE 2022, p209)

47. Refer to the [Appendix I: NHSCR Table of Required Data Items](#) for full list of required SSDIs.

## Outcomes

### Follow-up (STORE 2022, p331)

48. NHSCR is a population-based incidence registry responsible for collecting *all* cancer cases seen and/or treated in NH since June 1986. However, it is not required to conduct annual follow-up of cases reported to NHSCR once initial diagnosis and complete first-course treatment information has been reported.

Refer to [page E-15](#) of this supplement when cases are updated after they have been transmitted to NHSCR.

## Case Administration

### Abstracted By (STORE 2022, p343)

49. In a registry with more than one abstractor, *Abstracted By* should reflect the abstractor who completes the definitive case report.

### Date Case Completed - CoC (STORE 2022, p349)

50. NHSCR uses *Date Case Complete – CoC* [2092] to distinguish between a *rapid* (suspense) case and a *definitive* (completed) case. Cases without a *Date Case Complete – CoC* are flagged as rapid reports and not included in the NHSCR main database.

## References

<sup>1</sup>2022 *Implementation Guidelines and Recommendations*. (For NAACCR Data Standards and Data Dictionary, Version 22, effective with cases diagnosed on or after January 1, 2022). Available at:

<https://www.naacr.org/implementation-guidelines/>. (Accessed June 1, 2022.)

<sup>2</sup>Adamo M, Groves C, Dickie L, Ruhl J. (September 2021). SEER Program Coding and Staging Manual 2022. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Available at:

<https://seer.cancer.gov/tools/codingmanuals/index.html> (Accessed June 1, 2022.)

<sup>3</sup>Thornton ML, (ed). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Version 22, 23rd ed.* Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022. Available at: <https://www.naacr.org/data-standards-data-dictionary/>. (Accessed June 1, 2022.)

**APPENDIX F: NEW HAMPSHIRE RULES AND REGULATIONS**

## PART He-P 304 CANCER REGISTRY RULES

### He-P 304.01 Definitions.

(a) “Clinic” means a health care facility licensed by the state of New Hampshire, where a physician, nurse practitioner, or other health care professional provides cancer diagnosis and treatment or both, and that is not an operational entity of and not affiliated with a hospital. Such facilities include urology clinics, dermatology clinics, out-patient surgical centers, ambulatory oncology treatment centers, ambulatory radiation treatment centers, and physician group practices devoted to oncology.

(b) “Commissioner” means the commissioner of the department of health and human services.

(c) “Confidence interval” means an estimated range of values, which is likely to include an unknown population parameter, the estimated range being calculated from a given set of sample data.

(d) “Courier service” means a mail delivery service that provides guaranteed delivery of documents or packages by using a reliable tracking system.

(e) “Definitive report” means information or data in the format of an electronic or paper document, or report, describing a reportable cancer, including the information described in He-P 304.02(e), that is submitted to the state cancer registry (SCR) as follows:

(1) No sooner than 90 days and no later than 180 days of an initial diagnosis or treatment; or

(2) In cases where the patient has died, or is transferred to hospice care, within 90 days of death and transfer.

(f) “Department” means the New Hampshire department of health and human services.

(g) “Facility” means “facility” as defined in RSA 141-B:3, VI, namely, “a governmental or private agency, department, institution, clinic, laboratory, hospital, health maintenance organization, association, physician, or other similar unit diagnosing or providing treatment for cancer.”

(h) “Medical laboratory” means a facility performing tests or analyses of human samples from patients suspected to have cancer.

(i) “Mutual agreement” means an understanding, arrangement, or stipulation which establishes the responsible reporter to the SCR as made between 2 facilities, clinics, or physicians, which can be confirmed in writing, but for which written documentation is not required.

(j) “Pathology report” means electronic or paper report(s) prepared by a pathologist providing a description of laboratory test results, and an evaluation of cells, tissues, and organs based on evidence from a sample of body tissue, which is used to diagnose and characterize disease.

(k) “Protected health information” means protected health information as defined in 45 CFR 160.103.

(l) “Rapid report” means information or data in an electronic or paper document or report, describing a reportable cancer, including the information described in He-P 304.02(d), that is submitted to the SCR within 45 days of diagnosis.

(m) “Reportable cancer” means any syndrome, condition, or disease listed in “Table 2 “NAACCR Layout Version 15: Comparison of Reportable Cancers” (Thornton ML, (ed.)) “Standards and Registry Operations/Volume II/Data Standards and Data Dictionary,” Version 15, 19<sup>th</sup> ed. (Posted October 2014, Revised February 27, 2015)/Chapter III, “Standards for Tumor Inclusion and Reportability” “Table 2 NPCR

*Source: New Hampshire State Legislature, available at:*  
[http://www.gencourt.state.nh.us/rules/state\\_agencies/he-p300.html](http://www.gencourt.state.nh.us/rules/state_agencies/he-p300.html)  
(Accessed June 1, 2022)

Requirements”, Springfield, Ill., North American Association of Central Cancer Registries. As listed in Appendix A and available as a free electronic document at <http://www.naaccr.org>.

(n) “State cancer registry (SCR)” means the department or, if the department meets its statutory obligations by contract, an organization, system, or individual contracted by the department to collect, manage and store information on cases of reportable cancer pursuant to RSA 141-B:5 and RSA 141-B:10.

Source. #4055, eff 5-27-86; amd by #4869, eff 7-24-90; ss by #5601, eff 3-24-93; amd by #6075, eff 8-5-95; ss by #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

#### He-P 304.02 Reporting Requirements.

(a) In accordance with RSA 141-B:7, all facilities shall report diagnosis or treatment of a reportable cancer to the SCR in accordance with the rules specified below, and using the means described in He-P 304.02(f), (g) and (h). SCR may be contacted through <http://geiselmed.dartmouth.edu/nhscr/contact>.

(b) Pursuant to (a) above, all facilities shall include information and data in each report describing cancer diagnosis or treatment according to one of the following standards, as applicable:

(1) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries, Volume II/Data Standards and Data Dictionary, 19th Edition, Record Layout Version 15,” (January 1, 2015) Edited by Monica Thornton, Revised (February, 27, 2015.), as listed in Appendix A and available as a free document at [www.naaccr.org](http://www.naaccr.org);

(2) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries/Volume V: “Pathology Laboratory Electronic Reporting, Version 4.0.” Klein Wt., Havener L (eds.), Springfield (IL); North American Association of Central Cancer Registries, Inc., April, 2011, as listed in Appendix A and available as a free electronic document at [www.naaccr.org](http://www.naaccr.org); or

(3) The National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, “Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries HL7 Clinical Document Architecture (CDA) Release 1.1” (March, 2014), as listed in Appendix A and available as a free electronic document in PDF format at <http://cdc.gov/cancer/npcr/ehrmeaningfuluse/cancer.htm>.

(c) Each report shall contain information or data required by the appropriate standard in (b) above, as listed in elements (1)-(10) below, and include any supporting information, as follows:

- (1) Item numbers defining demographics;
- (2) Item numbers defining cancer identification;
- (3) Item numbers defining hospital-specific information;
- (4) Item numbers defining stage prognostic factors;
- (5) Item numbers defining the first course of treatment;
- (6) Item numbers defining follow-up, recurrence, and death;
- (7) Item numbers defining confidential patient information;

- (8) Item numbers defining confidential hospital information;
- (9) Item numbers defining other confidential information; and
- (10) Item numbers defining diagnosis.

(d) Of the item numbers specified in (b) and (c) above, the following shall require rapid reporting as defined in He-P 304.01(l) and described in He-P 304.03(b) and (c):

- (1) Item numbers defining demographics;
- (2) Item numbers defining cancer identification;
- (3) Item numbers defining hospital-specific information;
- (4) Item numbers defining confidential patient information; and
- (5) Item numbers defining other confidential information.

(e) The items listed in (c) above shall require definitive reporting as defined in He-P 304.01(e), and described in He-P 304.03(a), He-P 304.03(d), He-P 304.04(a), and He-P 304.06(a) and (b).

(f) All facilities making an electronic report to the SCR in accordance with (a) above, shall submit through a secure internet-based encrypted mechanism, such as a direct file transfer, or a web-based reporting form supported by the SCR.

(g) All facilities reporting electronically shall format reports as specified by one of the following standards, as applicable:

(1) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries, Volume II/Data Standards and Data Dictionary, 19th Edition, Record Layout Version 15.” (January 1, 2015) Edited by Monica Thornton, Revised (February, 27, 2015), as listed in Appendix A and available as a free document at <http://www.naacr.org>;

(2) The North American Association of Central Cancer Registries (NAACCR), “Standards for Cancer Registries/Volume V: Pathology Laboratory Electronic Reporting, Version 4.0.” Klein Wt., Havener L. (eds.) Springfield (IL); North American Association of Central Cancer Registries, Inc., (April, 2011), as listed in Appendix a and available as a free electronic document at <http://www.naacr.org>; or

(3) The National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, “Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries HL7 Clinical Document Architecture (CDA) Release 1.1” (March, 2014), as listed in Appendix A and available as a free electronic document in PDF format at <http://cdc.gov/cancer/npcr/ehrmeaningfuluse/cancer.htm>.

(h) Where electronic reporting is not feasible, facilities shall complete and file the New Hampshire State Cancer Registry (NHSCR) “Cancer Report Form” (July, 2015) provided by the SCR and faxed or mailed by the facilities to the SCR, via regular mail or a courier service.

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93; amd by #6075, eff 8-5-95; ss by #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.03 Reporting of Information by Hospitals Licensed by the State of New Hampshire.

(a) Hospitals licensed by the state of New Hampshire that diagnose or treat at least 105 new reportable cancer cases per year shall employ a cancer registrar to abstract the definitive report.

(b) Hospitals licensed by the state of New Hampshire that diagnose or treat at least 105 new reportable cancer cases per year shall provide a rapid report to SCR in accordance with He-P 304.01(l) and a definitive report in accordance with He-P 304.01(e).

(c) Hospitals licensed by the state of New Hampshire that diagnose or treat fewer than 105 reportable cancer cases per year shall provide a rapid report to SCR in accordance with He-P 304.01(l), and a paper or electronic report to SCR in accordance with He-P 304.02.

(d) Hospitals licensed by the state of New Hampshire that diagnose or treat fewer than 105 reportable cancer cases per year shall make available to SCR the medical records of all patients with a reportable cancer for the creation of the definitive report in accordance with He-P 304.01(e).

(e) Facilities owned by a hospital licensed by the state of New Hampshire shall have met the reporting requirements of this rule if reports are submitted to SCR on their behalf by the hospital.

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.04 Reporting of Information by a Physician Licensed by the State of New Hampshire.

(a) A physician, surgeon, or other licensed health care practitioner who diagnoses or treats cancer patients shall complete and provide a definitive report in accordance with He-P 304.01(d) for each newly diagnosed cancer case when that patient will not be immediately referred to a hospital or other treatment center for additional diagnosis or treatment.

(b) A physician, surgeon, or other licensed health care practitioner shall provide additional information to SCR regarding a patient as is considered necessary for abstraction of required cancer incidence data in accordance with He-P 304.07(a).

(c) A physician, surgeon, or other licensed health care practitioner may fulfill his or her responsibility for cancer reporting for a cancer patient through a mutual agreement allowing cases to be reported by a hospice or other facility that provided medical or nursing care to that cancer patient.

(d) A physician, surgeon or other licensed health care practitioner shall make available to the SCR the medical records of all patients with a reportable cancer for creation of the definitive report in accordance with He-P 304.01(e).

Source. #4055, eff 5-27-86, EXPIRED: 5-27-92

New. #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.05 Reporting of Information by a Medical Laboratory Licensed by the State of New Hampshire.

*Source: New Hampshire State Legislature, available at:*  
[http://www.gencourt.state.nh.us/rules/state\\_agencies/he-p300.html](http://www.gencourt.state.nh.us/rules/state_agencies/he-p300.html)  
(Accessed June 1, 2022)

(a) A medical laboratory licensed by the state of New Hampshire that obtains a specimen of human tissue which, upon examination, shows evidence of cancer, shall:

(1) Within 180 days after that pathology report is complete, provide information concerning its findings to the SCR; and

(2) Fax, mail, or electronically transmit a copy of the pathology report using procedures described in this section.

(b) A medical laboratory may fulfill its responsibility for cancer reporting through a mutual agreement allowing cases to be submitted by the cancer registrar at an affiliated hospital or other facility.

(c) The SCR shall be granted access to pathology reports used to confirm or rule out a diagnosis of cancer by medical laboratories for the purpose of case finding and quality assurance.

(d) The SCR shall be authorized to identify cancer cases from the pathology reports and request information about missing cancer reports from the reporting facility.

Source. #4055, eff 5-27-86; amd by #4869, eff 7-24-90; ss by #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

#### He-P 304.06 Reporting of Information by Clinics that Diagnose or Treat Patients With Cancer.

(a) A clinic shall provide a definitive report for each case in accordance with He-P 304.01(e).

(b) A clinic licensed by the state of New Hampshire shall:

(1) Be responsible for the submission of all definitive reports to the SCR; or

(2) Develop a mutual agreement with a cancer registrar at a hospital or other affiliated facility for the submission of a definitive report to the SCR.

(c) A clinic shall provide additional information to SCR regarding a cancer patient as necessary for abstraction of required cancer incidence data in accordance with He-P 304.07(a).

Source. #4055, eff 5-27-86; ss by #4377, eff 3-1-88; ss by #5601, eff 3-24-93, EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss by #11054, eff 3-15-16

#### He-P 304.07 Quality Assurance, Verification, and Confidentiality.

(a) All facilities shall respond to SCR requests for case information pursuant to He-P 304.02(b) and (c) within 14 working days of receipt of such requests.

(b) All facilities shall respond to SCR requests to perform a site visit.

(c) SCR shall perform a site visit at each facility in order to:

(1) Audit pathology reports and other information to ensure that no cancer cases are overlooked in reporting; and

(2) Monitor the completeness and accuracy of the cancer reports.

(d) Each facility shall make available for reviewing and copying all paper or electronically stored information including the following:

(1) Laboratory analyses including tissue, cytology, and pathology reports;

(2) Records regarding radiological examinations, in relation to cancer diagnoses or treatment;

(3) Reports of diagnoses of malignant disease, and notations of the reasons for such diagnoses, including both primary clinicians' reports and consultants' reports;

(4) Pharmacy records;

(5) Reports regarding any operations or an autopsy;

(6) Discharge plans and abstracts regarding cancer diagnoses; and

(7) A list of the applicable discharge diagnoses or treatment as identified in the "Casefinding Lists, Current Lists/Code List," (October 1, 2015-September 30, 2016), as listed in Appendix A and available as a free electronic document at <http://seer.cancer.gov/tools/casefinding/case2016-icd10cm.html>.

(e) Pursuant to 42 USC 280e(c)(2)(D)(viii), individuals complying with the law shall not be held liable in any civil action with respect to a report of cancer provided to the SCR, or with respect to access to data or information provided to the SCR.

Source. #4377, eff 3-1-88; ss by #5601, eff 3-24-93,  
EXPIRED: 3-24-99

New. #7406, eff 11-21-00; ss by #9046, eff 12-5-07; ss  
by #11054, eff 3-15-16

He-P 304.08 Procedures for Disclosure of Protected Health Information.

(a) The SCR shall use and disclose protected health information in accordance with RSA 141-B:9 and the provisions of 45 CFR 164 generally, and specifically, 45 CFR 164.502, 164.506 and 164.512.

(b) The department shall maintain the confidentiality of reports submitted to the SCR pursuant to RSA 141-B:9 except in accordance with (c) below.

(c) A report submitted to the SCR concerning an individual, and any other information maintained by the SCR, which, because of a personal identifier, can be readily associated with an individual, shall only be released:

(1) To the individual upon:

a. Receipt of a written request which shall be signed by the individual; and

b. Presentation of identification, such as a driver's license, by the individual;

(2) If the individual is a minor, to a parent of the individual upon:

a. Receipt of a written request, which shall be signed by the parent;

b. Receipt of a certified copy of the birth certificate of the individual; and

*Source: New Hampshire State Legislature, available at:*  
[http://www.gencourt.state.nh.us/rules/state\\_agencies/he-p300.html](http://www.gencourt.state.nh.us/rules/state_agencies/he-p300.html)  
(Accessed June 1, 2022)



- c. Receipt of a copy of the parent's identification, such as a driver's license of the parent;
- (3) If the individual has a court-appointed guardian or if the individual is deceased, to the court-appointed guardian or to the executor or administrator of the individual's estate upon:
- a. Receipt of a written request, which shall be signed by the court-appointed guardian, executor, or administrator of the estate;
  - b. Receipt of a certified copy of the order or decree which appoints the guardian, executor, or administrator; and
  - c. Receipt of a copy of identification, such as a driver's license, by the guardian, executor, or administrator;
- (4) To an attorney or other person designated by the individual upon receipt of a written medical release request which shall be signed by the individual;
- (5) To persons conducting health related research, upon receipt and approval pursuant to He-P 304.09 of a written application to the department, which shall be signed by the applicant and includes:
- a. The following information about the principal investigator:
    - 1. Name, address, and phone number;
    - 2. Organizational affiliation;
    - 3. Professional qualification; and
    - 4. Name and phone number of principal investigator's contact person, if any;
  - b. The following information about the data or record copies being requested:
    - 1. Type of event or record copies;
    - 2. Time period of the data or record copies;
    - 3. Specific data items required, if applicable;
    - 4. Medium in which the data or record copies are to be supplied by the bureau; and
    - 5. Any special format or layout of data required by the principal investigator;
  - c. A research protocol which shall contain:
    - 1. A summary of background and origin of the research;
    - 2. A statement of the health-related problem or issue to be addressed by the research;
    - 3. The primary research hypothesis to be tested;
    - 4. The research design, which shall include:
      - (i) Case definition;
      - (ii) Method of case selection; and

- (iii) Method of data analysis;
  - 5. The research methodology, which shall include:
    - (i) The way in which the requested data will be used; and
    - (ii) The procedures for follow-back to any persons or facilities named in records, if applicable;
  - 6. Procedures to obtain informed consent from the research participants, if applicable;
  - 7. The procedures that shall be followed to maintain the confidentiality of any data or copies of records provided to the requester; and
  - 8. The intended completion date;
- d. A statement signed by the principal investigator agreeing to the following:
- 1. The investigator shall acknowledge the department as the source of the data in any and all public reports, publications, or presentations generated by the requester from these data;
  - 2. The investigator shall specify that the analyses, conclusions, and recommendations drawn from such data are solely those of the requester and are not necessarily those of the department;
  - 3. Any data or record copies provided shall not be used for any purpose other than that described in the application;
  - 4. The principal investigator and the research staff shall not disclose the identity of individuals revealed in the data or record copies to any persons except as is necessary to perform the research described in the application;
  - 5. The data record shall not be further released to any other person or organization without the written consent of the commissioner or his designee; and
  - 6. No form of information derived from the data or record copies that identify any individuals shall be made public;
- e. A written statement ensuring that the investigator shall hold all information confidential; and
- f. When contact with patients will occur, submission of an Institutional Review Board (IRB) approval for the study by an IRB formed in accordance with the requirements of the U.S. Department of Health and Human Services Code of Federal Regulations for Protection of Human Subjects, 45 CFR 46, June 23, 2005; or
- (6) In association with an audit as required under Title III of Public Health Services Act, 42 U.S.C. 241 et seq.
- (d) Persons fraudulently requesting data or information shall be subject to penalty for unsworn falsification pursuant to RSA 641:3.

Source. #9046, eff 12-5-07; ss by #11054, eff 3-15-16

Source: New Hampshire State Legislature, available at:  
[http://www.gencourt.state.nh.us/rules/state\\_agencies/he-p300.html](http://www.gencourt.state.nh.us/rules/state_agencies/he-p300.html)  
(Accessed June 1, 2022)

He-P 304.09 Approval Criteria for Release of Confidential Data for Research Purposes.

(a) The commissioner shall review applications for the use of confidential SCR data, based on the following criteria:

- (1) Completeness of application, pursuant to He-P 304.08(b)(5);
- (2) Documentation of adequate measures to insure confidentiality of patients, pursuant to He-P 304.08(b)(5);
- (3) Determination of whether the study, if carried out according to the application submitted pursuant to He-P 304.08(b)(5), will be able to answer the research hypothesis as stated in this application; and
- (4) Qualifications of investigator(s) and research staff, as indicated by:
  - a. Documentation of training and previous research, such as peer reviewed publications, in the proposed or related area; and
  - b. Affiliation with a university, medical center or other institution, which will provide sufficient research resources.

(b) The commissioner shall deny an application in accordance with RSA 541-A: 29, II (a) when it has been determined that one or more of the requirements of He-P 304.08(b)(5) or He-P 304.09(a) have not been met.

Source. #9046, eff 12-5-07; ss by #11054, eff 3-15-16

He-P 304.10 Aggregate Data. The number of cancer cases shall not be released in any document where the numbers of cancer cases are between 1 and 4.

Source. #9046, eff 12-5-07; ss by #11054, eff 3-15-16

**APPENDIX G: Non-Analytic Tracking Form**

## APPENDIX G: NHSCR NON-ANALYTIC TRACKING FORM

### Non-Analytic Tracking Form Instructions

#### BACKGROUND

NHSCR requires the collection of complete cancer data for every patient seen in NH with a cancer diagnosis and/or cancer-directed treatment. As such, NHSCR requires NH reporting facilities to accession and abstract all cases seen with evidence of a reportable cancer or for cancer treatment, on or after the NHSCR reference date (June 1986). This includes patients receiving transient care, patients with active cancer admitted for medical conditions other than cancer, patients with a history of cancer that are now undergoing cancer-directed treatment, as well as pathology-only, physician-only, and consult-only cases (i.e. class case 30-99). NHSCR does not require the reporting of historical cases when there is no active disease and no cancer treatment. Place of diagnosis, initial treatment, residence, and class of case are not determining factors for reportability.

We understand that most hospitals do not collect these cases, and that abstracting non-analytics creates a burden in cancer reporting. As a compromise, NHSCR has developed this Non-Analytic Tracking Form to identify cases that have not been reported by any other source, or where the non-analytic hospital's information may better help define a case.

#### GENERAL INSTRUCTIONS

This form is to be used for cases that are non-analytic (class case 30-99).

Information should be entered electronically on the form.

In the "Comments" section, please provide information about the case that may be helpful for NHSCR to determine if the case is needed.

Complete all fields with the exception of the last column. In this column, NHSCR staff will indicate whether the case should be completed.

The information that you provide will be checked against the NHSCR database. If the case is not in the state registry, or if you have additional information not available in the NHSCR abstract, you will be asked to abstract and transmit that case to the NHSCR.

The Non-Analytic Tracking Form should be uploaded to WebPlus only once a week, every other week, once a month, or once a quarter, depending on your caseload.

Forms received by Friday, 4:00p.m. are processed at the beginning of the following week and returned by Wednesday of that week via Web Plus. NHSCR staff will notify you when the form has been reviewed, completed, and available on WebPlus for you to download.

Please retain a copy of the completed form for your records.



## APPENDIX H: CASEFINDING LISTS

These lists are taken from the National Institutes of Health, Surveillance Epidemiology and End Results (SEER) program. Available at: <http://seer.cancer.gov/tools/casefinding/>

This appendix consists of ICD-10-CM codes used to identify potentially reportable cancer cases. Some of these codes may contain conditions that are not considered reportable; however, these diagnoses may indicate a reportable cancer associated with the condition. Casefinding must include both primary and up to four (4) secondary diagnoses. At a minimum, cases with the codes listed under the “Reportable Neoplasms” should be screened. The patient medical record should be reviewed to verify whether or not the case is a reportable cancer to the NHSCR.

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- - C96.-	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies Note: The following neoplasm codes are new for FY2022 (10/1/2021) C56.3: Malignant neoplasm of bilateral ovaries C79.63: Secondary malignant neoplasm of bilateral ovaries C84.7A: Anaplastic large cell lymphoma, ALK-negative, breast
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS
D00.- - D05.-, D07.- - D09	In-situ neoplasms Note 1: Excludes carcinoma in situ tumors of the cervix (D06._) Note 2: Excludes prostatic intraepithelial neoplasia (PIN III) (8148/2) of the prostate. Other prostate in situ histologies are reportable Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions
D13.7	Benign neoplasm of endocrine pancreas Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Islet cell adenoma</li> <li>• Nesidioblastoma</li> <li>• Islet cell adenomatosis</li> <li>• Insulinoma</li> <li>• Beta cell adenoma</li> </ul>
D18.02	Hemangioma of intracranial structures and any site

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).*  
**NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases**



**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
D21.4, D48.1	Benign neoplasm of connective and other soft tissue of abdomen Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)</li> </ul>
D23.9	Other benign neoplasm of skin Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these code to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Aggressive digital papillary adenoma (c44_) (8408/1, but now 8408/3)</li> </ul>
D3A._	Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3)</li> <li>• Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)</li> </ul>
D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm of brain and other parts of central nervous system
D35.00 - D35.02	Benign neoplasm of adrenal gland Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3) <ul style="list-style-type: none"> <li>• Pheochromocytoma</li> <li>• Adrenal medullary paraganglioma</li> <li>• Chromaffin paraganglioma</li> <li>• Chromaffin tumor</li> <li>• Chromaffinoma</li> </ul>
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
 NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
D37.8	Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas) Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>• Islet cell tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>• Glucagonoma, NOS (C259, 8152/1, now 8152/3)</li> <li>• Alpha cell tumor, NOS (C259, 8152/1, now 8152/3)</li> <li>• Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3)</li> <li>• Somatostatinoma, NOS (8156/1, now 8156/3)</li> <li>• Somatostatin cell tumor, NOS (8156/1, now 8156/3)</li> <li>• Endocrine tumor, functioning, NOS (8158/1, now 8158/3)</li> <li>• ACTH-producing tumor (8158/1, now 8158/3)</li> </ul>
D42.-, D43.-	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D44.6	Neoplasm of uncertain behavior of carotid body Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3)</li> </ul>
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 <ul style="list-style-type: none"> <li>• Paraganglioma, NOS (8680/1, now 8680/3)</li> <li>• Sympathetic paraganglioma (8681/1, now 8681/3)</li> <li>• Parasympathetic paraganglioma (8682/1, now 8682/3)</li> <li>• Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3)</li> <li>• Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3)</li> <li>• Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3)</li> </ul>
D45	Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9993)

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
D47.02	Systemic mastocytosis
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthistic anemia & Myelophthisis (D61.82)
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia Secondary myelofibrosis in myeloproliferative disease
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) Note: Effective 1/1/2021, PTLD (9971/3) is no longer reportable (9971/1)
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Clear cell odontogenic tumor (9341/1, now 9341/3)
D49.2	Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas)Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3) • Pancreatic endocrine tumor, NOS • Islet cell tumor, NOS
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
D72.110	Hypereosinophilic syndrome [HES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia
D72.111	Lymphocytic Variant Hypereosinophilic Syndrome [LHES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia Syndrome [LHES]

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
D72.118	Other Hypereosonophilic syndrome (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia
D72.119	Hypereosonophilic syndrome (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia
K31.A22	Gastric intestinal metaplasia with high grade dysplasia
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM</b> <b>(EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
B20	Human immunodeficiency virus [HIV] disease with other diseases
B97.33, B97.34, B97.35	Human T-cell lymphotropic virus, (type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere
B97.7	Papillomavirus as the cause of diseases classified elsewhere
C44.01, C44.02	Basal/squamous cell carcinoma of skin of lip
C44.11-, C44.12-	Basal/squamous cell carcinoma of skin of eyelid
C44.21-, C44.22-	Basal/squamous cell carcinoma of skin of ear and external auricular canal
C44.31-, C44.32-	Basal/squamous cell carcinoma of skin of other and unspecified parts of face
C44.41, C44.42	Basal/squamous cell carcinoma of skin of scalp and neck
C44.51-, C44.52-	Basal/squamous cell carcinoma of skin of trunk
C44.61-, C44.62-	Basal/squamous cell carcinoma of skin of upper limb, including shoulder
C44.71-, C44.72-	Basal/squamous cell carcinoma of skin of lower limb, including hip
C44.81, C44.82	Basal/squamous cell carcinoma of skin of overlapping sites of skin
C44.91, C44.92	Basal/squamous cell carcinoma of skin of unspecified sites of skin
D06.-	Carcinoma in situ of the cervix
D10.- - D31.-, D34, D35.0, D35.1, D35.5-,D35.9, D36.-	Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.
D37. _ - D41. _	Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors
D44.0 - D44.2, D44.6-D44.9	Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors
D47.01	Cutaneous mastocytosis (9740/1)
D47.09	Other mast cell neoplasms of uncertain behavior
D47.2	Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia
D47.22	Castleman disease

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).*  
**NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases**

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
D48.-	Neoplasm of uncertain behavior of other and unspecified sites
D49.0 - D49.9	Neoplasm of unspecified behavior (except for D49.6 and D49.7)
D61.1	Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”) ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.82	Myelophthisis ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)
D63.0	Anemia in neoplastic disease ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)
D64.81	Anemia due to antineoplastic chemotherapy
D69.49, D69.59, D69.6	Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia
D70.1	Agranulocytosis secondary to cancer chemotherapy ICD-10-CM Coding instruction: code also underlying neoplasm
D75.81	Myelofibrosis (note: this is not primary myelofibrosis [9961/3]) ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)
D76.-	Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
D89.0, D89.1	Other disorders involving the immune mechanism, not elsewhere classified Note: Review for miscodes
D89.4-	Mast cell activation syndrome and related disorders
E08	Diabetes mellitus due to underlying condition ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)
E31.2-	Multiple endocrine neoplasia [MEN] syndromes ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes
E34.0	Carcinoid syndrome ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor
E83.52	Hypercalcemia
E88.09	Other disorders of plasma-protein metabolism, not elsewhere classified

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G13.0	Paraneoplastic neuromyopathy and neuropathy ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)
G13.1	Other systemic atrophy primarily affecting central nervous system in neoplastic disease ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)
G32.8-	Other specified degenerative disorders of nervous system in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)
G53	Cranial nerve disorders in diseases classified elsewhere Note: Code first underlying neoplasm (C00-D49)
G55	Nerve root and plexus compressions in diseases classified elsewhere ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49)
G63	Polyneuropathy in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)
G73.1	Lambert-Eaton syndrome in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)
G89.3	Neoplasm related pain (acute)(chronic)
G99.2	Myelopathy in diseases classified elsewhere ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)
H47.42	Disorders of optic chiasm in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
H47.52-	Disorders of visual pathways in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
H47.63-	Disorders of visual cortex in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition
J34.81	Nasal mucositis (ulcerative)
J91.0	Malignant pleural effusion ICD-10-CM Coding instruction: Code first underlying neoplasm

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*



**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM</b> <b>(EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List	
ICD-10-CM Code	Explanation of Code
J93.12	Secondary spontaneous pneumothorax ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34._) Secondary malignant neoplasm of lung (C78.0_)
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
K12.33	Oral mucositis (ulcerative) due to radiation
K22.711	Barrett's esophagus with high grade dysplasia
K62.7	Radiation proctitis
K62.82	Dysplasia of anus (AIN I and AIN II)
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)
L10.81	Paraneoplastic pemphigus
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy Note: Effective 10/1/2021
M36.0	Dermato(poly)myositis in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)
M36.1	Arthropathy in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm, such as: Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)
M84.5-	Pathologic fracture in neoplastic disease ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)
M90.6-	Osteitis deformans in neoplastic disease ICD-10-CM Coding instruction: Code first the neoplasm (C40._, C41._)
N42.3	Dysplasia of prostate (PIN I and PIN II)
N52.35	Erectile dysfunction following radiation therapy
N52.36	Erectile dysfunction following interstitial seed therapy
N76.81	Mucositis (ulcerative) of vagina and vulva
N87.-	Dysplasia of cervix uteri (CIN I and CIN II)
N89.0, N89.1, N89.3	Vaginal dysplasia (VIN I and VIN II)
N90.0, N90.1, N90.3	Vulvar dysplasia (VAIN I and VAIN II)
O01.-	Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3, ) malignancy code in the C00- C97 range
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) ICD-10-CM Coding instruction: Use additional code to identify neoplasm
P04.11	Newborn affected by maternal antineoplastic chemotherapy

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).*  
**NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases**



**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
P04.12	Newborn affected by maternal cytotoxic drugs
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable
R18.0	Malignant ascites ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56. _), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)
R53.0	Neoplastic (malignant) related fatigue ICD-10-CM Coding instruction: Code first associated neoplasm
R59.-	Enlarged lymph nodes
R85.6-	Abnormal findings on cytological and histological examination of digestive organs Note: see "must collect" list for R85.614
R87.61-, R87.62-	Abnormal findings on cytological/histological examination of female genital organs Note: see "must collect" list for R87.614 and R87.624
R92.-	Abnormal findings on diagnostic imaging of breast
R97.-	Abnormal tumor markers
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes
T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified
T66	Unspecified effects of radiation
T80.1	Vascular complications following infusion, transfusion and therapeutic injection
T80.2-	Infections following infusion, transfusion and therapeutic injection
T80.810	Extravasation of vesicant antineoplastic chemotherapy
T80.818	Extravasation of other vesicant agent
T80.82	Complication of immune effector cellular therapy - Complication of chimeric antigen receptor (CAR-T) cell therapy
T86.0	Complications of bone marrow transplant ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)
Y63.2	Overdose of radiation given during therapy

*1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/2021-9/30/2022)</b>	
<b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
<b>ICD-10-CM Code</b>	<b>Explanation of Code</b>
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Z03.89	Encounter for observation for other suspected diseases and conditions ruled out
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85._)
Z12.-	Encounter for screening for malignant neoplasms
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z15.0	Genetic susceptibility to malignant neoplasm ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85._)
Z17.0, Z17.1	Estrogen receptor positive and negative status ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50._)
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms
Z42.1	Encounter for breast reconstruction following mastectomy
Z48.290	Encounter for aftercare following bone marrow transplant
Z48.3	Aftercare following surgery for neoplasm ICD-10-CM Coding instruction: Use additional code to identify the neoplasm
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50._), malignant neoplasm of prostate (C61)
Z80.-	Family history of primary malignant neoplasm
Z85.-	Personal history of malignant neoplasm ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08)
Z86.0-, Z86.01-, Z86.03	Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).  
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

**ICD-10-CM Casefinding List, 2022**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2022**

<b>SUPPLEMENTAL LIST ICD-10-CM</b> <b>(EFFECTIVE DATES: 10/1/2021-9/30/2022)</b> <b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>	
ICD-10-CM Code	Explanation of Code
Z92.21, Z92.23, Z92.25, Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z92.850	Personal history of Chimeric Antigen Receptor T-cell therapy- Personal history of CAR-T-cell therapy
Z94.81, Z94.84	Bone marrow and stem cell transplant status

*I Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).*  
*NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases*

## **APPENDIX I: NHSCR TABLE OF REQUIRED DATA ITEMS**

**At a minimum, reporting facilities must collect the NHSCR required data items.**

**New Hampshire State Cancer Registry  
Table of Required Data Items**

**Code Description**

R = Required  
 R\* = Required, when available  
 RH = Required, SEER or CoC  
 RH = Historically collected and currently transmitted  
 RH\* = Historically collected & transmitted when available  
 RS = Required, site-specific  
 RS\* = sdfs

RC = Collected by SEER from CoC-approved hospitals  
 R^ = Required, these text requirements may be met with one or several text block fields  
 S = Supplemental/recommended  
 D = Derived  
 DH = Historically derived and currently transmitted  
 D\* = Derived, when available  
 D+/R+ = Derived/Required; central registries may collect either SEER Summary Stage 2000 or Collaborative Stage

Required data items are in accordance with RSA 141B and part He-P 304.0 of the New Hampshire Administrative Rules.

Source: Thornton ML, (ed). Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Version 22, 23rd ed. Springfield, Ill.: North American Association of Central Cancer Registries, July 2021, August, September, October 2021, May 2022. Available at <http://datadictionary.naacrr.org/default.aspx?c=1&Version=22> (Accessed June 1, 2022)

Revised data items are highlighted in blue.

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
10	Record Type	R	R	.	.	NAACCR	Record ID		Auto-coded by software
20	Patient ID Number	R	R	.	R	Reporting Registry	Record ID		NHSCR-use only; auto-coded by software
21	Patient System ID-Hosp	.	.	.	.	NAACCR	Record ID		
30	Registry Type	.	.	.	.	NAACCR	Record ID		
40	Registry ID	R	R	.	R	NAACCR	Record ID		Auto-coded by software
45	NPI--Registry ID	R	.	.	R*	CMS	Record ID		Auto-coded by software
50	NAACCR Record Version	R	R	.	R	NAACCR	Record ID		Auto-coded by software
60	Tumor Record Number	.	.	.	S	NAACCR	Record ID		NHSCR-use only
70	Addr at DX--City	R	R	R	R	CoC	Demographic		
80	Addr at DX--State	R	R	R	R	CoC	Demographic		
81	State at DX Geocode 1970/80/90	D	RH*	.	R	NAACCR	Demographic	Revised	NHSCR-use only
82	State at DX Geocode 2000	D	D	.	R	NAACCR	Demographic		NHSCR-use only
83	State at DX Geocode 2010	D	D	.	R*	NAACCR	Demographic		NHSCR-use only
84	State at DX Geocode 2020	D	D	.	.	NAACCR	Demographic		NHSCR-use only
89	County at DX Analysis	D	D	.	R	NAACCR	Demographic		NHSCR-use only
90	County at DX Reported	R	R	R	R	FIPS/SEER	Demographic		
94	County at DX Geocode 1970/80/90	D	RH*	.	D	NAACCR	Demographic	Revised	NHSCR-use only
95	County at DX Geocode2000	D	D	.	D	NAACCR	Demographic		NHSCR-use only
96	County at DX Geocode2010	D	D	.	D	NAACCR	Demographic		NHSCR-use only
97	County at DX Geocode2020	D	D	.	.	NAACCR	Demographic		NHSCR-use only
100	Addr at DX--Postal Code	R	R	R	R	CoC	Demographic		
102	Addr at DX--Country	R	.	R	R	NAACCR	Demographic		For cases diagnosed 2013+
110	Census Tract 1970/80/90	RH	RH*	.	RH	SEER	Demographic		NHSCR-use only
120	Census Cod Sys 1970/80/90	RH	RH*	.	RH	SEER	Demographic		NHSCR-use only
125	Census Tract 2020	D	D	.	R*	NAACCR	Demographic		NHSCR-use only
130	Census Tract 2000	RH	RH	.	RH	NAACCR	Demographic		NHSCR-use only
135	Census Tract 2010	R	R	.	R	NAACCR	Demographic		NHSCR-use only
145	Census Tr Poverty Indictcr	D	D	.	D	NAACCR	Demographic		NHSCR-use only
150	Marital Status at DX	R	.	.	R	SEER	Demographic		
160	Race 1	R	R	R	R	SEER/CoC	Demographic		
161	Race 2	R	R	.	R	SEER	Demographic		May be auto-coded by software
162	Race 3	R	R	.	R	SEER	Demographic		May be auto-coded by software
163	Race 4	R	R	.	R	SEER	Demographic		May be auto-coded by software
164	Race 5	R	R	.	R	SEER	Demographic		May be auto-coded by software
170	Race Coding Sys--Current	.	.	.	.	NAACCR	Demographic		May be auto-coded by software
180	Race Coding Sys--Original	.	.	.	.	NAACCR	Demographic		May be auto-coded by software
190	Spanish/Hispanic Origin	R	R	R	.	SEER/CoC	Demographic		
191	NHIA Derived Hisp Origin	D	D	.	D	NAACCR	Demographic		NHSCR-use only
192	IHS Link	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
193	Race--NAPIIA(derived API)	R	R	.	.	NAACCR	Demographic		NHSCR-use only
194	IHS Purchased/Referred Care Delivery Area	D	D	.	D	NPCR	Demographic	New	NHSCR-use only; For cases diagnosed 2022+
200	Computed Ethnicity	D	.	.	D	SEER	Demographic	Revised	NHSCR-use only
210	Computed Ethnicity Source	R	.	.	R	SEER	Demographic	Revised	NHSCR-use only
220	Sex	R	R	R	R	SEER/CoC	Demographic		
230	Age at Diagnosis	R	R	R	R	SEER/CoC	Demographic		Auto-coded by software
240	Date of Birth	R	R	R	R	SEER/CoC	Demographic		
241	Date of Birth Flag	R	R	.	R	NAACCR	Demographic		
250	Birthplace	RH	RH*	.	.	SEER/CoC	Demographic		
252	Birthplace--State	R	R*	R	R	NAACCR	Demographic		For cases diagnosed 2013+
254	Birthplace--Country	R	R*	R	R	NAACCR	Demographic		For cases diagnosed 2013+
270	Census Occ Code 1970-2000	R*	R*	.	.	Census/NPCR	Demographic		NHSCR-use only
272	Census Ind Code 2010 CDC	R*	R*	.	.	Census/NPCR	Demographic		NHSCR-use only
280	Census Ind Code 1970-2000	R*	R*	.	.	Census/NPCR	Demographic		NHSCR-use only
282	Census Occ Code 2010 CDC	R*	R*	.	.	Census/NPCR	Demographic		NHSCR-use only
284	Urban Indian Health Organization (UIHO)	D	D	.	D	NPCR	Demographic	New	NHSCR-use only; For cases diagnosed 2022+
285	UIHO City	D	D	.	D	NPCR	Demographic	New	NHSCR-use only; For cases diagnosed 2022+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
290	Occupation Source	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
300	Industry Source	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
310	Text--Usual Occupation	R	R*	.	.	NPCR	Demographic		
320	Text--Usual Industry	R	R*	.	.	NPCR	Demographic		
330	Census Occ/Ind Sys 70-00	R*	R*	.	.	NPCR	Demographic		NHSCR-use only
339	RUCA 2000	D	D	.	D	NAACCR	Demographic		NHSCR-use only
341	RUCA 2010	D	D	.	D	NAACCR	Demographic		NHSCR-use only
344	Tobacco Use Smoking Status	R	R*	R*	R*	NPCR	Demographic	New	For cases diagnosed 2022+
345	URIC 2000	D	D	.	D	NAACCR	Demographic		NHSCR-use only
346	URIC 2010	D	D	.	D	NAACCR	Demographic		NHSCR-use only
351	GeoLocationID - 1970/80/90	D	RH*	.	.	NAACCR	Demographic	Revised	NHSCR-use only
352	GeoLocationID - 2000	D	D	.	.	NAACCR	Demographic		NHSCR-use only
353	GeoLocationID - 2010	D	D	.	.	NAACCR	Demographic		NHSCR-use only
354	GeoLocationID - 2020	D	D	.	.	NAACCR	Demographic		NHSCR-use only
361	Census Block Group 2020	.	.	.	.	Census	Demographic		NHSCR-use only
362	Census Block Group 2000	S	.	.	S	Census	Demographic		NHSCR-use only
363	Census Block Group 2010	R	.	.	R	Census	Demographic		NHSCR-use only
364	Census Tr Cert 1970/80/90	RH	RH*	.	RH	SEER	Demographic		NHSCR-use only
365	Census Tr Certainty 2000	RH	RH	.	RH	NAACCR	Demographic		NHSCR-use only
366	GIS Coordinate Quality	R	R*	.	S	NAACCR	Demographic		NHSCR-use only
367	Census Tr Certainty 2010	R	R	.	R	NAACCR	Demographic		NHSCR-use only
368	Census Block Grp 1970/80/90	.	.	.	S	Census	Demographic		NHSCR-use only
369	Census Tract Certainty 2020	D	D	.	.	NAACCR	Demographic		NHSCR-use only
380	Sequence Number--Central	R	R	.	R	SEER	Cancer Identification		NHSCR-use only
390	Date of Diagnosis	R	R	R	R	SEER/CoC	Cancer Identification		
391	Date of Diagnosis Flag	R	R	.	R	NAACCR	Cancer Identification		
400	Primary Site	R	R	R	R	SEER/CoC	Cancer Identification		
410	Laterality	R	R	R	R	SEER/CoC	Cancer Identification		
419	Morph--Type&Behav ICD-O-2	.	.	.	.		Cancer Identification		
420	Histology (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed 1992-2000
430	Behavior (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed 1992-2000
439	Date of Mult Tumors Flag	RH	.	RH	RH	NAACCR	Cancer Identification		For cases diagnosed 2010-2012
440	Grade	RH	RH	RH	RH	SEER/CoC	Cancer Identification		For cases diagnosed <2018
441	Grade Path Value	RH	RH*	RH	RH	AJCC	Cancer Identification		For cases diagnosed 2010-2013
442	Ambiguous Terminology DX	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
443	Date Conclusive DX	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
444	Mult Tum Rpt as One Prim	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
445	Date of Mult Tumors	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
446	Multiplicity Counter	RH	.	RH	RH	SEER	Cancer Identification		For cases diagnosed 2006-2012
448	Date Conclusive DX Flag	RH	.	RH	RH	NAACCR	Cancer Identification		For cases diagnosed 2010-2012
449	Grade Path System	RH	RH*	RH	RH	AJCC	Cancer Identification		For cases diagnosed 2010-2013
450	Site Coding Sys--Current	R	R	.	.	NAACCR	Cancer Identification		Auto-coded by software
460	Site Coding Sys--Original	.	.	.	.	NAACCR	Cancer Identification		Auto-coded by software
470	Morph Coding Sys--Current	R	R	.	.	NAACCR	Cancer Identification		Auto-coded by software
480	Morph Coding Sys--Originl	.	.	.	.	NAACCR	Cancer Identification		Auto-coded by software
490	Diagnostic Confirmation	R	R	R	R	SEER/CoC	Cancer Identification		
500	Type of Reporting Source	R	R	.	R	SEER	Cancer Identification		
501	Casefinding Source	R	R*	.	.	NAACCR	Cancer Identification		For cases diagnosed 2006+
521	Morph--Type&Behav ICD-O-3	.	.	.	.		Cancer Identification		
522	Histologic Type ICD-O-3	R	R	R	R	SEER/CoC	Cancer Identification		For cases diagnosed 2001+
523	Behavior Code ICD-O-3	R	R	R	R	SEER/CoC	Cancer Identification		For cases diagnosed 2001+
530	EDP MDE Link Date	RS	RS	.	.	NPCR	Demographic	New	NHSCR-use only; For cases diagnosed 2022+
531	EDP MDE Link	RS	RS	.	.	NPCR	Demographic	New	NHSCR-use only; For cases diagnosed 2022+
540	Reporting Facility	R	R	R	R	CoC	Hospital-Specific		Auto-coded by software
545	NPI--Reporting Facility	R	R*	R	R*	CMS	Hospital-Specific		Auto-coded by software
550	Accession Number--Hosp	R	.	R	R	CoC	Hospital-Specific		
560	Sequence Number--Hospital	R	.	R	R	CoC	Hospital-Specific		
570	Abstracted By	R	.	R	R	CoC	Hospital-Specific		
580	Date of 1st Contact	R	R	R	.	CoC	Hospital-Specific		
581	Date of 1st Contact Flag	R	R	R	.	NAACCR	Hospital-Specific		
590	Date of Inpt Adm	.	.	.	.	NAACCR	Hospital-Specific		
591	Date of Inpt Adm Flag	.	.	.	.	NAACCR	Hospital-Specific		
600	Date of Inpt Disch	.	.	.	.	NAACCR	Hospital-Specific		
601	Date of Inpt Disch Flag	.	.	.	.	NAACCR	Hospital-Specific		
605	Inpatient Status	.	.	.	.	NAACCR	Hospital-Specific		
610	Class of Case	R	R	R	RC	CoC	Hospital-Specific		
630	Primary Payer at DX	R	R*	R	R	CoC	Hospital-Specific		
668	RX Hosp--Surg App 2010	R	.	R	.	CoC	Hospital-Specific		For cases diagnosed 2010+
670	RX Hosp--Surg Prim Site	R	.	R	R	CoC	Hospital-Specific		
672	RX Hosp--Scope Reg LN Sur	R	.	R	R	CoC	Hospital-Specific		
674	RX Hosp--Surg Oth Reg/Dis	R	.	R	R	CoC	Hospital-Specific		
676	RX Hosp--Reg LN Removed	RH	.	RH	.	CoC	Hospital-Specific		
682	Date Regional Lymph Node Dissection	R	.	R	RC	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2018+
683	Date Regional Lymph Node Dissection Flag	R	.	.	R*	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2018+
690	RX Hosp--Radiation	RH	.	.	RH	SEER	Hospital-Specific		
700	RX Hosp--Chemo	R	.	R	R	CoC	Hospital-Specific		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
710	RX Hosp--Hormone	R	.	R	R	CoC	Hospital-Specific		
720	RX Hosp--BRM	R	.	R	R	CoC	Hospital-Specific		
730	RX Hosp--Other	R	.	R	R	CoC	Hospital-Specific		
740	RX Hosp--DX/Stg Proc	R	.	R	.	CoC	Hospital-Specific		
746	RX Hosp--Surg Site 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
747	RX Hosp--Scope Reg 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
748	RX Hosp--Surg Oth 98-02	RH	.	RH	RH	CoC	Hospital-Specific		For cases diagnosed 1998-2002
752	Tumor Size Clinical	R	.	.	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
754	Tumor Size Pathologic	R	.	.	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
756	Tumor Size Summary	R	R	.	S	NPCR/CoC	Stage/Prognostic Factors		For cases diagnosed 2016+
759	SEER Summary Stage 2000	RH	RH	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed 2001-2003 & 2015-2017
760	SEER Summary Stage 1977	RH	RH	RH	.	SEER	Stage/Prognostic Factors		For cases diagnosed <2001
762	Derived Summary Stage 2018	D	.	.	D	SEER	Stage/Prognostic Factors		
764	Summary Stage 2018	R	R	.	R*	SEER	Stage/Prognostic Factors		
772	EOD Primary Tumor	S	.	.	R	SEER	Stage/Prognostic Factors		
774	EOD Regional Nodes	S	.	.	R	SEER	Stage/Prognostic Factors		
776	EOD Mets	S	.	.	R	SEER	Stage/Prognostic Factors		
779	Extent of Disease 10-Dig	.	.	.	.	.	Stage/Prognostic Factors		
780	EOD--Tumor Size	RH	.	RH	RH	SEER/CoC	Stage/Prognostic Factors		For cases diagnosed < 2004
785	Derived EOD 2018 T	.	.	.	D	SEER	Stage/Prognostic Factors		
790	EOD--Extension	.	.	.	RH	SEER	Stage/Prognostic Factors		
795	Derived EOD 2018 M	.	.	.	D	SEER	Stage/Prognostic Factors		
800	EOD--Extension Prost Path	.	.	.	RH	SEER	Stage/Prognostic Factors		
810	EOD--Lymph Node Involv	.	.	.	RH	SEER	Stage/Prognostic Factors		
815	Derived EOD 2018 N	.	.	.	D	SEER	Stage/Prognostic Factors		
818	Derived EOD 2018 Stage Group	.	.	.	D	SEER	Stage/Prognostic Factors		
820	Regional Nodes Positive	R	R	R	R	SEER/CoC	Stage/Prognostic Factors		
830	Regional Nodes Examined	R	R	R	R	SEER/CoC	Stage/Prognostic Factors		
832	Date of Sentinel Lymph Node Biopsy	R	.	RS	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+
833	Date of Sentinel Lymph Node Biopsy Flag	R	.	.	R*	SEER	Stage/Prognostic Factors		For cases diagnosed 2018+
834	Sentinel Lymph Nodes Examined	R	.	RS	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+
835	Sentinel Lymph Nodes Positive	R	.	RS	R*	CoC	Stage/Prognostic Factors		For cases diagnosed 2018+
840	EOD--Old 13 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
850	EOD--Old 2 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
860	EOD--Old 4 Digit	.	.	.	RH	SEER	Stage/Prognostic Factors		
870	Coding System for EOD	.	.	.	RH	SEER	Stage/Prognostic Factors		
880	TNM Path T	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
890	TNM Path N	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
900	TNM Path M	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
910	TNM Path Stage Group	RH	.	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
920	TNM Path Descriptor	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
930	TNM Path Staged By	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017
940	TNM Clin T	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
950	TNM Clin N	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
960	TNM Clin M	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
970	TNM Clin Stage Group	RH	.	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
980	TNM Clin Descriptor	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
990	TNM Clin Staged By	RH	.	RH	RH	CoC	Stage/Prognostic Factors		For cases diagnosed <2004 & 2015-2017; Breast & Rectum 2011-2014
995	AJCC ID	D	D	D	RC	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2018+
1001	AJCC TNM Clin T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1002	AJCC TNM Clin N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1003	AJCC TNM Clin M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1004	AJCC TNM Clin Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1011	AJCC TNM Path T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1012	AJCC TNM Path N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1013	AJCC TNM Path M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1014	AJCC TNM Path Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1021	AJCC TNM Post Therapy Path (yp) T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1022	AJCC TNM Post Therapy Path (yp) N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1023	AJCC TNM Post Therapy Path (yp) M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1024	AJCC TNM Post Therapy Path (yp) Stage Group	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1031	AJCC TNM Clin T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1032	AJCC TNM Path T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1033	AJCC TNM Post Therapy Path (yp) T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1034	AJCC TNM Clin N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1035	AJCC TNM Path N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1036	AJCC TNM Post Therapy Path (yp) N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2018+
1060	TNM Edition Number	RH	.	R	RH	CoC	Stage/Prognostic Factors		Auto-coded by software
1062	AJCC TNM Post Therapy Clin (yc) T	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1064	AJCC TNM Post Therapy Clin (yc) N	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1066	AJCC TNM Post Therapy Clin (yc) M	R	.	R	RC	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	R	.	R	.	AJCC	Stage/Prognostic Factors		For cases diagnosed 2021+
1068	Grade Post Therapy Clin (yc)	R	R*	.	RS	NAACCR	Stage/Prognostic Factors		For cases diagnosed 2021+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1112	Mets at DX-Bone	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1113	Mets at DX-Brain	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1114	Mets at Dx-Distant LN	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1115	Mets at DX-Liver	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1116	Mets at DX-Lung	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1117	Mets at DX-Other	R	.	R	R	SEER	Stage/Prognostic Factors		For cases diagnosed 2016+
1120	Pediatric Stage	.	.	.	.	CoC	Stage/Prognostic Factors		
1130	Pediatric Staging System	.	.	.	.	CoC	Stage/Prognostic Factors		
1140	Pediatric Staged By	.	.	.	.	CoC	Stage/Prognostic Factors		
1150	Tumor Marker 1	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed < 2004; Site-specific
1160	Tumor Marker 2	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed < 2004; Site-specific
1170	Tumor Marker 3	RH	.	RH	RH	SEER	Stage/Prognostic Factors		For cases diagnosed < 2004; Site-specific
1182	Lymphovascular Invasion	R	R*	R	RS	AUCC	Stage/Prognostic Factors		For cases diagnosed 2010+
1200	RX Date Surgery	R	R	R	RC	CoC	Treatment-1st Course		
1201	RX Date Surgery Flag	R	R	R	RC	NAACCR	Treatment-1st Course		
1210	RX Date Radiation	R	R	R	RC	CoC	Treatment-1st Course		
1211	RX Date Radiation Flag	R	R	.	R*	NAACCR	Treatment-1st Course		
1220	RX Date Chemo	R	R	R	RC	CoC	Treatment-1st Course		
1221	RX Date Chemo Flag	R	R	.	RC	NAACCR	Treatment-1st Course		
1230	RX Date Hormone	R	R	R	RC	CoC	Treatment-1st Course		
1231	RX Date Hormone Flag	R	R	R	RC	NAACCR	Treatment-1st Course		
1240	RX Date BRM	R	R	R	RC	CoC	Treatment-1st Course		
1241	RX Date BRM Flag	R	R	R	RC	NAACCR	Treatment-1st Course		
1250	RX Date Other	R	R	R	RC	CoC	Treatment-1st Course		
1251	RX Date Other Flag	R	R	.	R*	NAACCR	Treatment-1st Course		
1260	Date Initial RX SEER	.	R#	.	R	SEER	Treatment-1st Course		
1261	Date Initial RX SEER Flag	.	R#	.	R	NAACCR	Treatment-1st Course		
1270	Date 1st Crs RX CoC	R	R#	R	.	CoC	Treatment-1st Course		
1271	Date 1st Crs RX CoC Flag	R	R#	.	.	NAACCR	Treatment-1st Course		
1280	RX Date DX/Stg Proc	R	.	R	.	CoC	Treatment-1st Course		
1281	RX Date DX/Stg Proc Flag	R	.	R	.	NAACCR	Treatment-1st Course		
1285	RX Summ--Treatment Status	R	R#	R	R	SEER/CoC	Treatment-1st Course		For cases diagnosed 2010+
1290	RX Summ--Surg Prim Site	R	R	R	R	SEER/CoC	Treatment-1st Course		
1292	RX Summ--Scope Reg LN Sur	R	R	R	R	SEER/CoC	Treatment-1st Course		
1294	RX Summ--Surg Oth Reg/Dis	R	R	R	R	SEER/CoC	Treatment-1st Course		
1296	RX Summ--Reg LN Examined	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1310	RX Summ--Surgical Approch	RH	.	RH	.	CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1320	RX Summ--Surgical Margins	R	.	R	R*	CoC	Treatment-1st Course		
1330	RX Summ--Reconstruct 1st	RH	.	RH	.	SEER	Treatment-1st Course		For cases diagnosed 1998-2002
1340	Reason for No Surgery	R	R	R	R	SEER/CoC	Treatment-1st Course		
1350	RX Summ--DX/Stg Proc	R	.	R	.	CoC	Treatment-1st Course		
1360	RX Summ--Radiation	RH	RH	.	RH	SEER	Treatment-1st Course		For cases diagnosed <2003
1370	RX Summ--Rad to CNS	RH	.	.	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed <1998
1380	RX Summ--Surg/Rad Seq	R	R	R	R	SEER/CoC	Treatment-1st Course		
1390	RX Summ--Chemo	R	R	R	R	SEER/CoC	Treatment-1st Course		
1400	RX Summ--Hormone	R	R	R	R	SEER/CoC	Treatment-1st Course		
1410	RX Summ--BRM	R	R	R	R	SEER/CoC	Treatment-1st Course		
1420	RX Summ--Other	R	R	R	R	SEER/CoC	Treatment-1st Course		
1430	Reason for No Radiation	R	R	R	R	CoC	Treatment-1st Course		
1460	RX Coding System--Current	R	R	.	.	NAACCR	Treatment-1st Course		May be auto-coded by software
1501	Phase I Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1502	Phase I Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1503	Phase I Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1504	Phase I Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1505	Phase I Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1506	Phase I Radiation Treatment Modality	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1507	Phase I Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1510	Rad--Regional Dose: cGy	.	.	.	.	CoC	Treatment-1st Course		
1511	Phase II Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1512	Phase II Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1513	Phase II Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1514	Phase II Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1515	Phase II Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1516	Phase II Radiation Treatment Modality	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1517	Phase II Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1520	Rad--No of Treatment Vol	.	.	.	.	CoC	Treatment-1st Course		
1521	Phase III Dose per Fraction	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1522	Phase III Radiation External Beam Planning Tech	R	.	R	RC	CoC	Treatment-1st Course		For cases diagnosed 2018+
1523	Phase III Number of Fractions	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1524	Phase III Radiation Primary Treatment Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1525	Phase III Radiation to Draining Lymph Nodes	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1526	Phase III Radiation Treatment Modality	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2018+
1527	Phase III Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1531	Radiation Treatment Discontinued Early	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1532	Number of Phases of Rad Treatment to this Volume	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+
1533	Total Dose	R	.	R	R*	CoC	Treatment-1st Course		For cases diagnosed 2018+



Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1540	Rad--Treatment Volume	.	.	.	.	CoC	Treatment-1st Course		
1550	Rad--Location of RX	R	.	R	.	CoC	Treatment-1st Course		
1570	Rad--Regional RX Modality	RH	RH	.	.	CoC	Treatment-1st Course		For cases diagnosed 2003-2018
1632	Neoadjuvant Therapy	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1633	Neoadjuvant Therapy-Clinical Response	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1634	Neoadjuvant Therapy-Treatment Effect	R	.	.	R	SEER	Treatment-1st Course		For cases diagnosed 2021+
1639	RX Summ--Systemic/Sur Seq	R	R	R	R	CoC	Treatment-1st Course		For cases diagnosed 2006+
1640	RX Summ--Surgery Type	RH	.	.	RH	SEER	Treatment-1st Course		For cases diagnosed <1996; Derived
1646	RX Summ--Surg Site 98-02	RH	.	RH	.	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1647	RX Summ--Scope Reg 98-02	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1648	RX Summ--Surg Oth 98-02	RH	.	RH	RH	SEER/CoC	Treatment-1st Course		For cases diagnosed 1998-2002
1660	Subsq RX 2nd Course Date	RH	.	.	.	CoC	Treatment-Subsequent & Other		For Breast, Colorectal, CML cases diagnosed 2011
1661	Subsq RX 2ndCrS Date Flag	.	.	.	.	NAACCR	Treatment-Subsequent & Other		
1670	Subsq RX 2nd Course Codes	.	.	.	.		Treatment-Subsequent & Other		
1671	Subsq RX 2nd Course Surg	.	.	.	.	CoC	Treatment-Subsequent & Other		
1672	Subsq RX 2nd Course Rad	.	.	.	.	CoC	Treatment-Subsequent & Other		
1673	Subsq RX 2nd Course Chemo	.	.	.	.	CoC	Treatment-Subsequent & Other		
1674	Subsq RX 2nd Course Horm	.	.	.	.	CoC	Treatment-Subsequent & Other		
1675	Subsq RX 2nd Course BRM	.	.	.	.	CoC	Treatment-Subsequent & Other		
1676	Subsq RX 2nd Course Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1677	Subsq RX 2nd--Scope LN SU	.	.	.	.	CoC	Treatment-Subsequent & Other		
1678	Subsq RX 2nd--Surg Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1679	Subsq RX 2nd--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsequent & Other		
1680	Subsq RX 3rd Course Date	.	.	.	.	CoC	Treatment-Subsequent & Other		
1681	Subsq RX 3rdCrS Date Flag	.	.	.	.	NAACCR	Treatment-Subsequent & Other		
1690	Subsq RX 3rd Course Codes	.	.	.	.		Treatment-Subsequent & Other		
1691	Subsq RX 3rd Course Surg	.	.	.	.	CoC	Treatment-Subsequent & Other		
1692	Subsq RX 3rd Course Rad	.	.	.	.	CoC	Treatment-Subsequent & Other		
1693	Subsq RX 3rd Course Chemo	.	.	.	.	CoC	Treatment-Subsequent & Other		
1694	Subsq RX 3rd Course Horm	.	.	.	.	CoC	Treatment-Subsequent & Other		
1695	Subsq RX 3rd Course BRM	.	.	.	.	CoC	Treatment-Subsequent & Other		
1696	Subsq RX 3rd Course Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1697	Subsq RX 3rd--Scope LN Su	.	.	.	.	CoC	Treatment-Subsequent & Other		
1698	Subsq RX 3rd--Surg Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1699	Subsq RX 3rd--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsequent & Other		
1700	Subsq RX 4th Course Date	.	.	.	.	CoC	Treatment-Subsequent & Other		
1701	Subsq RX 4thCrS Date Flag	.	.	.	.	NAACCR	Treatment-Subsequent & Other		
1710	Subsq RX 4th Course Codes	.	.	.	.		Treatment-Subsequent & Other		
1711	Subsq RX 4th Course Surg	.	.	.	.	CoC	Treatment-Subsequent & Other		
1712	Subsq RX 4th Course Rad	.	.	.	.	CoC	Treatment-Subsequent & Other		
1713	Subsq RX 4th Course Chemo	.	.	.	.	CoC	Treatment-Subsequent & Other		
1714	Subsq RX 4th Course Horm	.	.	.	.	CoC	Treatment-Subsequent & Other		
1715	Subsq RX 4th Course BRM	.	.	.	.	CoC	Treatment-Subsequent & Other		
1716	Subsq RX 4th Course Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1717	Subsq RX 4th--Scope LN Su	.	.	.	.	CoC	Treatment-Subsequent & Other		
1718	Subsq RX 4th--Surg Oth	.	.	.	.	CoC	Treatment-Subsequent & Other		
1719	Subsq RX 4th--Reg LN Rem	.	.	.	.	CoC	Treatment-Subsequent & Other		
1741	Subsq RX--Reconstruct Del	.	.	.	.	CoC	Treatment-Subsequent & Other		
1750	Date of Last Contact	R	R	R	R	SEER/CoC	Follow-up/Recurrence/Death		
1751	Date of Last Contact Flag	R	R	.	R	NAACCR	Follow-up/Recurrence/Death		
1755	Date of Death--Canada	.	.	.	.	CCCR	Follow-up/Recurrence/Death		
1756	Date of Death--CanadaFlag	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1760	Vital Status	R	R	R	R	SEER/CoC	Follow-up/Recurrence/Death		
1762	Vital Status Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1770	Cancer Status	R	.	R	R*	CoC	Follow-up/Recurrence/Death	Revised	
1772	Date of Last Cancer (tumor) Status	R	.	R	R*	CoC	Follow-up/Recurrence/Death	Revised	For cases diagnosed 2018+
1773	Date of Last Cancer (tumor) Status Flag	R	.	.	R*	NAACCR	Follow-up/Recurrence/Death	Revised	For cases diagnosed 2018+
1775	Record Number Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1780	Quality of Survival	.	.	.	.	CoC	Follow-up/Recurrence/Death		
1782	Surv-Date Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1783	Surv-Flag Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1784	Surv-Mos Active Followup	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1785	Surv-Date Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1786	Surv-Flag Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1787	Surv-Mos Presumed Alive	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1788	Surv-Date DX Recode	D	D	.	D	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only; For cases diagnosed 2015+
1790	Follow-Up Source	R	R*	R	.	CoC	Follow-up/Recurrence/Death		
1791	Follow-up Source Central	R	R	.	.	NAACCR	Follow-up/Recurrence/Death		NHSCR-use only
1800	Next Follow-Up Source	R	.	R	.	CoC	Follow-up/Recurrence/Death		
1810	Addr Current--City	.	.	.	R	SEER	Follow-up/Recurrence/Death		
1820	Addr Current--State	.	.	.	R	SEER	Follow-up/Recurrence/Death		
1830	Addr Current--Postal Code	.	.	.	R	SEER	Follow-up/Recurrence/Death		
1832	Addr Current--Country	.	.	.	R	NAACCR	Demographic		
1840	County--Current	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1842	Follow-Up Contact--City	.	.	.	.	SEER	Follow-up/Recurrence/Death		
1844	Follow-Up Contact--State	.	.	.	.	SEER	Follow-up/Recurrence/Death		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
1846	Follow-Up Contact--Postal	.	.	.	.	SEER	Follow-up/Recurrence/Death		
1847	FollowUp Contact--Country	.	.	.	.	NAACCR	Demographic		
1850	Unusual Follow-Up Method	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1860	Recurrence Date--1st	R	.	R	RC	CoC	Follow-up/Recurrence/Death		
1861	Recurrence Date--1st Flag	R	.	.	R*	NAACCR	Follow-up/Recurrence/Death		
1880	Recurrence Type--1st	R	.	R	RC	CoC	Follow-up/Recurrence/Death		
1910	Cause of Death	R	R	.	R	SEER	Follow-up/Recurrence/Death		Reporting registries use 7777 or 7797
1914	SEER Cause Specific COD	D	D	.	D	SEER	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1915	SEER Other COD	D	D	.	D	SEER	Follow-up/Recurrence/Death		For cases diagnosed 2018+
1920	ICD Revision Number	R	R	.	R	SEER	Follow-up/Recurrence/Death		Auto-coded by software
1930	Autopsy	.	.	.	.	NAACCR	Follow-up/Recurrence/Death		
1940	Place of Death	RH	RH	.	.	NPCR	Follow-up/Recurrence/Death		
1942	Place of Death--State	R	R	.	R	NAACCR	Demographic		For cases diagnosed 2013+
1944	Place of Death--Country	R	R*	.	R	NAACCR	Demographic		For cases diagnosed 2013+
1960	Site (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides/Conversion History/System Admin		
1970	Morph (73-91) ICD-O-1	.	.	.	.	.	Edit Overrides/Conversion History/System Admin		
1971	Histology (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides/Conversion History/System Admin		
1972	Behavior (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides/Conversion History/System Admin		
1973	Grade (73-91) ICD-O-1	.	.	.	RH	SEER	Edit Overrides/Conversion History/System Admin		
1980	ICD-O-2 Conversion Flag	RH	.	.	R	SEER	Edit Overrides/Conversion History/System Admin		Auto-coded by software
1981	Over-ride SS/NodesPos	RH	.	.	RH	NAACCR	Edit Overrides/Conversion History/System Admin		
1982	Over-ride SS/TNM-N	RH	.	.	RH	NAACCR	Edit Overrides/Conversion History/System Admin		
1983	Over-ride SS/TNM-M	RH	.	.	RH	NAACCR	Edit Overrides/Conversion History/System Admin		
1985	Over-ride Acsn/Class/Seq	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
1986	Over-ride HospSeq/DxConf	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
1987	Over-ride CoC-Site/Type	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
1988	Over-ride HospSeq/Site	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
1989	Over-ride Site/TNM-StgGrp	R	.	.	R	NAACCR	Edit Overrides/Conversion History/System Admin		
1990	Over-ride Age/Site/Morph	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
1992	Over-ride TNM Stage	R	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018+
1993	Over-ride TNM Tis	R	.	.	R	NAACCR	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018+
1994	Over-ride TNM 3	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018+
2000	Over-ride SeqNo/DxConf	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2010	Over-ride Site/Lat/SeqNo	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2020	Over-ride Surg/DxConf	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2030	Over-ride Site/Type	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2040	Over-ride Histology	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2050	Over-ride Report Source	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2060	Over-ride Ill-define Site	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2070	Over-ride Leuk, Lymphoma	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2071	Over-ride Site/Behavior	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2072	Over-ride Site/EOD/DX Dt	R	.	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2073	Over-ride Site/Lat/EOD	R	.	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2074	Over-ride Site/Lat/Morph	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		
2078	Over-ride Name/Sex	R	R	.	R	NAACCR	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018+
2081	CRC CHECKSUM	.	.	.	S	NAACCR	Edit Overrides/Conversion History/System Admin		
2085	Date Case Initiated	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2090	Date Case Completed	R	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
2092	Date Case Completed--CoC	D	.	D	.	CoC	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2100	Date Case Last Changed	D	.	D	.	NAACCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2110	Date Case Report Exported	R	R	.	.	NPCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2111	Date Case Report Received	R	R	.	.	NPCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2112	Date Case Report Loaded	R	R	.	.	NPCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2113	Date Tumor Record Availbl	R	R	.	.	NPCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2116	ICD-O-3 Conversion Flag	R	R	.	R	SEER	Edit Overrides/Conversion History/System Admin		May be auto-coded by software
2117	Schema ID Version Current	D	D	D	D	SEER	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2021+
2118	Schema ID Version Original	D	D	D	D	SEER	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2021+
2120	SEER Coding Sys--Current	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
2130	SEER Coding Sys--Original	.	.	.	.	NAACCR	Edit Overrides/Conversion History/System Admin		
2140	CoC Coding Sys--Current	.	.	.	.	CoC	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2150	CoC Coding Sys--Original	.	.	.	.	CoC	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2152	CoC Accredited Flag	R	R	.	R	NPCR	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018+
2155	RQRS NCDDB Submission Flag	.	.	.	.	CoC	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2018-2020
2156	AJCC API Version Current	D	.	D	D*	AJCC	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2021+
2157	AJCC API Version Original	D	.	D	D*	AJCC	Edit Overrides/Conversion History/System Admin		For cases diagnosed 2021+
2158	AJCC Cancer Surveillance DLL Version Current	D	D	D	D*	AJCC	Edit Overrides/Conversion History/System Admin	Revised	Auto-coded by software; For cases diagnosed 2021+
2159	AJCC Cancer Surveillance DLL Version Original	D	D	D	D*	AJCC	Edit Overrides/Conversion History/System Admin	Revised	Auto-coded by software; For cases diagnosed 2021+
2170	Vendor Name	R	.	R	.	NAACCR	Edit Overrides/Conversion History/System Admin		Auto-coded by software
2180	SEER Type of Follow-Up	.	.	.	.	SEER	Edit Overrides/Conversion History/System Admin		
2190	SEER Record Number	.	.	.	.	SEER	Edit Overrides/Conversion History/System Admin		
2200	Diagnostic Proc 73-87	.	.	.	.	SEER	Edit Overrides/Conversion History/System Admin		
2230	Name--Last	R	R	.	R	SEER	Patient-Confidential		
2232	Name--Birth Surname	R	R	.	R	NAACCR	Patient-Confidential		For cases diagnosed 2021+
2240	Name--First	R	R	.	R	SEER	Patient-Confidential		
2250	Name--Middle	R	R	.	R	SEER	Patient-Confidential		
2260	Name--Prefix	R*	.	.	.	NAACCR	Patient-Confidential		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
2270	Name--Suffix	R*	.	.	R	NAACCR	Patient-Confidential		
2280	Name--Alias	R	R	.	R	NAACCR	Patient-Confidential		
2290	Name--Spouse/Parent	.	.	.	.	NAACCR	Patient-Confidential		
2300	Medical Record Number	R	R	.	R	NAACCR	Patient-Confidential		
2310	Military Record No Suffix	.	.	.	.	CoC	Patient-Confidential		
2315	Medicare Beneficiary Identifier	R*	R*	.	.	NAACCR	Patient-Confidential		For cases diagnosed 2018+
2320	Social Security Number	R	R	.	R	SEER	Patient-Confidential		
2330	Addr at DX--No & Street	R	R	.	R	SEER	Patient-Confidential		
2335	Addr at DX--Supplementl	R	R	.	R	SEER	Patient-Confidential		
2350	Addr Current--No & Street	.	.	.	R	SEER	Patient-Confidential		
2352	Latitude	R	R*	.	S	NAACCR	Patient-Confidential		NHSCR-use only
2354	Longitude	R	R*	.	S	NAACCR	Patient-Confidential		NHSCR-use only
2355	Addr Current--Supplementl	.	.	.	R*	SEER	Patient-Confidential		
2360	Telephone	S	.	.	R	SEER	Patient-Confidential		
2380	DC State File Number	R	R	.	R*	State	Patient-Confidential		NHSCR-use only
2390	Name--Maiden	RH	.	.	.	NAACCR	Patient-Confidential		For cases diagnosed <2021; replaced with #2232 effective 2021+
2392	Follow-Up Contact--No&St	.	.	.	.	SEER	Patient-Confidential		
2393	Follow-Up Contact--Suppl	.	.	.	.	SEER	Patient-Confidential		
2394	Follow-Up Contact--Name	.	.	.	.	SEER	Patient-Confidential		
2410	Institution Referred From	.	.	.	.	CoC	Hospital-Confidential		
2415	NPI--Inst Referred From	R	.	R	.	CMS	Hospital-Confidential		
2420	Institution Referred To	.	.	.	.	CoC	Hospital-Confidential		
2425	NPI--Inst Referred To	R	.	R	.	CMS	Hospital-Confidential		
2440	Following Registry	RH	.	.	RH	CoC	Hospital-Confidential		
2445	NPI--Following Registry	RH	.	.	RH*	CMS	Hospital-Confidential		
2460	Physician--Managing	RH	.	.	.	NAACCR	Other-Confidential		
2465	NPI--Physician--Managing	R	.	.	.	CMS	Other-Confidential		
2470	Physician--Follow-Up	R	.	.	R	CoC	Other-Confidential		
2475	NPI--Physician--Follow-Up	R	.	.	R*	CMS	Other-Confidential		
2480	Physician--Primary Surg	.	.	.	.	CoC	Other-Confidential		
2485	NPI--Physician--Primary Surg	R	.	R	.	CMS	Other-Confidential		
2490	Physician 3	.	.	.	.	CoC	Other-Confidential		
2495	NPI--Physician 3	R	.	R	.	CMS	Other-Confidential		
2500	Physician 4	.	.	.	.	CoC	Other-Confidential		
2505	NPI--Physician 4	R	.	R	.	CMS	Other-Confidential		
2508	EHR Reporting	.	.	.	.	NAACCR	Other-Confidential		
2520	Text--DX Proc--PE	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2530	Text--DX Proc--X-ray/Scan	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2540	Text--DX Proc--Scopes	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2550	Text--DX Proc--Lab Tests	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2560	Text--DX Proc--Op	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2570	Text--DX Proc--Path	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2580	Text--Primary Site Title	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2590	Text--Histology Title	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2600	Text--Staging	R	R^	.	R	NPCR	Text-Diagnosis		May be met with one or several text block fields
2610	RX Text--Surgery	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2620	RX Text--Radiation (Beam)	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2630	RX Text--Radiation Other	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2640	RX Text--Chemo	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2650	RX Text--Hormone	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2660	RX Text--BRM	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2670	RX Text--Other	R	R^	.	R	NPCR	Text-Treatment		May be met with one or several text block fields
2680	Text--Remarks	R	.	.	R	NPCR	Text-Miscellaneous		May be met with one or several text block fields
2690	Text--Place of Diagnosis	R	.	.	.	NPCR	Text-Miscellaneous		
2800	CS Tumor Size	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2810	CS Extension	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2820	CS Tumor Size/Ext Eval	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2830	CS Lymph Nodes	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2840	CS Lymph Nodes Eval	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2850	CS Mets at DX	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2851	CS Mets at Dx-Bone	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2852	CS Mets at Dx-Brain	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2853	CS Mets at Dx-Liver	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2854	CS Mets at Dx-Lung	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2860	CS Mets Eval	RH	RH*	RH	RH*	AJCC	Stage/Prognostic Factors		For cases diagnosed 2004-2015
2861	CS Site-Specific Factor 7	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2862	CS Site-Specific Factor 8	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2863	CS Site-Specific Factor 9	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2864	CS Site-Specific Factor10	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2865	CS Site-Specific Factor11	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2866	CS Site-Specific Factor12	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2867	CS Site-Specific Factor13	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2868	CS Site-Specific Factor14	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2869	CS Site-Specific Factor15	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2870	CS Site-Specific Factor16	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2871	CS Site-Specific Factor17	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
2872	CS Site-Specific Factor18	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2873	CS Site-Specific Factor19	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2874	CS Site-Specific Factor20	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2875	CS Site-Specific Factor21	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2876	CS Site-Specific Factor22	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2877	CS Site-Specific Factor23	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2878	CS Site-Specific Factor24	RH	.	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2879	CS Site-Specific Factor25	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2010-2017
2880	CS Site-Specific Factor 1	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2890	CS Site-Specific Factor 2	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2900	CS Site-Specific Factor 3	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2910	CS Site-Specific Factor 4	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2920	CS Site-Specific Factor 5	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2930	CS Site-Specific Factor 6	RH	RH*	RH	RH	AJCC	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2004-2017
2935	CS Version Input Original	RH	R*	RH	RH*	AJCC	Stage/Prognostic Factors		
2936	CS Version Derived	DH	RH*	DH	D*	AJCC	Stage/Prognostic Factors		
2937	CS Version Input Current	R*	R*	RH	RH*	AJCC	Stage/Prognostic Factors		
2940	Derived AJCC-6 T	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2950	Derived AJCC-6 T Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2960	Derived AJCC-6 N	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2970	Derived AJCC-6 N Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2980	Derived AJCC-6 M	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
2990	Derived AJCC-6 M Descript	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3000	Derived AJCC-6 Stage Grp	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3010	Derived SS1977	DH	.	DH	D*	AJCC	Stage/Prognostic Factors		
3020	Derived SS2000	DH	RH*	DH	D+	AJCC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3030	Derived AJCC--Flag	DH	.	DH	DH	AJCC	Stage/Prognostic Factors		
3040	Derived SS1977--Flag	DH	.	DH	D*	AJCC	Stage/Prognostic Factors		
3050	Derived SS2000--Flag	DH	RH*	DH	D*	AJCC	Stage/Prognostic Factors		
3100	Archive FIN	.	.	R	.	CoC	Hospital-Specific		
3105	NPI--Archive FIN	.	.	R	.	CMS	Hospital-Specific		
3110	Comorbid/Complication 1	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3120	Comorbid/Complication 2	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3130	Comorbid/Complication 3	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3140	Comorbid/Complication 4	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3150	Comorbid/Complication 5	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3160	Comorbid/Complication 6	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3161	Comorbid/Complication 7	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3162	Comorbid/Complication 8	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3163	Comorbid/Complication 9	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3164	Comorbid/Complication 10	RH	.	RH	.	CoC	Stage/Prognostic Factors		For cases diagnosed 1/1/2010-09/30/2015
3165	ICD Revision Comorbid	.	.	.	.	CoC	Stage/Prognostic Factors		May be auto-coded by software
3170	RX Date Mst Defn Srg	R	R	R	RC	CoC	Treatment-1st Course		
3171	RX Date Mst Defn Srg Flag	R	R	.	R*	NAACCR	Treatment-1st Course		
3180	RX Date Surg Disch	R	.	R	.	CoC	Treatment-1st Course		
3181	RX Date Surg Disch Flag	R	.	.	.	NAACCR	Treatment-1st Course		
3190	Readm Same Hosp 30 Days	R	.	R	.	CoC	Treatment-1st Course		
3200	Rad--Boost RX Modality	.	.	.	.	CoC	Treatment-1st Course		
3210	Rad--Boost Dose cGy	.	.	.	.	CoC	Treatment-1st Course		
3220	RX Date Rad Ended	R	.	R	.	CoC	Treatment-1st Course		
3221	RX Date Rad Ended Flag	.	.	.	.	NAACCR	Treatment-1st Course		
3230	RX Date Systemic	R	.	R	RC	CoC	Treatment-1st Course		
3231	RX Date Systemic Flag	R	.	.	R*	NAACCR	Treatment-1st Course		
3250	RX Summ--Transplnt/Endocr	R	R	R	R	CoC	Treatment-1st Course		
3270	RX Summ--Palliative Proc	R	.	R	.	CoC	Treatment-1st Course		
3280	RX Hosp--Palliative Proc	R	.	R	.	CoC	Hospital-Specific		
3300	RuralUrban Continuum 1993	D	D	.	.	NAACCR	Demographic		NHSCR-use only
3310	RuralUrban Continuum 2003	D	D	.	.	NAACCR	Demographic		NHSCR-use only
3312	RuralUrban Continuum 2013	D	D	.	D	NAACCR	Demographic		NHSCR-use only
3400	Derived AJCC-7 T	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3402	Derived AJCC-7 T Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3410	Derived AJCC-7 N	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3412	Derived AJCC-7 N Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3420	Derived AJCC-7 M	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3422	Derived AJCC-7 M Descript	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3430	Derived AJCC-7 Stage Grp	RH*	RH*	DH	DH	AJCC	Stage/Prognostic Factors		
3440	Derived PreRx-7 T	.	.	.	.	AJCC	Stage/Prognostic Factors		
3442	Derived PreRx-7 T Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors		
3450	Derived PreRx-7 N	.	.	.	.	AJCC	Stage/Prognostic Factors		
3452	Derived PreRx-7 N Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors		
3460	Derived PreRx-7 M	.	.	.	.	AJCC	Stage/Prognostic Factors		
3462	Derived PreRx-7 M Descrip	.	.	.	.	AJCC	Stage/Prognostic Factors		
3470	Derived PreRx-7 Stage Grp	.	.	.	.	AJCC	Stage/Prognostic Factors		
3480	Derived PostRx-7 T	.	.	.	.	AJCC	Stage/Prognostic Factors		
3482	Derived PostRx-7 N	.	.	.	.	AJCC	Stage/Prognostic Factors		
3490	Derived PostRx-7 M	.	.	.	.	AJCC	Stage/Prognostic Factors		

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3492	Derived PostRx-7 Stge Grp	.	.	.	.	AJCC	Stage/Prognostic Factors		
3600	Derived Neoadjuv Rx Flag	.	.	.	.	AJCC	Stage/Prognostic Factors		
3605	Derived SEER Path Stg Grp	.	.	.	DH	SEER	Stage/Prognostic Factors		
3610	Derived SEER Clin Stg Grp	.	.	.	DH	SEER	Stage/Prognostic Factors		
3614	Derived SEER Cmb Stg Grp	.	.	.	DH	SEER	Stage/Prognostic Factors		
3616	Derived SEER Combined T	.	.	.	DH	SEER	Stage/Prognostic Factors		
3618	Derived SEER Combined N	.	.	.	DH	SEER	Stage/Prognostic Factors		
3620	Derived SEER Combined M	.	.	.	DH	SEER	Stage/Prognostic Factors		
3622	Derived SEER Cmb T Src	.	.	.	DH	SEER	Stage/Prognostic Factors		
3624	Derived SEER Cmb N Src	.	.	.	DH	SEER	Stage/Prognostic Factors		
3626	Derived SEER Cmb M Src	.	.	.	DH	SEER	Stage/Prognostic Factors		
3645	NPCR Derived AJCC 8 TNM Clin Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors		NHSCR-use only
3646	NPCR Derived AJCC 8 TNM Path Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors		NHSCR-use only
3647	NPCR Derived AJCC 8 TNM Post Therapy Stg Grp	.	.	.	.	NPCR	Stage/Prognostic Factors		
3650	NPCR Derived Clin Stg Grp	RH	.	.	.	NPCR	Stage/Prognostic Factors		NHSCR-use only
3655	NPCR Derived Path Stg Grp	RH	.	.	.	NPCR	Stage/Prognostic Factors		NHSCR-use only
3700	SEER Site-Specific Fact 1	.	.	.	R	SEER	Stage/Prognostic Factors		
3702	SEER Site-Specific Fact 2	.	.	.	.	SEER	Stage/Prognostic Factors		
3704	SEER Site-Specific Fact 3	.	.	.	.	SEER	Stage/Prognostic Factors		
3706	SEER Site-Specific Fact 4	.	.	.	.	SEER	Stage/Prognostic Factors		
3708	SEER Site-Specific Fact 5	.	.	.	.	SEER	Stage/Prognostic Factors		
3710	SEER Site-Specific Fact 6	.	.	.	.	SEER	Stage/Prognostic Factors		
3720	NPCR Specific Field	RH	RH	.	.	NPCR			
3750	Over-ride CS 1	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3751	Over-ride CS 2	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3752	Over-ride CS 3	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3753	Over-ride CS 4	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3754	Over-ride CS 5	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3755	Over-ride CS 6	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3756	Over-ride CS 7	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3757	Over-ride CS 8	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3758	Over-ride CS 9	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3759	Over-ride CS 10	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3760	Over-ride CS 11	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3761	Over-ride CS 12	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3762	Over-ride CS 13	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3763	Over-ride CS 14	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3764	Over-ride CS 15	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3765	Over-ride CS 16	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3766	Over-ride CS 17	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3767	Over-ride CS 18	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3768	Over-ride CS 19	RH	.	RH	.	AJCC	Edit Overrides/Conversion History/System Admin		
3769	Over-ride CS 20	RH	RH	RH	RH	AJCC/NPCR	Edit Overrides/Conversion History/System Admin	Revised	
3780	Secondary Diagnosis 1	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3782	Secondary Diagnosis 2	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3784	Secondary Diagnosis 3	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3786	Secondary Diagnosis 4	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3788	Secondary Diagnosis 5	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3790	Secondary Diagnosis 6	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3792	Secondary Diagnosis 7	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3794	Secondary Diagnosis 8	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3796	Secondary Diagnosis 9	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3798	Secondary Diagnosis 10	R	.	R	.	CoC	Stage/Prognostic Factors		For cases diagnosed 10/1/15+
3800	Schema ID	D	D	D	D	NAACCR	Stage/Prognostic Factors		
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3803	Adenoid Cystic Basaloid Pattern	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3804	Adenopathy	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3805	AFP Post-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3806	AFP Post-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3807	AFP Pre-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3808	AFP Pre-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3809	AFP Pretreatment Interpretation	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3810	AFP Pretreatment Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3811	Anemia	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3812	B symptoms	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3813	Bilirubin Pretreatment Total Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3814	Bilirubin Pretreatment Unit of Measure	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3815	Bone Invasion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3816	Brain Molecular Markers	RS	RS	.	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3817	Breslow Tumor Thickness	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3818	CA-125 Pretreatment Interpretation	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3819	CEA Pretreatment Interpretation	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3820	CEA Pretreatment Lab Value	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3821	Chromosome 3 Status	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3822	Chromosome 8q Status	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+



Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3823	Circumferential Resection Margin (CRM)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3824	Creatinine Pretreatment Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3825	Creatinine Pretreatment Unit of Measure	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3826	Estrogen Receptor Percent Positive or Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3827	Estrogen Receptor Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3828	Estrogen Receptor Total Allred Score	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3829	Esophagus and EGJ Tumor Epicenter	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3830	Extranodal Extension Clin (non-Head and Neck)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3831	Extranodal Extension Head and Neck Clinical	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3832	Extranodal Extension Head and Neck Pathological	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3833	Extranodal Extension Path (non-Head and Neck)	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3834	Extravascular Matrix Patterns	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3835	Fibrosis Score	RS	RS	RS	RC	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3836	FIGO Stage	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3837	Gestational Trophoblastic Prognostic Scoring Index	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3838	Gleason Patterns Clinical	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3839	Gleason Patterns Pathological	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3840	Gleason Score Clinical	RS	RS	RS	RC	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3841	Gleason Score Pathological	RS	RS	RS	RC	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3842	Gleason Tertiary Pattern	RS	RS*	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3843	Grade Clinical	R	R	R	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3844	Grade Pathological	R	R	R	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3845	Grade Post Therapy Path (yp)	R	R*	R	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3846	hCG Post-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3847	hCG Post-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3848	hCG Pre-Orchiectomy Lab Value	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3849	hCG Pre-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3850	HER2 IHC Summary	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3851	HER2 ISH Dual Probe Copy Number	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3852	HER2 ISH Dual Probe Ratio	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3853	HER2 ISH Single Probe Copy Number	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3854	HER2 ISH Summary	.	.	.	.	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018-2021
3855	HER2 Overall Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3856	Heritable Trait	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3857	High Risk Cytogenetics	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3858	High Risk Histologic Features	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3859	HIV Status	RS	.	.	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3860	International Normalized Ratio Prothrombin Time	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3861	Ipsilateral Adrenal Gland Involvement	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3862	JAK2	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3863	Ki-67	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3864	Invasion Beyond Capsule	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3865	KIT Gene Immunohistochemistry	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3866	KRAS	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3867	LDH Post-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3868	LDH Pre-Orchiectomy Range	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3869	LDH Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3870	LDH Upper Limits of Normal	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3871	LN Assessment Method Femoral-Inguinal	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3872	LN Assessment Method Para-Aortic	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3873	LN Assessment Method Pelvic	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3874	LN Distant Assessment Method	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3875	LN Distant: Mediastinal, Scapular	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3876	LN Head and Neck Levels I-III	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3877	LN Head and Neck Levels IV-V	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3878	LN Head and Neck Levels VI-VII	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3879	LN Head and Neck Other	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3880	LN Isolated Tumor Cells (ITC)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3881	LN Laterality	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3882	LN Positive Axillary Level I-II	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3883	LN Size	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3884	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3885	Lymphocytosis	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3886	Major Vein Involvement	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3887	Measured Basal Diameter	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3888	Measured Thickness	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3889	Methylation of O6-Methylguanine-Methyltransferase	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3890	Microsatellite Instability (MSI)	RS	RS*	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3891	Microvascular Density	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3892	Mitotic Count Uveal Melanoma	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3893	Mitotic Rate Melanoma	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3894	Multigene Signature Method	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3895	Multigene Signature Results	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3896	NCCN International Prognostic Index (IPI)	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3897	Number of Cores Examined	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3898	Number of Cores Positive	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+

Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
3899	Number of Examined Para-Aortic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3900	Number of Examined Pelvic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3901	Number of Positive Para-Aortic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3902	Number of Positive Pelvic Nodes	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3903	Oncotype Dx Recurrence Score-DCIS	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3904	Oncotype Dx Recurrence Score-Invasive	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3905	Oncotype Dx Risk Level-DCIS	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3906	Oncotype Dx Risk Level-Invasive	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3907	Organomegaly	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3908	Percent Necrosis Post Neoadjuvant	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3909	Perineural Invasion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3910	Peripheral Blood Involvement	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3911	Peritoneal Cytology	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3913	Pleural Effusion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3914	Progesterone Receptor Percent Positive or Range	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3915	Progesterone Receptor Summary	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3916	Progesterone Receptor Total Allred Score	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3917	Primary Sclerosing Cholangitis	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3918	Profound Immune Suppression	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3919	EOD Prostate Pathologic Extension	RS	.	.	RS	SEER	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3920	PSA (Prostatic Specific Antigen) Lab Value	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3921	Residual Tumor Volume Post Cytoreduction	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3922	Response to Neoadjuvant Therapy	RS	.	RS	RC	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3923	S Category Clinical	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3924	S Category Pathological	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3925	Sarcomatoid Features	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3926	Schema Discriminator 1	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3927	Schema Discriminator 2	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3928	Schema Discriminator 3	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3929	Separate Tumor Nodules	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3930	Serum Albumin Pretreatment Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3931	Serum Beta-2 Microglobulin Pretreatment Level	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3932	LDH Lab Value	RS	RS	RS	RS	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3933	Thrombocytopenia	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3934	Tumor Deposits	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3935	Tumor Growth Pattern	RS	.	RS	.	NAACCR	Stage/Prognostic Factors	Revised	Site-specific; For cases diagnosed 2018+
3936	Ulceration	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3937	Visceral and Parietal Pleural Invasion	RS	.	RS	RS	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2018+
3938	ALK Rearrangement	R	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3939	EGFR Mutational Analysis	R	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3940	BRAF Mutational Analysis	R	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3941	NRAS Mutational Analysis	R	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3942	CA 19-9 PreTx Lab Value	R	.	RS	R	NAACCR	Stage/Prognostic Factors		Site-specific; For cases diagnosed 2021+
3943	NCDB--SARSCoV2--Test	RH*	.	RH	RH*	CoC	Special Use	Revised	For cases diagnosed 2020-2021
3944	NCDB--SARSCoV2--Pos	RH*	.	RH	RH*	CoC	Special Use	Revised	For cases diagnosed 2020-2021
3945	NCDB--SARSCoV2--Pos Date	RH*	.	RH	RH*	CoC	Special Use	Revised	For cases diagnosed 2020-2021
3946	NCDB--COVID19--Tx Impact	RH*	.	RH	RH*	CoC	Special Use	Revised	For cases diagnosed 2020-2021
3950	Macroscopic Evaluation of Mesorectum	RS	.	R	RC	CoC	Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
3955	Derived Rai Stage	D	.	.	D		Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
3956	p16	RS	RS	RS	RC	SEER	Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
3957	LN Status Pelvic	RS	.	RS	RC	SEER	Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
3958	LN Status Para-Aortic	RS	.	RS	RC	SEER	Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
3959	LN Status Femoral-Inguinal	RS	.	RS	RC	SEER	Stage/Prognostic Factors	New	Site-specific; For cases diagnosed 2022+
7010	Path Reporting Fac ID 1	.	.	.	.	HL7	Pathology		
7011	Path Reporting Fac ID 2	.	.	.	.	HL7	Pathology		
7012	Path Reporting Fac ID 3	.	.	.	.	HL7	Pathology		
7013	Path Reporting Fac ID 4	.	.	.	.	HL7	Pathology		
7014	Path Reporting Fac ID 5	.	.	.	.	HL7	Pathology		
7090	Path Report Number 1	.	.	.	.	HL7	Pathology		
7091	Path Report Number 2	.	.	.	.	HL7	Pathology		
7092	Path Report Number 3	.	.	.	.	HL7	Pathology		
7093	Path Report Number 4	.	.	.	.	HL7	Pathology		
7094	Path Report Number 5	.	.	.	.	HL7	Pathology		
7100	Path Order Phys Lic No 1	.	.	.	.	HL7	Pathology		
7101	Path Order Phys Lic No 2	.	.	.	.	HL7	Pathology		
7102	Path Order Phys Lic No 3	.	.	.	.	HL7	Pathology		
7103	Path Order Phys Lic No 4	.	.	.	.	HL7	Pathology		
7104	Path Order Phys Lic No 5	.	.	.	.	HL7	Pathology		
7190	Path Ordering Fac No 1	.	.	.	.	HL7	Pathology		
7191	Path Ordering Fac No 2	.	.	.	.	HL7	Pathology		
7192	Path Ordering Fac No 3	.	.	.	.	HL7	Pathology		
7193	Path Ordering Fac No 4	.	.	.	.	HL7	Pathology		
7194	Path Ordering Fac No 5	.	.	.	.	HL7	Pathology		
7320	Path Date Spec Collect 1	.	.	.	.	HL7	Pathology		
7321	Path Date Spec Collect 2	.	.	.	.	HL7	Pathology		
7322	Path Date Spec Collect 3	.	.	.	.	HL7	Pathology		





Item #	Item Name	NHSCR	NPCR	CoC	SEER	Source	Section	Note	NHSCR Notes
9832	Chemo 2 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9833	Chemo 3 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9834	Chemo 4 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9835	Chemo 5 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9836	Chemo 6 Start Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9841	Chemo 1 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9842	Chemo 2 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9843	Chemo 3 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9844	Chemo 4 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9845	Chemo 5 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9846	Chemo 6 End Date	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9851	Chemo 1 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9852	Chemo 2 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9853	Chemo 3 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9854	Chemo 4 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9855	Chemo 5 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9856	Chemo 6 End Date Flag	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9859	Chemo Completion Status	RS	RS			NPCR/CER	Treatment-1st Course		For Breast, Colorectal, CML cases diagnosed 2011
9861	Hormone 1 NSC Number	RS	RS			NPCR/CER	Hormone Therapy		For Breast, Colorectal, CML cases diagnosed 2011
9862	Hormone 2 NSC Number	RS	RS			NPCR/CER	Hormone Therapy		For Breast, Colorectal, CML cases diagnosed 2011
9871	BRM 1 NSC Number	RS	RS			NPCR/CER	Biological Response Modifier		For Breast, Colorectal, CML cases diagnosed 2011
9872	BRM 2 NSC Number	RS	RS			NPCR/CER	Biological Response Modifier		For Breast, Colorectal, CML cases diagnosed 2011
9880	Granulocyt CSF Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9881	Erythrocyte Growth Factor Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9882	Thrombocyte Growth Factor Status	RS	RS			NPCR/CER	Chemotherapy		For Breast, Colorectal, CML cases diagnosed 2011
9900	BCR-ABL Cytogenetic	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9901	BCR-ABL Cytogenetic Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9902	BCR-ABL Cytogenetic Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9903	BCR-ABL FISH	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9904	BCR-ABL FISH Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9905	BCR-ABL FISH Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9906	BCR-ABL RT-PCR Qualitative	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9907	BCR-ABL RT-PCR Qual Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9908	BCR-ABL RT-PCR Qual Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9909	BCR-ABL RT-PCR Quantitative	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9910	BCR-ABL RT-PCR Quant Date	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9911	BCR-ABL RT-PCR Quant Date Flag	RS	RS			NPCR/CER	Biomarkers BCR-ABL		For CML cases diagnosed 2011
9920	Reason Subsq RX	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9921	Subsq RX 2nd Course Surgery	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9922	Subsq RX 2nd Course Radiation	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9923	Subsq RX 2nd Course Chemotherapy	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9924	Subsq RX 2nd Course Hormone	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9925	Subsq RX 2nd Course BRM	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9926	Subsq RX 2nd Course Other	RS	RS			NPCR/CER/PCO	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9927	Subsq RX 2nd Course Trans/End	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9931	Subsq RX 2nd Chemo 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9932	Subsq RX 2nd Chemo 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9933	Subsq RX 2nd Chemo 3 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9934	Subsq RX 2nd Chemo 4 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9935	Subsq RX 2nd Chemo 5 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9936	Subsq RX 2nd Chemo 6 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9941	Subsq RX 2nd Horm 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9942	Subsq RX 2nd Horm 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9951	Subsq RX 2nd BRM 1 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9952	Subsq RX 2nd BRM 2 NSC	RS	RS			NPCR/CER	Subsequent Treatment		For Breast, Colorectal, CML cases diagnosed 2011
9955	Subsq RX 2nd Date Flag CER	RS	RS			NPCR/CER/PCO	Treatment-Subsq & Other		For Breast, Colorectal, CML cases diagnosed 2011
9960	Height	R	R			NPCR/CER	Work Up		For cases diagnosed 2011+
9961	Weight	R	R			NPCR/CER	Work Up		For cases diagnosed 2011+
9965	Tobacco Use Cigarettes	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9966	Tobacco Use Other Smoke	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9967	Tobacco Use Smokeless	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9968	Tobacco Use NOS	RH	R			NPCR/CER	Work Up		For cases diagnosed 2011-2021; replaced with Item #344 for 2022+
9970	Source Comorbidity	R	R			NPCR/CER	Comorbidities		For cases diagnosed 2011
9980	NBCCEDP Linkage Results	RS	RS			NPCR/CER	NBCCEDP		NHSCR-use only; For Breast & Cervix cases
9981	NBCCEDP Linkage Date	RS	RS			NPCR/CER	NBCCEDP		NHSCR-use only; For Breast & Cervix cases
TBD	Area Level Education	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Health Insurance Estimate	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Health Professional Availability	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Income	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Poverty	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Poverty Index	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011
TBD	Area Level Urban/Rural	R	R			NPCR/CER	Socio-Economic Status Indicator		NHSCR-use only; For cases diagnosed 2011